NZ733610B2 - Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres - Google Patents
Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres Download PDFInfo
- Publication number
- NZ733610B2 NZ733610B2 NZ733610A NZ73361012A NZ733610B2 NZ 733610 B2 NZ733610 B2 NZ 733610B2 NZ 733610 A NZ733610 A NZ 733610A NZ 73361012 A NZ73361012 A NZ 73361012A NZ 733610 B2 NZ733610 B2 NZ 733610B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- optionally substituted
- group
- certain embodiments
- formula
- alkyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract description 37
- 229940079593 drugs Drugs 0.000 title abstract description 26
- 150000003862 amino acid derivatives Chemical class 0.000 title description 3
- 239000004005 microsphere Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 148
- 239000000203 mixture Substances 0.000 claims abstract description 124
- 125000000623 heterocyclic group Chemical group 0.000 claims description 208
- 125000000217 alkyl group Chemical group 0.000 claims description 197
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 186
- 229910052739 hydrogen Inorganic materials 0.000 claims description 182
- 239000001257 hydrogen Substances 0.000 claims description 182
- -1 and en Chemical group 0.000 claims description 168
- 125000001072 heteroaryl group Chemical group 0.000 claims description 167
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 141
- 239000011780 sodium chloride Substances 0.000 claims description 127
- 150000003839 salts Chemical class 0.000 claims description 120
- 125000000304 alkynyl group Chemical group 0.000 claims description 117
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 110
- 125000003342 alkenyl group Chemical group 0.000 claims description 105
- 125000005842 heteroatoms Chemical group 0.000 claims description 103
- 239000003795 chemical substances by application Substances 0.000 claims description 100
- 229910052717 sulfur Inorganic materials 0.000 claims description 88
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 86
- 229920000023 polynucleotide Polymers 0.000 claims description 82
- 239000002157 polynucleotide Substances 0.000 claims description 82
- 125000003107 substituted aryl group Chemical group 0.000 claims description 82
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 78
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims description 76
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 74
- 229910052757 nitrogen Inorganic materials 0.000 claims description 71
- 229910052760 oxygen Inorganic materials 0.000 claims description 69
- 239000002245 particle Substances 0.000 claims description 69
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 67
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 61
- 125000003118 aryl group Chemical group 0.000 claims description 55
- 125000004122 cyclic group Chemical group 0.000 claims description 48
- 125000005418 aryl aryl group Chemical group 0.000 claims description 38
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 38
- 239000001301 oxygen Substances 0.000 claims description 38
- 239000011593 sulfur Chemical group 0.000 claims description 38
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 36
- 125000002947 alkylene group Chemical group 0.000 claims description 34
- 239000004055 small Interfering RNA Substances 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 29
- 150000002829 nitrogen Chemical group 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 25
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 24
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 23
- 108020004459 Small Interfering RNA Proteins 0.000 claims description 23
- 239000002502 liposome Substances 0.000 claims description 23
- 125000004430 oxygen atoms Chemical group O* 0.000 claims description 23
- 125000004434 sulfur atoms Chemical group 0.000 claims description 22
- 229940035295 Ting Drugs 0.000 claims description 21
- 125000004429 atoms Chemical group 0.000 claims description 20
- 150000002632 lipids Chemical class 0.000 claims description 20
- 230000025458 RNA interference Effects 0.000 claims description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 17
- 230000002987 rna-interference Effects 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 229960005486 vaccines Drugs 0.000 claims description 10
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 9
- 229940107161 Cholesterol Drugs 0.000 claims description 9
- 229920001891 Small hairpin RNA Polymers 0.000 claims description 9
- 238000010364 biochemical engineering Methods 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- 229920001239 microRNA Polymers 0.000 claims description 9
- 239000011859 microparticle Substances 0.000 claims description 9
- 239000002105 nanoparticle Substances 0.000 claims description 9
- 239000002679 microRNA Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 108020005544 Antisense RNA Proteins 0.000 claims description 7
- 108020004388 MicroRNAs Proteins 0.000 claims description 7
- 229920002847 antisense RNA Polymers 0.000 claims description 7
- 239000003184 complementary RNA Substances 0.000 claims description 7
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 7
- 229910006069 SO3H Inorganic materials 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 102000007592 Apolipoproteins Human genes 0.000 claims description 5
- 108010071619 Apolipoproteins Proteins 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 5
- 239000000677 immunologic agent Substances 0.000 claims description 5
- 230000003834 intracellular Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 210000001519 tissues Anatomy 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 239000002479 lipoplex Substances 0.000 claims description 4
- 239000002417 nutraceutical Substances 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 230000002062 proliferating Effects 0.000 claims description 4
- 229960002897 Heparin Drugs 0.000 claims description 3
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 3
- 238000004166 bioassay Methods 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 201000009673 liver disease Diseases 0.000 claims description 3
- 206010003816 Autoimmune disease Diseases 0.000 claims description 2
- 208000009760 Familial Amyloid Neuropathy Diseases 0.000 claims description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 2
- 200000000018 inflammatory disease Diseases 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 21
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 8
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 239000002924 silencing RNA Substances 0.000 claims 2
- 229910006074 SO2NH2 Inorganic materials 0.000 claims 1
- 101710006947 APPL1 Proteins 0.000 abstract description 46
- 102100014042 APPL1 Human genes 0.000 abstract description 46
- 150000001413 amino acids Chemical class 0.000 abstract description 38
- 125000003277 amino group Chemical group 0.000 abstract description 29
- 150000002118 epoxides Chemical group 0.000 abstract description 14
- 239000002773 nucleotide Substances 0.000 abstract description 8
- 125000003729 nucleotide group Chemical group 0.000 abstract description 8
- 150000001299 aldehydes Chemical group 0.000 abstract description 5
- 150000001252 acrylic acid derivatives Chemical group 0.000 abstract 2
- 235000002639 sodium chloride Nutrition 0.000 description 119
- 150000002431 hydrogen Chemical group 0.000 description 85
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 40
- 229920000642 polymer Polymers 0.000 description 37
- 210000004027 cells Anatomy 0.000 description 33
- 235000001014 amino acid Nutrition 0.000 description 27
- 125000004404 heteroalkyl group Chemical group 0.000 description 27
- 125000005549 heteroarylene group Chemical group 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 22
- 229920001985 Small interfering RNA Polymers 0.000 description 21
- 125000000753 cycloalkyl group Chemical group 0.000 description 21
- 229920001223 polyethylene glycol Polymers 0.000 description 19
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 17
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 17
- 229910052796 boron Inorganic materials 0.000 description 17
- 229910052698 phosphorus Inorganic materials 0.000 description 17
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 17
- 239000011574 phosphorus Substances 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 230000002335 preservative Effects 0.000 description 15
- 239000003755 preservative agent Substances 0.000 description 15
- 239000002202 Polyethylene glycol Substances 0.000 description 14
- 230000001225 therapeutic Effects 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 13
- VOVUARRWDCVURC-UHFFFAOYSA-N Thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 12
- 125000004419 alkynylene group Chemical group 0.000 description 12
- 125000000732 arylene group Chemical group 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000000693 micelle Substances 0.000 description 12
- 241000229754 Iva xanthiifolia Species 0.000 description 11
- 230000021615 conjugation Effects 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 229920001888 polyacrylic acid Polymers 0.000 description 11
- 229910052710 silicon Inorganic materials 0.000 description 11
- 239000010703 silicon Substances 0.000 description 11
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- 235000010443 alginic acid Nutrition 0.000 description 10
- 229920000615 alginic acid Polymers 0.000 description 10
- 125000003368 amide group Chemical group 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 10
- 239000001913 cellulose Substances 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 239000003995 emulsifying agent Substances 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000004450 alkenylene group Chemical group 0.000 description 9
- 235000010980 cellulose Nutrition 0.000 description 9
- 229920002678 cellulose Polymers 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 125000004474 heteroalkylene group Chemical group 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 101700025839 APOE Proteins 0.000 description 8
- 102100007877 APOE Human genes 0.000 description 8
- 229940032147 Starch Drugs 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000001268 conjugating Effects 0.000 description 8
- 239000010408 film Substances 0.000 description 8
- 230000002068 genetic Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 description 8
- 239000001993 wax Substances 0.000 description 8
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 7
- 208000009956 Adenocarcinoma Diseases 0.000 description 7
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 7
- 108020004461 Double-Stranded RNA Proteins 0.000 description 7
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000000783 alginic acid Substances 0.000 description 7
- 229960001126 alginic acid Drugs 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007172 antigens Proteins 0.000 description 7
- 102000038129 antigens Human genes 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 6
- 210000003719 B-Lymphocytes Anatomy 0.000 description 6
- 229940050390 Benzoate Drugs 0.000 description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 6
- 108010069514 Cyclic Peptides Proteins 0.000 description 6
- 102000001189 Cyclic Peptides Human genes 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 229940014259 Gelatin Drugs 0.000 description 6
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 6
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 6
- 210000001744 T-Lymphocytes Anatomy 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 230000000692 anti-sense Effects 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000003000 nontoxic Effects 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 125000003367 polycyclic group Chemical group 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 229910052727 yttrium Inorganic materials 0.000 description 6
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 5
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 229940083542 Sodium Drugs 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000000240 adjuvant Effects 0.000 description 5
- 235000010419 agar Nutrition 0.000 description 5
- 125000005025 alkynylaryl group Chemical group 0.000 description 5
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 5
- 235000012216 bentonite Nutrition 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 230000001413 cellular Effects 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 230000002209 hydrophobic Effects 0.000 description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 230000001965 increased Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 125000006574 non-aromatic ring group Chemical group 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000001743 silencing Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 235000015424 sodium Nutrition 0.000 description 5
- 239000008247 solid mixture Substances 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 4
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 4
- 229940023476 Agar Drugs 0.000 description 4
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 4
- 229960005069 Calcium Drugs 0.000 description 4
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 4
- 241000498849 Chlamydiales Species 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N Dipalmitoylphosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 4
- 206010020243 Hodgkin's disease Diseases 0.000 description 4
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 4
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 4
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 4
- 229920000272 Oligonucleotide Polymers 0.000 description 4
- 206010025310 Other lymphomas Diseases 0.000 description 4
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 4
- IJCWFDPJFXGQBN-BIFNRIDTSA-N Sorbitan tristearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-BIFNRIDTSA-N 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 125000005024 alkenyl aryl group Chemical group 0.000 description 4
- 125000002877 alkyl aryl group Chemical group 0.000 description 4
- 150000001450 anions Chemical group 0.000 description 4
- 108090001123 antibodies Proteins 0.000 description 4
- 102000004965 antibodies Human genes 0.000 description 4
- 239000000440 bentonite Substances 0.000 description 4
- 229910000278 bentonite Inorganic materials 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 4
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002708 enhancing Effects 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000006011 modification reaction Methods 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 235000011078 sorbitan tristearate Nutrition 0.000 description 4
- 229910052721 tungsten Inorganic materials 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 3
- 125000006587 (C5-C10) heteroarylene group Chemical group 0.000 description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 3
- 101700082784 APOH Proteins 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 102000018616 Apolipoproteins B Human genes 0.000 description 3
- 108010027006 Apolipoproteins B Proteins 0.000 description 3
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 3
- 229960003563 Calcium Carbonate Drugs 0.000 description 3
- 229960001927 Cetylpyridinium Chloride Drugs 0.000 description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M Cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- NALBLJLOBICXRH-UHFFFAOYSA-N Dinitrogen monohydride Chemical compound N=[N] NALBLJLOBICXRH-UHFFFAOYSA-N 0.000 description 3
- 208000002047 Essential Thrombocythemia Diseases 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108020004999 Messenger RNA Proteins 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N Oleyl alcohol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 3
- 229960003975 Potassium Drugs 0.000 description 3
- 208000003476 Primary Myelofibrosis Diseases 0.000 description 3
- 229960004063 Propylene glycol Drugs 0.000 description 3
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 3
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 108060008443 TPPP Proteins 0.000 description 3
- 210000000538 Tail Anatomy 0.000 description 3
- 229940116362 Tragacanth Drugs 0.000 description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960004217 benzyl alcohol Drugs 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 3
- 229940093471 ethyl oleate Drugs 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 125000003473 lipid group Chemical group 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229920002106 messenger RNA Polymers 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 201000005962 mycosis fungoide Diseases 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000001264 neutralization Effects 0.000 description 3
- 229940055577 oleyl alcohol Drugs 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 229920001282 polysaccharide Chemical class 0.000 description 3
- 239000005017 polysaccharide Chemical class 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 235000007686 potassium Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- SVIHRJIEKRFYDN-UHFFFAOYSA-N propanamide Chemical compound [CH2]CC(N)=O SVIHRJIEKRFYDN-UHFFFAOYSA-N 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 3
- 150000004760 silicates Chemical class 0.000 description 3
- 239000001187 sodium carbonate Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 3
- 238000003325 tomography Methods 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 230000001131 transforming Effects 0.000 description 3
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000003612 virological Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- RZTAQRMRWPYVRR-UHFFFAOYSA-N (4-methylsulfinylphenyl)methyl carbamate Chemical compound CS(=O)C1=CC=C(COC(N)=O)C=C1 RZTAQRMRWPYVRR-UHFFFAOYSA-N 0.000 description 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 2
- WGIMXKDCVCTHGW-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCO WGIMXKDCVCTHGW-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-hydroxypropyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 2
- MUAUTBNKPSNTFM-UHFFFAOYSA-N 2-phenylethyl carbamate Chemical compound NC(=O)OCCC1=CC=CC=C1 MUAUTBNKPSNTFM-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- HMFKFHLTUCJZJO-UHFFFAOYSA-N 2-{2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy}ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO HMFKFHLTUCJZJO-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 2
- MSFQEZBRFPAFEX-UHFFFAOYSA-N 4-methoxybenzenesulfonamide Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1 MSFQEZBRFPAFEX-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-Methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 2
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 102100013083 APOC1 Human genes 0.000 description 2
- 101700085019 APOC1 Proteins 0.000 description 2
- 102100006912 APOC2 Human genes 0.000 description 2
- 101700062022 APOC2 Proteins 0.000 description 2
- 102100017826 APOC3 Human genes 0.000 description 2
- 101700049216 APOC3 Proteins 0.000 description 2
- 229960000583 Acetic Acid Drugs 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 2
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 2
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 2
- 108010060219 Apolipoprotein E2 Proteins 0.000 description 2
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 2
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 2
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 2
- 206010073360 Appendix cancer Diseases 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 240000005781 Arachis hypogaea Species 0.000 description 2
- 229940065181 Bacillus anthracis Drugs 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229940052491 Bordetella pertussis Drugs 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- 210000000481 Breast Anatomy 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229960000800 CETRIMONIUM BROMIDE Drugs 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 229940095731 Candida albicans Drugs 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 229940063834 Carboxymethylcellulose Sodium Drugs 0.000 description 2
- 208000002458 Carcinoid Tumor Diseases 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- 229940113118 Carrageenan Drugs 0.000 description 2
- 229920002301 Cellulose acetate Polymers 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229960004926 Chlorobutanol Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- 229940038704 Clostridium perfringens Drugs 0.000 description 2
- 241000193468 Clostridium perfringens Species 0.000 description 2
- 241000193449 Clostridium tetani Species 0.000 description 2
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 2
- 241000709687 Coxsackievirus Species 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M Dioctyl sodium sulfosuccinate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 229960000878 Docusate Sodium Drugs 0.000 description 2
- 210000002969 Egg Yolk Anatomy 0.000 description 2
- 241000224432 Entamoeba histolytica Species 0.000 description 2
- 229940007078 Entamoeba histolytica Drugs 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- HEZNVIYQEUHLNI-UHFFFAOYSA-N Ethiofencarb Chemical compound CCSCC1=CC=CC=C1OC(=O)NC HEZNVIYQEUHLNI-UHFFFAOYSA-N 0.000 description 2
- 229940118764 FRANCISELLA TULARENSIS Drugs 0.000 description 2
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 2
- 241000589602 Francisella tularensis Species 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N Glycol stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 208000005252 Hepatitis A Diseases 0.000 description 2
- 208000002672 Hepatitis B Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 208000005331 Hepatitis D Diseases 0.000 description 2
- 208000007514 Herpes Zoster Diseases 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- 241000228404 Histoplasma capsulatum Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 229940047122 Interleukins Drugs 0.000 description 2
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 2
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 229940001447 Lactate Drugs 0.000 description 2
- 229940067606 Lecithin Drugs 0.000 description 2
- 229940115932 Legionella pneumophila Drugs 0.000 description 2
- 241000589242 Legionella pneumophila Species 0.000 description 2
- 206010024190 Leiomyosarcomas Diseases 0.000 description 2
- 206010024238 Leptospirosis Diseases 0.000 description 2
- 208000000015 Leukemia, Neutrophilic, Chronic Diseases 0.000 description 2
- 208000006557 Lymphoma, B-Cell, Marginal Zone Diseases 0.000 description 2
- 208000009285 Lymphoma, Large B-Cell, Diffuse Diseases 0.000 description 2
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 description 2
- 208000003002 Lymphoma, T-Cell, Peripheral Diseases 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- 206010026798 Mantle cell lymphomas Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 229940013390 Mycoplasma pneumoniae Drugs 0.000 description 2
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 2
- 206010028537 Myelofibrosis Diseases 0.000 description 2
- 206010028576 Myeloproliferative disease Diseases 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 229940052778 Neisseria meningitidis Drugs 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 208000009905 Neurofibromatosis Diseases 0.000 description 2
- 241000187678 Nocardia asteroides Species 0.000 description 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 2
- 229910004759 OSi Inorganic materials 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 229960002969 Oleic Acid Drugs 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 206010034590 Peripheral nerve sheath tumour malignant Diseases 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N Phenethyl alcohol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 229940067631 Phospholipids Drugs 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 229940044519 Poloxamer 188 Drugs 0.000 description 2
- 208000008696 Polycythemia Vera Diseases 0.000 description 2
- 239000004698 Polyethylene (PE) Substances 0.000 description 2
- 229920001451 Polypropylene glycol Polymers 0.000 description 2
- 229940068984 Polyvinyl Alcohol Drugs 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- BHZRJJOHZFYXTO-UHFFFAOYSA-L Potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 2
- 208000003991 Primitive Neuroectodermal Tumors Diseases 0.000 description 2
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 2
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 206010038038 Rectal cancer Diseases 0.000 description 2
- 241000606726 Rickettsia typhi Species 0.000 description 2
- 208000000705 Rift Valley Fever Diseases 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000242680 Schistosoma mansoni Species 0.000 description 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 229940005550 Sodium alginate Drugs 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 240000001016 Solanum tuberosum Species 0.000 description 2
- 229940075582 Sorbic Acid Drugs 0.000 description 2
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 2
- 229940076185 Staphylococcus aureus Drugs 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229940031008 Streptococcus mutans Drugs 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 241000223997 Toxoplasma gondii Species 0.000 description 2
- 229940118701 Toxoplasma gondii Drugs 0.000 description 2
- 229960002622 Triacetin Drugs 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N Triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241000224527 Trichomonas vaginalis Species 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000223105 Trypanosoma brucei Species 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 208000008383 Wilms Tumor Diseases 0.000 description 2
- 210000002268 Wool Anatomy 0.000 description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N Xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- 229940118695 Yersinia pestis Drugs 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 241000209149 Zea Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- IYFATESGLOUGBX-NDUCAMMLSA-N [2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-NDUCAMMLSA-N 0.000 description 2
- IYFATESGLOUGBX-CBOZIWPYSA-N [2-[(2R,3S,4R)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@@H](O)[C@@H]1O IYFATESGLOUGBX-CBOZIWPYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical class CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 201000003076 angiosarcoma Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000843 anti-fungal Effects 0.000 description 2
- 230000000845 anti-microbial Effects 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 150000001541 aziridines Chemical class 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 2
- 229940096529 carboxypolymethylene Drugs 0.000 description 2
- 201000009030 carcinoma Diseases 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 229960002798 cetrimide Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000005824 corn Nutrition 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000000249 desinfective Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- ORMNPSYMZOGSSV-UHFFFAOYSA-N dinitrooxymercury Chemical compound [Hg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ORMNPSYMZOGSSV-UHFFFAOYSA-N 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- SEKVTWKYOIVNGT-UHFFFAOYSA-L disodium;dodecan-1-ol;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCO SEKVTWKYOIVNGT-UHFFFAOYSA-L 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical class NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002538 fungal Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000019314 gum ghatti Nutrition 0.000 description 2
- 230000003394 haemopoietic Effects 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 201000010284 hepatitis E Diseases 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- RIGIWEGXTTUCIQ-UHFFFAOYSA-N hydroxy-imino-diphenyl-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(=O)(N)C1=CC=CC=C1 RIGIWEGXTTUCIQ-UHFFFAOYSA-N 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 229940074928 isopropyl myristate Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 201000004931 neurofibromatosis Diseases 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 230000000269 nucleophilic Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 150000002902 organometallic compounds Chemical class 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 201000005170 papillary thyroid carcinoma Diseases 0.000 description 2
- 230000003071 parasitic Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 201000007923 peripheral T-cell lymphoma Diseases 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- LCPDWSOZIOUXRV-UHFFFAOYSA-M phenoxyacetate Chemical compound [O-]C(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-M 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229940096992 potassium oleate Drugs 0.000 description 2
- 235000019252 potassium sulphite Nutrition 0.000 description 2
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(Z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940093625 propylene glycol monostearate Drugs 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 229940001607 sodium bisulfite Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 239000001589 sorbitan tristearate Substances 0.000 description 2
- 229960004129 sorbitan tristearate Drugs 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229940012831 stearyl alcohol Drugs 0.000 description 2
- 125000005156 substituted alkylene group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 150000003553 thiiranes Chemical class 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical group CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- BZVJOYBTLHNRDW-UHFFFAOYSA-N triphenylmethanamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N)C1=CC=CC=C1 BZVJOYBTLHNRDW-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- DFNJPPOAVCXQQQ-UHFFFAOYSA-N (1,1,1-trichloro-2-methylpropan-2-yl) carbamate Chemical compound ClC(Cl)(Cl)C(C)(C)OC(N)=O DFNJPPOAVCXQQQ-UHFFFAOYSA-N 0.000 description 1
- AXTXAVIVKGDCLE-UHFFFAOYSA-N (1,1-dibromo-2-methylpropan-2-yl) carbamate Chemical compound BrC(Br)C(C)(C)OC(N)=O AXTXAVIVKGDCLE-UHFFFAOYSA-N 0.000 description 1
- FTVXFBJENACRRL-UHFFFAOYSA-N (1-hydroxypiperidin-2-yl) carbamate Chemical compound NC(=O)OC1CCCCN1O FTVXFBJENACRRL-UHFFFAOYSA-N 0.000 description 1
- ZLIHDHDAJVINAN-UHFFFAOYSA-N (2,4,6-trimethyl-3-pyridin-2-ylphenyl)methanimine Chemical compound CC1=C(C=N)C(C)=CC(C)=C1C1=CC=CC=N1 ZLIHDHDAJVINAN-UHFFFAOYSA-N 0.000 description 1
- RIFDKYBNWNPCQK-IOSLPCCCSA-N (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 description 1
- YVOBGLMMNWZYCL-UHFFFAOYSA-N (3-nitrophenyl) carbamate Chemical compound NC(=O)OC1=CC=CC([N+]([O-])=O)=C1 YVOBGLMMNWZYCL-UHFFFAOYSA-N 0.000 description 1
- VJFDVDXXJRSPLZ-VIFPVBQESA-L (3S)-3-(1-carboxylatoethenoxy)cyclohepta-1,6-diene-1-carboxylate Chemical group [O-]C(=O)C(=C)O[C@H]1CCC=CC(C([O-])=O)=C1 VJFDVDXXJRSPLZ-VIFPVBQESA-L 0.000 description 1
- HIIOEWGKFCWTJU-UHFFFAOYSA-N (4-chlorophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(Cl)C=C1 HIIOEWGKFCWTJU-UHFFFAOYSA-N 0.000 description 1
- NULWVEYYQSYAHP-UHFFFAOYSA-N (4-cyanophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(C#N)C=C1 NULWVEYYQSYAHP-UHFFFAOYSA-N 0.000 description 1
- IERCGNSLWQVTPC-UHFFFAOYSA-N (4-decoxyphenyl)methyl carbamate Chemical compound CCCCCCCCCCOC1=CC=C(COC(N)=O)C=C1 IERCGNSLWQVTPC-UHFFFAOYSA-N 0.000 description 1
- OKLFHGKWEQKSDZ-UHFFFAOYSA-N (4-methoxyphenyl)methanimine Chemical compound COC1=CC=C(C=N)C=C1 OKLFHGKWEQKSDZ-UHFFFAOYSA-N 0.000 description 1
- SDEOSHAQCMPJIJ-UHFFFAOYSA-N (4-methoxyphenyl)methyl carbamate Chemical compound COC1=CC=C(COC(N)=O)C=C1 SDEOSHAQCMPJIJ-UHFFFAOYSA-N 0.000 description 1
- WNNZAHBBDIVWBB-UHFFFAOYSA-N (4-methylsulfanylphenyl) carbamate Chemical compound CSC1=CC=C(OC(N)=O)C=C1 WNNZAHBBDIVWBB-UHFFFAOYSA-N 0.000 description 1
- LRJOVUGHUMSKFA-UHFFFAOYSA-N (4-nitrophenyl)methanimine Chemical compound [O-][N+](=O)C1=CC=C(C=N)C=C1 LRJOVUGHUMSKFA-UHFFFAOYSA-N 0.000 description 1
- FKTJSPKILYZMHX-AATRIKPKSA-N (6E)-6-(aminomethylidene)cyclohexa-2,4-dien-1-one Chemical compound N\C=C1/C=CC=CC1=O FKTJSPKILYZMHX-AATRIKPKSA-N 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-M (E)-2-methylbut-2-enoate Chemical compound C\C=C(/C)C([O-])=O UIERETOOQGIECD-ONEGZZNKSA-M 0.000 description 1
- ZOJKRWXDNYZASL-NSCUHMNNSA-M (E)-4-methoxybut-2-enoate Chemical compound COC\C=C\C([O-])=O ZOJKRWXDNYZASL-NSCUHMNNSA-M 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- PJUIMOJAAPLTRJ-GSVOUGTGSA-N (R)-monothioglycerol Chemical compound OC[C@@H](O)CS PJUIMOJAAPLTRJ-GSVOUGTGSA-N 0.000 description 1
- BPWTVHKBLYOLHU-UHFFFAOYSA-N 1$l^{2}-azocane Chemical group C1CCC[N]CCC1 BPWTVHKBLYOLHU-UHFFFAOYSA-N 0.000 description 1
- GLUABPSZMHYCNO-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropyrrolo[3,2-b]pyrrole Chemical compound N1CCC2NCCC21 GLUABPSZMHYCNO-UHFFFAOYSA-N 0.000 description 1
- IJFVSSZAOYLHEE-SSEXGKCCSA-O 1,2-dilauroyl-sn-glycero-3-phosphocholine(1+) Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-O 0.000 description 1
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-dilinoleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VAYTZRYEBVHVLE-UHFFFAOYSA-N 1,3-dioxol-2-one Chemical compound O=C1OC=CO1 VAYTZRYEBVHVLE-UHFFFAOYSA-N 0.000 description 1
- GJFNRSDCSTVPCJ-UHFFFAOYSA-N 1,8-Bis(dimethylamino)naphthalene Chemical compound C1=CC(N(C)C)=C2C(N(C)C)=CC=CC2=C1 GJFNRSDCSTVPCJ-UHFFFAOYSA-N 0.000 description 1
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 1
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 1
- FJANNOJSTOGZHK-UHFFFAOYSA-N 1-adamantyl carbamate Chemical compound C1C(C2)CC3CC2CC1(OC(=O)N)C3 FJANNOJSTOGZHK-UHFFFAOYSA-N 0.000 description 1
- RFVFQQWKPSOBED-PSXMRANNSA-N 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCC RFVFQQWKPSOBED-PSXMRANNSA-N 0.000 description 1
- UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical class OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
- QPLJYAKLSCXZSF-UHFFFAOYSA-N 2,2,2-trichloroethyl carbamate Chemical compound NC(=O)OCC(Cl)(Cl)Cl QPLJYAKLSCXZSF-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- XNMOEWPBTNQAQB-UHFFFAOYSA-N 2,2,5,7,8-pentamethyl-3,4-dihydrochromene-6-sulfonamide Chemical compound C1CC(C)(C)OC2=C1C(C)=C(S(N)(=O)=O)C(C)=C2C XNMOEWPBTNQAQB-UHFFFAOYSA-N 0.000 description 1
- 125000005900 2,3-dihydrofuro[2,3-b]pyridinyl group Chemical group 0.000 description 1
- PXVUDLXXKGSXHH-UHFFFAOYSA-N 2,4,6-trimethoxybenzenesulfonamide Chemical compound COC1=CC(OC)=C(S(N)(=O)=O)C(OC)=C1 PXVUDLXXKGSXHH-UHFFFAOYSA-N 0.000 description 1
- YECJUZIGFPJWGQ-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonamide Chemical compound CC1=CC(C)=C(S(N)(=O)=O)C(C)=C1 YECJUZIGFPJWGQ-UHFFFAOYSA-N 0.000 description 1
- FFFIRKXTFQCCKJ-UHFFFAOYSA-M 2,4,6-trimethylbenzoate Chemical compound CC1=CC(C)=C(C([O-])=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-M 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- DWKLSWPFGOTZII-UHFFFAOYSA-N 2-(1-adamantyl)propan-2-yl carbamate Chemical compound C1C(C2)CC3CC2CC1(C(C)(OC(N)=O)C)C3 DWKLSWPFGOTZII-UHFFFAOYSA-N 0.000 description 1
- YURLCYGZYWDCHL-UHFFFAOYSA-M 2-(2,6-dichloro-4-methylphenoxy)acetate Chemical compound CC1=CC(Cl)=C(OCC([O-])=O)C(Cl)=C1 YURLCYGZYWDCHL-UHFFFAOYSA-M 0.000 description 1
- FGJAPOYTPXTLPY-UHFFFAOYSA-N 2-(benzylideneamino)-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1N=CC1=CC=CC=C1 FGJAPOYTPXTLPY-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- LJARBVLDSOWRJT-UHFFFAOYSA-O 2-[2,3-di(pentadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCC LJARBVLDSOWRJT-UHFFFAOYSA-O 0.000 description 1
- XTRFZKJEMAVUIK-UHFFFAOYSA-M 2-[2,6-dichloro-4-(2,4,4-trimethylpentan-2-yl)phenoxy]acetate Chemical compound CC(C)(C)CC(C)(C)C1=CC(Cl)=C(OCC([O-])=O)C(Cl)=C1 XTRFZKJEMAVUIK-UHFFFAOYSA-M 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- FCOXSVSQGYUZTB-UHFFFAOYSA-O 2-carbamoyloxyethylphosphanium Chemical compound NC(=O)OCC[PH3+] FCOXSVSQGYUZTB-UHFFFAOYSA-O 0.000 description 1
- UJRMHFPTLFNSTA-UHFFFAOYSA-M 2-chloro-2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(Cl)(C(=O)[O-])C1=CC=CC=C1 UJRMHFPTLFNSTA-UHFFFAOYSA-M 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-M 2-methoxyacetate Chemical compound COCC([O-])=O RMIODHQZRUFFFF-UHFFFAOYSA-M 0.000 description 1
- AUQKXXDHDKEBEY-UHFFFAOYSA-N 2-methylbutan-2-yl carbamate Chemical compound CCC(C)(C)OC(N)=O AUQKXXDHDKEBEY-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical class NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
- XSXPJNJLDYOPTF-UHFFFAOYSA-N 2-trimethylsilylethoxymethanamine Chemical class C[Si](C)(C)CCOCN XSXPJNJLDYOPTF-UHFFFAOYSA-N 0.000 description 1
- QWYTUBPAXJYCTH-UHFFFAOYSA-N 2-trimethylsilylethyl carbamate Chemical compound C[Si](C)(C)CCOC(N)=O QWYTUBPAXJYCTH-UHFFFAOYSA-N 0.000 description 1
- GPVOTFQILZVCFP-UHFFFAOYSA-M 2-trityloxyacetate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(=O)[O-])C1=CC=CC=C1 GPVOTFQILZVCFP-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ASJSAQIRZKANQN-UHFFFAOYSA-N 3,4,5-trihydroxypentanal Chemical compound OCC(O)C(O)CC=O ASJSAQIRZKANQN-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- PPIXDIXXOMMDEI-UHFFFAOYSA-N 3,5-dinitro-3H-pyridin-4-one Chemical class [O-][N+](=O)C1C=NC=C([N+]([O-])=O)C1=O PPIXDIXXOMMDEI-UHFFFAOYSA-N 0.000 description 1
- OEHZEBOCZWCVMK-UHFFFAOYSA-N 3-(4-hydroxyphenyl)propanamide Chemical compound NC(=O)CCC1=CC=C(O)C=C1 OEHZEBOCZWCVMK-UHFFFAOYSA-N 0.000 description 1
- SCLGGNBFBLJQFU-UHFFFAOYSA-N 3-aminopropyl acetate Chemical compound CC(=O)OCCCN SCLGGNBFBLJQFU-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-M 3-cyclopentylpropanoate Chemical compound [O-]C(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-M 0.000 description 1
- UVODFYVXDPJZFJ-UHFFFAOYSA-N 3-methyl-3-nitrobutanamide Chemical compound [O-][N+](=O)C(C)(C)CC(N)=O UVODFYVXDPJZFJ-UHFFFAOYSA-N 0.000 description 1
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical class NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 description 1
- 125000005902 4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl group Chemical group 0.000 description 1
- 125000005903 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl group Chemical group 0.000 description 1
- UBARRNXCKBFUEN-UHFFFAOYSA-N 4,5-diphenyl-5H-1,3-oxazol-2-one Chemical compound N=1C(=O)OC(C=2C=CC=CC=2)C=1C1=CC=CC=C1 UBARRNXCKBFUEN-UHFFFAOYSA-N 0.000 description 1
- BLEFBWAGWNSEGB-UHFFFAOYSA-N 4-[(4,8-dimethoxynaphthalen-1-yl)methyl]benzenesulfonamide Chemical compound C12=C(OC)C=CC=C2C(OC)=CC=C1CC1=CC=C(S(N)(=O)=O)C=C1 BLEFBWAGWNSEGB-UHFFFAOYSA-N 0.000 description 1
- XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 description 1
- WAGMYTXJRVPMGW-UHFFFAOYSA-M 4-azidobutanoate Chemical compound [O-]C(=O)CCCN=[N+]=[N-] WAGMYTXJRVPMGW-UHFFFAOYSA-M 0.000 description 1
- KHKJLJHJTQRHSA-UHFFFAOYSA-M 4-methyl-4-nitropentanoate Chemical compound [O-][N+](=O)C(C)(C)CCC([O-])=O KHKJLJHJTQRHSA-UHFFFAOYSA-M 0.000 description 1
- LUQVCHRDAGWYMG-UHFFFAOYSA-N 4-phenylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC=C1 LUQVCHRDAGWYMG-UHFFFAOYSA-N 0.000 description 1
- NNJMFJSKMRYHSR-UHFFFAOYSA-M 4-phenylbenzoate Chemical compound C1=CC(C(=O)[O-])=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-M 0.000 description 1
- 125000005896 5,6-dihydro-4H-furo[3,2-b]pyrrolyl group Chemical group 0.000 description 1
- 125000005898 5,7-dihydro-4H-thieno[2,3-c]pyranyl group Chemical group 0.000 description 1
- 125000005897 6,7-dihydro-5H-furo[3,2-b]pyranyl group Chemical group 0.000 description 1
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-Methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
- UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7H-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 description 1
- ILYBMUDLGFMEMU-UHFFFAOYSA-N 7-$l^{1}-oxidanyl-2,3,4,5,6,7-hexaoxoheptan-1-olate Chemical compound [O]C(=O)C(=O)C(=O)C(=O)C(=O)C(=O)C[O-] ILYBMUDLGFMEMU-UHFFFAOYSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- QXPJDKVEHRKBOE-UHFFFAOYSA-N 9-phenyl-9H-fluoren-1-amine Chemical compound C1=2C(N)=CC=CC=2C2=CC=CC=C2C1C1=CC=CC=C1 QXPJDKVEHRKBOE-UHFFFAOYSA-N 0.000 description 1
- ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9H-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
- 101000447413 APOE Proteins 0.000 description 1
- 206010059394 Acanthoma Diseases 0.000 description 1
- 229940022663 Acetate Drugs 0.000 description 1
- 208000004064 Acoustic Neuroma Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 240000006054 Agastache cana Species 0.000 description 1
- 235000006667 Aleurites moluccana Nutrition 0.000 description 1
- 244000136475 Aleurites moluccana Species 0.000 description 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical class NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 1
- 229940024545 Aluminum Hydroxide Drugs 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 208000003808 Amyloid Neuropathy Diseases 0.000 description 1
- 206010002022 Amyloidosis Diseases 0.000 description 1
- 206010002023 Amyloidosis Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 206010002449 Angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 235000011514 Anogeissus latifolia Nutrition 0.000 description 1
- 240000005415 Anogeissus latifolia Species 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 102000018655 Apolipoproteins C Human genes 0.000 description 1
- 108010027070 Apolipoproteins C Proteins 0.000 description 1
- 229920002395 Aptamer Polymers 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N Axona Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 229960001950 Benzethonium Chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 229960002747 Betacarotene Drugs 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N Bibenzyl Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N Bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 229940097269 Borrelia burgdorferi Drugs 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 244000188595 Brassica sinapistrum Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 240000001358 Bromus mango Species 0.000 description 1
- 208000003362 Bronchogenic Carcinoma Diseases 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 229940078480 CALCIUM LEVULINATE Drugs 0.000 description 1
- 201000004085 CLL/SLL Diseases 0.000 description 1
- JGYNXZIYXGSEJH-UHFFFAOYSA-M CSCOCC1=CC=CC=C1C([O-])=O Chemical compound CSCOCC1=CC=CC=C1C([O-])=O JGYNXZIYXGSEJH-UHFFFAOYSA-M 0.000 description 1
- LDZNCSVWVMBVST-UHFFFAOYSA-M C[Si](C)(C)CCOC([O-])=O Chemical compound C[Si](C)(C)CCOC([O-])=O LDZNCSVWVMBVST-UHFFFAOYSA-M 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 241000220450 Cajanus cajan Species 0.000 description 1
- 229960004256 Calcium Citrate Drugs 0.000 description 1
- 229960004494 Calcium Gluconate Drugs 0.000 description 1
- 229940095618 Calcium Glycerophosphate Drugs 0.000 description 1
- 229940095672 Calcium Sulfate Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H Calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 229940078512 Calcium gluceptate Drugs 0.000 description 1
- NEEHYRZPVYRGPP-IYEMJOQQSA-L Calcium gluconate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEEHYRZPVYRGPP-IYEMJOQQSA-L 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L Calcium glycerylphosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L Calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 229960001631 Carbomer Drugs 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229960003260 Chlorhexidine Drugs 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N Chloroacetamide Chemical class NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 229940089960 Chloroacetate Drugs 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N Chloroxylenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- 208000006990 Cholangiocarcinoma Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 240000002268 Citrus limon Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 229940013361 Cresol Drugs 0.000 description 1
- 229960005168 Croscarmellose Drugs 0.000 description 1
- 229960000913 Crospovidone Drugs 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 208000002445 Cystadenocarcinoma Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 210000000172 Cytosol Anatomy 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-α-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 229940039227 DIAGNOSTIC AGENTS Drugs 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 101700033074 DMAP1 Proteins 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N DMDM hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229940061607 Dibasic Sodium Phosphate Drugs 0.000 description 1
- 229940111685 Dibasic potassium phosphate Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229940120124 Dichloroacetate Drugs 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L Dipotassium phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 229940047652 Ear Drops Drugs 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 210000001163 Endosomes Anatomy 0.000 description 1
- 240000006775 Enicostema verticillatum Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N Erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N Ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 240000000437 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 235000010705 Eucalyptus maculata Nutrition 0.000 description 1
- 235000009683 Eucalyptus polybractea Nutrition 0.000 description 1
- 235000009687 Eucalyptus sargentii Nutrition 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- 229950003499 FIBRIN Drugs 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 229950002499 Fytic acid Drugs 0.000 description 1
- 229940087559 GRAPE SEED Drugs 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N Gadolinium Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 210000000232 Gallbladder Anatomy 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229940015001 Glycerin Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N Glycerol 3-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000001922 Gum ghatti Substances 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 229940047650 Haemophilus influenzae Drugs 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 210000004209 Hair Anatomy 0.000 description 1
- 108009000344 Head and Neck Squamous Cell Carcinoma Proteins 0.000 description 1
- 240000006669 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N Hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 241000835890 Hoa Species 0.000 description 1
- 241000384508 Hoplostethus atlanticus Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 208000009576 Hypercholesterolemia Diseases 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 229940113174 IMIDUREA Drugs 0.000 description 1
- 229960001438 IMMUNOSTIMULANTS Drugs 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 208000007866 Immunoproliferative Small Intestinal Disease Diseases 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- UGQMRVRMYYASKQ-KMPDEGCQSA-N Inosine Natural products O[C@H]1[C@H](O)[C@@H](CO)O[C@@H]1N1C(N=CNC2=O)=C2N=C1 UGQMRVRMYYASKQ-KMPDEGCQSA-N 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 Inositol Drugs 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000981924 Juniperus oxycedrus Species 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 150000007649 L alpha amino acids Chemical class 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 241000408747 Lepomis gibbosus Species 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 1
- 241001072282 Limnanthes Species 0.000 description 1
- 206010024627 Liposarcoma Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 229940115931 Listeria monocytogenes Drugs 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 235000012854 Litsea cubeba Nutrition 0.000 description 1
- 240000002262 Litsea cubeba Species 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 206010025224 Lymphangiosarcomas Diseases 0.000 description 1
- 208000003747 Lymphoid Leukemia Diseases 0.000 description 1
- 208000008968 Lymphoma, Large-Cell, Anaplastic Diseases 0.000 description 1
- 208000005194 Lymphoma, Large-Cell, Immunoblastic Diseases 0.000 description 1
- 229940037627 MAGNESIUM LAURYL SULFATE Drugs 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 229940091250 Magnesium supplements Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000008585 Mastocytosis Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 240000004119 Melissa officinalis Species 0.000 description 1
- 206010027191 Meningioma Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 240000009136 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 229940045641 Monobasic Sodium Phosphate Drugs 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 229940010383 Mycobacterium tuberculosis Drugs 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000005927 Myosarcoma Diseases 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 240000006984 Myristica fragrans Species 0.000 description 1
- 208000001611 Myxosarcoma Diseases 0.000 description 1
- PVRJOEAYRBQPLF-UHFFFAOYSA-N N-(2-hydroxypropyl)-N-(2-oxopropyl)nitrous amide Chemical compound CC(O)CN(N=O)CC(C)=O PVRJOEAYRBQPLF-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical class CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- PWXJULSLLONQHY-UHFFFAOYSA-M N-phenylcarbamate Chemical compound [O-]C(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-M 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M N-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical compound N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229940097496 Nasal Spray Drugs 0.000 description 1
- 210000000581 Natural Killer T-Cells Anatomy 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- SFDJOSRHYKHMOK-UHFFFAOYSA-N Nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 229940074730 OPHTHAMOLOGIC DIAGNOSTIC AGENTS Drugs 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 229940041678 Oral Spray Drugs 0.000 description 1
- 235000014643 Orbignya martiana Nutrition 0.000 description 1
- 244000021150 Orbignya martiana Species 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 229940116315 Oxalic Acid Drugs 0.000 description 1
- CFKMVGJGLGKFKI-UHFFFAOYSA-N P-Chlorocresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 1
- 102100005352 PCSK9 Human genes 0.000 description 1
- 101700000651 PCSK9 Proteins 0.000 description 1
- 208000001052 Pachyonychia Congenita Diseases 0.000 description 1
- 206010033369 Paget's disease of the vulva Diseases 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 235000003177 Panax trifolius Nutrition 0.000 description 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 208000004019 Papillary Adenocarcinoma Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 210000003899 Penis Anatomy 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N Peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- 240000008426 Persea americana Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 229960005323 Phenoxyethanol Drugs 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N Phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 229940067107 Phenylethyl Alcohol Drugs 0.000 description 1
- 229940068041 Phytic Acid Drugs 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229960000502 Poloxamer Drugs 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000004358 Polyneuropathy Diseases 0.000 description 1
- 229940103091 Potassium Benzoate Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M Potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L Potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940095574 Propionic acid Drugs 0.000 description 1
- 229940075579 Propyl Gallate Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 210000003705 Ribosomes Anatomy 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000003136 Rosmarinus officinalis Species 0.000 description 1
- YBKWIGSMABMNJZ-UHFFFAOYSA-N S-(2,3,4,5,6-pentachlorophenyl)thiohydroxylamine Chemical compound NSC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl YBKWIGSMABMNJZ-UHFFFAOYSA-N 0.000 description 1
- RTKRAORYZUBVGQ-UHFFFAOYSA-N S-(2,4-dinitrophenyl)thiohydroxylamine Chemical compound NSC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O RTKRAORYZUBVGQ-UHFFFAOYSA-N 0.000 description 1
- BDEZGPKAMAVGBE-UHFFFAOYSA-N S-(3-nitropyridin-2-yl)thiohydroxylamine Chemical compound NSC1=NC=CC=C1[N+]([O-])=O BDEZGPKAMAVGBE-UHFFFAOYSA-N 0.000 description 1
- DAXSYWBYJZACTA-UHFFFAOYSA-N S-(4-methoxy-2-nitrophenyl)thiohydroxylamine Chemical compound COC1=CC=C(SN)C([N+]([O-])=O)=C1 DAXSYWBYJZACTA-UHFFFAOYSA-N 0.000 description 1
- MAGSSGQAJNNDLU-UHFFFAOYSA-N S-phenylthiohydroxylamine Chemical compound NSC1=CC=CC=C1 MAGSSGQAJNNDLU-UHFFFAOYSA-N 0.000 description 1
- PIDYQAYNSQSDQY-UHFFFAOYSA-N S-tritylthiohydroxylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SN)C1=CC=CC=C1 PIDYQAYNSQSDQY-UHFFFAOYSA-N 0.000 description 1
- 101700037930 SC14 Proteins 0.000 description 1
- 229960005055 SODIUM ASCORBATE Drugs 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- 208000006938 Schwannomatosis Diseases 0.000 description 1
- 210000004706 Scrotum Anatomy 0.000 description 1
- 229910018165 SeH Inorganic materials 0.000 description 1
- 210000001732 Sebaceous Glands Anatomy 0.000 description 1
- 101710023234 Segment 5 Proteins 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 240000003670 Sesamum indicum Species 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 201000006984 Sezary's disease Diseases 0.000 description 1
- 238000006202 Sharpless epoxidation reaction Methods 0.000 description 1
- 229940057910 Shea butter Drugs 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 229960003885 Sodium Benzoate Drugs 0.000 description 1
- 229940005581 Sodium Lactate Drugs 0.000 description 1
- NGSFWBMYFKHRBD-UHFFFAOYSA-M Sodium lactate Chemical compound [Na+].CC(O)C([O-])=O NGSFWBMYFKHRBD-UHFFFAOYSA-M 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M Sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 229960003212 Sodium propionate Drugs 0.000 description 1
- 229940091252 Sodium supplements Drugs 0.000 description 1
- 241000003823 Soleirolia soleirolii Species 0.000 description 1
- 229940075554 Sorbate Drugs 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 description 1
- 229960005137 Succinic Acid Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 206010042863 Synovial sarcoma Diseases 0.000 description 1
- 102100014311 THEM4 Human genes 0.000 description 1
- 101700081616 THEM4 Proteins 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 206010062123 Testicular embryonal carcinoma Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N Tetrahydro-2-furanmethanol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N Tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960001295 Tocopherol Drugs 0.000 description 1
- 229940042585 Tocopherol Acetate Drugs 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 229940066528 Trichloroacetate Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229960005066 Trisodium edetate Drugs 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N Tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046766 Uterine cancer Diseases 0.000 description 1
- 206010046885 Vaginal cancer Diseases 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000007769 Vetiveria zizanioides Nutrition 0.000 description 1
- 244000284012 Vetiveria zizanioides Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 229940118696 Vibrio cholerae Drugs 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 229940045997 Vitamin A Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- LXKLUWFIBVXFGX-QPJJXVBHSA-N [(E)-3-phenylprop-2-enyl] carbamate Chemical compound NC(=O)OC\C=C\C1=CC=CC=C1 LXKLUWFIBVXFGX-QPJJXVBHSA-N 0.000 description 1
- OJUHIDQVEFLXSE-UHFFFAOYSA-N [2-(4-methoxyphenyl)-2-oxoethyl] carbamate Chemical compound COC1=CC=C(C(=O)COC(N)=O)C=C1 OJUHIDQVEFLXSE-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- GCPWJFKTWGFEHH-UHFFFAOYSA-N acetoacetamide Chemical compound CC(=O)CC(N)=O GCPWJFKTWGFEHH-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005585 adamantoate group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 229960005467 algeldrate Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000006177 alkyl benzyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 150000004808 allyl alcohols Chemical group 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 229940087168 alpha Tocopherol Drugs 0.000 description 1
- 201000008063 alpha chain disease Diseases 0.000 description 1
- 229960001452 alpha-Tocopherol Acetate Drugs 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- FKFZOFZWJNHJDE-UHFFFAOYSA-N anthracene-9-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)N)=C(C=CC=C3)C3=CC2=C1 FKFZOFZWJNHJDE-UHFFFAOYSA-N 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000001078 anti-cholinergic Effects 0.000 description 1
- 230000001430 anti-depressive Effects 0.000 description 1
- 230000003276 anti-hypertensive Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agents Drugs 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 230000000561 anti-psychotic Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 125000000089 arabinosyl group Chemical class C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- DUXANUSOCMOJSI-UHFFFAOYSA-N benzhydryl carbamate Chemical compound C=1C=CC=CC=1C(OC(=O)N)C1=CC=CC=C1 DUXANUSOCMOJSI-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OENHQHLEOONYIE-VYAWBVGESA-N beta-Carotene Natural products CC=1CCCC(C)(C)C=1\C=C\C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-VYAWBVGESA-N 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 239000003876 biosurfactant Substances 0.000 description 1
- HROGQYMZWGPHIB-UHFFFAOYSA-N bis(4-methoxyphenyl)methanamine Chemical compound C1=CC(OC)=CC=C1C(N)C1=CC=C(OC)C=C1 HROGQYMZWGPHIB-UHFFFAOYSA-N 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 235000008984 brauner Senf Nutrition 0.000 description 1
- 201000000135 breast papillary carcinoma Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 201000005200 bronchus cancer Diseases 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 230000003139 buffering Effects 0.000 description 1
- QJBRNNNJBVJKPK-UHFFFAOYSA-N but-1-en-3-yne Chemical group C=[C]C#C QJBRNNNJBVJKPK-UHFFFAOYSA-N 0.000 description 1
- ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- HUSUHZRVLBSGBO-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydroxide Chemical compound O.[Ca+2].OP([O-])([O-])=O HUSUHZRVLBSGBO-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 229960005443 chloroxylenol Drugs 0.000 description 1
- 201000009047 chordoma Diseases 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019516 cod Nutrition 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-M crotonate Chemical compound C\C=C\C([O-])=O LDHQCZJRKDOVOX-NSCUHMNNSA-M 0.000 description 1
- 201000007336 cryptococcosis Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 125000006449 cycloalkyl cyclopropyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- NNGAQKAUYDTUQR-UHFFFAOYSA-N cyclohexanimine Chemical compound N=C1CCCCC1 NNGAQKAUYDTUQR-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- JMFVWNKPLURQMI-UHFFFAOYSA-N cyclopentyl carbamate Chemical compound NC(=O)OC1CCCC1 JMFVWNKPLURQMI-UHFFFAOYSA-N 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 125000005891 decahydronaphthyridinyl group Chemical group 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-M dichloroacetate Chemical compound [O-]C(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-M 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 230000001882 diuretic Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-M dodecyl sulfate Chemical compound CCCCCCCCCCCCOS([O-])(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-M 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000011025 embryonal testis carcinoma Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-M ethyl carbonate Chemical compound CCOC([O-])=O CQDGTJPVBWZJAZ-UHFFFAOYSA-M 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 235000001612 eucalyptus Nutrition 0.000 description 1
- 235000001617 eucalyptus Nutrition 0.000 description 1
- 235000001621 eucalyptus Nutrition 0.000 description 1
- 235000006356 eucalyptus Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 201000008808 fibrosarcoma Diseases 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 201000003928 fungal infectious disease Diseases 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 229930008393 geraniol Natural products 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-M glycerate Chemical compound OCC(O)C([O-])=O RBNPOMFGQQGHHO-UHFFFAOYSA-M 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 201000008064 heavy chain disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000034547 human ApoE protein Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000887 hydrating Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- QWMUDOFWQWBHFI-UHFFFAOYSA-N hydroxy-imino-diphenoxy-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1OP(=O)(N)OC1=CC=CC=C1 QWMUDOFWQWBHFI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003344 immunostimulant Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 200000000003 influenza A Diseases 0.000 description 1
- 200000000004 influenza B Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 201000006439 lymphocytic leukemia Diseases 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 230000002132 lysosomal Effects 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 201000005505 measles Diseases 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 208000009018 medullary Thyroid cancer Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical class NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- NYEBKUUITGFJAK-UHFFFAOYSA-M methylsulfanylmethanethioate Chemical compound CSC([O-])=S NYEBKUUITGFJAK-UHFFFAOYSA-M 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000008050 mu chain disease Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000005893 naphthalimidyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000009494 neurilemmomatosis Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 201000004404 neurofibroma Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical class NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229920001894 non-coding RNA Polymers 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- YWIWOAJYWWVNBP-UHFFFAOYSA-N oct-1-en-7-yne Chemical group C=[C+]CCCCC#[C-] YWIWOAJYWWVNBP-UHFFFAOYSA-N 0.000 description 1
- 125000005890 octahydroisochromenyl group Chemical group 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000011029 ovarian embryonal carcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005880 oxathiolanyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- VZCFNJNTQPIJHV-UHFFFAOYSA-N penta-1,2-dien-4-yne Chemical group C=C=[C]C#[C-] VZCFNJNTQPIJHV-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 235000005426 persea americana Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- FAQJJMHZNSSFSM-UHFFFAOYSA-M phenylglyoxylate Chemical compound [O-]C(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-M 0.000 description 1
- ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-M phenylmethanesulfonate Chemical compound [O-]S(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-M 0.000 description 1
- AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical compound N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000011528 polyamide (building material) Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001444 polymaleic acid Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 201000007271 pre-malignant neoplasm Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- OCAAZRFBJBEVPS-UHFFFAOYSA-N prop-2-enyl carbamate Chemical compound NC(=O)OCC=C OCAAZRFBJBEVPS-UHFFFAOYSA-N 0.000 description 1
- BFASWJXWTSCDRR-UHFFFAOYSA-M prop-2-enyl carbonate Chemical compound [O-]C(=O)OC[C]=C BFASWJXWTSCDRR-UHFFFAOYSA-M 0.000 description 1
- ZNZJJSYHZBXQSM-UHFFFAOYSA-N propane-2,2-diamine Chemical compound CC(C)(N)N ZNZJJSYHZBXQSM-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 235000020236 pumpkin seed Nutrition 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- RWUGBYOALBYTGU-UHFFFAOYSA-N pyridin-4-ylmethyl carbamate Chemical compound NC(=O)OCC1=CC=NC=C1 RWUGBYOALBYTGU-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 235000005227 red mallee Nutrition 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000001718 repressive Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 201000000582 retinoblastoma Diseases 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003334 secondary amides Chemical class 0.000 description 1
- 201000010208 seminoma Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002333 serotherapy Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N silicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003393 splenic Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000008736 systemic mastocytosis Diseases 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000005887 tetrahydrobenzofuranyl group Chemical group 0.000 description 1
- 125000005886 tetrahydrobenzothienyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000003777 thiepinyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherols Natural products 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 201000007905 transthyretin amyloidosis Diseases 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QXZGXRIXJAVMTI-UHFFFAOYSA-N tribenzylsilicon Chemical group C=1C=CC=CC=1C[Si](CC=1C=CC=CC=1)CC1=CC=CC=C1 QXZGXRIXJAVMTI-UHFFFAOYSA-N 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-M trichloroacetate Chemical compound [O-]C(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-M 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- BZLZKLMROPIZSR-UHFFFAOYSA-N triphenylsilicon Chemical group C1=CC=CC=C1[Si](C=1C=CC=CC=1)C1=CC=CC=C1 BZLZKLMROPIZSR-UHFFFAOYSA-N 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- LVLANIHJQRZTPY-UHFFFAOYSA-N vinyl carbamate Chemical compound NC(=O)OC=C LVLANIHJQRZTPY-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N α-GPC Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- GLZPCOQZEFWAFX-JXMROGBWSA-N β-Geraniol Chemical compound CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/60—1,4-Diazines; Hydrogenated 1,4-diazines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B01F17/0042—
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Described herein are compounds and compositions that are characterized by the Markush formulae (I), (II), (III), (IV), (V), and (VI) underneath, where at least one terminal amino group is further functionalized. Such compounds are obtained by reacting a terminal or internal amino group with epoxides, acrylates, or aldehydes bearing lipophilic groups. The resulting amino acid, peptide, polypeptide-lipids (named "APPLs" in the application) are deemed useful as drug delivery systems including nucleotide delivery to cells. , acrylates, or aldehydes bearing lipophilic groups. The resulting amino acid, peptide, polypeptide-lipids (named "APPLs" in the application) are deemed useful as drug delivery systems including nucleotide delivery to cells.
Description
AMINO ACID DERIVATES FUNCTIONALIZED ON THE INAL CAPABLE OF FORMING DRUG
INCAPSULATING MICROSPHERES
Related Applications
The present application claims priority under 35 U.S.C. § 119(e) to US.
provisional patent ation, U.S.S.N. 61/552,423, filed October 27, 2011, which is
incorporated herein by reference.
Government t
This invention was made with government support under Grant No. R37
EB000244 awarded by the National Institutes of Health. The government has certain rights
in this ion.
Background of the Invention
The ability to silence genes via RNA erence (RNAi) was ed by
Mello and Fire in 1998. See Fire et al., Nature (1998) 391:806—81 1. Since then, scientists
have rushed to take advantage of the enormous therapeutic potential driven by targeted gene
knockdown. This is evidenced by the fact that the first report of small interfering RNA
(siRNA) mediated RNAi in human beings was reported only twelve years after the
phenomenon was described in Caenorhabditis s. See Davis et al., Nature (2010)
464: 1067—1070. It is well understood that development of genetic drugs is slowed by the
inability to deliver c acids effectively in vivo. When unprotected, genetic material
injected into the bloodstream can be degraded by DNAases and RNAases, or, if not degraded,
the genetic material can stimulate an immune response. See, e.g., Whitehead et al., Nature
Reviews Drug Discovery (2009) 8:129—138; Robbins et al., Oligonucleotides (2009) 19:89-
102. Intact siRNA must then enter the cytosol, where the antisense strand is incorporated into
the RNA—induced silencing complex (RISC) (Whitehead supra). The RISC associates with
and degrades mentary mRNA sequences, thereby preventing translation of the target
mRNA into protein, i.e., “silencing” the gene.
To overcome difficulties in ry, nucleotides have been complexed with a
wide variety of delivery s, including polymers, lipids, inorganic nanoparticles and
viruses. See, e.g., Peer et al. Nature Nanotechnology, (2007) 2:751—760. However, despite
promising data from ongoing clinical trials for the treatment of respiratory syncytial virus and
liver cancers (see, e.g., Zamora et al., Am. J. Respir. Crit. Care Med. (2011) 183:531—538),
the clinical use of siRNA continues to require development of safer and more effective
ry systems. Toward this end, numerous lipid—like molecules have been developed
including poly B—amino esters and amino alcohol lipids. See, e. 57., PCT Application
Publication Nos. ; ; ; ;
WC 2006/138380; and . Amino acid, e, polypeptide—lipids (APPL)
have also been studied for a variety of applications, ing use as therapeutics,
biosurfactants, and nucleotide delivery systems. See, e. g., Giuliani et al., Cellular and
Molecular Life Sciences (2011) 68:2255—2266; lkeda et al., t Medicinal
Chemistry (2007) 14: 111263-1275; Sen, es in Experimental Medicine and
Biology (2010) 672:316-323; and Damen et al., Journal of Controlled Release (2010)
145:33—39. However, there continues to remain a need to investigate and develop new APPL
systems with improved properties, such as new and improved APPL nucleotide delivery
systems.
y of the Invention
Described herein are inventive compounds and compositions terized, in
certain embodiments, by conjugation of various , such as lipophilic groups, to an
amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic
polypeptide, or structural isomer thereof, to provide compounds of the present invention,
collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of
ations, such as, for example, improved nucleotide delivery.
Exemplary APPLs include, but are not d to, compounds of Formula (I),
(II), (III), (IV), (V), and (VI), and salts thereof, as described herein:
z R5 W
F:3 1 R4
RZ—N m Y
R1 R'
R1 N
RB’ RL
R2\ Q R\ Q
N NIN
R1—< R1 R2‘ R1
Q R1
R2 Q
(V) (VI)
wherein m, n, p, R’, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein, provided that
the APPL comprises at least one instance of a group of formula (i), (ii), or (iii):
E—Q\ RL
RI g_/
0) (ii) (iii)
each instance of R’ is independently hydrogen or optionally substituted alkyl;
X is O, S, NRX, wherein RX is en, optionally substituted alkyl, optionally
substituted alkenyl, optionally substituted alkynyl, optionally substituted yclyl,
optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, or a nitrogen protecting group;
Y is O, S, NRY, wherein RY is hydrogen, optionally substituted alkyl, optionally
substituted alkenyl, optionally tuted alkynyl, optionally tuted carbocyclyl,
ally substituted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, or a nitrogen protecting group;
RP is en, optionally substituted alkyl, optionally substituted alkenyl, optionally
substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl,
optionally tuted aryl, ally substituted heteroaryl, an oxygen protecting group
when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom,
or a nitrogen protecting group when attached to a nitrogen atom; and
RL is optionally substituted C150 alkyl, optionally substituted C250 l, optionally
substituted C250 alkynyl, optionally substituted heteroC1_50 alkyl, optionally substituted
heteroC2_50 alkenyl, optionally substituted heteroC2_50 alkynyl, or a polymer.
In certain embodiments, the group of a (i) represents a group of formula
(i—a) or a group of formula (i—b):
L | I
R' RL
(i-a) (i-b).
In certain embodiments, the group of formula (i—a) is a group of formula (i—al)
or a group of formula (i—a2):
RL 8' Ra R'
EfYRP ngRP
RI RI
(i-al) (i-a2).
In certain embodiments, the group of formula (i—b) is a group of formula (i—bl)
or a group of a :
R' IRL R' RL
(i-bl) (i—b2)
In certain embodiments, at least one instance of R1 is a group of formula:
E—L—N
R7 (iV)
n L is an optionally substituted alkylene, ally substituted alkenylene,
optionally substituted alkynylene, optionally substituted heteroalkylene, optionally
substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted
yclylene, optionally substituted heterocyclylene, optionally substituted arylene, or
optionally substituted heteroarylene, and
R6 and R7 are independently selected from the group consisting of hydrogen,
optionally substituted alkyl, optionally substituted alkenyl, optionally substituted l,
ally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted
aryl, optionally substituted heteroaryl, and a nitrogen protecting group;
provided at least one instance of R6 and R7 is a group of formula:
. R‘ XRL
RQ—YRP
g—<R- § 0 R'-
R' or §_/
(1) (ii) (iii)
wherein:
each instance of R’ is independently hydrogen or optionally substituted alkyl;
X is O, S, NRX, wherein RX is hydrogen, optionally substituted alkyl, optionally
substituted alkenyl, optionally substituted alkynyl, ally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, or a nitrogen protecting group;
Y is O, S, NRY, wherein RY is hydrogen, optionally substituted alkyl, optionally
substituted l, optionally substituted alkynyl, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally tuted aryl, optionally substituted
heteroaryl, or a nitrogen protecting group;
RP is hydrogen, optionally substituted alkyl, optionally substituted l, optionally
substituted alkynyl, optionally tuted carbocyclyl, optionally tuted heterocyclyl,
ally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group
when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom,
or a nitrogen protecting group when attached to a nitrogen atom; and
RL is optionally substituted C150 alkyl, optionally tuted C250 alkenyl, ally
tuted C250 alkynyl, optionally substituted heteroC1_50 alkyl, optionally tuted
heteroC2_50 alkenyl, optionally substituted heteroC2_50 alkynyl, or a polymer.
In certain embodiments, each instance of R’ is hydrogen.
In certain embodiments, L is an optionally substituted alkylene.
In certain embodiments, the group of formula (iv) is of formula:
“WNW
n q is an integer between 1 and 50, inclusive.
In certain embodiments, each instance of R1 is a group of formula (iv).
An exemplary APPL of the present invention is compound (cKK-E12):
C10H21/S
N 0
C10H21
C10H21
C10H21
H0 (cKK-E12),
or a salt thereof.
In another aspect, provided are compositions comprising an APPL or a salt
thereof.
For example, in certain embodiments, provided is a composition comprising an
APPL or salt thereof and, ally, an excipient, wherein the APPL is an amino acid, a
linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, and
wherein an amino or amide group of the APPL is conjugated to a group of formula (i), (ii), or
(iii). In certain embodiments, the group of formula (i), (ii), or (iii) is attached to an amino
group present on the APPL scaffold. In certain embodiments, the composition is a
pharmaceutical composition, a cosmetic composition, a nutraceutical composition, or a
composition with non—medical application. In certain embodiments, the composition with
non—medical application is an emulsion or emulsifier useful as a food component, for
extinguishing fires, for disinfecting surfaces, or for oil cleanup.
In n embodiments, the composition further comprises an agent. In certain
embodiments, the agent is an organic molecule, inorganic molecule, nucleic acid, protein,
peptide, polynucleotide, ing agent, an isotopically d chemical compound, vaccine,
an immunological agent, or an agent useful bioprocessing, e.g., in the intracellular
manufacturing of proteins. In certain embodiments, the agent is a polynucleotide, and the
polynucleotide is DNA or RNA. In certain embodiments, the RNA is RNAi, dsRNA, siRNA,
shRNA, miRNA, or antisense RNA. In certain embodiments, the agent and the APPL are
not ntly attached, e.g., for e, the agent and the APPL are valently
complexed to each other. However, in n embodiments, the agent and the APPL are
covalently attached.
In certain ments, the composition is in the form of a particle. In certain
embodiments, the particle is a rticle or microparticle. In certain embodiments, the
particle is a micelle, liposome, or lipoplex. In certain embodiments, the particle encapsulates
an agent, 6.57., an agent to be delivered.
In r aspect, provided is a method of delivering a polynucleotide to a
biological cell, sing providing a composition comprising an APPL, or salt thereof, and
a polynucleotide, and exposing the composition to the biological cell under conditions
sufficient to facilitate delivery of the polynucleotide into the interior of the biological cell;
wherein the APPL is an amino acid, a linear or cyclic peptide, or a linear or cyclic
polypeptide, or structural isomer f, wherein an amino or amide group of the APPL is
conjugated to a group of formula (i), (ii), or (iii). In certain ments, the polynucleotide
is DNA or RNA. In certain embodiments, the RNA is RNAi, dsRNA, siRNA, shRNA,
miRNA, or antisense RNA. In n embodiments, upon delivery of the RNA into the cell,
the RNA is able to ere with the expression of a specific gene in the biological cell.
In yet another aspect, provided are screening methods. For example, in one
ment, provided is a method of screening a compound library, the method comprising
providing a plurality of different APPLs, or salts thereof, and performing at least one assay
with the compound library to determine the se or absence of a desired property;
wherein the APPL is an amino acid, a linear or cyclic peptide, or a linear or cyclic
polypeptide, or structural isomer thereof, wherein an amino or amide group of the APPL is
conjugated to a group of formula (i), (ii), or (iii). In certain embodiments, the desired
property is solubility in water, solubility at different pH, ability to bind polynucleotides,
ability to bind heparin, ability to bind small molecules, ability to bind protein, ability to form
microparticles, ability to increase tranfection efficiency, ability to t cell growth, ability
to support cell attachment, ability to support tissue growth, and/or intracellular delivery of the
APPL and/or an agent complexed or ed o to aid in bioprocessing.
In still yet another aspect, provided are s of use of the inventive APPLs
for the treatment of various diseases, disorders, or conditions. For example, in certain
embodiments, provided is a method of treating a disease, disorder, or condition from which
the subject suffers, comprising administering to a subject in need thereof an effective amount
of an APPL, or salt thereof, n the APPL is an amino acid, a linear or cyclic peptide, or
a linear or cyclic polypeptide, or ural isomer thereof, wherein an amino or amide group
of the APPL is conjugated to a group of formula (i), (ii), or (iii).
The s of one or more ments of the invention are set forth herein.
Other features, objects, and advantages of the invention will be apparent from the Detailed
Description, the Figures, the Examples, and the .
Definitions
Chemical definitions
Definitions of specific functional groups and chemical terms are described in
more detail below. The chemical elements are identified in accordance with the ic
Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside
cover, and specific functional groups are generally defined as bed therein.
onally, l principles of organic chemistry, as well as specific functional moieties
and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science
Books, Sausalito, 1999; Smith and March March’s Advanced Organic Chemistry, 5th Edition,
John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic
Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern
s of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987.
nds described herein can comprise one or more asymmetric centers,
and thus can exist in various isomeric forms, e. g., enantiomers and/or diastereomers. For
example, the compounds described herein can be in the form of an individual omer,
diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers,
including racemic mixtures and mixtures ed in one or more stereoisomer. Isomers can
be isolated from mixtures by methods known to those skilled in the art, including chiral high
pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts;
or preferred s can be prepared by asymmetric syntheses. See, for example, Jacques et
al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen
et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds
(McGraw—Hill, NY, 1962); and Wilen, S.H. Tables ofResolving Agents and Optical
Resolutions p. 268 (EL. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The
invention additionally encompasses compounds as individual isomers substantially free of
other isomers, and alternatively, as mixtures of various isomers.
When a range of values is , it is intended to encompass each value and
sub—range within the range. For example “C14 alkyl” is intended to encompass, C1, C2, C3,
C4, C5, C6, C176, C15, C14, C173, C172, C24, C25, C24, C273, C376, C375, C34, C46, C45, and
C54 alkyl.
As used herein, “alkyl” refers to a l of a straight—chain or branched
saturated hydrocarbon group having from 1 to 50 carbon atoms (“C150 alkyl”). In some
embodiments, an alkyl group has 1 to 40 carbon atoms (“C140 alkyl”). In some embodiments,
an alkyl group has 1 to 30 carbon atoms (“C130 alkyl”). In some embodiments, an alkyl
group has 1 to 20 carbon atoms (“C140 alkyl”). In some embodiments, an alkyl group has 1
to 10 carbon atoms (“C140 alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon
atoms (“C19 ). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C1,g
alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C14 alkyl”). In
some embodiments, an alkyl group has 1 to 6 carbon atoms (“C14 alkyl”). In some
embodiments, an alkyl group has 1 to 5 carbon atoms (“CH alkyl”). In some embodiments,
an alkyl group has 1 to 4 carbon atoms (“C14 alkyl”). In some embodiments, an alkyl group
has 1 to 3 carbon atoms (“CH alkyl”). In some embodiments, an alkyl group has 1 to 2
carbon atoms (“CH alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“C1
alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C2,6 alkyl”).
Examples of C14 alkyl groups include methyl (C1), ethyl (C2), n—propyl (C3), isopropyl (C3),
n—butyl (C4), tert—butyl (C4), sec—butyl (C4), iso—butyl (C4), n—pentyl (C5), 3—pentanyl (C5),
amyl (C5), neopentyl (C5), 3—methyl—2—butanyl (C5), tertiary amyl (C5), and n—hexyl (C6).
onal examples of alkyl groups e n—heptyl (C7), n—octyl (C8) and the like. Unless
otherwise specified, each instance of an alkyl group is independently unsubstituted (an
“unsubstituted alkyl”) or substituted (a ituted alkyl”) with one or more substituents. In
certain embodiments, the alkyl group is an unsubstituted C150 alkyl. In certain ments,
the alkyl group is a substituted C150 alkyl.
As used herein, “heteroalkyl” refers to an alkyl group as defined herein which
further includes at least one heteroatom (e.g., l to 25, e.g., l, 2, 3, or 4 heteroatoms) selected
from , , nitrogen, boron, silicon, or phosphorus within (i.e., inserted between
adjacent carbon atoms of) and/or placed at one or more terminal on(s) of the parent
chain. In certain embodiments, a heteroalkyl group refers to a saturated group haVing from 1
to 50 carbon atoms and l or more heteroatoms within the parent chain roCHo alkyl”).
In certain embodiments, a heteroalkyl group refers to a saturated group haVing from 1 to 40
carbon atoms and l or more atoms within the parent chain (“heteroCHO alkyl”). In
certain embodiments, a heteroalkyl group refers to a ted group haVing from 1 to 30
carbon atoms and l or more heteroatoms within the parent chain (“heteroCHo alkyl”). In
certain embodiments, a heteroalkyl group refers to a saturated group haVing from 1 to 20
carbon atoms and l or more heteroatoms within the parent chain (“heteroCHO alkyl”). In
certain embodiments, a alkyl group refers to a saturated group having from 1 to 10
carbon atoms and l or more heteroatoms Within the parent chain (“heteroCHo alkyl”). In
some embodiments, a heteroalkyl group is a ted group having 1 to 9 carbon atoms and
l or more heteroatoms Within the parent chain (“heteroC1,9 alkyl”). In some embodiments, a
heteroalkyl group is a saturated group having 1 to 8 carbon atoms and l or more heteroatoms
Within the parent chain (“heteroCHg alkyl”). In some ments, a heteroalkyl group is a
ted group having 1 to 7 carbon atoms and l or more heteroatoms Within the parent
chain (“heteroCH alkyl”). In some embodiments, a heteroalkyl group is a saturated group
having 1 to 6 carbon atoms and l or more atoms Within the parent chain (“heteroCM
alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 5 carbon
atoms and l or 2 heteroatoms Within the parent chain (“heteroC1,5 alkyl”). In some
ments, a heteroalkyl group is a saturated group having 1 to 4 carbon atoms and lor 2
heteroatoms Within the parent chain (“heteroCH alkyl”). In some embodiments, a
heteroalkyl group is a saturated group having 1 to 3 carbon atoms and l heteroatom Within
the parent chain (“heteroC1,3 alkyl”). In some embodiments, a heteroalkyl group is a
saturated group having 1 to 2 carbon atoms and l heteroatom Within the parent chain
(“heteroCH alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1
carbon atom and l atom roC1 alkyl”). In some embodiments, a heteroalkyl group
is a saturated group haVing 2 to 6 carbon atoms and l or 2 heteroatoms Within the parent
chain (“heteroC2,6 alkyl”). Unless otherwise specified, each instance of a heteroalkyl group
is ndently unsubstituted (an “unsubstituted heteroalkyl”) or substituted (a “substituted
heteroalkyl”) with one or more substituents. In certain embodiments, the heteroalkyl group is
an unsubstituted heteroC1,50 alkyl. In certain embodiments, the heteroalkyl group is a
substituted heteroC1,50 alkyl.
As used herein, “alkenyl” refers to a radical of a ht—chain or branched
hydrocarbon group haVing from 2 to 50 carbon atoms and one or more carbon—carbon double
bonds (e.g., l, 2, 3, or 4 double bonds) (“C250 alkenyl”). In some embodiments, an alkenyl
group has 2 to 40 carbon atoms (“C240 alkenyl”). In some embodiments, an alkenyl group
has 2 to 30 carbon atoms (“C230 alkenyl”). In some embodiments, an alkenyl group has 2 to
carbon atoms (“C240 alkenyl”). In some embodiments, an alkenyl group has 2 to 10
carbon atoms (“C240 alkenyl”). In some embodiments, an alkenyl group has 2 to 9 carbon
atoms (“C2,9 l”). In some embodiments, an alkenyl group has 2 to 8 carbon atoms
(“C24, alkenyl”). In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C24
alkeny ”). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“ng alkenyl”).
In some embodiments, an l group has 2 to 5 carbon atoms (“C2,5 alkenyl”). In some
embodiments, an alkenyl group has 2 to 4 carbon atoms (“C24 alkenyl”). In some
embodiments, an alkenyl group has 2 to 3 carbon atoms (“CH alkenyl”). In some
embodiments, an alkenyl group has 2 carbon atoms (“C2 alkenyl”). The one or more
carbon—carbon double bonds can be internal (such as in 2—butenyl) or terminal (such as in l—
l). Examples of C24 alkenyl groups include ethenyl (C2), l—propenyl (C3), 2—propenyl
(C3), l—butenyl (C4), 2—butenyl (C4), butadienyl (C4), and the like. Examples of C24 alkenyl
groups include the aforementioned C24 alkenyl groups as well as pentenyl (C5), pentadienyl
(C5), hexenyl (C6), and the like. Additional examples of alkenyl include heptenyl (C7),
octenyl (C3), octatrienyl (C3), and the like. Unless ise specified, each ce of an
alkenyl group is independently unsubstituted (an “unsubstituted alkenyl”) or tuted (a
“substituted alkenyl”) with one or more substituents. In certain embodiments, the alkenyl
group is an unsubstituted C240 alkenyl. In certain embodiments, the alkenyl group is a
substituted C240 l.
As used herein, “heteroalkenyl” refers to an alkenyl group as d herein
which further includes at least one heteroatom (e.g., l to 25, e.g., l, 2, 3, or 4 heteroatoms)
selected from oxygen, sulfur, en, boron, silicon, or phosphorus within (i.e., inserted
between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the
parent chain. In n embodiments, a heteroalkenyl group refers to a group haVing from 2
to 50 carbon atoms, at least one double bond, and l or more heteroatoms within the parent
chain (“heteroC2,50 alkenyl”). In certain embodiments, a heteroalkenyl group refers to a
group haVing from 2 to 40 carbon atoms, at least one double bond, and l or more heteroatoms
within the parent chain (“heteroC240 alkenyl”). In certain ments, a heteroalkenyl
group refers to a group haVing from 2 to 30 carbon atoms, at least one double bond, and l or
more atoms within the parent chain (“heteroCHo alkenyl”). In certain embodiments, a
heteroalkenyl group refers to a group haVing from 2 to 20 carbon atoms, at least one double
bond, and l or more heteroatoms within the parent chain (“heteroC2,20 alkenyl”). In certain
embodiments, a heteroalkenyl group refers to a group haVing from 2 to 10 carbon atoms, at
least one double bond, and l or more heteroatoms within the parent chain (“heteroCHo
alkeny ”). In some embodiments, a heteroalkenyl group has 2 to 9 carbon atoms at least one
double bond, and l or more heteroatoms within the parent chain (“heteroC2,9 alkenyl”). In
some embodiments, a heteroalkenyl group has 2 to 8 carbon atoms, at least one double bond,
and l or more heteroatoms within the parent chain (“heteroCHg alkenyl”). In some
embodiments, a heteroalkenyl group has 2 to 7 carbon atoms, at least one double bond, and l
or more heteroatoms Within the parent chain (“heteroCzq alkenyl”). In some embodiments, a
heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and l or more
heteroatoms Within the parent chain (“heteroC2,6 l”). In some embodiments, a
heteroalkenyl group has 2 to 5 carbon atoms, at least one double bond, and l or 2
heteroatoms Within the parent chain (“heteroC2,5 alkenyl”). In some embodiments, a
heteroalkenyl group has 2 to 4 carbon atoms, at least one double bond, and lor 2 heteroatoms
Within the parent chain (“heteroC24 alkenyl”). In some embodiments, a heteroalkenyl group
has 2 to 3 carbon atoms, at least one double bond, and l heteroatom Within the parent chain
(“heteroCH alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 6 carbon
atoms, at least one double bond, and l or 2 heteroatoms Within the parent chain (“heteroC2,6
alkeny ”). Unless otherwise specified, each instance of a alkenyl group is
independently unsubstituted (an “unsubstituted heteroalkenyl”) or substituted (a “substituted
heteroalkenyl”) with one or more substituents. In certain embodiments, the heteroalkenyl
group is an tituted C2,50 alkenyl. In certain embodiments, the heteroalkenyl
group is a substituted heteroC2,50 alkenyl.
As used herein, “alkynyl” refers to a radical of a straight—chain or branched
hydrocarbon group haVing from 2 to 50 carbon atoms and one or more —carbon triple
bonds (e.g., l, 2, 3, or 4 triple bonds) and optionally one or more double bonds (e.g., l, 2, 3,
or 4 double bonds) (“C250 alkynyl”). An l group that has one or more triple bonds
and one or more double bonds is also referred to as an “ene—yene”. In some embodiments, an
alkynyl group has 2 to 40 carbon atoms (“C240 alkynyl”). In some embodiments, an alkynyl
group has 2 to 30 carbon atoms (“C230 alkynyl”). In some embodiments, an l group
has 2 to 20 carbon atoms (“C240 alkynyl”). In some embodiments, an alkynyl group has 2 to
carbon atoms (“C240 alkynyl”). In some embodiments, an alkynyl group has 2 to 9 carbon
atoms (“C2,9 alkynyl”). In some embodiments, an alkynyl group has 2 to 8 carbon atoms
(“C24, alkynyl”). In some embodiments, an alkynyl group has 2 to 7 carbon atoms (“C24
alkynyl”). In some embodiments, an l group has 2 to 6 carbon atoms (“C24 alkynyl”).
In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C2,5 l”). In some
embodiments, an alkynyl group has 2 to 4 carbon atoms (“C24 alkynyl”). In some
embodiments, an alkynyl group has 2 to 3 carbon atoms (“CH alkynyl”). In some
embodiments, an alkynyl group has 2 carbon atoms (“C2 l”). The one or more carbon—
carbon triple bonds can be internal (such as in 2—butynyl) or terminal (such as in l—butynyl).
Examples of C24 alkynyl groups e, Without limitation, ethynyl (C2), l—propynyl (C3),
2—propynyl (C3), l—butynyl (C4), 2—butynyl (C4), and the like. Examples of C24 alkenyl
groups include the aforementioned C24 alkynyl groups as well as pentynyl (C5), hexynyl
(C6), and the like. Additional examples of alkynyl include heptynyl (C7), octynyl (C3), and
the like. Unless otherwise specified, each instance of an alkynyl group is independently
unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or
more substituents. In certain embodiments, the alkynyl group is an unsubstituted C250
alkynyl. In certain embodiments, the alkynyl group is a tuted C250 alkynyl.
As used herein, “heteroalkynyl” refers to an alkynyl group as defined herein
which further includes at least one heteroatom (e.g., l to 25, e.g., l, 2, 3, or 4 heteroatoms)
selected from oxygen, sulfur, nitrogen, boron, n, or phosphorus within (i.e., inserted
between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the
parent chain. In certain embodiments, a alkynyl group refers to a group haVing from 2
to 50 carbon atoms, at least one triple bond, and l or more heteroatoms within the parent
chain roC2,50 alkynyl”). In certain embodiments, a alkynyl group refers to a
group haVing from 2 to 40 carbon atoms, at least one triple bond, and l or more heteroatoms
within the parent chain (“heteroC240 alkynyl”). In certain ments, a heteroalkynyl
group refers to a group haVing from 2 to 30 carbon atoms, at least one triple bond, and l or
more heteroatoms within the parent chain (“heteroCHo alkynyl”). In certain embodiments, a
heteroalkynyl group refers to a group haVing from 2 to 20 carbon atoms, at least one triple
bond, and l or more heteroatoms within the parent chain (“heteroC2,20 l”). In certain
embodiments, a heteroalkynyl group refers to a group haVing from 2 to 10 carbon atoms, at
least one triple bond, and l or more heteroatoms within the parent chain (“heteroCHo
alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 9 carbon atoms, at least one
triple bond, and l or more atoms within the parent chain (“heteroC2,9 alkynyl”). In
some embodiments, a heteroalkynyl group has 2 to 8 carbon atoms, at least one triple bond,
and l or more heteroatoms within the parent chain (“heteroCHg alkynyl”). In some
embodiments, a heteroalkynyl group has 2 to 7 carbon atoms, at least one triple bond, and l
or more heteroatoms within the parent chain (“heterngq alkynyl”). In some embodiments, a
heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and l or more
heteroatoms within the parent chain (“heteroC2,6 alkynyl”). In some embodiments, a
heteroalkynyl group has 2 to 5 carbon atoms, at least one triple bond, and l or 2 heteroatoms
within the parent chain (“heteroC2,5 alkynyl”). In some ments, a heteroalkynyl group
has 2 to 4 carbon atoms, at least one triple bond, and lor 2 atoms within the parent
chain (“heteroC24 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 3 carbon
atoms, at least one triple bond, and l heteroatom within the parent chain (“heteroCH
2012/062222
alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one
triple bond, and l or 2 heteroatoms within the parent chain (“heteroC2,6 alkynyl”). Unless
otherwise specified, each instance of a heteroalkynyl group is independently unsubstituted
(an “unsubstituted heteroalkynyl”) or substituted (a “substituted heteroalkynyl”) with one or
more substituents. In certain embodiments, the heteroalkynyl group is an unsubstituted
heteroC2,50 l. In certain embodiments, the heteroalkynyl group is a substituted
C2,50 alkynyl.
As used , cyclyl” or cyclic” refers to a l of a non—
aromatic cyclic hydrocarbon group haVing from 3 to 10 ring carbon atoms (“C340
carbocycly ”) and zero heteroatoms in the non—aromatic ring system. In some embodiments,
a carbocyclyl group has 3 to 8 ring carbon atoms (“C3,g carbocyclyl”). In some
embodiments, a carbocyclyl group has 3 to 7 ring carbon atoms (“C34 carbocyclyl”). In some
embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C34 yclyl”). In
some embodiments, a carbocyclyl group has 4 to 6 ring carbon atoms (“C44 carbocyclyl”). In
some embodiments, a carbocyclyl group has 5 to 6 ring carbon atoms (“C54 carbocyclyl”). In
some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C540 carbocyclyl”).
Exemplary C34 carbocyclyl groups include, without limitation, cyclopropyl (C3),
cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5),
cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. Exemplary C34;
carbocyclyl groups include, without tion, the aforementioned C34 yclyl groups
as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7),
cyclooctyl (C3), cyclooctenyl (C3), bicyclo[2.2.l]heptanyl (C7), bicyclo[2.2.2]octanyl (C3),
and the like. Exemplary C340 carbocyclyl groups include, without limitation, the
aforementioned C34; carbocyclyl groups as well as onyl (C9), cyclononenyl (C9),
cyclodecyl (C10), cyclodecenyl (C10), octahydro—lH—indenyl (C9), decahydronaphthalenyl
(C10), 4.5]decanyl (C10), and the like. As the foregoing examples illustrate, in certain
embodiments, the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or
polycyclic (e.g., containing a fused, bridged or spiro ring system such as a bicyclic system
(“bicyclic carbocyclyl”) or tricyclic system (“tricyclic carbocyclyl”)) and can be saturated or
can contain one or more carbon—carbon double or triple bonds. “Carbocyclyl” also includes
ring systems n the carbocyclyl ring, as defined above, is fused with one or more aryl or
heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such
instances, the number of carbons continue to designate the number of carbons in the
carbocyclic ring . Unless otherwise specified, each instance of a carbocyclyl group is
independently unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a “substituted
carbocyclyl”) with one or more substituents. In certain embodiments, the carbocyclyl group
is an unsubstituted C340 carbocyclyl. In certain embodiments, the carbocyclyl group is a
substituted C340 carbocyclyl.
In some embodiments, cyclyl” or “carbocyclic” is referred to as a
“cycloalkyl”, i.e., a monocyclic, saturated carbocyclyl group having from 3 to 10 ring carbon
atoms (“C340 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon
atoms (“C3,g cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon
atoms (“C34 cycloalkyl”). In some embodiments, a cycloalkyl group has 4 to 6 ring carbon
atoms (“C44 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon
atoms (“C54 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon
atoms (“C540 cycloalkyl”). Examples of C54 lkyl groups include cyclopentyl (C5)
and cyclohexyl (C5). Examples of C3,6 cycloalkyl groups include the aforementioned C5,6
cycloalkyl groups as well as cyclopropyl (C3) and cyclobutyl (C4). Examples of C34;
cycloalkyl groups include the aforementioned C34 cycloalkyl groups as well as cycloheptyl
(C7) and cyclooctyl (C3). Unless otherwise specified, each instance of a cycloalkyl group is
independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted
cycloalkyl”) with one or more substituents. In certain embodiments, the cycloalkyl group is
an unsubstituted C340 cycloalkyl. In certain embodiments, the lkyl group is a
substituted C340 cycloalkyl.
As used , “heterocyclyl” or “heterocyclic” refers to a radical of a 3— to
l4—membered non—aromatic ring system having ring carbon atoms and l or more (e.g., l, 2,
3, or 4) ring heteroatoms, wherein each heteroatom is independently selected from oxygen,
sulfur, nitrogen, boron, n, or phosphorus (“3—14 membered heterocyclyl”). In
cyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a
carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic
(“monocyclic heterocyclyl”) or polycyclic (e.g., a fused, bridged or spiro ring system such as
a bicyclic system (“bicyclic heterocyclyl”) or tricyclic system (“tricyclic heterocyclyl”)), and
can be saturated or can n one or more carbon—carbon double or triple bonds.
cyclyl polycyclic ring systems can e one or more heteroatoms in one or both
rings. “Heterocyclyl” also es ring systems wherein the heterocyclyl ring, as d
above, is fused with one or more yclyl groups wherein the point of attachment is either
on the yclyl or heterocyclyl ring, or ring systems wherein the cyclyl ring, as
defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of
WO 63468
attachment is on the heterocyclyl ring, and in such instances, the number of ring members
continue to designate the number of ring members in the heterocyclyl ring system. Unless
otherwise specified, each instance of heterocyclyl is independently unsubstituted (an
“unsubstituted cyclyl”) or substituted (a “substituted heterocyclyl”) with one or more
substituents. In certain embodiments, the heterocyclyl group is an unsubstituted 3—l4
membered heterocyclyl. In n embodiments, the heterocyclyl group is a substituted 3—l4
ed heterocyclyl.
In some ments, a heterocyclyl group is a 5—10 membered non—aromatic
ring system haVing ring carbon atoms and l or more (e.g., l, 2, 3, or 4) ring heteroatoms,
wherein each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron,
silicon, or phosphorus (“5—10 membered heterocyclyl”). In some embodiments, a
heterocyclyl group is a 5—8 membered non—aromatic ring system haVing ring carbon atoms
and l or more (e.g., l, 2, 3, or 4) ring atoms, wherein each heteroatom is independently
selected from oxygen, sulfur, nitrogen, boron, n, or phosphorus (“5—8 membered
heterocyclyl”). In some embodiments, a heterocyclyl group is a 5—6 membered non—aromatic
ring system haVing ring carbon atoms and l or more (e.g., l, 2, 3, or 4) ring heteroatoms,
n each heteroatom is independently selected from oxygen, sulfur, en, boron,
n, or phosphorus (“5—6 membered heterocyclyl”). In some ments, the 5—6
membered heterocyclyl has 1 or more (e.g., l, 2, or 3) ring heteroatoms selected from
oxygen, sulfur, en, boron, silicon, or phosphorus. In some embodiments, the 5—6
membered cyclyl has 1 or 2 ring heteroatoms selected from oxygen, sulfur, nitrogen,
boron, n, or phosphorus. In some embodiments, the 5—6 membered heterocyclyl has 1
ring heteroatom selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorus.
Exemplary 3—membered heterocyclyl groups containing 1 heteroatom include,
without limitation, azirdinyl, oxiranyl, thiorenyl. Exemplary 4—membered heterocyclyl
groups containing 1 heteroatom include, without limitation, azetidinyl, oxetanyl and
thietanyl. Exemplary 5—membered heterocyclyl groups containing 1 heteroatom include,
without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl,
dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl—2,5—dione. ary 5—
membered heterocyclyl groups ning 2 heteroatoms include, without limitation,
dioxolanyl, oxathiolanyl and dithiolanyl. Exemplary 5—membered heterocyclyl groups
containing 3 heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and
thiadiazolinyl. Exemplary 6—membered heterocyclyl groups containing 1 heteroatom
include, without limitation, piperidinyl, ydropyranyl, dihydropyridinyl, and thianyl.
Exemplary 6—membered heterocyclyl groups containing 2 heteroatoms include, without
limitation, zinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6—membered
heterocyclyl groups containing 2 heteroatoms include, without limitation, triazinanyl.
Exemplary 7—membered heterocyclyl groups containing 1 heteroatom include, without
limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8—membered heterocyclyl groups
containing 1 heteroatom include, without limitation, azocanyl, yl and nyl.
Exemplary bicyclic heterocyclyl groups include, without limitation, indolinyl, isoindolinyl,
dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, tetrahydrobenzofuranyl,
ydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl,
decahydroisoquinolinyl, drochromenyl, octahydroisochromenyl,
decahydronaphthyridinyl, decahydro—l ,8—naphthyridinyl, octahydropyrrolo[3,2—b]pyrrole,
indolinyl, phthalimidyl, naphthalimidyl, chromanyl, chromenyl, zo[e][l,4]diazepinyl,
l,4,5,7—tetrahydropyrano[3,4—b]pyrrolyl, 5,6—dihydro—4H—furo[3,2—b]pyrrolyl, 6,7—dihydro—
5H—furo[3,2—b]pyranyl, 5,7—dihydro—4H—thieno[2,3—c]pyranyl, hydro—lH—
pyrrolo[2,3—b]pyridinyl, 2,3—dihydrofuro[2,3—b]pyridinyl, 4,5,6,7—tetrahydro—lH—pyrrolo—
[2,3—b]pyridinyl, 4,5,6,7—tetrahydrofuro[3,2—c]pyridinyl, 4,5,6,7—tetrahydrothieno[3,2—
b]pyridinyl, l,2,3,4—tetrahydro—l,6—naphthyridinyl, and the like.
As used herein, “aryl” refers to a radical of a monocyclic or polycyclic (e.g.,
bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., haVing 6, 10, or 14 at electrons shared
in a cyclic array) haVing 6—l4 ring carbon atoms and zero heteroatoms provided in the
aromatic ring system (“C644 aryl”). In some embodiments, an aryl group has 6 ring carbon
atoms (“C6 aryl”; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon
atoms (“C10 aryl”; e.g., yl such as l—naphthyl and 2—naphthyl). In some
embodiments, an aryl group has 14 ring carbon atoms (“C14 aryl”; e.g., anthracyl). “Aryl”
also includes ring systems wherein the aryl ring, as defined above, is fused with one or more
carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl
ring, and in such instances, the number of carbon atoms continue to designate the number of
carbon atoms in the aryl ring . Unless otherwise specified, each instance of an aryl
group is ndently unsubstituted (an stituted aryl”) or substituted (a “substituted
aryl”) with one or more substituents. In certain embodiments, the aryl group is an
unsubstituted C644 aryl. In certain embodiments, the aryl group is a substituted C644 aryl.
As used herein, “heteroaryl” refers to a radical of a 5—14 membered clic
or clic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., haVing 6, 10, or 14
at electrons shared in a cyclic array) having ring carbon atoms and l or more (e.g., l, 2, 3, or
4 ring heteroatoms) ring heteroatoms provided in the ic ring system, wherein each
heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, or
phosphorus (“5—14 membered heteroaryl”). In heteroaryl groups that contain one or more
nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits.
Heteroaryl clic ring systems can include one or more heteroatoms in one or both rings.
“Heteroaryl” includes ring systems wherein the heteroaryl ring, as defined above, is fused
with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on
the heteroaryl ring, and in such instances, the number of ring s continue to designate
the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring
systems wherein the heteroaryl ring, as d above, is fused with one or more aryl groups
wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances,
the number of ring members designates the number of ring members in the fused polycyclic
(aryl/heteroaryl) ring . Polycyclic heteroaryl groups wherein one ring does not contain
a heteroatom (e.g., l, quinolinyl, carbazolyl, and the like) the point of attachment can
be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2—indolyl) or the ring that
does not contain a heteroatom (e.g., 5—indolyl).
In some embodiments, a heteroaryl group is a 5—10 membered aromatic ring
system having ring carbon atoms and l or more (e.g., l, 2, 3, or 4) ring heteroatoms ed
in the aromatic ring system, n each heteroatom is independently selected from oxygen,
sulfur, nitrogen, boron, n, or phosphorus (“5—10 membered heteroaryl”). In some
embodiments, a heteroaryl group is a 5—8 membered aromatic ring system having ring carbon
atoms and l or more (e.g., l, 2, 3, or 4) ring heteroatoms ed in the aromatic ring
system, wherein each heteroatom is independently selected from oxygen, sulfur, nitrogen,
boron, silicon, or phosphorus (“5—8 membered heteroaryl”). In some embodiments, a
heteroaryl group is a 5—6 membered aromatic ring system having ring carbon atoms and l or
more (e.g., l, 2, 3, or 4) ring heteroatoms provided in the aromatic ring , wherein each
heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, or
phosphorus (“5—6 membered heteroaryl”). In some ments, the 5—6 membered
heteroaryl has 1 or more (e.g., l, 2, or 3) ring atoms selected from oxygen, sulfur,
nitrogen, boron, silicon, or phosphorus. In some embodiments, the 5—6 ed heteroaryl
has 1 or 2 ring atoms selected from oxygen, sulfur, nitrogen, boron, silicon, or
phosphorus. In some embodiments, the 5—6 membered heteroaryl has 1 ring heteroatom
selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorus. Unless otherwise
specified, each instance of a heteroaryl group is independently unsubstituted (an
“unsubstituted heteroaryl”) or substituted (a ituted heteroaryl”) with one or more
substituents. In certain embodiments, the aryl group is an tituted 5—14
membered heteroaryl. In certain embodiments, the heteroaryl group is a substituted 5—14
membered aryl.
Exemplary 5—membered heteroaryl groups containing 1 heteroatom include,
Without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5—membered heteroaryl
groups containing 2 atoms include, Without limitation, olyl, pyrazolyl, oxazolyl,
isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5—membered heteroaryl groups containing
3 heteroatoms include, t limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary
—membered heteroaryl groups containing 4 atoms include, Without limitation,
tetrazolyl. Exemplary 6—membered heteroaryl groups containing 1 heteroatom include,
t limitation, pyridinyl. Exemplary ered heteroaryl groups containing 2
heteroatoms include, Without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary
6—membered heteroaryl groups ning 3 or 4 heteroatoms include, Without limitation,
triazinyl and tetrazinyl, respectively. Exemplary 7—membered heteroaryl groups containing 1
heteroatom e, Without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6—
bicyclic heteroaryl groups include, Without limitation, indolyl, isoindolyl, indazolyl,
benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl,
benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, iazolyl,
benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary cyclic
heteroaryl groups include, Without limitation, naphthyridinyl, pteridinyl, quinolinyl,
isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. ary lic
heteroaryl groups include, Without limitation, phenanthridinyl, dibenzofuranyl, carbazolyl,
acridinyl, phenothiazinyl, phenoxazinyl and phenazinyl.
As used herein, the term “partially unsaturated” refers to a ring moiety that
includes at least one double or triple bond. The term “partially unsaturated” is ed to
encompass rings haVing multiple sites of unsaturation, but is not intended to include aromatic
groups (e.g., aryl or heteroaryl moieties) as herein defined.
As used herein, the term “saturated” refers to a ring moiety that does not contain a
double or triple bond, i.e., the ring ns all single bonds.
Affixing the suffix “—ene” to a group indicates the group is a divalent moiety, e.g.,
alkylene is the divalent moiety of alkyl, alkenylene is the divalent moiety of alkenyl,
alkynylene is the divalent moiety of alkynyl, heteroalkylene is the divalent moiety of
heteroalkyl, heteroalkenylene is the divalent moiety of heteroalkenyl, heteroalkynylene is the
divalent moiety of heteroalkynyl, carbocyclylene is the divalent moiety of carbocyclyl,
heterocyclylene is the divalent moiety of heterocyclyl, arylene is the divalent moiety of aryl,
and arylene is the divalent moiety of heteroaryl.
As understood from the above, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,
heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups, as d herein, are,
in certain embodiments, optionally tuted. Optionally substituted refers to a group which
may be substituted or unsubstituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted”
or stituted” l, “substituted” or “unsubstituted” l, “substituted” or
“unsubstituted” heteroalkyl, “substituted” or “unsubstituted” heteroalkenyl, “substituted” or
stituted” heteroalkynyl, “substituted” or “unsubstituted” carbocyclyl, “substituted” or
stituted” heterocyclyl, “substituted” or “unsubstituted” aryl or “substituted” or
“unsubstituted” aryl group). In general, the term “substituted” means that at least one
hydrogen present on a group is replaced with a permissible substituent, e.g., a substituent
which upon substitution results in a stable compound, e.g., a compound which does not
spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or
other reaction. Unless otherwise indicated, a “substituted” group has a tuent at one or
more substitutable positions of the group, and when more than one position in any given
structure is tuted, the substituent is either the same or different at each on. The
term “substituted” is contemplated to include substitution with all permissible substituents of
organic compounds, any of the substituents described herein that results in the formation of a
stable compound. The present ion contemplates any and all such combinations in order
to arrive at a stable compound. For purposes of this invention, heteroatoms such as nitrogen
may have hydrogen substituents and/or any suitable substituent as described herein which
satisfy the ies of the heteroatoms and results in the formation of a stable moiety.
Exemplary carbon atom substituents include, but are not limited to, halogen, —
CN, —N02, —N3, —SOZH, —SO3H, —OH, —0Raa, —ON(Rbb)2, —N(Rbb)2, —N(Rbb)3+X’, —
N(OR°°)Rbb, -SeH, -SeRaa, —SH, —SRaa, —SSR°°, Raa, —C02H, —CHO, —C(OR°°)2, —
, —0C(=0)Raa, —ocozRaa, —C(=O)N(Rbb)2, —OC(=O)N(Rbb)2, —NRbbC(=O)Raa, —
NRbbcozRaa, —NRbbC(=O)N(Rbb)2, —C(=NRbb)Raa, —C(=NRbb)ORaa, —OC(=NRbb)Raa, —
OC(=NRbb)ORaa, —C(=NRbb)N(Rbb)2, Rbb)N(Rbb)2, —NRbbC(=NRbb)N(Rbb)2, —
C(=O)NRbbSOZRaa, —NRbb802Raa, —SOZN(Rbb)2, —sozRaa, 502011”, —osozRaa, —S(=0)Raa,
—OS(=O)Raa, —Si(Raa)3, —OSi(Raa)3 —C(=S)N(Rbb)2, —C(=O)SRaa, —C(=S)SRaa, —SC(=S)SRaa,
—SC(=O)SRaa, —OC(=O)SRaa, —SC(=O)ORaa, —SC(=O)Raa, —P(=O)2Raa, —OP(=O)2Raa, —
P<=0><Raa>2, —0P<=0><Raa>2, —0P<=0><0R°°>2, —P<=0>2N<Rbb>2, >2N<Rbb>2, —
P<=0><NRbb>2, —0P<=0><NR"">2, —NR""P<=0><0R°°>2, —NRbbP<=0><NRbb>2, —P<R°°>2, —
P(R°°)3, —OP(R°°)2, —OP(R°°)3, —B(Raa)2, —B(OR°°)2, —BRaa(OR°°), C140 alkyl, C240 alkenyl,
C240 alkynyl, C344 carbocyclyl, 3—l4 membered heterocyclyl, C644 aryl, and 5—14
membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl,
and heteroaryl is independently substituted with 0, l, 2, 3, 4, or 5 Rdd groups;
or two geminal ens on a carbon atom are replaced with the group =0, :8,
=NN(Rbb)2, =NNRbbC(=O)Raa, =NNRbbC(=O)ORaa, =NNRbbS(=O)2Raa, =NRbb, or =NOR°°;
each instance of Raa is, independently, selected from C140 alkyl, C240 alkenyl, C250
alkynyl, C340 carbocyclyl, 3—l4 membered heterocyclyl, C644 aryl, and 5—14 membered
heteroaryl, or two Raa groups are joined to form a 3—14 membered heterocyclyl or 5—14
membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl,
aryl, and heteroaryl is independently substituted with 0, l, 2, 3, 4, or 5 Rdd groups;
each ce of Rbb is, independently, selected from hydrogen, —OH, —ORaa, —
N(RC°)2, —CN, —C(=O)Raa, —C(=O)N(R°C)2, —C02Raa, —SOzRaa, —C(=NR°°)ORaa, —
C(=NR°°)N(R°°)2, —SOZN(RCC)2, —SOZR°°, —SOZOR°°, —SORaa, —C(=S)N(R°°)2, —C(=O)SR°°, —
C(=S)SRCC, —P(=O)2Raaa —P(=O)(Raa)2, —P(=O)2N(RCC)2, (NRCC)2, C1750 alkyl, C2750
alkenyl, C240 alkynyl, C340 yclyl, 3—l4 membered heterocyclyl, C644 aryl, and 5—14
membered heteroaryl, or two Rbb groups are joined to form a 3—14 membered heterocyclyl or
—14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl,
heterocyclyl, aryl, and heteroaryl is independently substituted with 0, l, 2, 3, 4, or 5 Rdd
groups;
each ce of RCC is, independently, ed from en, C150 alkyl, C240
alkenyl, C240 alkynyl, C340 carbocyclyl, 3—l4 membered heterocyclyl, C644 aryl, and 5—14
membered aryl, or two RCC groups are joined to form a 3—14 membered cyclyl or
—14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl,
heterocyclyl, aryl, and heteroaryl is independently substituted with 0, l, 2, 3, 4, or 5 Rdd
groups;
each ce of Rdd is, independently, selected from halogen, —CN, —N02, —N3, —
SOZH, —SO3H, —OH, —0Ree, —ON(Rff)2, —N(Rff)2, —N(Rff)3+X’, —N(ORee)Rff, —SH, —SRee, —
SSRee, —C(=0)Ree, —C02H, —C02Ree, —0C(=0)Ree, —ocozRei —C(=O)N(Rff)2, —
OC(=O)N(Rff)2, (=O)Ree, OZRee, (=O)N(Rff)2, —C(=NRff)ORee, —
OC(=NRff)Ree, —OC(=NRff)ORee, —C(=NRff)N(Rff)2, —OC(=NRff)N(Rff)2, —
2012/062222
NRffC(=NRff)N(Rff)2,—NRffSOzRee, —SOZN(Rff)2, —sozRee, 50201166, —osozRee, Ree,
—Si(Ree)3, —OSi(Ree)3, —C(=S)N(Rff)2, —C(=O)SRee, SRee, —SC(=S)SRee, —P(=O)2Ree, —
P(=O)(Ree)2, —OP(=O)(Ree)2, —OP(=O)(ORee)2, C140 alkyl, C250 alkenyl, C240 alkynyl, C340
carbocyclyl, 3—10 membered heterocyclyl, C640 aryl, 5—10 membered heteroaryl, wherein
each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and aryl is ndently
substituted with 0, l, 2, 3, 4, or 5 Rgg groups, or two geminal Rdd substituents can be joined to
form =0 or :8;
each instance of R66 is, independently, ed from C140 alkyl, C240 alkenyl, C240
alkynyl, C340 carbocyclyl, CMO aryl, 3—10 ed heterocyclyl, and 3—10 membered
heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and
heteroaryl is ndently substituted with 0, l, 2, 3, 4, or 5 Rgg groups;
each instance of Rff is, independently, selected from hydrogen, C140 alkyl, C240
alkenyl, C240 alkynyl, C340 carbocyclyl, 3—10 membered heterocyclyl, C640 aryl and 5—10
membered heteroaryl, or two Rff groups are joined to form a 3—14 membered heterocyclyl or
—14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl,
heterocyclyl, aryl, and heteroaryl is independently substituted with 0, l, 2, 3, 4, or 5 Rgg
groups; and
each instance of Rgg is, independently, halogen, —CN, —N02, —N3, —SOZH, —SO3H, —
OH, 0 alkyl, —ON(C1,50 alkyl)2, —N(C1,50 alkyl)2, —N(C1,50 alkyl)3+X’, —NH(C1,50
alkyl)2+X’, —NH2(C1,50 alkyl) +X’, —NH3+X’, —N(OC1,50 alkyl)(C1,50 alkyl), —N(OH)(C1,50
alkyl), —NH(OH), —SH, 0 alkyl, —SS(C1,50 alkyl), —C(=O)(C1,50 alkyl), —C02H, —
C02(C1,50 alkyl), —OC(=O)(C1,50 alkyl), —OC02(C1,50 alkyl), —C(=O)NH2, —C(=O)N(C1,50
alkyl)2, —OC(=O)NH(C1,50 alkyl), —NHC(=O)( C140 alkyl), —N(C1,50 alkyl)C(=O)( C140
alkyl), —NHC02(C1,50 alkyl), —NHC(=O)N(C1,50 alkyl)2, —NHC(=O)NH(C1,50 alkyl), —
NHC(=O)NH2, —C(=NH)O(C1,50 alkyl),—OC(=NH)(C1,50 alkyl), —OC(=NH)OC1,50 alkyl, —
C(=NH)N(C1,50 alkyl)2, —C(=NH)NH(C1,50 alkyl), )NH2, —OC(=NH)N(C1,50
alkyl)2, —OC(NH)NH(C1,50 alkyl), —OC(NH)NH2, —NHC(NH)N(C1,50 alkyl)2, —
NHC(=NH)NH2, —NHSOZ(C1,50 alkyl), C1,50 alkyl)2, —SOZNH(C1,50 alkyl), —
,—SOZC1,50 alkyl, —SOZOC1,50 alkyl, —OSOZC14 alkyl, —SOC1,6 alkyl, —Si(C1,50
alkyl)3, 14 3 —C(=S)N(C1,50 2, C(=S)NH(C1,50 alkyl), C(=S)NH2, —
C(=O)S(C1,6 alkyl), —C(=S)SC1,6 alkyl, —SC(=S)SC14 alkyl, —P(=O)2(C1,50 alkyl), —
P(=O)(C1,50 2, —OP(=O)(C1,50 alkyl)2, —OP(=O)(OC1,50 alkyl)2, C150 alkyl, C240
alkenyl, C240 alkynyl, C340 carbocyclyl, C640 aryl, 3—10 ed heterocyclyl, 5—10
membered heteroaryl; or two geminal Rgg substituents can be joined to form =0 or :8;
wherein X’ is a counterion.
As used herein, the term “halo” or “halogen” refers to fluorine (fluoro, —F),
chlorine (chloro, —Cl), bromine (bromo, —Br), or iodine (iodo, —I).
As used herein, a “counterion” is a negatively charged group associated with a
positively charged quarternary amine in order to maintain electronic lity. Exemplary
counterions include halide ions (e.g., F Cl Br I
, , ), N03 OH
, , C104 , , H2P04’, H8047,
sulfonate ions (e.g., methansulfonate, trifluoromethanesulfonate, p—toluenesulfonate,
benzenesulfonate, lO—camphor sulfonate, alene—2—sulfonate, naphthalene—l—sulfonic
acid—5—sulfonate, ethan—l—sulfonic acid—2—sulfonate, and the like), and carboxylate ions
(e.g., acetate, ethanoate, propanoate, benzoate, glycerate, lactate, tartrate, glycolate, and the
like).
en atoms can be substituted or unsubstituted as valency permits, and
include primary, secondary, tertiary, and quarternary nitrogen atoms. Exemplary nitrogen
atom substitutents e, but are not limited to, hydrogen, —OH, —ORaa, —N(R°°)2, —CN, —
C(=0)Raa, N(RCC)2, —C02Raa, —sozRaa, bb)Raa, —C(=NR°°)ORaa, —
C(=NR°°)N(R°°)2, —SOzN(RCC)2, —SOgR°°, —SOgOR°°, —SORaa, —C(=S)N(RC°)2, —C(=O)SRC°, —
C(=S)SRCC, —P(=O)2Raaa —P(=O)(Raa)2, —P(=O)2N(RCC)2, —P(=O)(NRCC)2, C1750 alkyl, C2750
alkenyl, C240 alkynyl, C340 carbocyclyl, 3—14 membered heterocyclyl, C644 aryl, and 5—14
membered heteroaryl, or two RCC groups ed to an N atom are joined to form a 3—14
membered heterocyclyl or 5—14 ed heteroaryl ring, wherein each alkyl, alkenyl,
alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, l,
2, 3, 4, or 5 Rdd groups, and wherein R”, Rbb, RCC and Rdd are as d above.
Nitrogen atoms can be substituted or unsubstituted as valency permits, and
include primary, secondary, tertiary, and rnary nitrogen atoms. Exemplary nitrogen
atom substitutents include, but are not limited to, hydrogen, —OH, —ORaa, —N(R°°)2, —CN, —
C(=0)Raa, —C(=O)N(RCC)2, —C02Raa, —sozRaa, —C(=NRbb)Raa, —C(=NR°°)ORaa, —
C(=NR°°)N(R°°)2, —SOzN(RCC)2, —SOgR°°, —SOgOR°°, —SORaa, —C(=S)N(RC°)2, —C(=O)SRC°, —
C(=S)SRC°, 2Raa, —P(=0)(Raa)2, —P(=O)2N(RC°)2, —P(=0)(NR°°)2, C1710 alkyl, C1710
oalkyl, C240 alkenyl, C240 alkynyl, C340 carbocyclyl, 3—14 membered heterocyclyl,
C644 aryl, and 5—14 membered heteroaryl, or two RCC groups attached to a nitrogen atom are
joined to form a 3—14 membered heterocyclyl or 5—14 ed heteroaryl ring, wherein
each alkyl, l, alkynyl, carbocyclyl, cyclyl, aryl, and heteroaryl is independently
substituted with 0, l, 2, 3, 4, or 5 Rdd groups, and wherein R”, Rbb, RCC and Rdd are as defined
above.
In certain embodiments, the tuent present on a nitrogen atom is a nitrogen
protecting group (also referred to as an amino protecting group). Nitrogen protecting groups
include, but are not d to, —OH, —ORaa, —N(R°°)2, Raa, —C(=O)N(R°C)2, a,
—SOgRaa, —C(=NR°°)Raa, —C(=NR°°)ORaa, —C(=NR°°)N(R°°)2, —SOzN(R°°)2, —SOgR°°, —
C, —SORaa, —C(=S)N(R°°)2, —C(=O)SR°°, —C(=S)SR°°, C140 alkyl (e.g., aralkyl,
heteroaralkyl), C240 alkenyl, C240 alkynyl, C340 carbocyclyl, 3—14 membered heterocyclyl,
C644 aryl, and 5—14 membered heteroaryl groups, n each alkyl, alkenyl, alkynyl,
carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is independently substituted with 0, 1,
2, 3, 4, or 5 Rdd groups, and wherein R”, Rbb, RCC and Rdd are as defined herein. Nitrogen
protecting groups are well known in the art and e those described in detail in Protecting
Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley &
Sons, 1999, incorporated herein by reference.
For example, nitrogen protecting groups such as amide groups (e.g., —
C(=O)Raa) include, but are not limited to, formamide, acetamide, chloroacetamide,
trichloroacetamide, roacetamide, phenylacetamide, 3—phenylpropanamide,
picolinamide, 3—pyridylcarboxamide, N—benzoylphenylalanyl derivative, benzamide, p—
phenylbenzamide, 0—nitophenylacetamide, 0—nitrophenoxyacetamide, acetoacetamide, (N’—
dithiobenzyloxyacylamino)acetamide, 3—(p—hydroxyphenyl)propanamide, 3—(0—
nitrophenyl)propanamide, 2—methyl—2—(0—nitrophenoxy)propanamide, 2—methyl—2—(0—
phenylazophenoxy)propanamide, robutanamide, 3—methyl—3—nitrobutanamide, 0—
nitrocinnamide, N—acetylmethionine derivative, 0—nitrobenzamide and 0—
(benzoyloxymethyl)benzamide.
en protecting groups such as carbamate groups (e.g., —C(=O)ORaa)
include, but are not limited to, methyl carbamate, ethyl carbamante, 9—fluorenylmethyl
carbamate (Fmoc), 9—(2—sulfo)fluorenylmethyl carbamate, 9—(2,7—dibromo)fluoroenylmethyl
carbamate, 2,7 di t butyl [9 (10,10 dioxo 10,10,10,10—tetrahydrothioxanthyl)]methyl
carbamate (DBD—Tmoc), 4—methoxyphenacyl carbamate (Phenoc), 2,2,2—trichloroethyl
carbamate (Troc), 2—trimethylsilylethyl carbamate (Teoc), 2—phenylethyl carbamate (hZ), 1—
(1—adamantyl)—1—methylethyl carbamate (Adpoc), 1,1—dimethyl—2—haloethyl ate,
1,1—dimethyl—2,2—dibromoethyl carbamate (DB—t—BOC), 1,1—dimethyl—2,2,2—trichloroethyl
carbamate (TCBOC), 1—methyl—1—(4—biphenylyl)ethyl ate (Bpoc), 1—(3,5—di—t—
henyl)—1—methylethyl carbamate (t—Bumeoc), 2—(2’— and 4’—pyridyl)ethyl carbamate
(Pyoc), 2—(N,N—dicycloheXylcarboxamido)ethyl carbamate, t—butyl carbamate (BOC), 1—
adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1—
isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4—nitrocinnamy1 carbamate
(Noe), 8—quinoly1 carbamate, N—hydroxypiperidinyl carbamate, alkyldithio carbamate,
benzyl carbamate (Cbz), p—methoxybenzyl carbamate (Moz), p—nitobenzyl carbamate, 1)—
bromobenzyl carbamate, p—chlorobenzyl carbamate, chlorobenzy1 carbamate, 4—
methylsulfinylbenzyl carbamate (Msz), 9—anthry1methy1 carbamate, diphenylmethyl
carbamate, 2—methy1thioethy1 carbamate, 2—methy1sulfony1ethy1 carbamate, 2—(p—
toluenesulfony1)ethy1 ate, [2—(1,3—dithiany1)]methy1 carbamate (Dmoc), 4—
methylthiophenyl carbamate (Mtpc), 2,4—dimethy1thiopheny1 carbamate (Bmpc), 2—
phosphonioethyl carbamate (Peoc), 2—tripheny1phosphonioisopropyl carbamate , 1,1—
dimethyl—Z—cyanoethyl carbamate, m—chloro—p—acyloxybenzyl carbamate, 1)—
(dihydroxybory1)benzy1 carbamate, 5—benzisoxazolylmethy1 carbamate, 2—(trifluoromethy1)—
6—chromony1methy1 carbamate (Tcroc), m—nitrophenyl carbamate, 3,5—dimethoxybenzy1
carbamate, 0—nitrobenzy1 carbamate, 3,4—dimethoxy—6—nitrobenzy1 carbamate, pheny1(0—
heny1)methy1 carbamate, t—amyl carbamate, S—benzyl rbamate, p—cyanobenzyl
carbamate, utyl carbamate, exyl carbamate, cyclopentyl carbamate,
cyclopropylmethyl ate, p—decyloxybenzyl carbamate, 2,2—dimethoxyacy1viny1
ate, 0—(N,N—dimethylcarboxamido)benzy1 carbamate, 1,1—dimethy1—3—(N,N—
dimethylcarboxamido)propy1 carbamate, 1,1—dimethy1propyny1 carbamate, di(2—
pyridy1)methy1 carbamate, 2—furany1methy1 carbamate, 2—iodoethy1 carbamate, isoborynl
carbamate, isobutyl ate, isonicotinyl carbamate, p—(p’—methoxyphenylazo)benzy1
carbamate, 1—methy1cyclobuty1carbamate, 1—methy1cyclohexy1carbamate, 1—methy1—1—
cyclopropylmethyl carbamate, 1—methy1—1—(3,5—dimethoxypheny1)ethy1 carbamate, 1—
methyl—1—(p—pheny1azopheny1)ethy1 carbamate, 1—methy1—1—pheny1ethy1 carbamate, 1—
methyl—l—(4—pyridy1)ethy1 carbamate, phenyl carbamate, p—(phenylazo)benzy1 carbamate,
2,4,6—tri—t—butylpheny1 carbamate, 4—(trimethy1ammonium)benzy1 carbamate, and 2,4,6—
trimethylbenzyl ate.
en ting groups such as sulfonamide groups (e.g., —S(=O)2Raa)
include, but are not limited to, p—toluenesulfonamide (Ts), esulfonamide, 2,3,6,—
trimethy1—4—methoxybenzenesulfonamide (Mtr), 2,4,6—trimethoxybenzenesulfonamide
(Mtb), 2,6—dimethy1—4—methoxybenzenesulfonamide (Pme), 2,3,5,6—tetramethy1—4—
methoxybenzenesulfonamide (Mte), 4—methoxybenzenesulfonamide (Mbs), 2,4,6—
trimethylbenzenesulfonamide (Mts), methoxy—4—methy1benzenesulfonamide (iMds),
2,2,5,7,8—pentamethylchroman—6—sulfonamide (Pmc), methanesulfonamide (Ms), B—
trimethylsilylethanesulfonamide (SES), 9—anthracenesulfonamide, 4—(4’,8’—
dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide,
romethylsulfonamide, and phenacylsulfonamide.
Other en protecting groups include, but are not limited to,
phenothiazinyl—(lO)—acyl derivative, N’—p—toluenesulfonylaminoacyl derivative, N’—
phenylaminothioacyl derivative, N—benzoylphenylalanyl derivative, ylmethionine
derivative, 4,5—diphenyl—3—oxazolin—2—one, N—phthalimide, N—dithiasuccinimide (Dts), N—
2,3—diphenylmaleimide, N—2,5—dimethylpyrrole, N—l , l ,4,4—
tetramethyldisilylazacyclopentane adduct SE), 5—substituted l,3—dimethyl—l,3,5—
triazacyclohexan—2—one, tituted l,3—dibenzyl—l,3,5—triazacyclohexan—2—one, l—
substituted 3,5—dinitro—4—pyridone, N—methylamine, N—allylamine, N—[2—
(trimethylsilyl)ethoxy]methylamine (SEM), N—3—acetoxypropylamine, N—(l—isopropyl—4—
nitro—2—oxo—3—pyroolin—3—yl)amine, quaternary ammonium salts, N—benzylamine, N—di(4—
methoxyphenyl)methylamine, N—S—dibenzosuberylamine, N—triphenylmethylamine (Tr), N—
thoxyphenyl)diphenylmethyl]amine (MMTr), N—9—phenylfluorenylamine (PhF), N—
2,7—dichloro—9—fluorenylmethyleneamine, N—ferrocenylmethylamino (ch), N—2—
picolylamino de, N—l,l—dimethylthiomethyleneamine, N—benzylideneamine, N—p—
methoxybenzylideneamine, N—diphenylmethyleneamine, N—[(2—
pyridyl)mesityl]methyleneamine, N—(N’,N’—dimethylaminomethylene)amine, N,N’—
isopropylidenediamine, N—p—nitrobenzylideneamine, N—salicylideneamine, N—S—
chlorosalicylideneamine, N—(5—chloro—2—hydroxyphenyl)phenylmethyleneamine, N—
cyclohexylideneamine, N—(S,5—dimethyl—3—oxo—l—cyclohexenyl)amine, N—borane
derivative, N—diphenylborinic acid tive, N—[phenyl(pentaacylchromium— or
tungsten)acyl]amine, N—copper chelate, N—zinc chelate, N—nitroamine, N—nitrosoamine,
amine N—oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt),
diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl oramidate,
diphenyl phosphoramidate, benzenesulfenamide, 0—nitrobenzenesulfenamide (Nps), 2,4—
dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2—nitro—4—
methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3—nitropyridinesulfenamide
(prs).
In certain embodiments, the substituent present on an oxygen atom is an oxygen
protecting group (also referred to as a hydroxyl ting group). Oxygen protecting groups
include, but are not limited to, —Raa, —N(Rbb)2, SRaa, —C(=0)Raa, —C02Raa, —
C(=O)N(Rbb)2, —C(=NRbb)Raa, bb)ORaa, —C(=NRbb)N(Rbb)2, —S(=0)Raa, —sozRaa, —
Si<Raa>i —P<R°°>2, —P<R°°>3, —P<=0>2Raa, —P<=0><Raa>2, —P<=0><0R°C>2, —P<=0>2N<Rbb>2, and —
P(=O)(NRbb)2, wherein R”, Rbb, and RCC are as defined herein. Oxygen protecting groups are
well known in the art and include those described in detail in ting Groups in Organic
Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999,
incorporated herein by reference.
ary oxygen protecting groups include, but are not limited to, methyl,
methoxylmethyl (MOM), methylthiomethyl (MTM), t—butylthiomethyl,
(phenyldimethylsilyl)methoxymethyl , benzyloxymethyl (BOM), p—
methoxybenzyloxymethyl (PMBM), (4—methoxyphenoxy)methyl ), guaiacolmethyl
(GUM), xymethyl, 4—pentenyloxymethyl (POM), siloxymethyl, 2—
methoxyethoxymethyl (MEM), 2,2,2—trichloroethoxymethyl, bis(2—chloroethoxy)methyl, 2—
(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3—
bromotetrahydropyranyl, tetrahydrothiopyranyl, l—methoxycyclohexyl, 4—
methoxytetrahydropyranyl (MTHP), 4—methoxytetrahydrothiopyranyl, 4—
methoxytetrahydrothiopyranyl S,S—dioxide, l—[(2—chloro—4—methyl)phenyl]—4—
methoxypiperidin—4—yl (CTMP), l,4—dioxan—2—yl, tetrahydrofuranyl, tetrahydrothiofuranyl,
2,3,3a,4,5,6,7,7a—octahydro—7,8,8—trimethyl—4,7—methanobenzofuran—2—yl, l—ethoxyethyl,
l—(2—chloroethoxy)ethyl, l—methyl—l—methoxyethyl, l—methyl—l—benzyloxyethyl, l—
methyl—l—benzyloxy—2—fluoroethyl, 2,2,2—trichloroethyl, 2—trimethylsilylethyl, 2—
(phenylselenyl)ethyl, t—butyl, allyl, p—chlorophenyl, p—methoxyphenyl, 2,4—dinitrophenyl,
benzyl (Bn), oxybenzyl, 3,4—dimethoxybenzyl, 0—nitrobenzyl, p—nitrobenzyl, p—
halobenzyl, 2,6—dichlorobenzyl, p—cyanobenzyl, p—phenylbenzyl, 2—picolyl, 4—picolyl, 3—
methyl—2—picolyl N—oxido, diphenylmethyl, p,p ’—dinitrobenzhydryl, 5—dibenzosuberyl,
nylmethyl, (x—naphthyldiphenylmethyl, p—methoxyphenyldiphenylmethyl, di(p—
methoxyphenyl)phenylmethyl, tri(p—methoxyphenyl)methyl, 4—(4’—
bromophenacyloxyphenyl)diphenylmethyl, 4,4’,4"—tris(4,5—
rophthalimidophenyl)methyl, 4,4’,4"—tris(levulinoyloxyphenyl)methyl, 4,4’,4"—
tris(benzoyloxyphenyl)methyl, dazol—l—yl)bis(4’,4"—dimethoxyphenyl)methyl, l, l—
bis(4—methoxyphenyl)—l’—pyrenylmethyl, ryl, 9—(9—phenyl)xanthenyl, 9—(9—phenyl—
lO—oxo)anthryl, l,3—benzodisulfuran—2—yl, benzisothiazolyl S,S—dioxido, trimethylsilyl
(TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS),
diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t—butyldimethylsilyl (TBDMS), t—
butyldiphenylsilyl (TBDPS), tribenzylsilyl, xylylsilyl, triphenylsilyl,
ylmethylsilyl (DPMS), t—butylmethoxyphenylsilyl (TBMPS), formate,
benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate,
methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, rophenoxyacetate, 3—
phenylpropionate, 4—oxopentanoate (levulinate), 4,4—(ethylenedithio)pentanoate
(levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4—methoxycrotonate, benzoate, p—
phenylbenzoate, 2,4,6—trimethylbenzoate (mesitoate), alkyl methyl carbonate, 9—
fluorenylmethyl ate (Fmoc), alkyl ethyl carbonate, alkyl trichloroethyl carbonate
(Troc), 2—(trimethylsilyl)ethyl carbonate (TMSEC), 2—(phenylsulfonyl) ethyl carbonate
(Psec), 2—(triphenylphosphonio) ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl Vinyl
carbonate alkyl allyl carbonate, alkyl p—nitrophenyl carbonate, alkyl benzyl carbonate, alkyl
p—methoxybenzyl ate, alkyl 3,4—dimethoxybenzyl carbonate, alkyl 0—nitrobenzyl
carbonate, alkyl p—nitrobenzyl carbonate, alkyl S—benzyl thiocarbonate, 4—ethoxy—l—
napththyl carbonate, methyl dithiocarbonate, benzoate, 4—azidobutyrate, 4—nitro—4—
methylpentanoate, 0—(dibromomethyl)benzoate, ylbenzenesulfonate, 2—
(methylthiomethoxy)ethyl, hylthiomethoxy)butyrate, 2—
(methylthiomethoxymethyl)benzoate, 2,6—dichloro—4—methylphenoxyacetate, 2,6—dichloro—
4—( l , 1,3 ,3—tetramethylbutyl)phenoxyacetate, 2,4—bis( l , l—dimethylpropyl)phenoxyacetate,
chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)—2—methyl—2—butenoate, 0—
(methoxyacyl)benzoate, a—naphthoate, e, alkyl N,N,N’,N’—
tetramethylphosphorodiamidate, alkyl N—phenylcarbamate, borate, dimethylphosphinothioyl,
alkyl 2,4—dinitrophenylsulfenate, sulfate, esulfonate (mesylate), benzylsulfonate, and
tosylate (Ts).
In certain embodiments, the substituent present on an sulfur atom is an sulfur
protecting group (also referred to as a thiol protecting group). Sulfur protecting groups
e, but are not limited to, —Raa, —N(Rbb)2, —C(=O)SRaa, —C(=0)Raa, —C02Raa, —
C(=O)N(Rbb)2, —C(=NRbb)Raa, —C(=NRbb)ORaa, —C(=NRbb)N(Rbb)2, —S(=0)Raa, —sozRaa, —
Si(Raa)3, )2, —P(R°°)3, —P(=O)2Raa, —P(=0)(Raa)2, —P(=0)(OR°°)2, —P(=0)2N(Rbb)2, and —
P(=O)(NRbb)2, wherein R”, Rbb, and RCC are as defined . Sulfur protecting groups are
well known in the art and include those described in detail in Protecting Groups in Organic
Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999,
incorporated herein by reference.
As used herein, a “leaVing group” is an art—understood term referring to a
lar fragment that departs with a pair of electrons in heterolytic bond cleavage, wherein
the molecular fragment is an anion or neutral molecule. See, for example, Smith, March
Advanced Organic Chemistry 6th ed. (501—502). Exemplary leaVing groups include, but are
not limited to, halo (e.g., chloro, bromo, iodo) and yl substituted hydroxyl groups (e.g.,
tosyl, mesyl, besyl).
These and other exemplary substituents are described in more detail in the
Detailed ption, Examples, Figures, and Claims. The invention is not intended to be
limited in any manner by the above exemplary listing of substituents.
Other definitions
As used herein, use of the phrase “at least one instance” refers to one instance,
but also encompasses more than one instance, 6.57., for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
instances, and up to 100 instances.
An “amino acid” refers to natural and ral D/L alpha—amino acids, as well
as natural and unnatural beta— and gamma— amino acids. A “peptide” refers to two amino
acids joined by a peptide bond. A “polypeptide” refers to three or more amino acids joined
by peptide bonds. An “amino acid side chain” refers to the group(s) pended to the alpha
carbon (if an alpha amino acid), alpha and beta carbon (if a beta amino acid), or the alpha,
beta, and gamma carbon (if a gamma amino acid). Exemplary amino acid side chains are
depicted herein; see, e.g., Table l of the es.
As used herein, a “polymer” refers to a nd comprised of at least 3 (e.g.,
at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, etc.) repeating covalently bound structural
units.
“Conjugated” and “attached” refer to the covalent attachment of a group, and
are used interchangeably herein.
As used herein, “lipophilic” refers to the ability of a group to dissolve in fats,
oils, lipids, and lipophilic non—polar solvents such as hexane or toluene. In general, a
lipophilic group refers to an unsubstituted n—alkyl or unsubstituted nyl group having 6
to 50 carbon atoms, e.g., 6 to 40, 6 to 30, 6 to 20, 8 to 20, 8 to 19, 8 to 18, 8 to 17, 8 to 16, or
8 to 15 carbon atoms.
Use of the terms tural isomer,77 nic molecule,” and “inorganic
molecule” are meant to encompass the common meaning of each term as known in the art.
As used herein, a “small organic molecule” or “small molecule” refers to an
organic molecule with a molecular weight of 800 g/mol or less (e.g., less than 700 g/mol, less
than 600 g/mol, less than 500 g/mol, less than 400 g/mol, less than 300 g/mol, less than 200
g/mol, less than 100 g/mol, between 50 to 800 g/mol, inclusive, between 100 to 800 g/mol,
inclusive, or between 100 to 500 g/mol, ive). In certain embodiments, the small
organic molecule is a therapeutically active agent such as a drug (e.g., a small organic
molecule approved by the US. Food and Drug Administration as provided in the Code of
Federal Regulations (CFR)). The small organic molecule may also be complexed with a
metal. In this instance, the small organic molecule is also referred to as an “small
organometallic le.”
As used herein, a “large organic molecule” or “large molecule” refers to an
organic compound with a molecular weight of r than 800 g/mol (e.g., r than 800
g/mol, greater than 900 g/mol, greater than 1000 g/mol, greater than 2000 g/mol, between
801 to 2000 g/mol, inclusive, between 900 to 2000 g/mol, ive, between 1000 to 2000
g/mol, inclusive, or between 801 to 1000 g/mol, inclusive). In certain embodiments, the large
c molecule is a therapeutically active agent such as a drug (e.g., a large organic
molecule approved by the US. Food and Drug Administration as provided in the Code of
l Regulations (CFR)).The large organic molecule may also be complexed with a metal.
In this instance, the large c molecule is also ed to as an “large organometallic
compound.”
As used herein, a “small inorganic molecule” refers to an inorganic compound
with a molecular weight of 800 g/mol or less (e.g. less than 700 g/mol, less than 600 g/mol,
less than 500 g/mol, less than 400 g/mol, less than 300 g/mol, less than 200 g/mol, less than
100 g/mol, between 50 to 800 g/mol, inclusive, between 100 to 800 g/mol, inclusive, or
between 100 to 500 g/mol, inclusive). In certain embodiments, the small nic molecule
is a therapeutically active agent such as a drug (e.g., a small inorganic molecule approved by
the US. Food and Drug Administration as provided in the Code of Federal Regulations
(CFR)).
As used , a “large inorganic molecule” refers to an inorganic compound
with a molecular weight of greater than 800 g/mol (e.g., greater than 800 g/mol, greater than
900 g/mol, greater than 1000 g/mol, greater than 2000 g/mol, between 801 to 2000 g/mol,
inclusive, between 900 to 2000 g/mol, inclusive, between 1000 to 2000 g/mol, inclusive, or
between 801 to 1000 g/mol, inclusive). In certain embodiments, the large inorganic molecule
is a therapeutically active agent such as a drug (e.g., a large inorganic molecule approved by
the US. Food and Drug Administration as provided in the Code of Federal Regulations
(CFR)).
As used herein, the term “salt” or aceutically acceptable salt” refers to
those salts which are, within the scope of sound medical nt, suitable for use in contact
with the s of humans and lower animals without undue toxicity, irritation, allergic
response and the like, and are commensurate with a reasonable benefit/risk ratio.
Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al.,
describes pharmaceutically acceptable salts in detail in J. Pharmaceutical es (1977)
66: 1—19. ceutically acceptable salts of the nds of this invention include those
derived from suitable inorganic and c acids and bases. Examples of pharmaceutically
acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic
acids such as hloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and
oric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric
acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such
as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate,
aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate,
camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate,
hemisulfate, heptanoate, hexanoate, odide, 2—hydroxy—ethanesulfonate, ionate,
lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2—
naphthalenesulfonate, nicotinate, e, oleate, oxalate, palmitate, pamoate, pectinate,
fate, 3—phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate,
sulfate, tartrate, thiocyanate, p—toluenesulfonate, undecanoate, valerate salts, and the like.
Salts derived from appropriate bases include alkali metal, alkaline earth metal, um
and N+(C14alkyl)4 salts. entative alkali or alkaline earth metal salts include sodium,
lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable
salts include, when appropriate, nontoxic ammonium, quaternary um, and amine
cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate,
nitrate, sulfonate and aryl sulfonate. Further pharmaceutically acceptable salts include salts
formed from the quartemization of an amine using an appropriate electrophile, e. 57., an alkyl
halide, to form a quarternized alkylated amino salt.
Brief Description of the Drawings
Figure 1 depicts the ural design and optimization through in viva
evaluation in mice. Single amino acid—based lipid derivatives were tested at a dose of lmg/kg
in mice, which indicated that lysine was a favorable amino acid. Lysine—based peptide and
polypeptide—lipid derivatives were then igated at the same dose. The hit rate was
improved from 1.7% to 23% (including those compounds not screened due to particle
instability or no entrapment of siRNA). The top hits and their analogs were explored at a
lower dose of 0.1 mg/kg, which led to selection of cKK—E12 as the lead compound. K—ElZ;
K: abbreviation of , E: epoxide, A: aldehyde, 0: acrylate, 12: carbon tail length. cKK—
E12; c: cyclic; Control, phosphate—buffered saline.
Figure 2 depicts the stribution of free Cy5.5—labled siRNA and Cy5.5—
labled siRNA—cKK—E12 formulation in mice at 1 hr and 24 hr.
Figure 3 depicts the silencing effects of apolipoproteins on cKK—E12 in HeLa
cells. Apolipoproteins including ApoA—I (recombinant Human ApoA—I protein), ApoA—II
(native Human ApoA—II protein), ApoB (native Human ApoB n), ApoC—I (native
Human ApoC—I protein), ApoC—II (native Human ApoC—II protein), ApoC—III e Human
ApoC—III protein), ApoE (native Human ApoE protein), ApoE2 (recombinant Human ApoE2
protein), ApoE3 (recombinant Human ApoE3 protein), ApoE4 (recombinant Human ApoE4
protein), ApoH (native Human ApoH protein).
Figure 4 depicts the effects of ApoE on gene silencing and cell uptake. A).
Silencing effects of ApoE on cKK—ElZ, cKK—AlZ, and cKK—012 in vitro : 50
ng/well). With addition of ApoE, the order of silencing effects was cKK—E12 > cKK—A12 >
cKK—OlZ, correlating well with in vivo activity. B). Cellular internalization of cKK—E12 with
47 labeled siRNA after 3 hr of tion is demonstrated by HT automated al
copy. ApoE enhanced cell uptake and endosomal escape of cKK—E12; Scale bar: 20
Detailed Description of Certain Embodiments of the Invention
Described herein are inventive compounds and itions, certain
embodiments of which involve conjugation of various groups, such as lipophilic groups, to an
amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic
polypeptide, or structural isomer f, to provide compounds of the present invention,
collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of
applications, such as, for example, improved nucleotide delivery.
ary APPLs include, but are not limited to, compounds of Formula (I),
(II), (III), (IV), (V), and (VI), and salts thereof, as described herein:
(11)
R1 B2
R1 Q
R2 Q
(1V)
2 Q
R2 Q R\
\ N
1 1 R2'—N/ R1
R —< R
R2 Q R1
(V) (VI)
wherein m, n, p, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.
Various RL groups, e.g., lipophilic groups, may be attached to the APPL Via
conjugation of a primary or ary amino group or amide of the amino acid, peptide, or
polypeptide precursor, or structural isomer thereof, with an epoxide, thiirane, or aziridine of
formula (i—X), Michael on to an OL,B—unsaturated ester, thioester, or amide of formula (ii—
X), or reductive ion to an aldehyde of formula (iii—X) (Scheme 1).
Scheme 1.
H i RL (iii-x)
L R'-
g—ill—g or g—NHZ i> §_Nr_§ §_H_/R g—N_/
mono addition bis addition
Thus, in the broadest , the present invention provides APPLs, and in
certain ments, compounds of Formula (I), (II), (III), (IV), (V), and (VI), comprising at
least one instance of a group attached thereto of the formula:
H\ R'-
RI $4
(1) (ii) (iii)
wherein:
each instance of R’ is ndently hydrogen or optionally substituted alkyl;
X is O, S, NRX, wherein RX is hydrogen, optionally tuted alkyl, optionally
substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, or a nitrogen ting group;
Y is O, S, NRY, wherein RY is hydrogen, optionally tuted alkyl, optionally
substituted l, optionally substituted l, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, or a nitrogen protecting group;
RP is hydrogen, optionally substituted alkyl, optionally tuted alkenyl, ally
substituted l, optionally substituted carbocyclyl, ally substituted heterocyclyl,
optionally substituted aryl, optionally substituted heteroaryl, an oxygen ting group
when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom,
or a nitrogen protecting group when attached to a nitrogen atom; and
RL is optionally substituted C150 alkyl, optionally substituted C250 alkenyl, optionally
substituted C250 alkynyl, optionally substituted C150 heteroalkyl, optionally substituted C250
heteroalkenyl, optionally substituted C250 heteroalkynyl, or a polymer.
Various embodiments of formula (i), (ii), and (iii), and variables RL, RP, X, and
Y are described in greater detail herein.
Compounds ofFormula (I)
Compounds of Formula (I) encompasses amino acids, linear peptides, and
linear polypeptides which comprise one or more sites of conjugation, e.g., to the terminal
amino group, to an amino substituent, and/or to an imino nitrogen, of a group of formula (i),
(ii), or (iii).
WO 63468 2012/062222
imino nitrogens
Thus, in one aspect, provided is a compound of Formula (I):
” (I)
or salt thereof;
wherein:
n is 0 or is an r between 1 and 100,000, inclusive;
each instance of m is independently l, 2, or 3;
each instance of Z is independently O, S, or NRZ, wherein RZ is hydrogen, optionally
substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, ally
substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl,
optionally substituted heteroaryl, a nitrogen protecting group, or a group of the formula (i),
(ii), or (iii);
each instance of R1 is independently hydrogen, optionally substituted alkyl, optionally
substituted l, optionally substituted alkynyl, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, halogen, —ORA1, —N(RA1)2, or —SRA1; wherein each ence of RAl is
independently hydrogen, optionally tuted alkyl, optionally substituted alkenyl,
optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted
heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen
2012/062222
protecting group when attached to an oxygen atom, a sulfur protecting group when attached
to an sulfur atom, a nitrogen ting group when attached to a nitrogen atom, or two RAl
groups are joined to form an optionally substituted cyclic or optionally substituted
heteroaryl ring;
R2 is a group of formula (i), (ii), or (iii);
R3 is hydrogen, ally substituted alkyl, optionally substituted alkenyl, optionally
substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl,
optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a
group of the formula (i), (ii), or (iii);
or R3 and an R1 group are joined to form an optionally tuted 5—6 membered
heterocyclic ring;
R4 is —ORA4, —N(RA4)2, or —SRA4; wherein each occurrence of RA4 is ndently
hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted
l, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally
substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached
to an oxygen atom, a sulfur protecting group when attached to an sulfur atom, a nitrogen
protecting group when attached to a nitrogen atom, or two RA4 groups are joined to form an
optionally tuted heterocyclic or optionally substituted aryl ring;
R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally
substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl,
optionally substituted aryl, optionally tuted heteroaryl, or a nitrogen protecting group;
Formulae (i), (ii), and (iii) are:
RQ—YRP
é—flR. gJRL
(i) (ii) (iii)
wherein:
each instance of R’ is independently hydrogen or optionally substituted alkyl;
X is O, S, NRX, wherein RX is hydrogen, optionally substituted alkyl, optionally
substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl,
optionally tuted heterocyclyl, optionally tuted aryl, optionally tuted
heteroaryl, or a nitrogen protecting group;
Y is O, S, NRY, wherein RY is hydrogen, optionally substituted alkyl, optionally
substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, or a nitrogen protecting group;
RP is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally
substituted alkynyl, optionally tuted carbocyclyl, optionally substituted heterocyclyl,
optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group
when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom,
or a nitrogen ting group when attached to a nitrogen atom; and
RL is optionally substituted C150 alkyl, optionally substituted C250 l, optionally
substituted C250 alkynyl, optionally substituted heteroC1_50 alkyl, optionally substituted
C2_50 alkenyl, optionally substituted heteroC2_50 alkynyl, or a r.
In certain embodiments, when n is greater than 10, then neither R2 nor R3 is a
group of the a (iii). In certain embodiments, when n is greater than 9, then neither R2
nor R3 is a group of the formula (iii). In certain embodiments, when n is r than 8, then
neither R2 nor R3 is a group of the formula (iii). In certain embodiments, when n is greater
than 7, then neither R2 nor R3 is a group of the formula (iii). In certain embodiments, when n
is greater than 6, then neither R2 nor R3 is a group of the formula (iii). In certain
ments, when n is r than 5, then neither R2 nor R3 is a group of the formula (iii).
In n embodiments, when n is greater than 4, then neither R2 nor R3 is a group of the
formula (iii). In certain embodiments, when n is greater than 3, then r R2 nor R3 is a
group of the a (iii). In certain embodiments, when n is greater than 2, then neither R2
nor R3 is a group of the formula (iii). In certain embodiments, when n is greater than 1, then
neither R2 nor R3 is a group of the formula (iii). In certain embodiments, neither R2 nor R3 is a
group of the formula (iii).
In certain embodiments, wherein n is 0 and Z is 0, one or more of the following
compounds are excluded:
3 0 R2’ OH
2 R2
R3\ VL R\N OH
[ll NH2 HN/WJkOH \N/YkOH
R2 K/NH K/N\RZ K/N
and \R2
, , , ,
and salts f; wherein R2 is a group of the formula (i), R3 and R6 are independently
hydrogen or a group of formula (i), and Y is O.
As generally defined above, n is 0 or is an integer between 1 and 100,000,
inclusive. It is thus understood that Formula (I) asses amino acids ated to a
lipid group, as well as linear peptides and linear polypeptides conjugated to lipid groups.
In certain embodiments, n is 0 or is an integer between 1 and 90,000, ive.
In certain embodiments, n is 0 or is an integer between 1 and 80,000, inclusive. In certain
embodiments, n is 0 or is an integer between 1 and 70,000, inclusive. In certain embodiments,
n is 0 or is an integer between 1 and 50,000, inclusive. In certain embodiments, n is 0 or is an
integer between 1 and 40,000, inclusive. In certain embodiments, n is 0 or is an integer
between 1 and 30,000, inclusive. In certain ments, n is 0 or is an integer between 1
and 20,000, inclusive. In certain embodiments, n is 0 or is an integer between 1 and 10,000,
inclusive. In certain embodiments, n is 0 or is an integer between 1 and 9,000, inclusive. In
certain embodiments, n is 0 or is an integer between 1 and 8,000, inclusive. In certain
embodiments, n is 0 or is an r between 1 and 7,000, inclusive. In certain embodiments,
n is 0 or is an integer between 1 and 6,000, inclusive. In certain embodiments, n is 0 or is an
integer n 1 and 5,000, inclusive. In certain embodiments, n is 0 or is an integer
between 1 and 4,000, inclusive. In certain embodiments, n is 0 or is an integer between 1 and
3,000, ive. In n embodiments, n is 0 or is an integer between 1 and 2,000,
inclusive. In certain embodiments, n is 0 or is an integer between 1 and 1,000, inclusive. In
n embodiments, n is 0 or is an r between 1 and 900, inclusive. In certain
embodiments, n is 0 or is an r between 1 and 800, inclusive. In certain embodiments, n
is 0 or is an integer n 1 and 700, inclusive. In certain embodiments, n is 0 or is an
integer between 1 and 600, inclusive. In certain embodiments, n is 0 or is an integer between
1 and 500, inclusive. In certain embodiments, n is 0 or is an integer between 100 and 80,000,
inclusive. In n embodiments, n is 0 or is an integer between 200 and 80,000, inclusive.
In certain embodiments, n is 0 or is an integer between 300 and 80,000, inclusive. In certain
embodiments, n is 0 or is an r between 400 and 80,000, inclusive. In certain
embodiments, n is 0 or is an r between 500 and , inclusive. In certain
embodiments, n is 0 or is an integer between 500 and 40,000, inclusive. In certain
embodiments, n is 0 or is an integer between 500 and , inclusive. In certain
embodiments, n is 0 or is an integer between 1 and 400, inclusive. In n embodiments, n
is 0 or is an integer between 1 and 300, inclusive. In certain embodiments, n is 0 or is an
r between 1 and 200, inclusive. In certain embodiments, n is 0 or is an integer between
1 and 100, inclusive. In certain embodiments, n is 0 or is an integer between 1 and 75,
inclusive. In certain embodiments, n is 0 or is an r between 1 and 50, inclusive. In
certain embodiments, n is 0 or is an integer between 1 and 25, inclusive. In certain
embodiments, n is 0 or is an integer between 1 and 15, inclusive. In certain embodiments, n
is 0 or is an integer between 1 and 10, I nclusive. In certain embodiments, n is 0, l, 2, 3, 4,
, 6, 7, 8, 9, or 10.
For example, when n is 0, the compound of Formula (I) is a compound of the
Formula (I—a):
Fr Z
R2—N R4
R1 <I-a>
or salt thereof.
In certain embodiments, when n is l, the compound of Formula (I) is a
compound of the Formula (I—b):
Fr Z t5 Z
RZ—N N R4
m m
R1 R1 (Lb)
or salt thereof.
In certain embodiments, when n is 2, the compound of Formula (I) is a
compound of the Formula (I—c):
FI<3 z F|<5 2 1'25 z
RZ—N N N R4
m m m
or salt thereof.
In certain embodiments, when n is 3, the nd of Formula (I) is a
compound of the a (I—d):
R3 z R5 z R5 z R5 z
Fez—I l l l R4
m m m m
R1 R1 R1 R1 (1-d)
or salt thereof.
In certain embodiments, when n is 4, the compound of a (I) is a
compound of the Formula (I—e):
F|<3z|52F|<5ZIT5z|5z
RZ—N.( )JJ—NE j,U—Né l’U—NE )J—NWJLR“m m m m m
R R1 R1 R1 R1 (1-6)
or salt thereof.
As generally defined above, each instance of m is independently l, 2, or 3. In
certain embodiments, at least one instance of m is 1. In certain embodiments, each instance of
m is 1. In certain embodiments, at least one instance of m is 2. In certain embodiments, at
least one instance of m is 3.
As generally defined above, each instance of R’ is independently hydrogen or
optionally tuted alkyl. In certain embodiments, at least one instance of R’ is hydrogen.
In certain embodiments, at least two ces of R’ is hydrogen. In certain embodiments,
each ce of R’ is hydrogen. In certain embodiments, at least one instance of R’ is
optionally substituted alkyl, e.g., methyl. In certain embodiments, at least two instances of R’
is optionally tuted alkyl, e.g., methyl. In certain ments, one instance of R’ is
optionally substituted alkyl, and the rest are hydrogen.
As lly defined above, each instance of Z is independently O, S, or NRZ,
wherein RZ is en, optionally substituted alkyl, optionally substituted alkenyl,
optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted
heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen
protecting group, or a group of the a (i), (ii), or (iii). In certain embodiments, at least
one instance of Z is O. In certain embodiments, each instance of Z is O. In certain
embodiments, at least one instance of Z is S. In certain embodiments, each instance of Z is S.
In certain embodiments, at least one instance of Z is NRZ. In certain embodiments, each
instance of Z is NRZ. In certain embodiments, each instance of RZ is independently hydrogen
or a group of the formula (i), (ii), or (iii).
As generally defined above, each instance of R1 is independently hydrogen,
optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl,
ally tuted carbocyclyl, optionally substituted heterocyclyl, optionally substituted
aryl, optionally tuted heteroaryl, halogen, —ORA1, —N(RA1)2, or —SRA1.
In certain embodiments, at least one instance of R1 is optionally substituted
alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally tuted
carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally
substituted heteroaryl.
In n embodiments, at least one instance of R1 is ally substituted
alkyl; e.g., optionally tuted kyl, optionally substituted C2_6alkyl, optionally
substituted C3_6alkyl, optionally substituted C4_6alkyl, optionally substituted C4_5alkyl, or
optionally substituted C34alkyl.
In certain embodiments, at least one ce of R1 is optionally substituted
alkenyl, e.g., optionally substituted C2_6alkenyl, optionally substituted C3_6alkenyl, optionally
substituted C4_6alkenyl, ally substituted C4_5alkenyl, or optionally substituted C3-
4alkenyl.
In certain embodiments, at least one instance of R1 is optionally substituted
alkynyl, e.g., optionally substituted C2_6alkynyl, optionally substituted C3_6alkynyl, optionally
substituted C4_6alkynyl, ally substituted kynyl, or ally substituted C3-
4alkynyl.
In certain embodiments, at least one instance of R1 is optionally substituted
carbocyclyl, e.g., optionally substituted C3_10 carbocyclyl, optionally substituted C5_g
carbocyclyl, optionally substituted C5_6 carbocyclyl, optionally substituted C5 carbocyclyl, or
optionally substituted C6 carbocyclyl.
In certain embodiments, at least one instance of R1 is optionally tuted
heterocyclyl, e.g., ally substituted 3—14 membered heterocyclyl, optionally tuted
3—10 membered heterocyclyl, optionally substituted 5—8 membered heterocyclyl, optionally
substituted 5—6 membered heterocyclyl, optionally substituted 5 membered cyclyl, or
optionally substituted 6 membered heterocyclyl.
In certain embodiments, at least one instance of R1 is optionally substituted
aryl, e.g., optionally substituted phenyl.
In certain embodiments, at least one instance of R1 is optionally substituted
heteroaryl, e.g., optionally substituted 5—14 membered heteroaryl, optionally substituted 5—10
membered heteroaryl, optionally substituted 5—6 membered heteroaryl, optionally substituted
membered heteroaryl, or ally substituted 6 membered heteroaryl.
] In any of the above embodiments, the R1 alkyl, alkenyl, alkynyl, carbocyclyl,
heterocyclyl, aryl, or heteroaryl group may be tuted, for example, with an optionally
substituted amino group (e.g., —NR6R7), an optionally substituted hydroxyl group (e.g., —OR6),
an optionally substituted thiol group (e.g., —SR6), or with a group of formula (i), (ii), or (iii),
wherein each instance of R6 and R7 is independently hydrogen, optionally tuted alkyl,
optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted
yclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally
substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an
oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group
when attached to a sulfur atom, or a group of formula (i), (ii), or (iii).
For example, in certain embodiments, at least one instance of R1 is an alkyl,
alkenyl, alkynyl, yclyl, heterocyclyl, aryl, or heteroaryl group tuted with an
amino group of the formula —N(R6)(R7). In that instance, in certain embodiments, at least one
instance of R1 is a group of formula:
L is an optionally substituted alkylene, ally substituted lene, optionally
substituted alkynylene, optionally substituted heteroalkylene, optionally substituted
heteroalkenylene, optionally substituted heteroalkynylene, optionally tuted
carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, or
optionally tuted heteroarylene, or combination thereof, and
R6 and R7 are independently selected from the group consisting of hydrogen,
optionally tuted alkyl, optionally substituted alkenyl, optionally substituted alkynyl,
optionally substituted carbocyclyl, optionally tuted heterocyclyl, optionally substituted
aryl, optionally substituted heteroaryl, and a nitrogen protecting group;
provided at least one instance of R6 and R7 is a group of the formula (i), (ii), or (iii):
. R‘ XRL
RQ—YRP
g—<R- § 0 R'-
R' or §_/
(1) (ii) (iii)
wherein R’, X, Y, RL, and RP are as defined herein.
In certain embodiments, at least two instances of R1 is a group of formula (iv).
In certain ments, at least three instances of R1 is a group of formula (iv). In certain
ments, at least four instances of R1 is a group of formula (iv). In certain embodiments,
at least five instances of R1 is a group of formula (iv). In certain embodiments, each instance
of R1 is a group of formula (iv).
In certain ments, L is an optionally substituted alkylene; e.g., optionally
substituted C1_50alkylene, optionally substituted C1_40alkylene, optionally substituted C1-
30alkylene, optionally substituted C1_20alkylene, optionally substituted C4_20alkylene,
optionally substituted C6_20alkylene, optionally substituted Cg_20all<ylene, optionally
substituted C10_20alkylene, ally substituted C1_6alkylene, optionally substituted C2-
6alkylene, ally substituted C3_6alkylene, optionally substituted C4_6alkylene, ally
substituted C4_5alkylene, or optionally substituted C3_4alkylene.
In certain embodiments, L is an optionally substituted alkenylene, e.g.,
optionally substituted C2_50alkenylene, optionally substituted C2_40alkenylene, optionally
substituted C2_30alkenylene, optionally substituted Cnoalkenylene, ally substituted C4-
nylene, optionally substituted C6_20alkenylene, optionally substituted Cg_20all<enylene,
optionally tuted C10_20alkenylene, optionally substituted C2_6alkenylene, ally
substituted C3_6alkenylene, ally substituted C4_6alkenylene, optionally substituted C4-
5alkenylene, or optionally substituted C3_4alkenylene.
In certain embodiments, L is an optionally substituted alkynylene, e.g.,
optionally tuted C2_50alkynylene, optionally substituted C2_40alkynylene, optionally
substituted C2_30alkynylene, optionally substituted Cnoalkynylene, optionally substituted C4-
goalkynylene, optionally substituted C6_20alkynylene, optionally substituted Cg_20all<ynylene,
optionally substituted C10_20alkynylene, optionally substituted C2_6alkynylene, ally
substituted C3_6alkynylene, optionally substituted C4_6alkynylene, optionally substituted C4-
5alkynylene, or optionally substituted C3_4alkynylene.
In certain embodiments, L is an optionally tuted heteroalkylene; e.g.,
optionally substituted C1_50alkylene, optionally substituted heteroC1_40alkylene,
optionally tuted heteroC1_30alkylene, optionally substituted heteroC1_20alkylene,
optionally substituted heteroC4_20alkylene, optionally substituted heteroC6_20alkylene,
optionally substituted heterng_20all<ylene, optionally substituted heteroC10_20alkylene,
optionally substituted heteroC1_6alkylene, optionally substituted heteroC2_6alkylene,
optionally substituted heteroC3_6alkylene, optionally substituted heteroC4_6alkylene,
optionally substituted C4_5alkylene, or optionally substituted heteroC3_4alkylene.
In certain ments, L is an optionally substituted heteroalkenylene, e.g.,
optionally substituted heteroC2_50alkenylene, optionally substituted heteroC2_40alkenylene,
optionally substituted heteroC2_30alkenylene, optionally substituted C2_20alkenylene,
optionally substituted heteroC4_20alkenylene, optionally substituted heteroC6_20alkenylene,
optionally substituted heterng_20all<enylene, optionally substituted heteroC10_20alkenylene,
ally substituted heteroC2_6alkenylene, ally substituted C3_6alkenylene,
optionally substituted heteroC4_6alkenylene, ally substituted heteroC4_5alkenylene, or
optionally substituted C3_4alkenylene.
In certain embodiments, L is an optionally substituted alkynylene, e.g.,
optionally substituted heteroC2_50alkynylene, optionally substituted heteroC2_40alkynylene,
optionally substituted heteroC2_30alkynylene, optionally tuted C2_20alkynylene,
optionally substituted heteroC4_20alkynylene, optionally substituted C6_20alkynylene,
optionally substituted heterng_20alkynylene, optionally substituted heteroC10_20alkynylene,
optionally substituted heteroC2_6alkynylene, optionally substituted C3_6alkynylene, optionally
substituted heteroC4_6alkynylene, optionally substituted heteroC4_5alkynylene, or optionally
substituted heteroC3_4alkynylene.
In certain ments, L is an optionally substituted carbocyclylene, e.g.,
optionally substituted C340 carbocyclylene, optionally substituted C5_g carbocyclylene,
optionally substituted C5_6 carbocyclylene, optionally substituted C5 carbocyclylene, or
optionally substituted C6 carbocyclylene.
In n embodiments, L is an optionally tuted heterocyclylene, e.g.,
optionally substituted 3— l4 membered heterocyclylene, optionally substituted 3—10 membered
heterocyclylene, ally substituted 5—8 membered heterocyclylene, optionally substituted
—6 membered heterocyclylene, optionally substituted 5 membered heterocyclylene, or
ally substituted 6 membered heterocyclylene.
In certain embodiments, L is an optionally substituted arylene, e.g., optionally
substituted phenylene.
In certain embodiments, L is an optionally substituted heteroarylene, e.g.,
ally substituted 5— l4 membered heteroarylene, optionally substituted 5—10 membered
heteroarylene, optionally substituted 5—6 membered heteroarylene, optionally substituted 5
membered heteroarylene, or optionally substituted 6 membered heteroarylene.
For example, in certain embodiments, wherein L is an optionally substituted
alkylene group, the group of formula (iv) is a group of the formula:
wherein q is an r between 1 and 50, inclusive.
In certain embodiments, q is an integer n 1 and 40, inclusive. In certain
embodiments, q is an r between 1 and 30, inclusive. In certain embodiments, q is an
integer between 1 and 20, inclusive. In certain embodiments, q is an integer between 4 and
, inclusive. In certain embodiments, q is an integer between 6 and 20, ive. In certain
embodiments, q is an integer between 8 and 20, ive. In n embodiments, q is 1. In
certain embodiments, q is 2. In certain embodiments, q is 3. In certain embodiments, q is 4. In
certain embodiments, q is 5. In certain embodiments, q is 6. In certain embodiments, q is 7. In
certain ments, q is 8. In certain ments, q is 9. In n embodiments, q is 10.
In certain embodiments, both R6 and R7 are hydrogen. In certain embodiments,
R6 is en and R7 is a group of the formula (i), (ii), or (iii). In certain embodiments, R6 is
hydrogen and R7 is a group of the formula (i). In certain embodiments, R6 is hydrogen and
R7 is a group of the formula (ii). In certain embodiments, R6 is hydrogen and R7 is a group of
the formula (iii). In certain ments, both R6 and R7 are independently a group of the
formula (i), (ii), or (iii). In certain embodiments, both R6 and R7 are ndently a group of
the formula (i). In certain embodiments, both R6 and R7 are independently a group of the
formula (ii). In certain embodiments, both R6 and R7 are independently a group of the
formula (iii). In certain embodiments, both R6 and R7 are the same group, selected from a
group of the formula (i), (ii), or (iii).
It is understood that R1 encompasses amino acid side chains such as
exemplified in Table l of the Examples. In certain embodiments, R1 is a group selected from
any one of the amino acid side chain groups listed n.
In certain embodiments, each instance of R1 is the same. In certain
embodiments, at least one R1 group is different. In n embodiments, each R1 group is
different.
As generally defined above, R2 is a group of the formula (i), (ii), or (iii):
R‘ XRL
RQ—YRP
é—flR. § 0 RL
R. or ;_/
(i) (ii) (iii)
wherein R’, X, Y, RL, and RP are as defined herein.
In certain embodiments, R2 is a group of the a (i). In certain
embodiments, R2 is a group of the formula (ii). In certain ments, R2 is a group of the
formula (iii).
] As generally defined above, R3 is hydrogen, optionally substituted alkyl,
optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted
carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally
substituted aryl, a nitrogen ting group, or a group of the formula (i), (ii), or (iii);
optionally n R3 and an R1 group are joined to form an optionally substituted 5—6
membered heterocyclic ring;
In n embodiments, R3 is en. In certain embodiments, R3 is
optionally substituted alkyl; e.g., optionally tuted C1_6alkyl, optionally substituted C2-
6alkyl, optionally substituted C3_6alkyl, optionally substituted C4_6alkyl, optionally substituted
C4_5alkyl, or optionally substituted C34alkyl.
In certain embodiments, R3 is optionally substituted alkenyl, e.g., optionally
substituted C2_6alkenyl, optionally substituted C3_6alkenyl, optionally substituted C4_6alkenyl,
optionally substituted C4_5alkenyl, or optionally substituted C3_4alkenyl.
In certain embodiments, R3 is ally substituted alkynyl, e.g., optionally
substituted kynyl, optionally substituted C3_6alkynyl, optionally substituted C4_6alkynyl,
optionally substituted C4_5alkynyl, or optionally substituted C3_4alkynyl.
] In certain embodiments, R3 is optionally substituted carbocyclyl, e.g.,
optionally substituted C340 carbocyclyl, optionally substituted C5_g yclyl, optionally
substituted C5_6 carbocyclyl, optionally substituted C5 carbocyclyl, or optionally substituted
C6 carbocyclyl.
] In certain embodiments, R3 is optionally substituted heterocyclyl, e.g.,
optionally substituted 3— l4 membered heterocyclyl, optionally substituted 3— 10 membered
heterocyclyl, optionally tuted 5—8 membered cyclyl, optionally substituted 5—6
membered heterocyclyl, optionally substituted 5 ed heterocyclyl, or optionally
substituted 6 membered heterocyclyl.
In certain embodiments, R3 is optionally substituted aryl, e.g., optionally
substituted phenyl.
In certain embodiments, R3 is optionally substituted heteroaryl, e.g., optionally
substituted 5— l4 membered heteroaryl, ally substituted 5—10 membered heteroaryl,
ally substituted 5—6 membered heteroaryl, optionally substituted 5 ed
heteroaryl, or optionally substituted 6 membered heteroaryl.
] In certain embodiments, R3 is a nitrogen protecting group.
In certain embodiments, R3 is group of the formula (i), (ii), or (iii). In certain
embodiments, R3 is group of the formula (i). In certain embodiments, R3 is group of the
formula (ii). In certain embodiments, R3 is group of the formula (iii).
In certain embodiments, R3 and an nt R1 group are joined to form an
optionally substituted 5—6 membered heterocyclic ring, e.g., a 5—membered heterocyclic ring,
e.g., an optionally substituted pyrrolidinyl ring.
In n embodiments, R3 is hydrogen and R2 is a group of the formula (i),
(ii), or (iii). In certain ments, R3 is hydrogen and R2 is a group of the formula (i). In
certain embodiments, R3 is hydrogen and R2 is a group of the formula (ii). In certain
embodiments, R3 is hydrogen and R2 is a group of the formula (iii). In certain embodiments,
both R2 and R3 are independently a group of the formula (i), (ii), or (iii). In certain
embodiments, both R2 and R3 are independently a group of the formula (i). In certain
ments, both R2 and R3 are independently a group of the formula (ii). In certain
embodiments, both R2 and R3 are ndently a group of the formula (iii). In certain
embodiments, both R2 and R3 are the same group, selected from a group of the a (i),
(ii), or (iii).
As generally defined above, R4 is —ORA4, —N(RA4)2, or —SRA4; wherein each
occurrence of RA4 is independently hydrogen, optionally substituted alkyl, optionally
substituted alkenyl, optionally substituted l, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting
group when attached to an sulfur atom, a nitrogen protecting group when ed to a
nitrogen atom, or two RA4 groups are joined to form an optionally substituted heterocyclic or
optionally substituted heteroaryl ring.
2012/062222
In certain embodiments, R4 is —ORA4, wherein RA4 is hydrogen, optionally
substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally
substituted carbocyclyl, optionally tuted cyclyl, optionally substituted aryl,
optionally substituted heteroaryl, or an oxygen protecting group. In certain embodiments,
RA4 is hydrogen or optionally tuted alkyl. In certain embodiments, RA4 is hydrogen.
In certain embodiments, R4 is —N(RA4)2, wherein each occurrence of RA4 is
independently hydrogen, optionally substituted alkyl, ally substituted alkenyl,
optionally substituted alkynyl, optionally tuted carbocyclyl, optionally substituted
cyclyl, optionally substituted aryl, optionally substituted heteroaryl, a en
protecting group when attached to a nitrogen atom, or two RA4 groups are joined to form an
optionally substituted heterocyclic or optionally substituted heteroaryl ring. In certain
embodiments, at least one instance of RA4 is hydrogen or optionally substituted alkyl. In
certain embodiments, at least one instance of RA4 is en.
In certain embodiments, R4 is —SRA4, wherein RA4 is hydrogen, optionally
substituted alkyl, optionally substituted alkenyl, optionally tuted alkynyl, optionally
tuted carbocyclyl, optionally tuted heterocyclyl, optionally substituted aryl,
optionally substituted heteroaryl, or sulfur protecting group. In n embodiments, RA4 is
hydrogen or optionally tuted alkyl. In certain embodiments, RA4 is hydrogen.
As generally defined above, R5 is hydrogen, optionally substituted alkyl,
optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted
carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally
substituted heteroaryl, or a nitrogen protecting group. In certain embodiments, at least one
instance of R5 is hydrogen. In certain embodiments, each instance of R5 is hydrogen.
Various combinations of the above embodiments of Formula (I) are
contemplated .
For example, in certain embodiments, wherein each instance of m is l and each
instance of Z is O, the compound of Formula (I) is a compound of Formula (I—f):
3 I5 R4
“ (1-f)
or salt thereof. In certain embodiments, at least one R1 is a group of a (iV). In certain
embodiments, R2 is a group of formula (i). In certain embodiments, R2 is a group of formula
(ii). In certain embodiments, R2 is a group of formula (iii). In certain embodiments, R3 is a
group of a (i). In certain embodiments, R3 is a group of formula (ii). In certain
embodiments, R3 is a group of formula (iii). In certain embodiments, R4 is —ORA4. In certain
ments, R5 is hydrogen. In certain embodiments, n is 0. In certain embodiments, n is
1. In certain embodiments, n is 2. In n embodiments, n is 3. In certain embodiments,
n is 4. In certain embodiments, n is 5.
] For example, in certain embodiments of a (I—f), wherein each instance of
R1 is a group of the formula (iv), provided is a compound of Formula (I—fl):
(I—fl)
or salt thereof. In certain ments, L is an optionally substituted alkylene. In certain
ments, R6 is a group of formula (i). In certain embodiments, R6 is a group of formula
(ii). In certain embodiments, R6 is a group of formula (iii). In certain embodiments, R7 is a
group of formula (i). In certain embodiments, R7 is a group of formula (ii). In certain
embodiments, R7 is a group of formula (iii).
In certain embodiments of Formula (I—f), wherein R2 is a group of formula (i),
the compound is of a (I—f2):
RL I
‘ N
RPY—/ R 1
” (1-f2)
or salt thereof. In certain embodiments, at least one R1 is a group of formula (iv). In certain
embodiments, R3 is a group of formula (i). In certain embodiments, R3 is a group of formula
(ii). In certain ments, R3 is a group of formula (iii). In certain ments, R4 is —
ORA4. In certain embodiments, R5 is hydrogen. In certain embodiments, n is 0. In certain
embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In
n embodiments, n is 4. In certain embodiments, n is 5.
For example, in certain embodiments of Formula (I—f2), wherein each instance
of R1 is a group of the formula (iv), provided is a compound of Formula (I—f3):
(I—f3)
or salt thereof. In certain embodiments, L is an ally substituted alkylene. In certain
embodiments, R6 is a group of formula (i). In certain embodiments, R6 is a group of formula
(ii). In certain embodiments, R6 is a group of formula (iii). In certain embodiments, R7 is a
group of formula (i). In certain embodiments, R7 is a group of a (ii). In certain
embodiments, R7 is a group of formula (iii).
In certain embodiments of Formula (I—f), wherein R2 and R3 are each
independently a group of formula (i), the compound is of Formula (I—f4):
| R4
” (I—f4)
or salt thereof. In certain embodiments, at least one R1 is a group of formula (iV). In certain
embodiments, R4 is —ORA4. In certain embodiments, R5 is en. In certain
embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In
n embodiments, n is 3. In certain ments, n is 4. In certain embodiments, n is 5.
For example, in certain embodiments of Formula (I—f4), wherein each instance
of R1 is a group of the formula (iV), provided is a compound of Formula (I—f5):
RL 0
RPYfi/ o F|e5 R4
RL\ N
RPY_/ L\ /R6
L R5
‘N’ Ii]
I n R7
R7 (I—f5)
or salt f. In certain embodiments, L is an optionally substituted alkylene. In certain
embodiments, R6 is a group of a (i). In certain embodiments, R6 is a group of formula
(ii). In n embodiments, R6 is a group of formula (iii). In certain embodiments, R7 is a
group of a (i). In certain embodiments, R7 is a group of formula (ii). In certain
embodiments, R7 is a group of formula (iii).
In certain embodiments of Formula (I—f), wherein R2 is a group of formula (ii),
the compound is of Formula (I—f6):
RLX n (I—f6)
or salt thereof. In certain embodiments, at least one R1 is a group of formula (iV). In certain
embodiments, R3 is a group of formula (i). In certain embodiments, R3 is a group of formula
(ii). In certain embodiments, R3 is a group of formula (iii). In certain ments, R4 is —
ORA4. In certain embodiments, R5 is hydrogen. In certain ments, n is 0. In certain
embodiments, n is 1. In n embodiments, n is 2. In certain embodiments, n is 3. In
certain embodiments, n is 4. In certain embodiments, n is 5.
For example, in certain embodiments of Formula (I—f6), wherein each instance
of R1 is a group of the formula (iV), ed is a compound of Formula (I—f7):
(1-f7 )
or salt thereof. In certain embodiments, L is an optionally tuted alkylene. In certain
embodiments, R6 is a group of formula (i). In certain embodiments, R6 is a group of formula
(ii). In certain embodiments, R6 is a group of a (iii). In certain embodiments, R7 is a
group of formula (i). In n embodiments, R7 is a group of formula (ii). In certain
embodiments, R7 is a group of formula (iii).
In certain embodiments of Formula (I—f), wherein R2 and R3 are ndently a
group of formula (ii), the compound is of Formula (I—f8):
RLX o
o R5
l R4
0V—N
RLX n (I—f8)
or salt thereof. In certain embodiments, at least one R1 is a group of formula (iV). In certain
embodiments, R4 is —ORA4. In certain embodiments, R5 is hydrogen. In certain
WO 63468
embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In
certain ments, n is 3. In certain embodiments, n is 4. In certain embodiments, n is 5.
For example, in n embodiments of Formula (I—f8), wherein each instance
of R1 is a group of the formula (iV), provided is a nd of Formula (I—f9):
(1-f9)
or salt thereof. In n embodiments, L is an optionally substituted alkylene. In certain
embodiments, R6 is a group of formula (i). In certain embodiments, R6 is a group of formula
(ii). In certain embodiments, R6 is a group of formula (iii). In n embodiments, R7 is a
group of formula (i). In certain embodiments, R7 is a group of formula (ii). In certain
embodiments, R7 is a group of formula (iii).
In certain ments of Formula (I—f), wherein R2 is a group of formula (iii),
the compound is of a (I—f10):
” (I—f10)
or salt f. In certain ments, at least one R1 is a group of formula (iV). In certain
embodiments, R3 is a group of formula (i). In certain embodiments, R3 is a group of formula
(ii). In certain embodiments, R3 is a group of formula (iii). In certain embodiments, R4 is —
ORA4. In certain embodiments, R5 is hydrogen. In certain embodiments, n is 0. In certain
embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In
certain embodiments, n is 4. In certain embodiments, n is 5.
For example, in certain embodiments of Formula (I—f10), wherein each instance
of R1 is a group of the formula (iV), provided is a compound of Formula (I—fl l):
(I—fl 1)
or salt f. In certain embodiments, L is an optionally substituted alkylene. In certain
embodiments, R6 is a group of formula (i). In certain embodiments, R6 is a group of formula
(ii). In certain embodiments, R6 is a group of a (iii). In certain embodiments, R7 is a
group of formula (i). In certain embodiments, R7 is a group of formula (ii). In certain
embodiments, R7 is a group of formula (iii).
In certain embodiments of Formula (I—f), wherein R2 and R3 are independently a
group of formula (iii), the compound is of Formula (I—f12):
RL 0 R5
W l R4
RL R1
n (I—f12)
or salt thereof. In certain embodiments, at least one R1 is a group of formula (iV). In certain
embodiments, R4 is —ORA4. In n embodiments, R5 is hydrogen. In certain
embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In
certain embodiments, n is 3. In certain embodiments, n is 4. In certain embodiments, n is 5.
For example, in certain embodiments of Formula (I—f12), n each instance
of R1 is a group of the formula (iV), provided is a nd of Formula (I—fl3):
(I—fl 3)
or salt thereof. In certain embodiments, L is an optionally substituted alkylene. In certain
embodiments, R6 is a group of formula (i). In certain embodiments, R6 is a group of formula
(ii). In n embodiments, R6 is a group of formula (iii). In certain embodiments, R7 is a
group of a (i). In certain ments, R7 is a group of a (ii). In certain
embodiments, R7 is a group of formula (iii).
Compounds ofFormula (II)
Compounds of a (11) may be prepared Via internal cyclization of the
addition t of a primary or secondary amine or amide of an amino acid, peptide, or
polypeptide, and an epoxide, thiirane, or aziridine of formula (i—X) (Scheme 2).
Scheme 2.
Compounds of Formula (11) may encompass additional sites of conjugation,
e.g., the secondary amino group, appended to a group attached to the secondary amino group,
an amino substituent, and/or an imino nitrogen, to a group of formula (i), (ii), or (iii):
w w :'\'/\'/':
R1VLY [RE-":L 1
. \N : \HLY
.- ----- R'
: 5 '7: R' RWAY R'
E_B?:'_\l_: RL '____B_iR8’N RL R8’N\H<RL
R' R' R'
secondary amino group amino substituents imino nitrogens
Thus, in a second , provided is a compound of a (II):
or salt thereof;
wherein:
each instance of R’ is independently hydrogen or optionally substituted alkyl;
each instance of R1 is ndently en, optionally substituted alkyl, ally
substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl,
optionally tuted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, halogen, —ORA1, —N(RA1)2, or —SRA1; wherein each occurrence of RAl is
independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl,
optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted
heterocyclyl, optionally substituted aryl, optionally substituted aryl, an oxygen
protecting group when attached to an oxygen atom, a sulfur protecting group when attached
to an sulfur atom, a nitrogen protecting group when attached to a en atom, or two RAl
groups are joined to form an optionally substituted heterocyclic or optionally substituted
heteroaryl ring;
R8 is hydrogen, a group of the formula (i), (ii), or (iii), or a group of the formula (V):
R3 $5
N g
” (V)
wherein Z, R2, R3, R5, m, and n are as defined for Formula (I);
or R8 and an R1 group are joined to form an optionally substituted 5—6 membered
heterocyclic ring;
each instance of W is independently O, S, or NRW, wherein RW is hydrogen,
optionally tuted alkyl, optionally substituted l, optionally substituted alkynyl,
optionally substituted carbocyclyl, optionally substituted heterocyclyl, ally substituted
aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of the formula
(i), (ii), or (iii); and
each instance of Y is independently O, S, or NRY, wherein RY is hydrogen, optionally
substituted alkyl, optionally substituted l, optionally substituted alkynyl, optionally
tuted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl,
optionally tuted heteroaryl, or a nitrogen protecting group;
Formulae (i), (ii), and (iii) are:
R‘ XRL
RQ—YRP
§—§RI § 0 R'-
R. or §_/
(1) (ii) (iii)
wherein:
X is O, S, NRX, n RX is hydrogen, optionally tuted alkyl, optionally
substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, or a nitrogen protecting group;
2012/062222
Y is O, S, NRY, wherein RY is hydrogen, optionally substituted alkyl, optionally
substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally substituted aryl, ally substituted
heteroaryl, or a nitrogen protecting group;
RP is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally
substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl,
optionally substituted aryl, optionally tuted heteroaryl, an oxygen protecting group
when attached to an oxygen atom, a sulfur protecting group when ed to a sulfur atom,
or a nitrogen protecting group when attached to a nitrogen atom; and
RL is optionally substituted C150 alkyl, optionally substituted C250 alkenyl, optionally
substituted C250 alkynyl, optionally substituted heteroC1_50 alkyl, optionally substituted
heteroC2_50 alkenyl, optionally substituted heteroC2_50 alkynyl, or a polymer.
In certain embodiments, wherein Y is O and W is O, the following compounds
are specifically ed:
0 o o 0
0 o 0 R60 0
N\)\ ,N\)\ ,N
Me/ RL, R8 RL, R8 RL, R8,N\)\RL,
0 o
(R60)OZS o o
R8,N\)\ R50 R8,N¢\ RL, RL,
wherein R8 and R6 are independently hydrogen or a group of formula (i), and salts thereof.
In certain embodiments, at least one instance of RW, R2, R3, R6 or R8 is a
, R7,
group of the formula (i), (ii), or (iii).
As lly defined above, each instance of R’ is ndently hydrogen or
ally substituted alkyl. In certain ments, at least one instance of R’ is hydrogen.
In certain embodiments, at least two instances of R’ is en. In certain embodiments,
each instance of R’ is hydrogen. In n embodiments, at least one ce of R’ is
optionally substituted alkyl, e.g., methyl. In certain embodiments, at least two instances of R’
is optionally substituted alkyl, e.g., . In certain embodiments, one instance of R’ is
optionally substituted alkyl, and the rest are hydrogen.
As generally defined above, each ce of R1 is independently hydrogen,
optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl,
2012/062222
optionally substituted carbocyclyl, ally substituted heterocyclyl, optionally substituted
aryl, optionally tuted heteroaryl, halogen, —ORA1, —N(RA1)2, or —SRA1.
In certain embodiments, at least one instance of R1 is optionally substituted
alkyl, ally substituted alkenyl, optionally substituted alkynyl, optionally substituted
carbocyclyl, optionally substituted cyclyl, optionally substituted aryl, or ally
substituted heteroaryl.
In certain ments, at least one ce of R1 is optionally substituted
alkyl; e.g., optionally substituted C1_6alkyl, optionally substituted C2_6alkyl, optionally
substituted C3_6alkyl, optionally substituted C4_6alkyl, optionally substituted C4_5alkyl, or
optionally substituted C34alkyl.
In certain embodiments, at least one instance of R1 is optionally substituted
alkenyl, e.g., optionally substituted C2_6alkenyl, optionally substituted C3_6alkenyl, optionally
substituted C4_6alkenyl, optionally substituted C4_5alkenyl, or optionally substituted C3-
4alkenyl.
In certain embodiments, at least one instance of R1 is optionally substituted
alkynyl, e.g., optionally substituted kynyl, optionally substituted C3_6alkynyl, ally
substituted C4_6alkynyl, ally substituted C4_5alkynyl, or optionally substituted C3-
4alkynyl.
In certain embodiments, at least one instance of R1 is optionally substituted
carbocyclyl, e.g., optionally substituted C3_10 carbocyclyl, optionally substituted C5_g
carbocyclyl, optionally substituted C5_6 carbocyclyl, optionally substituted C5 carbocyclyl, or
optionally tuted C6 carbocyclyl.
In certain embodiments, at least one instance of R1 is optionally substituted
heterocyclyl, e.g., optionally substituted 3—14 membered heterocyclyl, optionally substituted
3—10 membered heterocyclyl, optionally substituted 5—8 ed cyclyl, optionally
substituted 5—6 membered heterocyclyl, optionally substituted 5 membered heterocyclyl, or
optionally substituted 6 membered heterocyclyl.
In certain embodiments, at least one instance of R1 is ally substituted
aryl, e.g., optionally substituted phenyl.
In certain embodiments, at least one instance of R1 is optionally substituted
heteroaryl, e.g., ally tuted 5—14 membered heteroaryl, optionally tuted 5—10
membered heteroaryl, optionally substituted 5—6 membered heteroaryl, optionally substituted
membered heteroaryl, or optionally substituted 6 membered heteroaryl.
In any of the above embodiments, the R1 alkyl, alkenyl, alkynyl, carbocyclyl,
heterocyclyl, aryl, or aryl group may be substituted, for example, with an optionally
substituted amino group (e.g., —NR6R7), an optionally substituted hydroxyl group (e.g., —OR6),
an optionally substituted thiol group (e.g., —SR6), or with a group of formula (i), (ii), or (iii),
wherein each instance of R6 and R7 is independently hydrogen, optionally substituted alkyl,
optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted
carbocyclyl, ally substituted heterocyclyl, optionally substituted aryl, optionally
substituted heteroaryl, a nitrogen protecting group when attached to a en atom, an
oxygen ting group when ed to an oxygen atom, and a sulfur protecting group
when attached to a sulfur atom, or a group of formula (i), (ii), or (iii).
For example, in certain embodiments, at least one instance of R1 is an alkyl,
alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl group tuted with an
amino group of the formula (R7). In that ce, in certain embodiments, at least one
instance of R1 is a group of formula:
é—L—Nf
R7 (iv)
wherein:
L is an optionally substituted alkylene, optionally substituted alkenylene, optionally
substituted alkynylene, optionally substituted heteroalkylene, optionally substituted
heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted
carbocyclylene, optionally tuted heterocyclylene, optionally tuted arylene, or
optionally substituted heteroarylene, or combination thereof, and
R6 and R7 are independently selected from the group consisting of hydrogen,
optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl,
optionally substituted yclyl, optionally substituted heterocyclyl, optionally substituted
aryl, optionally substituted heteroaryl, and a nitrogen protecting group;
provided at least one instance of R6 and R7 is a group of the formula (i), (ii), or (iii):
(i) (ii) (iii)
wherein R’, X, Y, RL, and RP are as defined herein.
In certain embodiments, at least two ces of R1 is a group of formula (iv).
In certain embodiments, at least three instances of R1 is a group of formula (iv). In certain
embodiments, at least four instances of R1 is a group of a (iv). In certain embodiments,
at least five instances of R1 is a group of formula (iv). In certain embodiments, each instance
of R1 is a group of formula (iv).
In certain embodiments, R1 alpha to the group —C(=W)—Y— is a group of formula
(iv).
In certain ments, at least one instance of R1 provided in group R8 is a
group of formula (iv). In certain embodiments, at least two instances of R1 ed in group
R8 is a group of formula (iv). In certain embodiments, at least three instances of R1 provided
in group R8 is a group of a (iv). In certain embodiments, at least four instances of R1
provided in group R8 is a group of formula (iv). In certain embodiments, at least five
instances of R1 provided in group R8 is a group of formula (iv). In certain embodiments, each
instance of R1 provided in group R8 is a group of formula (iv).
] In certain embodiments, L is an optionally substituted alkylene; e.g., optionally
substituted C1_50alkylene, optionally substituted C1_40alkylene, optionally substituted C1-
30alkylene, optionally substituted C1_20alkylene, optionally substituted C4_20alkylene,
optionally substituted C6_20alkylene, ally substituted Cg_20alkylene, optionally
substituted C10_20alkylene, optionally substituted C1_6alkylene, optionally substituted C2-
6alkylene, optionally substituted C3_6alkylene, optionally tuted C4_6alkylene, optionally
substituted C4_5alkylene, or optionally substituted C3_4alkylene.
In certain embodiments, L is an optionally substituted alkenylene, e.g.,
optionally tuted C2_50alkenylene, optionally substituted C2_40alkenylene, optionally
substituted lkenylene, optionally substituted Cnoalkenylene, optionally substituted C4-
goalkenylene, optionally tuted C6_20alkenylene, optionally substituted Cg_20all<enylene,
optionally substituted C10_20alkenylene, optionally substituted C2_6alkenylene, ally
substituted C3_6alkenylene, optionally substituted C4_6alkenylene, optionally tuted C4-
5alkenylene, or optionally substituted C3_4alkenylene.
In n embodiments, L is an optionally substituted alkynylene, e.g.,
optionally substituted C2_50alkynylene, optionally substituted C2_40alkynylene, ally
substituted C2_30alkynylene, optionally substituted Cnoalkynylene, optionally tuted C4-
goalkynylene, optionally tuted C6_20alkynylene, optionally substituted Cg_20all<ynylene,
optionally substituted C10_20alkynylene, optionally substituted C2_6alkynylene, optionally
substituted C3_6alkynylene, optionally substituted C4_6alkynylene, ally substituted C4-
5alkynylene, or optionally substituted C3_4alkynylene.
In certain embodiments, L is an optionally substituted heteroalkylene; e.g.,
ally substituted heteroC1_50alkylene, optionally substituted heteroC1_40alkylene,
ally substituted heteroC1_30alkylene, optionally substituted heteroC1_20alkylene,
optionally substituted C4_20alkylene, optionally substituted heteroC6_20alkylene,
optionally substituted heterng_20all<ylene, optionally tuted heteroC10_20alkylene,
optionally substituted heteroC1_6alkylene, optionally substituted heteroC2_6alkylene,
optionally substituted heteroC3_6alkylene, optionally substituted heteroC4_6alkylene,
optionally substituted heteroC4_5alkylene, or optionally substituted heteroC3_4alkylene.
In certain ments, L is an optionally substituted heteroalkenylene, e.g.,
optionally substituted heteroC2_50alkenylene, optionally substituted heteroC2_40alkenylene,
optionally substituted heteroC2_30alkenylene, optionally substituted heteroC2_20alkenylene,
optionally substituted C4_20alkenylene, ally substituted heteroC6_20alkenylene,
optionally substituted heterng_20all<enylene, optionally substituted heteroC10_20alkenylene,
optionally substituted heteroC2_6alkenylene, optionally substituted C3_6alkenylene,
optionally substituted heteroC4_6alkenylene, optionally substituted heteroC4_5alkenylene, or
optionally substituted heteroC3_4alkenylene.
In n embodiments, L is an optionally substituted alkynylene, e.g.,
optionally substituted heteroC2_50alkynylene, optionally substituted heteroC2_40alkynylene,
optionally substituted C2_30alkynylene, optionally tuted heteroC2_20alkynylene,
optionally substituted heteroC4_20alkynylene, optionally substituted heteroC6_20alkynylene,
optionally substituted heterng_20all<ynylene, optionally substituted heteroC10_20alkynylene,
optionally substituted heteroC2_6alkynylene, optionally substituted C3_6alkynylene, optionally
substituted heteroC4_6alkynylene, optionally substituted C4_5alkynylene, or optionally
substituted heteroC3_4alkynylene.
In certain embodiments, L is an optionally substituted carbocyclylene, e.g.,
optionally substituted C340 carbocyclylene, optionally substituted C5_g carbocyclylene,
optionally substituted C5_6 carbocyclylene, optionally substituted C5 carbocyclylene, or
ally substituted C6 carbocyclylene.
In n embodiments, L is an optionally tuted heterocyclylene, e.g.,
optionally substituted 3— l4 membered heterocyclylene, optionally substituted 3—10 ed
heterocyclylene, ally substituted 5—8 membered cyclylene, optionally substituted
—6 ed heterocyclylene, optionally substituted 5 membered heterocyclylene, or
optionally substituted 6 membered heterocyclylene.
In certain ments, L is an optionally substituted arylene, e.g., optionally
substituted phenylene.
In certain embodiments, L is an optionally substituted heteroarylene, e.g.,
optionally tuted 5— l4 membered heteroarylene, optionally substituted 5—10 membered
heteroarylene, optionally substituted 5—6 membered heteroarylene, optionally substituted 5
membered heteroarylene, or optionally substituted 6 membered heteroarylene.
For example, in certain embodiments, n L is an optionally substituted
ne group, the group of formula (iv) is a group of the formula:
wherein q is an integer between 1 and 50, inclusive.
In certain embodiments, q is an integer between 1 and 40, ive. In certain
embodiments, q is an integer between 1 and 30, inclusive. In certain embodiments, q is an
r between 1 and 20, inclusive. In certain embodiments, q is an integer between 4 and
, inclusive. In certain embodiments, q is an integer between 6 and 20, inclusive. In certain
embodiments, q is an integer between 8 and 20, inclusive. In certain embodiments, q is 1. In
certain embodiments, q is 2. In certain embodiments, q is 3. In n embodiments, q is 4. In
n ments, q is 5. In certain ments, q is 6. In certain embodiments, q is 7. In
certain embodiments, q is 8. In certain ments, q is 9. In certain embodiments, q is 10.
In certain embodiments, both R6 and R7 are en. In certain embodiments,
R6 is hydrogen and R7 is a group of the formula (i), (ii), or (iii). In certain embodiments, R6 is
hydrogen and R7 is a group of the formula (i). In certain embodiments, R6 is hydrogen and
R7 is a group of the formula (ii). In certain embodiments, R6 is hydrogen and R7 is a group of
the formula (iii). In certain embodiments, both R6 and R7 are independently a group of the
formula (i), (ii), or (iii). In certain embodiments, both R6 and R7 are independently a group of
the formula (i). In n embodiments, both R6 and R7 are independently a group of the
formula (ii). In certain embodiments, both R6 and R7 are ndently a group of the
formula (iii). In certain embodiments, both R6 and R7 are the same group, selected from a
group of the formula (i), (ii), or (iii).
It is understood that R1 encompasses amino acid side chains such as
exemplified in Table l of the Examples. In certain embodiments, R1 is a group selected from
any one of the amino acid side chain groups listed n.
In certain embodiments, each instance of R1 is the same. In n
embodiments, at least one R1 group is different. In n embodiments, each R1 group is
different.
As generally defined above, each instance of W is independently O, S, or NRW,
wherein RW is hydrogen, optionally substituted alkyl, optionally substituted alkenyl,
optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted
heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen
ting group, or a group of the formula (i), (ii), or (iii). In certain embodiments, W is O.
In certain embodiments, W is S. In certain embodiments, W is NRW. In certain
embodiments, RW is hydrogen or a group of the formula (i), (ii), or (iii).
As generally defined above, each instance of Y is independently O, S, or NRY,
wherein RY is hydrogen, optionally substituted alkyl, optionally substituted alkenyl,
optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted
heterocyclyl, optionally substituted aryl, ally tuted aryl, or a nitrogen
ting group. In certain embodiments, Y is O. In certain embodiments, each instance of
Y is S. In certain embodiments, Yis NRY. In certain embodiments, RY is en or a
nitrogen protecting group.
In certain embodiments, W is O and Y is O. In certain embodiments, W is O
and Y is S. In certain embodiments, W is O and Y is NRY. In certain ments, W is S
and Y is O. In certain embodiments, W is S and Y is S. In certain ments, W is S and
Y is NRY. In certain embodiments, W is NRW and Y is O. In certain embodiments, W is
NRW and Y is S. In certain ments, W is NRW and Y is NRY.
As generally defined above, R8 is hydrogen, a group of the formula (i), (ii), or
(iii), or a group of the formula (v):
wherein R2, R3, R5, Z, m, and n are as defined in Formula (I), provided at least one ce
of RW, R2, 113,118,116 or R8 is a group of the formula (i),
, R7, (ii), or (iii).
] In certain embodiments, R8 is hydrogen.
In certain embodiments, R8 is a group of the formula (i), (ii), or (iii). In certain
embodiments, R8 is a group of the formula (i). In certain embodiments, R8 is a group of the
formula (ii). In certain embodiments, R8 is a group of the formula (iii).
In certain embodiments, R8 is a group of the formula (V). In certain
ments, R8 is a group of the formula (V) and R2 is a group of the formula (i), (ii), or
(iii). In certain embodiments, R8 is a group of the formula (V) and R3 is a group of the
formula (i), (ii), or (iii).
In certain embodiments, at least one R1 is a group of formula (iv) and R6 is a
group of the formula (i), (ii), or (iii). In certain embodiments, at least one R1 is a group of
formula (iv) and R7 is a group of the a (i), (ii), or (iii). In n embodiments, at least
one R1 is a group of formula (iv), and both R6 and R7 are independently groups of the formula
(i), (ii), or (iii).
Alternatively, in certain embodiments, R8 and the nt R1 group are joined
to form an ally substituted 5—6 membered heterocyclic ring, e.g., a 5—membered
heterocyclic ring, e.g., an optionally substituted pyrrolidinyl ring.
Various combinations of the above embodiments of a (II) are
contemplated herein.
For example, in certain embodiments, wherein each instance of R’ is hydrogen,
W is O and Y is O, the compound of Formula (II) is a nd of Formula (II—a):
RS’N\ARL (II—a)
or salt f. In certain embodiments, R8 is a group of the formula (i), (ii), or (iii). In
certain embodiments, R8 is a group of the formula (V) and R2 is a group of the formula (i),
(ii), or (iii). In n embodiments, R8 is a group of the formula (V) and R3 is a group of the
formula (i), (ii), or (iii). In certain embodiments, at least one R1 is a group of formula (iv). In
certain embodiments, R1 is a group of formula (iv) and R6 is a group of the formula (i), (ii), or
(iii). In certain embodiments, R1 is a group of formula (iv) and R7 is a group of the formula
(i), (ii), or (iii). In certain embodiments, both R6 and R7 are independently groups of the
formula (i), (ii), or (iii).
In certain embodiments of Formula (II—a), wherein R1 alpha to the group —
C(=O)—O— is a group of formula (iv), provided is a compound of Formula (II—b):
R7—N—LWJKFf o
RS’N\ARL (II-b)
or salt thereof. In certain embodiments, L is an optionally substituted alkylene. In certain
embodiments, R6 is a group of formula (i). In certain embodiments, R6 is a group of formula
(ii). In certain embodiments, R6 is a group of formula (iii). In certain embodiments, R7 is a
group of formula (i). In certain embodiments, R7 is a group of formula (ii). In certain
embodiments, R7 is a group of formula (iii). In certain embodiments, both R6 and R7 are
independently groups of the formula (i), (ii), or (iii).
In certain embodiments of Formula (II—a), wherein R8 is a group of formula (V),
provided is a nd of Formula (II—c):
“ (II-c)
or salt thereof. In certain embodiments, at least one R1 is a group of formula (iV). In certain
embodiments, R2 is a group of a (i). In n embodiments, R2 is a group of formula
(ii). In certain embodiments, R2 is a group of formula (iii). In certain ments, R3 is a
group of formula (i). In certain embodiments, R3 is a group of formula (ii). In certain
embodiments, R3 is a group of formula (iii). In certain embodiments, R5 is hydrogen. In
n embodiments, Z is O. In certain embodiments, n is 0. In certain embodiments, n is 1.
In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is
4. In certain embodiments, n is 5. In n embodiments, m is 1.
In n embodiments of Formula (II—c), wherein R1 alpha to the group —
C(=O)—O— is a group of a (iV), ed is a compound of Formula (II—cl):
Fr 0
R7—N—L\‘/U\O2
R3 I5 N\)\RL
| N
RZ—N m
n (II—cl)
or salt thereof. In certain embodiments, L is an optionally substituted alkylene. In certain
embodiments, R6 is a group of formula (i). In certain embodiments, R6 is a group of a
(ii). In certain embodiments, R6 is a group of formula (iii). In certain embodiments, R7 is a
group of formula (i). In certain embodiments, R7 is a group of formula (ii). In certain
embodiments, R7 is a group of formula (iii). In certain embodiments, both R6 and R7 are
independently groups of the formula (i), (ii), or (iii).
In certain embodiments of Formula (II—c), n each ce of R1 provided
in group R8 is a group of formula (iv), provided is a compound of Formula (II—c2):
(II-c2)
or salt thereof. In certain embodiments, L is an ally substituted alkylene. In certain
embodiments, R6 is a group of formula (i). In certain ments, R6 is a group of formula
(ii). In certain embodiments, R6 is a group of formula (iii). In n embodiments, R7 is a
group of formula (i). In certain embodiments, R7 is a group of formula (ii). In certain
ments, R7 is a group of a (iii). In certain embodiments, both R6 and R7 are
independently groups of the formula (i), (ii), or (iii).
In certain embodiments of Formula (II—c), wherein each instance of R1 is a
group of formula (iv), provided is a nd of Formula (II—c3):
R6 o
(II—c3)
or salt thereof. In certain embodiments, L is an optionally substituted alkylene. In certain
embodiments, R6 is a group of formula (i). In certain ments, R6 is a group of formula
(ii). In certain embodiments, R6 is a group of formula (iii). In certain embodiments, R7 is a
group of formula (i). In certain embodiments, R7 is a group of formula (ii). In certain
ments, R7 is a group of formula (iii). In certain embodiments, both R6 and R7 are
independently groups of the a (i), (ii), or (iii).
In certain embodiments of Formula (II—a), wherein R8 is a group of formula (i),
provided is a nd of Formula (II—d):
R YP /\\/N\)\RL
RL (II—d)
or salt thereof. In certain embodiments, R1 is hydrogen. In certain ments, R1 is a
group of formula (iv). In certain embodiments, R1 is a group of formula (iv) and R6 is a group
of the formula (i), (ii), or (iii). In certain ments, R1 is a group of formula (iv) and both
R6 and R7 are independently groups of the formula (i), (ii), or (iii).
In certain embodiments of Formula (II—d), wherein R1 alpha to the group —
C(=O)—O— is a group of formula (iv), provided is a compound of Formula (II—dl):
RL (II—d1)
or salt thereof. In certain ments, L is an optionally tuted alkylene. In certain
embodiments, R6 is a group of formula (i). In certain embodiments, R6 is a group of a
(ii). In certain embodiments, R6 is a group of formula (iii). In certain embodiments, R7 is a
group of formula (i). In certain embodiments, R7 is a group of a (ii). In n
embodiments, R7 is a group of formula (iii). In certain embodiments, both R6 and R7 are
independently groups of the formula (i), (ii), or (iii).
In certain embodiments of Formula (II—a), wherein R8 is a group of formula (ii),
provided is a compound of Formula (II—e):
O (II—e)
or salt thereof. In certain embodiments, R1 is hydrogen. In certain embodiments, R1 is a
group of formula (iv). In certain embodiments, R1 is a group of formula (iv) and R6 is a group
of the formula (i), (ii), or (iii). In certain embodiments, R1 is a group of formula (iv) and both
R6 and R7 are independently groups of the formula (i), (ii), or (iii).
In certain ments of Formula (II—e), n R1 alpha to the group —
C(=O)—O— is a group of formula (iv), provided is a nd of Formula (II—el):
R6 o
R —N—L7
\ARL
O (II-el)
or salt thereof. In certain embodiments, L is an optionally substituted alkylene. In certain
embodiments, R6 is a group of formula (i). In certain embodiments, R6 is a group of formula
(ii). In certain embodiments, R6 is a group of formula (iii). In certain embodiments, R7 is a
group of formula (i). In certain embodiments, R7 is a group of formula (ii). In n
embodiments, R7 is a group of formula (iii). In certain embodiments, both R6 and R7 are
ndently groups of the a (i), (ii), or (iii).
In certain embodiments of Formula (II—a), wherein R8 is a group of formula
(iii), provided is a nd of Formula (II—f):
RLVN\ARL (II-f)
or salt thereof. In certain embodiments, R1 is hydrogen. In certain embodiments, R1 is a
group of formula (iv). In certain embodiments, R1 is a group of formula (iv) and R6 is a group
of the formula (i), (ii), or (iii). In certain embodiments, R1 is a group of formula (iv) and both
R6 and R7 are independently groups of the formula (i), (ii), or (iii).
In certain embodiments of Formula (II—f), wherein R1 alpha to the group —
C(=O)—O— is a group of formula (iv), provided is a compound of Formula (II—fl):
R6 o
R7—rlJ—L\Hko
RVNL \ARL (II—f1)
or salt thereof. In certain embodiments, L is an optionally substituted alkylene. In certain
embodiments, R6 is a group of a (i). In certain embodiments, R6 is a group of formula
(ii). In certain ments, R6 is a group of formula (iii). In certain ments, R7 is a
group of formula (i). In certain embodiments, R7 is a group of formula (ii). In certain
embodiments, R7 is a group of formula (iii). In certain embodiments, both R6 and R7 are
independently groups of the formula (i), (ii), or (iii).
] In certain embodiments of Formula (II—a), wherein R1 and R8 are joined to form
an optionally substituted 5—6 membered heterocyclic ring, provided is a compound of
Formula (11—g):
KARL (II-g)
or salt thereof. In certain embodiments, L is an optionally substituted alkylene.
Compounds ofFormula (111)
Compounds of Formula (111) are the cyclic condensation t of the same or
different two, three, four, five, siX, seven, eight, nine, or ten amino acids, and which further
comprise one or more sites of conjugation attached thereto, e.g., to an internal amide
nitrogen, to an amino substituent, and/or to an imino nitrogen, of a group of formula (i), (iii),
or (iii). Such groups may be conjugated before cyclization, i.e., to the amino acid precursors
of the cyclization product, or after cyclization.
internal amide
nitrogens amino tuents imino nitrogens
] Thus, in a third , ed is a compound of Formula (111):
or salt thereof;
wherein:
p is an integer of n 1 and 9, inclusive;
each instance of Q is independently O, S, or NRQ, wherein RQ is hydrogen, optionally
substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally
substituted carbocyclyl, optionally substituted heterocyclyl, optionally tuted aryl,
optionally substituted heteroaryl, a nitrogen protecting group, or a group of the formula (i),
(ii), (iii);
each instance of R1 is independently hydrogen, optionally substituted alkyl, optionally
substituted l, optionally substituted alkynyl, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally substituted aryl, ally tuted
heteroaryl, halogen, —ORA1, —N(RA1)2, or —SRA1; wherein each occurrence of RAl is
independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl,
optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted
heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen
ting group when attached to an oxygen atom, a sulfur protecting group when attached
to an sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two RAl
groups are joined to form an optionally substituted cyclic or optionally substituted
heteroaryl ring; and
each instance of R2 is independently hydrogen, optionally substituted alkyl, optionally
substituted l, optionally substituted alkynyl, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, a nitrogen ting group, or a group of the formula (i), (ii), or (iii); and
Formulae (i), (ii), and (iii) are:
RLB—YRP
H\ RL
RI :4
(1) (ii) (iii)
wherein:
each ce of R’ is independently hydrogen or ally substituted alkyl;
X is O, S, NRX, wherein RX is hydrogen, optionally substituted alkyl, optionally
substituted alkenyl, optionally substituted alkynyl, optionally tuted carbocyclyl,
optionally substituted heterocyclyl, ally substituted aryl, optionally substituted
heteroaryl, or a nitrogen protecting group;
Y is O, S, NRY, wherein RY is hydrogen, optionally substituted alkyl, optionally
substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, ally substituted aryl, optionally substituted
heteroaryl, or a nitrogen protecting group;
RP is hydrogen, optionally substituted alkyl, ally substituted alkenyl, optionally
substituted alkynyl, optionally substituted yclyl, optionally substituted heterocyclyl,
optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group
when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom,
or a nitrogen protecting group when attached to a nitrogen atom; and
RL is optionally substituted C150 alkyl, optionally tuted C250 alkenyl, optionally
substituted C250 alkynyl, ally substituted heteroC1_50 alkyl, optionally substituted
heteroC2_50 alkenyl, optionally substituted heteroC2_50 alkynyl, or a polymer;
provided that at least one instance of RQ, R2, R6, or R7 is a group of the formula (i),
(ii), or (iii).
As generally defined above, p is an integer of between 1 and 9, inclusive. In
certain embodiments, p is 1. In certain ments, p is 2. In certain embodiments, p is 3. In
certain embodiments, p is 4. In certain ments, p is 5. In certain embodiments, p is 6.
In certain embodiments, p is 7. In certain embodiments, p is 8. In n embodiments, p is
For example, in certain embodiments, wherein p is l, the compound of Formula
(III) is a compound of Formula (III—a):
R2 R1
0&0\N
R1 R2 (III—a)
or salt thereof.
In certain embodiments, wherein p is 2, the compound of Formula (III) is a
compound of Formula (III—b):
RRZ/Nfi
Q (III-b)
or salt f.
In n embodiments, wherein p is 3, the compound of Formula (III) is a
compound of Formula (III—c):
R2 R1 (III-c)
or salt thereof.
In certain embodiments, wherein p is 4, the compound of Formula (III) is a
compound of Formula (III—d):
Q R1
RVkILJYQR2 R2
Q R (III-d)
or salt thereof.
] In certain ments, wherein p is 5, the compound of Formula (III) is a
compound of Formula (III—e):
Q R1
RKkaJYQ
Q R1
Rj:N’R2 $2 R2\N:\l:oN\R2 R2 Rz,N
QA/Nfiw
R1 0 )
or salt thereof.
In certain embodiments, wherein p is 6, the compound of Formula (III) is a
compound of Formula (III—f):
Q (III-f)
or salt thereof.
In certain embodiments, wherein p is 7, the compound of a (111) is a
compound of Formula (III—g):
1 Q
Q R1
R1 N\ IN Q
R2 R2
R1QjN\R2N/R2 R2RZ’NZW\ Q
R2 2
R1 a Q
Q R1 (111-g)
or salt thereof.
In certain embodiments, wherein p is 8, the nd of Formula (111) is a
compound of Formula (III—h):
R1 R2 (III—h)
or salt thereof.
2012/062222
] In certain embodiments, wherein p is 9, the compound of Formula (III) is a
compound of a (III—i):
QR1RZQR1
RVfNJYlfideJYQ
or salt thereof.
As generally defined above, each instance of R’ is independently hydrogen or
optionally substituted alkyl. In certain embodiments, at least one instance of R’ is hydrogen.
In certain embodiments, at least two instances of R’ is hydrogen. In certain ments,
each instance of R’ is hydrogen. In certain embodiments, at least one instance of R’ is
optionally substituted alkyl, e.g., . In certain embodiments, at least two instances of R’
is optionally substituted alkyl, e.g., . In certain embodiments, one instance of R’ is
optionally substituted alkyl, and the rest are hydrogen.
As generally defined above, each ce of Q is independently O, S, or NRQ,
wherein RQ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl,
optionally substituted l, optionally substituted carbocyclyl, ally substituted
heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen
protecting group, or a group of the formula (i), (ii), or (iii). In certain ments, at least
one instance of Q is O. In n embodiments, each instance of Q is O. In certain
embodiments, at least one instance of Q is S. In certain embodiments, each instance of Q is
S. In certain embodiments, at least one instance of Q is NRZ. In certain embodiments, each
instance of Q is NRZ. In certain embodiments, each instance of RQ is independently
hydrogen or a group of the formula (i), (ii), or (iii).
] As generally defined above, each instance of R1 is independently hydrogen,
optionally tuted alkyl, optionally substituted alkenyl, optionally substituted alkynyl,
optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted
aryl, optionally tuted heteroaryl, halogen, —ORA1, —N(RA1)2, or —SRA1.
In certain embodiments, at least one instance of R1 is optionally substituted
alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted
carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally
substituted heteroaryl.
In certain embodiments, at least one instance of R1 is optionally substituted
alkyl; e.g., optionally substituted C1_6alkyl, ally substituted C2_6alkyl, optionally
tuted C3_6alkyl, optionally substituted C4_6alkyl, optionally substituted C4_5alkyl, or
optionally substituted C34alkyl.
In certain embodiments, at least one ce of R1 is optionally substituted
alkenyl, e.g., optionally substituted C2_6alkenyl, optionally substituted C3_6alkenyl, optionally
substituted C4_6alkenyl, optionally substituted C4_5alkenyl, or optionally substituted C3-
4alkenyl.
In certain embodiments, at least one instance of R1 is optionally tuted
alkynyl, e.g., optionally substituted C2_6alkynyl, optionally substituted C3_6alkynyl, optionally
substituted C4_6alkynyl, optionally substituted C4_5alkynyl, or optionally substituted C3-
4alkynyl.
In certain embodiments, at least one instance of R1 is optionally substituted
carbocyclyl, e.g., optionally substituted C3_10 carbocyclyl, optionally substituted C5_g
carbocyclyl, optionally substituted C5_6 yclyl, optionally substituted C5 yclyl, or
ally tuted C6 carbocyclyl.
In certain ments, at least one instance of R1 is optionally substituted
heterocyclyl, e.g., optionally substituted 3—14 membered heterocyclyl, optionally substituted
3—10 membered heterocyclyl, optionally substituted 5—8 membered heterocyclyl, ally
substituted 5—6 membered heterocyclyl, optionally substituted 5 membered heterocyclyl, or
optionally substituted 6 ed heterocyclyl.
In certain embodiments, at least one instance of R1 is optionally substituted
aryl, e.g., optionally substituted phenyl.
In certain embodiments, at least one instance of R1 is optionally substituted
heteroaryl, e.g., optionally substituted 5—14 membered heteroaryl, optionally tuted 5—10
membered heteroaryl, optionally substituted 5—6 ed heteroaryl, optionally substituted
membered heteroaryl, or optionally substituted 6 membered heteroaryl.
In any of the above embodiments, the R1 alkyl, alkenyl, alkynyl, carbocyclyl,
cyclyl, aryl, or heteroaryl group may be tuted, for example, with an optionally
substituted amino group (e.g., ), an optionally tuted hydroxyl group (e.g., —OR6),
an ally substituted thiol group (e.g., —SR6), or with a group of formula (i), (ii), or (iii),
wherein each instance of R6 and R7 is independently hydrogen, optionally substituted alkyl,
ally substituted alkenyl, optionally substituted alkynyl, optionally substituted
carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, ally
substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an
oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group
when attached to a sulfur atom, or a group of formula (i), (ii), or (iii).
For example, in certain embodiments, at least one ce of R1 is an alkyl,
alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl group tuted with an
amino group of the formula —N(R6)(R7). In that instance, in certain embodiments, at least one
instance of R1 is a group of formula:
wherein:
L is an optionally substituted alkylene, optionally tuted alkenylene, optionally
substituted alkynylene, optionally substituted heteroalkylene, optionally substituted
heteroalkenylene, optionally substituted heteroalkynylene, ally substituted
carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, or
ally substituted heteroarylene, or combination thereof, and
R6 and R7 are independently selected from the group consisting of hydrogen,
optionally substituted alkyl, optionally tuted alkenyl, optionally tuted alkynyl,
optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted
aryl, optionally substituted heteroaryl, and a nitrogen protecting group;
provided at least one instance of R6 and R7 is a group of the formula (i), (ii), or (iii):
R‘ XRL
RQ—YRP
§—§RI § 0 R'-
R. or g_/
(i) (ii) (iii)
wherein R’, X, Y, RL, and RP are as defined herein.
In certain embodiments, at least two instances of R1 is a group of formula (iv).
In certain embodiments, at least three instances of R1 is a group of formula (iv). In certain
embodiments, at least four instances of R1 is a group of formula (iv). In certain embodiments,
at least five ces of R1 is a group of formula (iv). In certain embodiments, at least six
instances of R1 is a group of a (iv). In certain embodiments, at least seven ces of
R1 is a group of formula (iv). In certain embodiments, at least eight instances of R1 is a group
2012/062222
of formula (iV). In certain embodiments, at least nine instances of R1 is a group of formula
(iv). In certain embodiments, each instance of R1 is a group of formula (iv).
In certain ments, L is an optionally substituted alkylene; e.g., optionally
substituted C1_50alkylene, optionally substituted C1_40alkylene, optionally tuted C1-
lene, optionally substituted lkylene, optionally substituted C4_20alkylene,
optionally substituted C6_20alkylene, optionally substituted Cg_20all<ylene, optionally
substituted C10_20alkylene, optionally substituted C1_6alkylene, optionally substituted C2-
6alkylene, optionally substituted C3_6alkylene, optionally substituted C4_6alkylene, optionally
substituted C4_5alkylene, or optionally substituted C3_4alkylene.
] In certain embodiments, L is an optionally substituted lene, e.g.,
optionally substituted C2_50alkenylene, optionally substituted C2_40alkenylene, optionally
substituted C2_30alkenylene, optionally substituted Cnoalkenylene, optionally substituted C4-
nylene, optionally substituted lkenylene, optionally substituted Cg_20all<enylene,
optionally substituted C10_20alkenylene, optionally substituted kenylene, optionally
substituted C3_6alkenylene, optionally substituted C4_6alkenylene, optionally substituted C4-
5alkenylene, or optionally substituted C3_4alkenylene.
In certain embodiments, L is an optionally substituted alkynylene, e.g.,
optionally substituted C2_50alkynylene, optionally substituted C2_40alkynylene, ally
substituted C2_30alkynylene, optionally substituted Cnoalkynylene, ally substituted C4-
goalkynylene, optionally substituted C6_20alkynylene, optionally substituted ll<ynylene,
optionally substituted C10_20alkynylene, ally substituted C2_6alkynylene, optionally
substituted C3_6alkynylene, optionally substituted C4_6alkynylene, optionally substituted C4-
5alkynylene, or optionally substituted C3_4alkynylene.
In certain embodiments, L is an optionally substituted heteroalkylene; e.g.,
optionally substituted heteroC1_50alkylene, optionally substituted heteroC1_40alkylene,
optionally substituted C1_30alkylene, optionally substituted heteroC1_20alkylene,
optionally substituted C4_20alkylene, optionally substituted heteroC6_20alkylene,
optionally substituted heterng_20all<ylene, optionally substituted heteroC10_20alkylene,
optionally tuted C1_6alkylene, optionally substituted heteroC2_6alkylene,
optionally substituted heteroC3_6alkylene, optionally substituted heteroC4_6alkylene,
optionally substituted heteroC4_5alkylene, or ally substituted heteroC3_4alkylene.
In n embodiments, L is an optionally substituted heteroalkenylene, e.g.,
optionally tuted heteroC2_50alkenylene, optionally substituted heteroC2_40alkenylene,
optionally substituted heteroC2_30alkenylene, optionally substituted heteroC2_20alkenylene,
optionally substituted heteroC4_20alkenylene, optionally substituted heteroC6_20alkenylene,
optionally substituted g_20all<enylene, optionally substituted heteroC10_20alkenylene,
optionally substituted heteroC2_6alkenylene, optionally substituted heteroC3_6alkenylene,
optionally tuted heteroC4_6alkenylene, ally substituted C4_5alkenylene, or
optionally substituted heteroC3_4alkenylene.
In certain embodiments, L is an optionally substituted heteroalkynylene, e.g.,
optionally substituted heteroC2_50alkynylene, optionally substituted heteroC2_40alkynylene,
optionally tuted heteroC2_30alkynylene, optionally substituted heteroC2_20all<ynylene,
optionally substituted heteroC4_20alkynylene, optionally substituted heteroC6_20alkynylene,
optionally substituted heterng_20all<ynylene, optionally substituted heteroC10_20alkynylene,
optionally substituted heteroC2_6alkynylene, optionally substituted heteroC3_6alkynylene,
optionally substituted heteroC4_6alkynylene, optionally substituted heteroC4_5alkynylene, or
optionally substituted heteroC3_4alkynylene.
In certain embodiments, L is an optionally substituted carbocyclylene, e.g.,
optionally substituted C340 carbocyclylene, optionally substituted C5_g carbocyclylene,
optionally substituted C5_6 yclylene, optionally substituted C5 carbocyclylene, or
optionally substituted C6 carbocyclylene.
In certain embodiments, L is an optionally substituted heterocyclylene, e.g.,
optionally substituted 3— l4 membered heterocyclylene, optionally substituted 3—10 membered
heterocyclylene, ally substituted 5—8 membered heterocyclylene, optionally substituted
—6 membered heterocyclylene, optionally substituted 5 membered heterocyclylene, or
ally substituted 6 membered heterocyclylene.
In certain ments, L is an optionally substituted arylene, e.g., optionally
substituted phenylene.
In certain embodiments, L is an optionally substituted heteroarylene, e.g.,
optionally substituted 5— l4 membered heteroarylene, optionally tuted 5—10 membered
heteroarylene, ally substituted 5—6 membered heteroarylene, optionally substituted 5
membered heteroarylene, or optionally tuted 6 membered heteroarylene.
For example, in certain embodiments, wherein L is an ally substituted
ne group, the group of formula (iV) is a group of the a:
wherein q is an integer between 1 and 50, inclusive.
In n embodiments, q is an integer between 1 and 40, inclusive. In certain
embodiments, q is an integer between 1 and 30, inclusive. In certain embodiments, q is an
r between 1 and 20, inclusive. In certain embodiments, q is an integer n 4 and
, inclusive. In certain embodiments, q is an integer between 6 and 20, inclusive. In certain
embodiments, q is an integer n 8 and 20, inclusive. In n embodiments, q is 1. In
n embodiments, q is 2. In certain embodiments, q is 3. In certain embodiments, q is 4. In
certain embodiments, q is 5. In certain embodiments, q is 6. In certain embodiments, q is 7. In
certain embodiments, q is 8. In certain embodiments, q is 9. In certain embodiments, q is 10.
In certain embodiments, both R6 and R7 are hydrogen. In certain embodiments,
R6 is hydrogen and R7 is a group of the formula (i), (ii), or (iii). In certain embodiments, R6 is
hydrogen and R7 is a group of the a (i). In certain embodiments, R6 is hydrogen and
R7 is a group of the formula (ii). In certain embodiments, R6 is hydrogen and R7 is a group of
the a (iii). In certain embodiments, both R6 and R7 are independently a group of the
formula (i), (ii), or (iii). In certain ments, both R6 and R7 are independently a group of
the formula (i). In certain embodiments, both R6 and R7 are independently a group of the
formula (ii). In certain embodiments, both R6 and R7 are independently a group of the
formula (iii). In certain embodiments, both R6 and R7 are the same group, selected from a
group of the formula (i), (ii), or (iii).
It is tood that R1 encompasses amino acid side chains such as
exemplified in Table l of the Examples. In certain embodiments, R1 is a group selected from
any one of the amino acid side chain groups listed therein.
In certain embodiments, each instance of R1 is the same. In certain
embodiments, at least one R1 group is different. In certain embodiments, each R1 group is
different.
As generally d above, each instance of R2 is independently hydrogen,
ally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl,
optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted
aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of the formula
(i), (ii), or (iii):
. Fa' )(FRL
H; o
R, 01' §_/RL
(i) (ii) (iii)
wherein R’, X, Y, RL, and RP are as defined herein.
In certain ments, at least one ce of R2 is optionally substituted
alkyl; e.g., optionally substituted C1_6alkyl, optionally substituted C2_6alkyl, optionally
substituted kyl, optionally substituted C4_6alkyl, optionally substituted C4_5alkyl, or
ally substituted C34alkyl.
In certain embodiments, at least one instance of R2 is optionally substituted
alkenyl, e.g., optionally substituted kenyl, optionally substituted kenyl, optionally
substituted C4_6alkenyl, optionally substituted C4_5alkenyl, or optionally substituted C3-
4alkenyl.
In certain embodiments, at least one instance of R2 is ally substituted
alkynyl, e.g., optionally substituted C2_6alkynyl, optionally substituted C3_6alkynyl, optionally
substituted kynyl, optionally substituted C4_5alkynyl, or optionally substituted C3-
4alkynyl.
In certain embodiments, at least one instance of R2 is optionally substituted
carbocyclyl, e.g., optionally substituted C3_10 carbocyclyl, optionally substituted C5_g
carbocyclyl, optionally substituted C5_6 carbocyclyl, ally substituted C5 carbocyclyl, or
optionally substituted C6 carbocyclyl.
In certain embodiments, at least one instance of R2 is optionally substituted
heterocyclyl, e.g., optionally substituted 3—14 membered heterocyclyl, optionally substituted
3—10 ed heterocyclyl, optionally substituted 5—8 ed heterocyclyl, optionally
substituted 5—6 membered heterocyclyl, optionally substituted 5 membered heterocyclyl, or
optionally substituted 6 membered heterocyclyl.
] In certain embodiments, at least one instance of R2 is optionally substituted
aryl, e.g., optionally substituted phenyl.
In certain embodiments, at least one instance of R2 is optionally substituted
heteroaryl, e.g., optionally substituted 5—14 membered heteroaryl, optionally substituted 5—10
membered heteroaryl, optionally substituted 5—6 membered heteroaryl, optionally tuted
ed heteroaryl, or ally substituted 6 membered heteroaryl.
In certain embodiments, at least one instance of R2 is a nitrogen ting
group.
In certain embodiments, at least one instance of R2 is a group of the formula (i).
In certain embodiments, at least one instance of R2 is a group of the formula (ii). In certain
ments, at least one instance of R2 is a group of the formula (iii).
In certain embodiments, each instance of R2 is a group other than formula (i),
(ii), or (iii); in that instance, it follows that at least one RQ is a group of the formula (i), (ii), or
(iii), or at least one R1 is a group of a (iv), and at least one of R6 or R7 encompassed by
R1 is a group of the formula (i), (ii), or (iii). For example, in n embodiments, both
instances of R2 are hydrogen, and thus at least one RQ is a group of the formula (i), (ii), or
(iii), or at least one R1 is a group of formula (iv), and at least one of R6 or R7 encompassed by
R1 is a group of the formula (i), (ii), or (iii).
s combinations of the above embodiments of Formula (III) are
contemplated .
] For example, in certain ments, wherein each instance of Q is O, the
compound of Formula (III) is a compound of Formula (III—a):
p (III-a)
or salt thereof. In certain embodiments, at least one R1 is a group of formula (iv). In certain
embodiments, each instance of R1 is a group of formula (iv). In certain embodiments, each
instance of R2 is hydrogen. In certain embodiments, at least one instance of R2 is a group of
formula (i). In n embodiments, at least one instance of R2 is a group of formula (ii). In
certain embodiments, at least one instance of R2 is a group of formula (iii). In certain
embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3.
In n embodiments of Formula (III—a), wherein at least one R1 is a group
the formula (iv), provided is a compound of Formula (III—b):
(III-b)
or salt thereof. In certain embodiments, each instance of R1 is a group of formula (iv). In
certain embodiments, R2 is hydrogen. In certain ments, each instance of R2 is
hydrogen. In certain embodiments, at least one instance of R2 is a group of formula (i). In
n embodiments, at least one instance of R2 is a group of formula (ii). In certain
embodiments, at least one instance of R2 is a group of formula (iii). In certain embodiments,
p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain
embodiments, L is an optionally tuted alkylene. In certain embodiments, R6 is a group
of formula (i). In certain embodiments, R6 is a group of formula (ii). In n embodiments,
R6 is a group of formula (iii). In certain embodiments, R7 is a group of formula (i). In certain
embodiments, R7 is a group of a (ii). In certain embodiments, R7 is a group of a
(iii). In certain embodiments, both R6 and R7 are independently groups of formula (i), (ii), or
(iii).
In certain embodiments of Formula (III—a), wherein each instance of R1 is a
group the formula (iV), provided is a compound of Formula ):
(III-c)
or salt thereof. In certain embodiments, each instance of R2 is hydrogen. In certain
embodiments, at least one instance of R2 is a group of formula (i). In certain embodiments, at
least one instance of R2 is a group of formula (ii). In certain embodiments, at least one
instance of R2 is a group of formula (iii). In certain ments, p is 1. In certain
embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, L is an
optionally substituted alkylene. In certain embodiments, R6 is a group of formula (i). In
certain embodiments, R6 is a group of formula (ii). In n embodiments, R6 is a group of
formula (iii). In n embodiments, R7 is a group of formula (i). In certain embodiments,
R7 is a group of formula (ii). In certain embodiments, R7 is a group of formula (iii). In n
embodiments, both R6 and R7 are independently groups of formula (i), (ii), or (iii).
In certain embodiments of Formula (III—c), wherein p is 1, provided is a
compound of Formula (III—cl):
Riff/R7
R7 (III-cl)
or salt f. In certain embodiments, each instance of R2 is hydrogen. In certain
embodiments, at least one instance of R2 is a group of formula (i). In certain embodiments, at
least one instance of R2 is a group of formula (ii). In n embodiments, at least one
instance of R2 is a group of formula (iii). In certain embodiments, L is an optionally
substituted alkylene. In certain embodiments, R6 is a group of formula (i). In certain
embodiments, R6 is a group of formula (ii). In certain embodiments, R6 is a group of formula
(iii). In certain ments, R7 is a group of formula (i). In certain embodiments, R7 is a
group of formula (ii). In certain embodiments, R7 is a group of formula (iii). In certain
embodiments, both R6 and R7 are independently groups of formula (i), (ii), or (iii).
In certain ments of Formula (III—cl), wherein each instance of R2 is
hydrogen, provided is a compound of Formula (III—c2):
R6\N,R7
R§N_L 0:31HN—$:o 6 NH
R7 (III-c2)
or salt thereof. In certain ments, L is an optionally substituted alkylene. In certain
ments, R6 is a group of formula (i). In certain embodiments, R6 is a group of formula
(ii). In certain embodiments, R6 is a group of formula (iii). In certain ments, R7 is a
group of formula (i). In n ments, R7 is a group of formula (ii). In certain
embodiments, R7 is a group of formula (iii). In certain embodiments, both R6 and R7 are
groups of formula (i), (ii), or (iii).
In certain embodiments of Formula (III—cl), wherein L is an optionally
substituted alkylene, provided is a compound of Formula 3):
R6\N,R7
o o
R\6 NH
IN q
R7 (III-c3)
or salt thereof, wherein q is an integer between 1 and 10, inclusive. In certain embodiments,
R6 is a group of formula (i). In certain embodiments, R6 is a group of formula (ii). In certain
ments, R6 is a group of formula (iii). In certain embodiments, R7 is a group of formula
WO 63468
(i). In certain embodiments, R7 is a group of formula (ii). In certain embodiments, R7 is a
group of formula (iii). In certain embodiments, both R6 and R7 are independently groups of
formula (i), (ii), or (iii).
In certain embodiments of Formula (III—a), wherein at least one instance of R2 is
a group of formula (i) and each instance of R’ is hydrogen, provided is a compound of
Formula (III—d):
p (III-d)
or salt thereof. In certain embodiments, at least one R1 is a group of a (iv). In certain
embodiments, each instance of R1 is a group of formula (iv). In certain embodiments, each
instance of R2 is en. In certain embodiments, at least one instance of R2 is a group of
formula (i). In certain embodiments, at least one instance of R2 is a group of a (ii). In
certain embodiments, at least one instance of R2 is a group of formula (iii). In n
embodiments, R2 is a group of formula (iii). In certain embodiments, p is 1. In certain
embodiments, p is 2. In certain embodiments, p is 3.
In n embodiments of Formula (III—a), n at least one instance of R2 is
a group of formula (ii) and each instance of R’ is hydrogen, provided is a compound of
Formula (III—e):
p (III-e)
or salt thereof. In certain ments, at least one R1 is a group of formula (iv). In certain
embodiments, each instance of R1 is a group of formula (iv). In certain embodiments, each
instance of R2 is hydrogen. In certain embodiments, at least one instance of R2 is a group of
formula (i). In certain embodiments, at least one instance of R2 is a group of formula (ii). In
certain embodiments, at least one instance of R2 is a group of formula (iii). In certain
embodiments, p is 1. In certain ments, p is 2. In certain embodiments, p is 3.
In certain embodiments of Formula (III—a), n at least one ce of R2 is
a group of formula (iii), ed is a compound of Formula (III—f):
or salt thereof. In certain embodiments, at least one R1 is a group of formula (iv). In certain
embodiments, each instance of R1 is a group of formula (iv). In n embodiments, each
instance of R2 is hydrogen. In certain embodiments, at least one instance of R2 is a group of
formula (i). In certain embodiments, at least one instance of R2 is a group of formula (ii). In
certain embodiments, at least one instance of R2 is a group of formula (iii). In certain
embodiments, p is 1. In certain embodiments, p is 2. In certain ments, p is 3.
Compounds ofFormula (IV), (V), and (V1)
Compounds of Formula (IV), (V), and (VI), while not ucted from amino
acid starting materials, share the same molecular formula and cyclic motif, and are thus
structural isomers of compounds of Formula (III—a). The present invention embraces each as
exemplary APPL structural isomers of the present invention.
ng:§=Q=_W—2—:g:QR1—<::(:E—R1R2_:;N:l§:jwR2 R1
R1 \R2
(III—a) (IV) (V1)
Thus, in yet another aspect, provided is a compound of a (IV), (V), or
Q} R1jgi§1§£§
(V1)
or salt thereof;
each instance of Q is independently O, S, or NRQ, wherein RQ is hydrogen, optionally
substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally
substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl,
optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii),
(iii);
each instance of R1 is independently hydrogen, optionally substituted alkyl, optionally
substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, halogen, —ORA1, —N(RA1)2, or —SRA1; wherein each occurrence of RAl is
independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl,
optionally substituted l, optionally substituted carbocyclyl, optionally substituted
heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen
protecting group when attached to an oxygen atom, a sulfur protecting group when attached
to an sulfur atom, a en protecting group when attached to a nitrogen atom, or two RAl
groups are joined to form an optionally tuted heterocyclic or optionally substituted
heteroaryl ring;
each instance of R2 is independently hydrogen, ally substituted alkyl, optionally
substituted alkenyl, optionally substituted alkynyl, ally substituted carbocyclyl,
optionally tuted heterocyclyl, optionally substituted aryl, ally substituted
heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii), or (iii); and
Formulae (i), (ii), and (iii) are:
RLB—YRP
H\ RL
RI :4
(1) (ii) (iii)
wherein:
each instance of R’ is ndently hydrogen or optionally substituted alkyl;
X is O, S, NRX, wherein RX is hydrogen, optionally substituted alkyl, optionally
tuted alkenyl, ally substituted alkynyl, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally tuted aryl, optionally substituted
heteroaryl, or a nitrogen protecting group;
Y is O, S, NRY, wherein RY is hydrogen, optionally substituted alkyl, ally
substituted alkenyl, ally substituted alkynyl, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, or a nitrogen protecting group;
RP is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally
substituted alkynyl, optionally substituted yclyl, optionally substituted heterocyclyl,
optionally tuted aryl, optionally substituted heteroaryl, an oxygen protecting group
when attached to an oxygen atom, a sulfur protecting group when ed to a sulfur atom,
or a nitrogen protecting group when attached to a en atom; and
RL is optionally substituted C150 alkyl, ally substituted C250 alkenyl, optionally
substituted C250 alkynyl, optionally substituted heteroC1_50 alkyl, optionally tuted
heteroC2_50 alkenyl, ally substituted heteroC2_50 alkynyl, or a polymer;
provided that at least one instance of RQ, R2, R6, or R7 is a group of the formula (i),
(ii), or (iii).
As generally defined above, each instance of Q is independently O, S, or NRQ,
wherein RQ is hydrogen, optionally tuted alkyl, optionally substituted alkenyl,
optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted
heterocyclyl, optionally substituted aryl, optionally tuted heteroaryl, a nitrogen
protecting group, or a group of the formula (i), (ii), or (iii). In certain embodiments, at least
one instance of Q is O. In certain embodiments, each instance of Q is O. In certain
embodiments, at least one instance of Q is S. In certain ments, each instance of Q is
S. In certain embodiments, at least one instance of Q is NRZ. In certain ments, each
instance of Q is NRZ. In certain embodiments, each ce of RQ is independently
hydrogen or a group of the formula (i), (ii), or (iii).
As generally defined above, each instance of R’ is independently hydrogen or
optionally substituted alkyl. In certain embodiments, at least one instance of R’ is hydrogen.
In certain embodiments, at least two instances of R’ is hydrogen. In certain embodiments,
each instance of R’ is hydrogen. In certain embodiments, at least one instance of R’ is
optionally substituted alkyl, e.g., methyl. In certain embodiments, at least two instances of R’
is ally substituted alkyl, e.g., methyl. In certain embodiments, one instance of R’ is
optionally substituted alkyl, and the rest are hydrogen.
As generally defined above, each instance of R1 is independently hydrogen,
optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl,
optionally substituted yclyl, optionally substituted heterocyclyl, optionally tuted
aryl, optionally substituted heteroaryl, n, —ORA1, —N(RA1)2, or —SRA1.
In certain embodiments, at least one instance of R1 is optionally tuted
alkyl, optionally substituted alkenyl, optionally substituted alkynyl, ally substituted
carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally
substituted heteroaryl.
In n embodiments, at least one instance of R1 is optionally substituted
alkyl; e.g., optionally substituted C1_6alkyl, optionally tuted kyl, optionally
substituted C3_6alkyl, optionally tuted C4_6alkyl, optionally substituted C4_5alkyl, or
ally substituted C34alkyl.
In certain embodiments, at least one instance of R1 is ally substituted
alkenyl, e.g., optionally tuted C2_6alkenyl, optionally substituted C3_6alkenyl, optionally
substituted C4_6alkenyl, optionally substituted C4_5alkenyl, or optionally substituted C3-
4alkenyl.
In certain embodiments, at least one instance of R1 is optionally substituted
alkynyl, e.g., optionally substituted kynyl, optionally substituted C3_6alkynyl, optionally
substituted C4_6alkynyl, optionally substituted kynyl, or optionally substituted C3-
4alkynyl.
In certain embodiments, at least one instance of R1 is optionally substituted
carbocyclyl, e.g., optionally substituted C3_10 carbocyclyl, optionally substituted C5_g
carbocyclyl, optionally substituted C5_6 carbocyclyl, optionally substituted C5 carbocyclyl, or
ally substituted C6 carbocyclyl.
] In certain embodiments, at least one instance of R1 is optionally substituted
heterocyclyl, e.g., optionally substituted 3—14 membered heterocyclyl, optionally substituted
3—10 membered heterocyclyl, optionally substituted 5—8 membered heterocyclyl, ally
substituted 5—6 ed heterocyclyl, optionally substituted 5 membered heterocyclyl, or
optionally substituted 6 membered heterocyclyl.
In certain embodiments, at least one instance of R1 is optionally substituted
aryl, e.g., optionally tuted phenyl.
In certain embodiments, at least one instance of R1 is optionally substituted
heteroaryl, e.g., optionally substituted 5—14 ed aryl, optionally substituted 5—10
membered heteroaryl, optionally substituted 5—6 membered heteroaryl, optionally substituted
membered heteroaryl, or optionally substituted 6 membered heteroaryl.
In any of the above embodiments, the R1 alkyl, l, alkynyl, carbocyclyl,
heterocyclyl, aryl, or heteroaryl group may be substituted, for example, with an optionally
substituted amino group (e.g., —NR6R7), an optionally substituted hydroxyl group (e.g., —OR6),
an optionally substituted thiol group (e.g., —SR6), or with a group of formula (i), (ii), or (iii),
n each instance of R6 and R7 is independently hydrogen, optionally substituted alkyl,
WO 63468
optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted
carbocyclyl, ally substituted heterocyclyl, optionally substituted aryl, optionally
substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an
oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group
when ed to a sulfur atom, or a group of formula (i), (ii), or (iii).
For example, in certain embodiments, at least one instance of R1 is an alkyl,
alkenyl, alkynyl, yclyl, heterocyclyl, aryl, or heteroaryl group substituted with an
amino group of the formula —N(R6)(R7). In that instance, in certain embodiments, at least one
instance of R1 is a group of formula:
wherein:
L is an optionally substituted alkylene, optionally substituted alkenylene, ally
substituted alkynylene, optionally substituted heteroalkylene, optionally substituted
alkenylene, ally substituted heteroalkynylene, optionally substituted
carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, or
optionally substituted heteroarylene, or combination thereof, and
R6 and R7 are independently selected from the group ting of hydrogen,
optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl,
optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted
aryl, optionally substituted heteroaryl, and a nitrogen protecting group;
provided at least one instance of R6 and R7 is a group of the formula (i), (ii), or (iii):
é—flR.\ RL
(1) (ii) (iii)
wherein R’, X, Y, RL, and RP are as defined herein.
In n embodiments, both instances of R1 are groups of formula (iv).
In certain embodiments, L is an optionally substituted ne; e.g., optionally
substituted C1_50alkylene, optionally substituted C1_40alkylene, optionally substituted C1-
30alkylene, optionally substituted C1_20alkylene, optionally substituted C4_20alkylene,
optionally substituted C6_20alkylene, ally substituted Cg_20all<ylene, optionally
substituted C10_20alkylene, ally substituted C1_6alkylene, optionally substituted C2-
6alkylene, optionally substituted C3_6alkylene, optionally substituted C4_6alkylene, optionally
tuted C4_5alkylene, or ally substituted C3_4alkylene.
In certain embodiments, L is an optionally substituted alkenylene, e.g.,
optionally substituted C2_50alkenylene, optionally substituted C2_40alkenylene, optionally
substituted C2_30alkenylene, ally substituted C2_20alkenylene, optionally substituted C4-
goalkenylene, optionally substituted C6_20alkenylene, optionally substituted Cg_20all<enylene,
optionally substituted C10_20alkenylene, optionally substituted kenylene, optionally
substituted C3_6alkenylene, optionally substituted C4_6alkenylene, optionally substituted C4-
5alkenylene, or optionally substituted kenylene.
In certain embodiments, L is an optionally substituted alkynylene, e.g.,
ally substituted C2_50alkynylene, optionally substituted C2_40alkynylene, ally
substituted C2_30alkynylene, optionally tuted Cnoalkynylene, optionally substituted C4-
goalkynylene, optionally substituted C6_20alkynylene, optionally substituted Cg_20all<ynylene,
optionally substituted C10_20alkynylene, optionally substituted kynylene, optionally
substituted C3_6alkynylene, optionally substituted C4_6alkynylene, optionally tuted C4-
5alkynylene, or optionally substituted C3_4alkynylene.
In n embodiments, L is an optionally substituted alkylene; e.g.,
optionally substituted heteroC1_50alkylene, optionally substituted C1_40alkylene,
optionally substituted C1_30alkylene, optionally substituted heteroC1_20alkylene,
optionally substituted heteroC4_20alkylene, optionally substituted heteroC6_20alkylene,
optionally substituted heterng_20all<ylene, optionally substituted heteroC10_20alkylene,
optionally tuted heteroC1_6alkylene, optionally substituted heteroC2_6alkylene,
optionally substituted heteroC3_6alkylene, optionally substituted heteroC4_6alkylene,
ally substituted heteroC4_5alkylene, or optionally substituted heteroC3_4alkylene.
In certain embodiments, L is an optionally substituted heteroalkenylene, e.g.,
optionally substituted heteroC2_50alkenylene, optionally substituted heteroC2_40alkenylene,
optionally tuted heteroC2_30alkenylene, optionally substituted heteroC2_20all<enylene,
optionally substituted C4_20alkenylene, optionally tuted heteroC6_20alkenylene,
optionally substituted heterng_20alkenylene, optionally substituted heteroC10_20alkenylene,
optionally tuted heteroC2_6alkenylene, optionally substituted heteroC3_6alkenylene,
optionally substituted heteroC4_6alkenylene, optionally substituted heteroC4_5alkenylene, or
optionally substituted heteroC3_4alkenylene.
In certain embodiments, L is an optionally substituted heteroalkynylene, e.g.,
optionally substituted heteroC2_50alkynylene, optionally substituted heteroC2_40alkynylene,
optionally substituted heteroC2_30alkynylene, optionally substituted heteroC2_20alkynylene,
optionally substituted heteroC4_20alkynylene, optionally substituted heteroC6_20alkynylene,
optionally substituted g_20all<ynylene, optionally substituted heteroC10_20alkynylene,
optionally substituted heteroC2_6alkynylene, optionally substituted C3_6alkynylene,
optionally substituted heteroC4_6alkynylene, optionally substituted heteroC4_5alkynylene, or
optionally substituted heteroC3_4alkynylene.
In n embodiments, L is an optionally substituted carbocyclylene, e.g.,
optionally substituted C340 carbocyclylene, optionally substituted C5_g carbocyclylene,
optionally substituted C5_6 carbocyclylene, optionally tuted C5 carbocyclylene, or
optionally substituted C6 yclylene.
In certain embodiments, L is an optionally substituted heterocyclylene, e.g.,
ally substituted 3— l4 membered cyclylene, optionally substituted 3—10 membered
heterocyclylene, optionally substituted 5—8 membered heterocyclylene, optionally substituted
—6 membered cyclylene, optionally tuted 5 membered heterocyclylene, or
optionally substituted 6 membered heterocyclylene.
In certain embodiments, L is an optionally substituted arylene, e.g., optionally
substituted phenylene.
In certain ments, L is an optionally substituted heteroarylene, e.g.,
optionally substituted 5— l4 membered heteroarylene, optionally substituted 5—10 membered
arylene, optionally substituted 5—6 membered heteroarylene, optionally substituted 5
membered heteroarylene, or optionally substituted 6 membered heteroarylene.
For example, in certain embodiments, wherein L is an optionally substituted
alkylene group, the group of formula (iv) is a group of the formula:
wherein q is an integer between 1 and 50, inclusive.
] In certain embodiments, q is an integer between 1 and 40, inclusive. In certain
embodiments, q is an integer n 1 and 30, inclusive. In certain embodiments, q is an
integer between 1 and 20, inclusive. In certain embodiments, q is an integer between 4 and
, inclusive. In certain ments, q is an integer between 6 and 20, inclusive. In certain
embodiments, q is an integer n 8 and 20, inclusive. In certain embodiments, q is 1. In
certain embodiments, q is 2. In certain embodiments, q is 3. In certain embodiments, q is 4. In
certain embodiments, q is 5. In certain embodiments, q is 6. In certain embodiments, q is 7. In
certain embodiments, q is 8. In certain ments, q is 9. In certain embodiments, q is 10.
In certain embodiments, both R6 and R7 are hydrogen. In certain embodiments,
R6 is hydrogen and R7 is a group of the formula (i), (ii), or (iii). In certain embodiments, R6 is
hydrogen and R7 is a group of the formula (i). In certain embodiments, R6 is hydrogen and
R7 is a group of the formula (ii). In certain ments, R6 is hydrogen and R7 is a group of
the formula (iii). In certain embodiments, both R6 and R7 are ndently a group of the
formula (i), (ii), or (iii). In n embodiments, both R6 and R7 are independently a group of
the formula (i). In certain embodiments, both R6 and R7 are independently a group of the
formula (ii). In certain ments, both R6 and R7 are independently a group of the
formula (iii). In certain embodiments, both R6 and R7 are the same group, selected from a
group of the formula (i), (ii), or (iii).
It is understood that R1 encompasses amino acid side chains such as
exemplified in Table l of the Examples. In n embodiments, R1 is a group selected from
any one of the amino acid side chain groups listed therein.
In certain embodiments, each instance of R1 is the same. In certain
embodiments, at least one R1 group is different. In certain embodiments, each R1 group is
different.
As generally defined above, each instance of R2 is independently hydrogen,
optionally substituted alkyl, ally substituted alkenyl, optionally substituted l,
optionally substituted carbocyclyl, optionally substituted cyclyl, optionally substituted
aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of the formula
(i), (ii), or (iii):
é—flR.\ RL
(1) (ii) (iii)
wherein R’, X, Y, RL, and RP are as defined herein.
In certain embodiments, at least one instance of R2 is optionally substituted
alkyl; e.g., optionally tuted C1_6alkyl, optionally substituted C2_6alkyl, ally
substituted C3_6alkyl, optionally substituted C4_6alkyl, optionally substituted C4_5alkyl, or
ally substituted C34alkyl.
In certain embodiments, at least one ce of R2 is optionally substituted
alkenyl, e.g., optionally substituted C2_6alkenyl, optionally substituted C3_6alkenyl, ally
tuted C4_6alkenyl, optionally substituted C4_5alkenyl, or optionally substituted C3-
4alkenyl.
In certain embodiments, at least one instance of R2 is optionally tuted
alkynyl, e.g., optionally tuted C2_6alkynyl, optionally substituted C3_6alkynyl, optionally
substituted C4_6alkynyl, optionally substituted C4_5alkynyl, or ally substituted C3-
4alkynyl.
In certain embodiments, at least one instance of R2 is optionally substituted
carbocyclyl, e.g., ally substituted C3_10 carbocyclyl, optionally substituted C5_g
carbocyclyl, optionally substituted C5_6 carbocyclyl, optionally substituted C5 carbocyclyl, or
optionally substituted C6 carbocyclyl.
In certain embodiments, at least one instance of R2 is optionally substituted
heterocyclyl, e.g., ally substituted 3—14 membered cyclyl, optionally substituted
3—10 ed heterocyclyl, optionally substituted 5—8 membered heterocyclyl, optionally
substituted 5—6 membered heterocyclyl, optionally substituted 5 membered heterocyclyl, or
optionally substituted 6 membered heterocyclyl.
In certain embodiments, at least one instance of R2 is optionally substituted
aryl, e.g., ally substituted phenyl.
] In certain embodiments, at least one instance of R2 is optionally substituted
heteroaryl, e.g., optionally substituted 5—14 membered heteroaryl, optionally substituted 5—10
membered heteroaryl, optionally substituted 5—6 membered heteroaryl, optionally substituted
ed heteroaryl, or optionally tuted 6 membered heteroaryl.
In n embodiments, at least one instance of R2 is a nitrogen protecting
group.
In certain embodiments, at least one instance of R2 is a group of the formula (i).
In certain embodiments, at least one instance of R2 is a group of the formula (ii). In certain
ments, at least one instance of R2 is a group of the formula (iii).
In certain embodiments, each instance of R2 is a group other than formula (i),
(ii), or (iii); in that ce, it follows that at least one RQ is a group of the formula (i), (ii), or
(iii), or at least one R1 is a group of formula (iV), and at least one of R6 or R7 encompassed by
R1 is a group of the formula (i), (ii), or (iii). For example, in certain embodiments, both
instances of R2 are hydrogen, and thus at least one RQ is a group of the formula (i), (ii), or
(iii), or at least one R1 is a group of formula (iv), and at least one of R6 or R7 encompassed by
R1 is a group of the formula (i), (ii), or (iii).
Various combinations of the above embodiments of Formula (IV), (V), and (VI)
are contemplated herein. For example, in certain embodiments, wherein each instance of Q is
O, the compound of a (IV), (V), or (VI) is a compound of Formula (IV—a), (V—a), or
{i} 1:1i1fii1
R(—IVa)0 (V—a)0 0(—VIa)R
or salt thereof. In certain embodiments, at least one instance of R1 is a group of formula (iv).
In n embodiments, each instance of R1 is a group of formula (iv). In certain
embodiments, at least one ce of R2 is optionally substituted alkyl, optionally substituted
alkenyl, or ally tuted alkynyl. In certain embodiments, at least one instance of R2
is a group of formula (i). In certain ments, at least one instance of R2 is a group of
formula (ii). In certain embodiments, at least one instance of R2 is a group of formula (iii).
In certain embodiments of Formula (IV—a), (V—a), or (VI—a), wherein at least one
R1 is a group the formula (iv), provided is a compound of Formula (IV—b), (V—b), or :
R5—N: Rig}
R7 R21): £4? R7 R2 O:R6—N
(IV—b) (V-b) (VI-b)
or salt thereof. In certain embodiments, at least one instance of R2 is optionally substituted
alkyl, optionally substituted alkenyl, or optionally tuted alkynyl. In certain
embodiments, at least one instance of R2 is a group of formula (i). In n embodiments, at
least one instance of R2 is a group of formula (ii). In certain embodiments, at least one
instance of R2 is a group of formula (iii). In certain ments, L is an optionally
substituted alkylene. In certain embodiments, R6 is a group of formula (i). In certain
embodiments, R6 is a group of formula (ii). In certain embodiments, R6 is a group of formula
(iii). In certain embodiments, R7 is a group of formula (i). In certain embodiments, R7 is a
group of formula (ii). In certain embodiments, R7 is a group of a (iii). In certain
embodiments, both R6 and R7 are independently groups of formula (i), (ii), or (iii).
WO 63468
In certain embodiments of Formula (IV—b), (V—b), or (VI—b), wherein both R1
groups are a group the formula (iv), ed is a compound of Formula (IV—c), (V—c), or
(VI—c):
R\6 R\2 o
N—R7 R2 0 /N
L/ /R2 ‘N R2— L
N L L IN_R7
L o Re—N/ N N—R7 o L R5
/ \ ’ é /
REL—N 6
N R7 R2 o R R —N\
\R7 R2 o R7
(IV—c) (V—c) (VI-C)
or salt thereof. In certain embodiments, at least one instance of R2 is optionally substituted
alkyl, optionally tuted alkenyl, or optionally substituted alkynyl. In certain
embodiments, at least one instance of R2 is a group of formula (i). In certain embodiments, at
least one instance of R2 is a group of formula (ii). In certain embodiments, at least one
instance of R2 is a group of formula (iii). In certain embodiments, L is an optionally
substituted alkylene. In certain embodiments, R6 is a group of formula (i). In certain
embodiments, R6 is a group of formula (ii). In certain embodiments, R6 is a group of formula
(iii). In certain embodiments, R7 is a group of formula (i). In certain embodiments, R7 is a
group of formula (ii). In certain embodiments, R7 is a group of formula (iii). In certain
embodiments, both R6 and R7 are independently groups of formula (i), (ii), or (iii).
In certain embodiments of Formulae (IV—a), (V—a), and , wherein at least
one instance of R2 is a group of formula (i) and each instance of R’ is hydrogen, provided is a
compound of ae (IV—d), (V—d), and :
@on.32: O R1
RF’Y\_|_/N RPY\_|_/N RPY—/
R(IV—d) R(V-d) (VI-d)
or salt thereof. In certain embodiments, at least one instance of R1 is a group of a (iv).
In certain embodiments, each instance of R1 is a group of formula (iv). In certain
embodiments, R2 is optionally substituted alkyl, ally substituted alkenyl, or optionally
substituted alkynyl. In n embodiments, R2 is a group of formula (i). In certain
embodiments, R2 is a group of formula (ii). In certain embodiments, R2 is a group of formula
(iii).
In certain embodiments of Formulae (IV—a), (V—a), and (VI—a), wherein both
instances of R2 is a group of formula (i) and each instance of R’ is hydrogen, provided is a
compound of Formulae (IV—e), (V—e), and (VI—e):
(IV—e) (V—e) (VI—e)
or salt thereof. In certain embodiments, at least one instance of R1 is a group of a (iv).
In certain embodiments, each instance of R1 is a group of formula (iv).
In certain ments of Formulae (IV—a), (V—a), and (VI—a), wherein at least
one instance of R2 is a group of formula (ii) and each instance of R’ is hydrogen, provided is a
compound of Formulae (I\72—f), (V—f), and (VI—f):
:?“REMthM
O(IV-f) (V-f) (VI-f)
or salt thereof. In certain embodiments, at least one instance of R1 is a group of formula (iv).
In n embodiments, each instance of R1 is a group of formula (iv). In certain
embodiments, R2 is optionally substituted alkyl, optionally substituted alkenyl, or optionally
substituted alkynyl. In certain embodiments, R2 is a group of formula (i). In n
embodiments, R2 is a group of formula (ii). In certain embodiments, R2 is a group of formula
(iii).
In certain embodiments of ae , (V—a), and (VI—a), wherein both
instances of R2 is a group of formula (ii) and each instance of R’ is hydrogen, provided is a
nd of Formulae (IV—g), (V-g), and (VI-g):
RLX O
O RLX—<O—_\ RLX
R1 O
WQO N
N N
1 R1 R —<N
RLX N/ R1
RLx-<—J o H
O o o R1
R X‘<—JL
(IV-g) (V-g) (VI-g)
or salt thereof. In certain embodiments, at least one instance of R1 is a group of formula (iv).
In certain embodiments, each instance of R1 is a group of a (iv).
In certain ments of Formulae (IV—a), (V—a), and , wherein at least
one instance of R2 is a group of formula (iii), provided is a nd of Formulae (IV—h),
(V—h), and (VI—h):
R1 /R2 2
R2\ 0 R\N o
R12—N N
0 R1-<N R1 N R1
N Rf
FRL-—-’/ C) FzL-J/ (D C) le
(IV-h) (V—h) (VI—h)
or salt thereof. In certain embodiments, at least one instance of R1 is a group of formula (iv).
In certain embodiments, each ce of R1 is a group of formula (iv). In certain
embodiments, R2 is optionally substituted alkyl, optionally substituted alkenyl, or optionally
tuted alkynyl. In certain embodiments, R2 is a group of formula (i). In certain
embodiments, R2 is a group of formula (ii). In certain embodiments, R2 is a group of formula
(iii).
] In certain embodiments of Formulae (IV—a), (V—a), and (VI—a), wherein both
instances of R2 are a group of formula (iii), provided is a compound of Formulae (IV—e), (V—
e), and (VI—e):
RN>L L
R1 RL_\N O <: o
WQO R1—<N R1 /—N/ R1
N RLJ RL
RL-/ 0
o 0 R1
(IV—i) (V—i) (VI—i)
or salt thereof. In certain embodiments, at least one instance of R1 is a group of formula (iv).
In certain embodiments, each instance of R1 is a group of formula (iv).
Groups offormula (1'), (ii), and (iii)
As understood from the above sion, APPLs, and in particular, APPL
compounds of Formulae (I), (III), (IV), (V), and (VI), each include at least one instance of a
group of the formula (i), (ii), or (iii):
. R‘ XRL
RQ—YRP
g—<R- § 0 R'-
R' or §_/
(1) (ii) (iii)
wherein:
each instance of R’ is independently hydrogen or optionally substituted alkyl;
X is O, S, NRX, wherein RX is hydrogen, ally substituted alkyl, optionally
substituted l, optionally substituted alkynyl, optionally substituted carbocyclyl,
optionally tuted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, or a nitrogen protecting group;
Y is O, S, NRY, wherein RY is hydrogen, optionally substituted alkyl, optionally
tuted alkenyl, optionally substituted l, optionally substituted carbocyclyl,
optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted
heteroaryl, or a nitrogen protecting group;
RP is en, optionally substituted alkyl, optionally substituted alkenyl, optionally
substituted alkynyl, optionally substituted carbocyclyl, optionally tuted heterocyclyl,
optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group
when ed to an oxygen atom, a sulfur protecting group when attached to a sulfur atom,
or a nitrogen protecting group when attached to a nitrogen atom; and
RL is optionally substituted C150 alkyl, optionally substituted C250 alkenyl, optionally
substituted C250 alkynyl, optionally substituted C1_50 alkyl, optionally substituted
heteroC2_50 alkenyl, ally substituted heteroC2_50 alkynyl, or a polymer.
In the case of Formula (II), the at least one instance of group of formula (i) is
orated as part of the scaffold, e.g., by monoaddition of a compound (i—X), followed by
internal cyclization. See, e.g., Scheme 2.
In certain embodiments, an APPL, and in particular, a compound of Formulae
(I), (II), (III), (IV), (V), or (VI), comprises at least one instance of a group of the formula (i)
attached thereto:
R' (1).
In certain embodiments of formula (i), Y is O. In certain embodiments of
formula (i), Y is S. In certain embodiments of formula (i), Y is NRY, wherein RY is
hydrogen, optionally substituted alkyl, optionally substituted alkenyl, ally substituted
l, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally
tuted aryl, optionally substituted heteroaryl, or a nitrogen ting group. In certain
embodiments of formula (i), Y is NRY, wherein RY is hydrogen, optionally substituted alkyl,
or a nitrogen protecting group. In certain embodiments of formula (i), each instance of R’ is
hydrogen.
As used herein, when the group RL is depicted as bisecting a carbon—carbon
bond, 6.57., of the group of the formula (i), it is tood that RL may be substituted at either
carbon. Nucleophilic attack of an amino or amide group at the least sterically hindered
carbon of the e, thiirane, or aziridine of formula (i—X) provides a group of the formula
(i—al), (i—a2), or (i—a3) (route a), while nucleophilic attack at the more sterically hindered
carbon of the e, thiirane, or aziridine of formula (i—X) provides a group of the formula
(i—bl), (i—b2), or (i—b3) (route b), n RP is hydrogen (Scheme 6). It is understood that
compounds of the present invention may comprise a e of products attached thereto
arising from route (a) and route (b) depending on the preference, or lack thereof, of the mode
of addition. The bisecting group RL depicted in the Formulae seeks to encompasses all
contemplated modes of on.
Scheme 6.
RP RP RP
. R. RL RL R'-
RWRL
. RP
(a) g—N_§ é—NH
("’0 é—NVR/LR'
(I-a1) (i-a2) (i-a3) RL
g—N—gI or g—NHZ RP RP RP
Y RL
, R. . RL R' RL R.
(b) R\A< —>R R
R. R'
RL g—N—§ g—NH E—N
(i'x)
(i-b1) (i-b2) (i-b3) RL
The resulting hydroxyl, thiol, or amino group —YRP, wherein RP is hydrogen,
may ally be converted to a tuted group, wherein RP is a group other than
hydrogen, i.e., wherein RP is independently selected from optionally substituted alkyl,
optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted
carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally
substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur
ting group when attached to a sulfur atom, or a nitrogen protecting group when
attached to a nitrogen atom; using conventional methods. tion, acylation, and/or
protection of a yl, thiol, or amino moiety are methods well—known in the art; see, e.g.,
Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, edition, John
Wiley & Sons, 1999; Smith and March, March’s Advanced Organic Chemistry, 5th Edition,
John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic
Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern
Methods of Organic Synthesis, 3rd n, Cambridge University Press, Cambridge, 1987.
For example, in certain non—limiting embodiments, the hydroxyl, thiol, or amino moiety —
YRP, wherein RP is hydrogen, may be reacted with an electrophile of the formula RP—X2
wherein RP is a group other than hydrogen, and X2 is a leaving group, to provide a substituted
hydroxyl, thiol, and amino group in formula (i).
In certain embodiments of formula (i), RP is hydrogen. In certain embodiments
of formula (i), RP is optionally substituted alkyl. In certain embodiments of formula (i), RP is
optionally substituted alkenyl. In certain embodiments of formula (i), RP is optionally
substituted alkynyl. In certain embodiments of formula (i), RP is optionally substituted
carbocyclyl. In n ments of formula (i), RP is optionally tuted heterocyclyl.
In certain embodiments of formula (i), RP is optionally substituted aryl. In certain
embodiments of formula (i), RP is optionally substituted heteroaryl. In certain ments
of formula (i), RP is an oxygen protecting group when attached to an oxygen atom. In certain
embodiments of formula (i), RP is a sulfur protecting group when attached to a sulfur atom.
In certain embodiments of a (i), RP is a nitrogen ting group when attached to a
en atom.
It is understood from the present disclosure that the group of a (i)
represents a group of formula (i—a) or a group of formula (i—b):
R' R'-
(i—a) (i—b).
In certain embodiments, the reaction mixture provides a mixture of APPLs
comprising more APPLs conjugated to a group of a (i—a) than formula (i—b), e.g., the
reaction mixture ses greater than 50%, greater than 60%, greater than 70%, greater
than 80%, greater than 90%, greater than 95%, greater than 99%, n about 60% to
about 100%, between about 70% to about 100%, between about 80% to about 100%, between
about 90% to about 100%, between about 95% to about 100%, or between about 99% to
about 100%, of an APPL ed to formula (i—a).
In certain embodiments, the epoxide, thiirane, or ine of formula (i—x) is
, i.e., having (R) or (S) stereochemistry. Chiral epoxides, thiiranes, and aziridines can
be obtained from a variety of sources which are familiar to those skilled in the art of organic
synthesis. In some embodiments, the chiral e, thiirane, or aziridine is obtained
cially. In some embodiments, the chiral epoxide, thiirane, or aziridine is synthesized
according to s known to those of skill in the art, such as, but not limited to the
Sharpless epoxidation of primary and secondary allylic alcohols into 2,3—epoxyalcohols (see,
e.g., Katsuki et al., J. Am. Chem. Soc. 1980, 102, 5974; Hill et al., Org. Syn, Coll. Vol. 7,
p.461 ; Vol. 63, p.66 (1985); Katsuki et al., Org. React. 1996, 48, 1—300). In some
embodiments, the chiral epoxide, thiirane, or aziridine is obtained from the resolution of a
mixture (e.g., racemic mixture) of epoxides, thiiranes, or aziridines. In some embodiments,
the chiral epoxide, thiirane, or aziridine is obtained by the separation of enantiomers or
diastereoisomers using chiral chromatography. Chirality can be characterized in a variety of
ways, e.g., obtaining a crystal structure of the nd containing a heavy atom attached
thereto, obtaining the optical rotation of the nd, and/or NMR analysis after chemical
modification of the optically active compound with a chiral derivatizing agent are some
methods useful in evaluating chirality.
RA”RL R'ARL
(1x1) (1x2)
RL \' Ra R' R' R'
ngRP §~<LYRP 7>~YRP gimp
R' R' ER' ERL R's. RL
(i—a1) (i—a2) (i—bl) (i—b2)
In certain ments, wherein the epoxide, thiirane, or aziridine of formula
(i—x1) is chiral, the conjugation reaction is elective, and the reaction provides a chiral
mixture of APPLs comprising more APPLs conjugated to a group of formula (i—a1) than
formula (i—b1), 6.57., the on mixture comprises greater than 50%, r than 60%,
greater than 70%, greater than 80%, greater than 90%, greater than 95%, greater than 99%,
between about 60% to about 100%, between about 70% to about 100%, between about 80%
to about 100%, between about 90% to about 100%, between about 95% to about 100%, or
between about 99% to about 100%, of an APPL attached to formula (i—a1).
In other embodiments, wherein the epoxide, thiirane, or ine of formula (i—
x2) is chiral, the conjugation reaction is regioselective, and the reaction es a chiral
mixture of APPLs comprising more APPLs conjugated to a group of formula (i—a2) than
formula (i—b2), 6.57., the reaction mixture comprises greater than 50%, greater than 60%,
greater than 70%, greater than 80%, greater than 90%, greater than 95%, greater than 99%,
between about 60% to about 100%, between about 70% to about 100%, between about 80%
to about 100%, between about 90% to about 100%, between about 95% to about 100%, or
between about 99% to about 100%, of an APPL ed to formula (i—a2).
In certain embodiments, an APPL, and in ular, a compound of Formulae
(I), (II), (III), (IV), (V), or (VI), comprises at least one instance of a group of the formula (ii)
ed thereto:
R' (ii).
In n embodiments of formula (ii), X is O. In certain embodiments of
formula (ii), X is S. In certain embodiments of formula (ii), X is NRX, n RX is
hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted
alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally
substituted aryl, ally substituted heteroaryl, or a nitrogen protecting group. In certain
embodiments of formula (ii), X is NRX, wherein RX is hydrogen, optionally tuted alkyl,
or a nitrogen protecting group. In certain embodiments of formula (i), each instance of R’ is
hydrogen.
In certain embodiments, an APPL, and in particular, a compound of Formulae
(I), (II), (III), (IV), (V), or (VI), comprises at least one instance of a group of the formula (ii)
attached thereto:
2012/062222
(iii).
As generally defined above, RL is optionally substituted C150 alkyl, ally
substituted C250 alkenyl, optionally substituted C250 alkynyl, optionally substituted C150
heteroalkyl, ally substituted C250 heteroalkenyl, optionally substituted C250
heteroalkynyl, or a polymer. The group RL seeks to encompass lipophilic, hydrophobic,
and/or non—polar , but such terms should not limit the scope of RL.
] In certain embodiments, at least one instance of RL is an optionally substituted
C150 alkyl. In certain embodiments, RL is an optionally substituted C6_50alkyl. In certain
embodiments, RL is an ally tuted C6_40alkyl. In certain embodiments, RL is an
ally substituted C6_30alkyl. In certain embodiments, RL is an optionally substituted C6-
goalkyl. In certain embodiments, RL is an optionally substituted Cg_20alkyl. In certain
embodiments, RL is an optionally substituted Cgalkyl. In certain embodiments, RL is an
optionally substituted Cgalkyl. In certain embodiments, RL is an optionally substituted
Cloalkyl. In certain embodiments, RL is an optionally substituted C11alkyl. In certain
embodiments, RL is an optionally tuted Clgalkyl. In certain embodiments, RL is an
optionally substituted C13alkyl. In certain embodiments, RL is an optionally substituted
C14alkyl. In certain embodiments, RL is an optionally substituted C15alkyl. In certain
ments, RL is an optionally tuted yl. In certain embodiments, RL is an
optionally substituted C17alkyl. In certain embodiments, RL is an optionally substituted
Clgalkyl. In certain embodiments, RL is an optionally tuted C19alkyl. In certain
embodiments, RL is an optionally substituted Czoalkyl. In any of the above embodiments, the
group RL is an unsubstituted alkyl group.
In n embodiments, at least one instance of RL is an unsubstituted alkyl.
Exemplary unsubstituted alkyl groups include, but are not limited to, —CH3, —C2H5, —C3H7, —
C4H9, -C5H11,-C6H13, -C7H15, -C8H17, -C9H19, -C10H21, -C11H23, -C12H25,-C13H27, -C14H29, -
C15H31, -C16H33, -C17H35, -C18H37, -C19H39, -C20H41, -C21H43, -C22H45, 7, -C24H49, and
-C25H51-
In certain embodiments, at least one instance of RL is a substituted alkyl. For
example, in n menets, at least one instance of RL is an alkyl substituted with one
or more fluorine substituents. Exemplary fluorinated alkyl groups include, but are not limited
«9‘ F FFFFFFFFFF
FFFF
FFFF MW
FFFFFFFFF FF FFF
F a“ FFFFFFFFFFFF
FFFF
F tr”
FM F FFFFFFF FF FFF
,rr’ F
FFFFFF FFFFFFFFFFFFFF
FFFFFF PW
9898986;rr F F FFFFFFFFFFFF
FF F
FFFFFF F FFFFFFFFFFF
FFFFFF Fr"
F FFFFFFFFFFFFFFF
FFFFFFFF FFFFFFFFFF
F FFFFF WF s"
F FFFFFFFFFFFFFFFF
FFFFFFFFFrrrr FFFFFFFFFFFFFFFFF
FFFFFFFF x
F FFFFFFFFFFFFFFFF
FFFFFFFFFF FFFFFFFFFFFFFFFFFF
FFFFFFFFF F 9“
FWe! FFFFFFFFFFFFFFFFFF
FFFFFFFFFF FFFF FFFFFFFFFFFFFF
FFFFFFFFFF WWW
FWEFFFFFFFFFFFFFFFFFFF
FFFFFFFFFFF
In certain embodiments, at least one instance of RL is an optionally substituted
C250 alkenyl. In certain embodiments, RL is an optionally substituted C6_50alkenyl. In
certain embodiments, RL is an optionally substituted lkenyl. In certain embodiments,
RL is an optionally substituted lkenyl. In certain embodiments, RL is an ally
substituted C6_20alkenyl. In certain embodiments, RL is an optionally substituted Cg_20alkenyl.
In certain embodiments, RL is an optionally substituted Cgalkenyl. In certain embodiments,
RL is an optionally tuted Cgalkenyl. In certain embodiments, RL is an optionally
substituted Cloalkenyl. In certain embodiments, RL is an optionally substituted C11alkenyl.
In n embodiments, RL is an optionally substituted Clzalkenyl. In certain ments,
RL is an optionally substituted C13alkenyl. In certain embodiments, RL is an optionally
substituted C14alkenyl. In certain embodiments, RL is an optionally substituted enyl.
In certain embodiments, RL is an optionally substituted C16alkenyl. In certain ments,
RL is an optionally substituted enyl. In certain embodiments, RL is an optionally
tuted Clgalkenyl. In certain embodiments, RL is an optionally substituted Clgalkenyl.
In certain embodiments, RL is an optionally substituted Cgoalkenyl. In any of the above
embodiments, the group RL is an unsubstituted alkenyl group.
] Exemplary unsubstituted alkenyl groups e, but are not limited to:
/\”H W
My“,
N63:
Wt“:
/\/\/\/\/\/\/\/\r‘yv
W\/\/\/\/\/\/\\ arr
W\ Jr, g
oleic —(CH2)7CH=CH(CH2)3CH3,
Palmitoliec —(CH2)7CH=CH(CH2)5CH3,
Sapienic —(CH2)4CH=CH(CH2)3CH3,
Oleic —(CH2)7CH=CH(CH2)7CH3,
Linoleic 7CH=CHCH2CH=CH(CH2)4CH3,
OL-Linolenic -(CH2)7CH=CHCHZCH=CHCH2CH=CHCH2CH3,
Arachinodonic -(CH2)3CH=CHCHZCHzCHCHZCHzCHCHZCHzCH(CH2)4CH3,
Eicosapentaenoic —(CH2)3CH=CHCHZCHzCHCHZCH=CHCHZCH=CHCH2CH=CHCH2CH3,
Erucic —(CH2)11CH=CH(CH2)7CH3, and
Docosahexaenoi —
c (CH2)2CH=CHCH2CH=CHCHZCHzCHCHzCHzCHCHZCHzCHCHZCH=C
H-CH2CH3.
In embodiments, wherein RL is defined as a C6_50alkyl or C6_50alkenyl groups,
such groups are meant to encompass lipophilic groups (also referred to as a “lipid tail”).
ilic groups comprise a group of molecules that include fats, waxes, oils, fatty acids,
and the like. Lipid tails present in these lipid groups can be saturated and unsaturated,
depending on whether or not the lipid tail comprises double bonds. The lipid tail can also
comprise different lengths, often categorized as medium (i.e., with tails between 7—12
carbons, e.g., C742 alkyl or C742 alkenyl), long (i.e., with tails greater than 12 carbons and up
to 22 carbons, e.g., C1342 alkyl or C1342 l), or very long (i.e., with tails greater than 22
carbons, e.g., C2330 alkyl or C2330 alkenyl).
In certain embodiments, RL is an optionally tuted C250 l. In certain
embodiments, RL is an ally substituted C6_50alkynyl. In certain ments, RL is an
optionally substituted C640alkynyl. In certain embodiments, RL is an optionally substituted
C6_30alkynyl. In certain embodiments, RL is an optionally substituted C6_20alkynyl. In certain
embodiments, RL is an optionally substituted Cg_20all<ynyl. In certain embodiments, RL is an
optionally substituted Cgalkynyl. In certain embodiments, RL is an optionally substituted
Cgalkynyl. In certain embodiments, RL is an optionally substituted Cloalkynyl. In certain
embodiments, RL is an optionally substituted C11alkynyl. In certain embodiments, RL is an
optionally substituted Clzalkynyl. In certain embodiments, RL is an optionally tuted
C13alkynyl. In n embodiments, RL is an optionally substituted ynyl. In certain
embodiments, RL is an optionally substituted C15alkynyl. In certain embodiments, RL is an
optionally substituted C16alkynyl. In certain embodiments, RL is an optionally substituted
C17alkynyl. In certain ments, RL is an optionally substituted Clgalkynyl. In certain
ments, RL is an optionally substituted Clgalkynyl. In certain embodiments, RL is an
optionally substituted Czoalkynyl. In any of the above embodiments, the group RL is an
unsubstituted alkynyl group.
In certain embodiments, at least one instance of RL is an ally substituted
heteroC1_50 alkyl. In certain embodiments, RL is an optionally substituted heteroC6_50 alkyl.
In n embodiments, RL is an ally substituted heteroC6_40 alkyl. In certain
embodiments, RL is an optionally substituted heteroC6_30alkyl. In certain embodiments, RL is
an optionally substituted C6_20alkyl. In certain ments, RL is an optionally
substituted heteroC10_20alkyl. In certain embodiments, RL is an optionally substituted
heterngalkyl. In certain embodiments, RL is an optionally substituted heterngalkyl. In
certain embodiments, RL is an optionally substituted heteroCloalkyl. In certain embodiments,
RL is an optionally substituted heteroC11alkyl. In certain embodiments, RL is an optionally
substituted heteroClzalkyl. In certain embodiments, RL is an optionally substituted
heteroC13alkyl. In certain ments, RL is an optionally substituted heteroC14alkyl. In
certain embodiments, RL is an optionally substituted heteroC15alkyl. In certain embodiments,
RL is an optionally substituted heteroC16alkyl. In certain ments, RL is an optionally
substituted heteroC17alkyl. In certain embodiments, RL is an optionally substituted
heteroClgalkyl. In certain embodiments, RL is an optionally substituted heteroClgalkyl. In
certain embodiments, RL is an optionally substituted heteroCzoalkyl. In any of the above
embodiments, the group RL is an tituted heteroalkyl group.
Exemplary unsubstituted heteroalkyl groups include, but are not limited to,
\O/\..r"r W\/\/\O/\rr,.r
/\o/\ve‘ /\/\/\/\/\O/\rfi.r
V\O/\(H’ W\/\/\/\O/\;,:
/\/\O/\rrrr /\/\/\/\/\/\O/\‘J,J
\/\/\/\/\/\/\O/\
WOAé-‘I
NWOj‘44:
WOA‘J": WOAHH
/\/\/\/\/\/\/\/\ /\O
O/\IJJJ r51
In certain embodiments, at least one instance of RL is an optionally tuted
heteroC2_50alkenyl. In certain embodiments, RL is an optionally substituted heteroC6_
50alkenyl. In certain embodiments, RL is an optionally substituted heteroC6_40alkenyl. In
n embodiments, RL is an optionally substituted heteroC6_30alkenyl. In certain
embodiments, RL is an ally substituted heteroC6_20alkenyl. In certain embodiments, RL
is an optionally substituted heterng_20alkenyl. In certain embodiments, RL is an optionally
substituted heterngalkenyl. In certain embodiments, RL is an optionally substituted
galkenyl. In certain embodiments, RL is an optionally substituted Cloalkenyl.
In certain embodiments, RL is an optionally substituted heteroC11alkenyl. In certain
embodiments, RL is an optionally substituted heteroClzalkenyl. In n embodiments, RL
is an ally tuted heteroC13alkenyl. In certain embodiments, RL is an optionally
substituted heteroC14alkenyl. In certain embodiments, RL is an optionally substituted
C15alkenyl. In certain embodiments, RL is an ally substituted heteroC16alkenyl.
In certain embodiments, RL is an optionally substituted heteroC17alkenyl. In certain
embodiments, RL is an optionally substituted heteroClgalkenyl. In certain embodiments, RL
is an ally substituted heteroC19alkenyl. In certain embodiments, RL is an optionally
substituted heteroCzoalkenyl. In any of the above embodiments, the group RL is an
unsubstituted heteroalkenyl group.
In certain embodiments, RL is an optionally substituted heteroC2_50alkynyl. In
certain embodiments, RL is an optionally substituted heteroC6_50alkynyl. In certain
embodiments, RL is an ally substituted heteroC6_40alkynyl. In certain embodiments, RL
2012/062222
is an optionally substituted heteroC6_30alkynyl. In certain embodiments, RL is an optionally
substituted heteroC6_20alkynyl. In certain embodiments, RL is an optionally substituted
heterng_20alkynyl. In n ments, RL is an optionally substituted heterngalkynyl.
In certain embodiments, RL is an optionally substituted heterngalkynyl. In certain
embodiments, RL is an optionally substituted heteroCloalkynyl. In n ments, RL
is an optionally substituted heteroC11alkynyl. In certain embodiments, RL is an optionally
tuted heteroClgalkynyl. In certain embodiments, RL is an optionally tuted
heteroC13alkynyl. In certain embodiments, RL is an optionally substituted heteroC14alkynyl.
In certain embodiments, RL is an optionally substituted heteroC15alkynyl. In n
embodiments, RL is an optionally substituted heteroC16alkynyl. In certain ments, RL
is an optionally tuted heteroC17alkynyl. In certain embodiments, RL is an optionally
substituted heteroClgalkynyl. In certain embodiments, RL is an optionally tuted
heteroClgalkynyl. In certain embodiments, RL is an optionally substituted heteroCzoalkynyl.
In any of the above embodiments, the group RL is an unsubstituted heteroalkynyl group.
In certain embodiments, at least one instance of RL is a polymer. As used
herein, a er” refers to a compound comprised of at least 3 (e.g., at least 10, 20, 30, 40,
50, 60, 70, 80, 90, 100, etc.) repeating covalently bound structural units. The polymer is in
certain embodiments biocompatible (i. 6., non—toxic). Exemplary polymers include, but are
not limited to, cellulose polymers (e.g., hydroxyethylcellulose, ethylcellulose,
ymethylcellulose, methylc cellulose, hydroxypropylmethylcellulose ), dextran
polymers, polymaleic acid polymers, poly(acrylic acid) polymers, poly(vinylalcohol)
polymers, polyvinylpyrrolidone (PVP) polymers, and polyethyleneglycol (PEG) polymers,
and combinations thereof.
Additional Methods ofPreparation
As described herein, in order to provide compounds of the present invention, an
APPL precursor is treated with one or more conjugating reagents, e.g., selected from an
epoxide, thiirane, or aziridine of formula (i—X), an OL,B—unsaturated ester, thioester, or amide of
formula (ii—X), or an an aldehyde of formula (iii—X), to provide the APPL.
R' o O
. R'
R\A<RL RIJYkXRL HJLRL
(i-x) (ii-x) (iii-x)
2012/062222
For example, in one aspect, provided is a method of preparing an APPL
functionalized with a group of formula (i) comprising heating the precursor in an organic
solvent (e.g., EtOH) with one or more conjugating reagents of formula (i—x) to provide the
desired APPL. In certain embodiments, the mixture is heated between about 100 to about
200 OC, ive, e.g., about 150 0C.
In another aspect, provided is a method of preparing an APPL functionalized
with a group of formula (ii) comprising heating the precursor in an organic solvent (e.g.,
EtOH) with one or more conjugating ts of formula (ii—x) to provide the desired APPL.
In certain embodiments, the mixture is heated between about 50 to about 100 OC, inclusive,
e.g., about 90°C.
In another aspect, ed is a method of preparing an APPL functionalized
with a group of formula (iii) comprising mixing the precursor in an organic solvent (e.g.,
THF) with one or more conjugating reagents of formula (iii—x) and a reducing agent (e.g.,
NaBH(OAc)3) to e the d APPL. In certain embodiments, the temperature of the
reaction mixture is room temperature e.
In certain embodiments, wherein only one conjugating reagent is used, each
instance of RL is the same in the APPL. For example, in n embodiments, each instance
of RL is the same wherein RL is an optionally substituted alkyl. In certain embodiments, each
instance of RL is the same wherein RL is an unsubstituted alkyl. In certain embodiments,
each instance of RL is the same wherein RL is selected from the group consisting of —CH3, —
C2H5, -C3H7, -C4H9, -C5H11, , -C7H15, , -C9H19, -C10H21, -C11H23, -C12H25, -
C13H27, -C14H29, -C15H31, -C16H33, -C17H35, -C18H37, -C19H39, and -C20H41- In certain
embodiments, each instance of RL is the same wherein RL is an n—alkyl group selected from —
CsH17, -C9H19, -C10H21, -C11H23, -C12H25,-C13H27, -C14H29, -C15H31, and -C16H33-
atively, in certain embodiments, wherein more than one conjugating
reagent is used in the conjugation reaction (e.g., two, three, four, five, six, seven, eight, nine,
or ten different conjugating reagents), the APPL may comprise two or more (e.g.
, two, three,
four, five, six, seven, eight, nine, or ten) different groups of the formula (i), (ii), and/or (iii)
ed thereto.
For example, in certain embodiments, two different epoxides are used in the
conjugation reaction. In this instance, in certain embodiments, the APPL comprises two
ent RL groups. For example, in n embodiments, the APPL ses a mixture of
two different RL groups, wherein the first RL group is an ally substituted alkyl, and the
second RL group is a polymer.
As would be appreciated by one of skill in this art, the degree of conjugation
may be controlled by the reaction conditions (e.g. , temperature, starting materials,
tration, solvent, etc.) used in the synthesis. The synthesized APPL may be purified by
any technique known in the art including, but not limited to, precipitation, llization,
chromatography, distillation, etc.
] In n embodiments, the APPL is isolated as a salt. For example, in certain
embodiments, the APPL is reacted with an acid (e. 57., an organic acid or inorganic acid) to
form the corresponding salt. In other embodiments, tertiary amines are ted to form a
quaternary ammonium salt of the APPL. The tertiary amines may be alkylated with any
ting agent, for example, alkyl halides such as methyl iodide may be used to from the
quaternary amino groups. The anion associated with the quaternary amine may be any
organic or inorganic anion. In certain embodiments, the anion is a pharmaceutically
acceptable anion.
The invention also provides libraries of APPLs prepared by the ive
methods. For example, in certain embodiments, provided is a method of screening a
compound library, the method comprising providing a plurality of different APPLs, or salts
thereof; and performing at least one assay with the compound library to determine the
presense or absence of a desired property. These APPLs may be prepared and/or screened
using high—throughput techniques involving liquid handlers, robots, microtiter plates,
computers, etc. In certain embodiments, the APPLs are screened for their ability to ect
polynucleotides or other agents (e. 57., proteins, peptides, small molecules) into the cell. For
example, in one embodiment, provided is a method of screening a compound library, the
method comprising providing a plurality of two or more different APPLs and ing the
compound library for a d ty.
In one embodiment, a library of different APPLs is ed in parallel. A
different precursor and/or conjugating reagent is added to each vial in a set of vials or to each
well of a multi—well plate used to prepare the library. The array of reaction mixtures is
incubated at a temperature and length of time sufficient to allow formation of the APPL. The
APPL may then be isolated and purified using techniques known in the art. The APPL may
then be screened using high—throughput ques to identify APPLs with a desired property,
e. g. wherein the desired property is solubility in water, solubility at different pH, y to
bind polynucleotides, ability to bind heparin, y to bind small molecules, ability to bind
protein, ability to form microparticles, ability to increase ction efficiency, y to
support cell growth, ability to support cell attachment, ability to support tissue growth, and/or
ellular delivery of the APPL and/or an agent complexed or attached thereto to aid in
bioprocessing, e. g., for the purpose of manufacturing ns. In certain embodiments the
APPLs may be screened for properties or characteristics useful as coatings, additives,
materials, and excipients in biotechnology and biomedical applications such as the coating of
medical devices or implants with films or multilayer films, as non—biofouling agents,
micropatterning agents, and cellular encapsulation agents. In certain embodiments the APPL
may be screened for properties or teristics useful in gene therapy (e.g. , the ability to
bind polynucleotides and/or increase in transfection efficiency), bioprocessing (e.g., aiding in
the intracellular manufacturing of proteins), or the administration and/or delivery of a
therapeutic agent (e.g., polynucleotide, small molecule, antigen, drug, protein, peptide, etc.)
to a subject, , organ, or cell.
Exemplary Compounds ofthe Present Invention
Certain nds of the present invention are specifically contemplated
. For example, compounds comprising tituted n—alkyl RL groups containing 8, 9,
, ll, 12, 13, and 14 carbon atoms are ically contemplated. In certain embodiments
R1 of such compounds is an amino acid side chain as defined in Table l of the Examples.
] Exemplary amino acid, peptide, and polypeptide compounds of Formula (I)
include, but are not limited to:
H0C8H17R HOC9H19R
ORA4 ORA4
HO \C8H17 HO \C9H19
9 9
1 1
HOC10H21 R HO\—C11H23 R
ORA4 ORA4
HO \C10H21 HO \OC11H23
9 9
R1 HO\C13H27 R1
ORA4 ORA4
HO \OC12H25 HOf\OC13H27
9 9
HO\—C14H29R
ORA4
HOf\OC14Hzg
O O
1 1
N N
N ORA4 N ORA4
O n R1 O n R1
CsH17—O C9H19_O
o O
, ,
O O
C10H21—O/<fi R 1 O R 1 O
H H
N 3—O%fl N
N 0RA4 N 0RA4
O n R1 O n R1
C10Hz1—O C11H23—O
o o
O O
C12H25—0/</\ R1 O R 1 O
H C13H27—0//</\ H
N N
N ORA4 N ORA4
O n R1 O n R1
C12st—O C13Hz7—O
o o
C14H29—O//</\ R1 O
N ORA4
o n R1
(314st;—0
o o
”/<fi R 1 O 1 R O
H C9H19—”/<fi H
N N
N ORA4 N ORA4
O n R1 O n R1
C H —Ns 17 C H —N9 19
H O H O
O O
(WWW—Mk R 1 O 1 O
H Cums—”k R H
N N
N 0RA4 N 0RA4
O n R1 O n R1
C10H —N21 C11 H —N23
H O H O
O O
C12H25—”/</\ R1 O 1 R O
H C13H27—HJ</\ H
N N
N ORA4 N ORA4
o n R1 o n R1
C12H —N25 C 13H —N27
H O H O
N 0RA4
o n R1
C14H —N29
H O
C8H17/\JN»F1\n/NNMORA4CaH17J C9H19/\JN»F1\H/N“IMORA409H19J
C10H21/\JN,P1\n/NNMORA“ C11"|2s/\JNAPYNNMORA“C10H21J C11H23J
R1 o R1 o
H H
C12Hz5/\ N /\ N
N ORA4 N ORA4
C12H25J n R 1 C13H27J n R 1 O O
, ,
R1 o
C14"‘29/\ N
N 0RA4
C14l‘l29 O n R1
and salts thereof.
Exemplary cyclized compounds of Formula (11), include, but are not limited to:
O O O O
R1 R1 R1 R1
O O O O
HN\)\ HN\)\ HN\)\ HN\)\
CsH17, C9H19, C10H21 (311st
o o 0
R1 R1 R1 O
O 0 0
HN\)\ HN\)\ HN\)\ HOA/VwkCsH17
C12H25, , C14H29 CSH17
, ,
O O O
R1 R1 R1
O O O
HO/\/\/N\J\ HO/\/\/N\)\ N
ch19 C10H21 HO/\/\/ C11H23
CQH19 C10Hz1 C11H23
, , ,
O O O
R1 R1 R1
O O 0
/wk wk N
C12H25 HO/\/\/ C13H27 HO/\/\/ C14H29
C12Hz5 C13Hz7 and C14"‘29
, , ,
and salts thereof.
Exemplary cyclic dipeptide and cyclic polypeptide compounds of Formula (111)
include, but are not limited to:
2012/062222
HO C1on1
\|—\
O O
HO C12H25
|—\ x|_\
N N
HO C14"‘29
\l_\
WO 63468
and, in particular, —KK and polycyclic lysine APPLs of the formula:
CsH17\
WO 63468
WO 63468
CgH1g—O
2012/062222
C11H23—O
C12"‘25“O
C14H29_O
2012/062222
CBH17_NH
CsH17
H O
C9H19_N
CgH19‘NH
CQH’IQ
C10H21_NH ‘NH
O O
HN\ HN\
C10H21 C11H23
H O
H O
C H —N
C12H25—N 13 27
O O
C12H25‘NH C13H27—NH
2012/062222
C10H21
C10H21
/_ /_
C13H27 > C14H29 >
C13Hz7 and C14H29
and salts thereof.
Compositions
The present invention contemplates an APPL as a ent of a composition.
For example, in certain embodiments, ed is a composition comprising an APPL, or salt
thereof, and an excipient, wherein the APPL is an amino acid, a linear or cyclic e, or a
linear or cyclic polypeptide, or structural isomer thereof, and wherein an amino or amide
group of the APPL is conjugated to a group of formula (i), (ii), or (iii). In certain
embodiments, the group of formula (i), (ii), or (iii) is ed to an amino group present on
the APPL scaffold.
] Compositions, as described herein, comprising an APPL and an excipient of
some sort may be useful in a variety of medical and non—medical applications. For example,
pharmaceutical compositions sing an APPL and an excipient may be useful in the
delivery of an effective amount of an agent to a subject in need thereof. Nutraceutical
compositions comprising an APPL and an excipient may be useful in the delivery of an
effective amount of a nutraceutical, e.g., a dietary supplement, to a subject in need f.
Cosmetic compositions comprising an APPL and an excipient may be formulated as a cream,
ointment, balm, paste, film, or liquid, etc, and may be useful in the application of make—up,
hair ts, and materials useful for personal e, etc. Compositions comprising an
APPL and an excipient may be useful for non—medical applications, e.g., such as an emulsion
or emulsifier, useful, for example, as a food ent, for extinguishing fires, for
disinfecting surfaces, for oil cleanup, etc.
Peptides play significant roles in endogenous cellular signaling and trafficking
pathways, and offer tremendous potential in leveraging such interactions to enhance the
delivery efficiency of s which incorporate peptide moieties. Thus, compositions
comprising an APPL and an excipient may further be useful in cessing, such as a cell’s
bioprocessing of a commercially useful chemical or fuel. For example, intracellular delivery
of the APPL or an agent complexed thereto may be useful in bioprocessing by maintaining
the cell’s health and/or growth, e.g., in the manufacturing of proteins.
The composition may comprise one type of APPL but may also comprise any
number of different types of APPLs, e.g., l, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different types of
APPLs.
In certain embodiments, the composition further comprises an agent, as
described herein. For example, in certain embodiments, the agent is a small molecule,
organometallic compound, nucleic acid, n, peptide, polynucleotide, metal, targeting
agent, an isotopically d chemical compound, drug, vaccine, immunological agent, or an
agent useful in bioprocessing. In certain embodiments, the agent is a polynucleotide. In
certain embodiments, the polynucleotide is DNA or RNA. In n embodiments, the RNA
is RNAi, dsRNA, siRNA, shRNA, miRNA, or antisense RNA. In certain embodiments, the
polynucleotide and the one or more APPLs are not covalently attached.
In certain embodiments, the one or more APPLs are in the form of a particle. In
certain embodiments, the particle is a nanoparticle or microparticle. In n embodiments,
the one or more APPLs are in the form of liposomes or micelles. It is understood that, in
certain embodiments, these APPLs ssemble to provide a particle, micelle, or liposome.
In certain embodiments, the particle, micelle, or liposome encapsulates an agent. The agent
to be delivered by the particle, micelle, or liposome may be in the form of a gas, liquid, or
solid. The APPLs may be combined with polymers etic or natural), tants,
cholesterol, ydrates, proteins, lipids etc. to form the les. These particles may be
further combined with an ent to form the ition.
“Excipients” e any and all solvents, diluents or other liquid es,
sion or suspension aids, surface active agents, isotonic agents, thickening or
emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the
particular dosage form desired. General considerations in formulation and/or manufacture
can be found, for example, in Remington ’s Pharmaceutical Sciences, Sixteenth Edition, E.
W. Martin (Mack Publishing Co., , Pa., 1980), and Remington: The Science and
Practice ofPharmacy, 21st n (Lippincott Williams & Wilkins, 2005).
Exemplary excipients include, but are not limited to, any non—toxic, inert solid,
semi—solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any
type. Some examples of materials which can serve as excipients include, but are not limited
to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato
; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose,
and cellulose acetate; powdered tragacanth; malt; gelatin; talc; ents such as cocoa butter
and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive
oil; corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and
ethyl laurate; agar; detergents such as Tween 80; buffering agents such as magnesium
hydroxide and aluminum hydroxide; alginic acid; pyrogen—free water; isotonic saline;
Ringer’s solution; ethyl alcohol; and phosphate buffer solutions, as well as other non—toxic
compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as
coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming
agents, preservatives and idants can also be present in the composition, according to
the judgment of the formulator. As would be appreciated by one of skill in this art, the
excipients may be chosen based on what the ition is useful for. For example, with a
pharmaceutical composition or cosmetic composition, the choice of the excipient will depend
on the route of administration, the agent being delivered, time course of delivery of the agent,
etc, and can be administered to humans and/or to animals, orally, rectally, parenterally,
intracistemally, intravaginally, intranasally, intraperitoneally, topically (as by powders,
creams, nts, or drops), bucally, or as an oral or nasal spray.
ary diluents include calcium carbonate, sodium carbonate, calcium
phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium
phosphate lactose, sucrose, cellulose, microcrystalline ose, kaolin, mannitol, sorbitol,
inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc, and combinations
thereof.
Exemplary granulating and/or dispersing agents include potato starch, corn
starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp,
agar, bentonite, cellulose and wood products, natural , cation—exchange resins,
calcium ate, silicates, sodium carbonate, cross—linked inyl—pyrrolidone)
(crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl
cellulose, cross—linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose,
pregelatinized starch (starch 1500), microcrystalline , water insoluble starch, calcium
carboxymethyl cellulose, magnesium aluminum te (Veegum), sodium lauryl sulfate,
quaternary um compounds, etc, and combinations thereof.
Exemplary surface active agents and/or emulsifiers include natural emulsifiers
(e.g. acacia, agar, alginic acid, sodium te, anth, chondrux, cholesterol, xanthan,
pectin, gelatin, egg yolk, casein, wool fat, terol, wax, and lecithin), dal clays (e.g.
bentonite [aluminum silicate] and Veegum [magnesium aluminum silicate]), long chain
amino acid derivatives, high molecular weight alcohols (e.g. stearyl alcohol, cetyl alcohol,
oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and
propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene,
polyacrylic acid, acrylic acid polymer, and carboxyvinyl r), carrageenan, cellulosic
derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl
cellulose, ypropyl cellulose, hydroxypropyl methylcellulose, cellulose),
sorbitan fatty acid esters (e.g. polyoxyethylene sorbitan monolaurate [Tween 20],
polyoxyethylene sorbitan [Tween 60], polyoxyethylene sorbitan monooleate [Tween 80],
sorbitan monopalmitate [Span 40], sorbitan monostearate [Span 60], sorbitan tristearate [Span
65], glyceryl monooleate, an monooleate [Span 80]), polyoxyethylene esters (e.g.
polyoxyethylene earate [Myrj 45], polyoxyethylene hydrogenated castor oil,
hoxylated castor oil, polyoxymethylene stearate, and Solutol), e fatty acid esters,
polyethylene glycol fatty acid esters (e.g. Cremophor), polyoxyethylene ethers, (e.g.
polyoxyethylene lauryl ether [Brij 30]), poly(vinyl—pyrrolidone), diethylene glycol
monolaurate, triethanolamine , sodium oleate, potassium oleate, ethyl oleate, oleic acid,
ethyl laurate, sodium lauryl e, ic F 68, Poloxamer 188, cetrimonium bromide,
cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations
thereof.
Exemplary binding agents include starch (e.g. cornstarch and starch paste),
gelatin, sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol,
eta), natural and synthetic gums (e.g. acacia, sodium alginate, extract of Irish moss, panwar
gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose,
ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl
methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl—pyrrolidone),
magnesium aluminum silicate m), and larch arabogalactan), alginates, polyethylene
oxide, polyethylene glycol, nic calcium salts, silicic acid, polymethacrylates, waxes,
water, alcohol, eta, and/or combinations thereof.
Exemplary preservatives include antioxidants, chelating agents, antimicrobial
preservatives, antifungal preservatives, alcohol preservatives, acidic vatives, and other
preservatives.
Exemplary antioxidants include alpha tocopherol, ascorbic acid, l
palmitate, butylated yanisole, ted hydroxytoluene, monothioglycerol, potassium
sulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium
metabisulfite, and sodium sulfite.
Exemplary chelating agents e ethylenediaminetetraacetic acid (EDTA)
and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate,
calcium disodium edetate, dipotassium edetate, and the like), citric acid and salts and
hydrates thereof (e.g., citric acid monohydrate), fumaric acid and salts and hydrates thereof,
malic acid and salts and hydrates thereof, phosphoric acid and salts and es thereof, and
tartaric acid and salts and hydrates thereof. Exemplary antimicrobial preservatives e
benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide,
cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol,
ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol,
mercuric nitrate, propylene glycol, and thimerosal.
Exemplary antifungal preservatives include butyl paraben, methyl paraben,
ethyl paraben, propyl paraben, benzoic acid, ybenzoic acid, potassium benzoate,
ium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
Exemplary alcohol preservatives e ethanol, polyethylene , phenol,
phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and ethyl alcohol.
Exemplary acidic preservatives include vitamin A, vitamin C, n E, beta—
carotene, citric acid, acetic acid, oacetic acid, ascorbic acid, sorbic acid, and phytic
acid.
Other preservatives include tocopherol, tocopherol acetate, deteroxime
mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT),
ethylenediamine, sodium lauryl e (SLS), sodium lauryl ether sulfate (SLES), sodium
bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus,
Phenonip, paraben, l llS, Germaben II, Neolone, Kathon, and Euxyl. In
certain embodiments, the preservative is an anti—oxidant. In other embodiments, the
preservative is a chelating agent.
Exemplary buffering agents include citrate buffer solutions, acetate buffer
solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, m
chloride, calcium citrate, calcium nate, calcium gluceptate, calcium gluconate, D—
gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate,
pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate,
calcium hydroxide phosphate, potassium e, potassium chloride, potassium gluconate,
potassium mixtures, dibasic potassium phosphate, monobasic ium phosphate,
potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium
citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium
phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid,
pyrogen—free water, isotonic saline, Ringer’s solution, ethyl alcohol, etc, and combinations
thereof.
Exemplary lubricating agents include magnesium stearate, calcium stearate,
stearic acid, silica, talc, malt, glyceryl te, hydrogenated vegetable oils, polyethylene
glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate,
sodium lauryl sulfate, etc, and combinations f.
Exemplary natural oils include almond, t kernel, avocado, babassu,
bergamot, black current seed, , cade, camomile, canola, caraway, a, castor,
cinnamon, cocoa butter, t, cod liver, , corn, cotton seed, emu, eucalyptus,
evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl
myristate, jojoba, kukui nut, in, er, lemon, litsea cubeba, macademia nut,
mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm,
palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary,
er, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone,
soybean, sunflower, tea tree, thistle, tsubaki, vetiver, , and wheat germ oils.
ary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride,
capric triglyceride, cyclomethicone, diethyl te, dimethicone 360, isopropyl myristate,
mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and combinations thereof.
Additionally, the composition may se a phospholipid. Exemplary
phospholipids include, but are not limited to, disteroylphosphatidylcholine (DSPC),
dimyristoylphosphatidylcholine (DMPC), Dipalmitoylphosphatidylcholine (DPPC), and
dioleoyl—sn—glycero—3—phosphocholine (DOPC), l,2—Dilauroyl—sn—Glycero—3—Phosphocholine
(dilauroylphosphatidylcholine, DLPC), myristoyl—sn—Glycero—3—Phosphocholine
(dimyristoylphosphatidylcholine, DMPC), l,2—Dipentadecanoyl—sn—Glycero—3—
Phosphocholine (dipentadecanoylphosphatidylcholine, DPDPC), l,2—dipalmitoyl—sn—Glycero—
3—Phosphocholine (dipalmitoylphosphatidylcholine, DPPC), stoyl—2—Palmitoyl—sn—
Glycero—3—Phosphocholine (l—myristoyl—2—palmitoylphosphatidylcholine, MPPC), 1,2—
Dimyristoyl—sn—Glycero—3—[Phospho—rac—(l—glycerol)] (DMPG), and l,2—Dimyristoyl—3—
Trimethylammonium—propane.
Additionally, the ition may further comprise a polymer. Exemplary
polymers contemplated herein include, but are not limited to, cellulosic polymers and
copolymers, for example, cellulose ethers such as methylcellulose (MC),
hydroxyethylcellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl
cellulose , hydroxyethylcellulose (MHEC), methylhydroxypropylcellulose
(MHPC), ymethyl cellulose (CMC) and its various salts, including, e.g., the sodium
salt, hydroxyethylcarboxymethylcellulose (HECMC) and its various salts,
carboxymethylhydroxyethylcellulose (CMHEC) and its various salts, other polysaccharides
and polysaccharide derivatives such as starch, dextran, dextran derivatives, chitosan, and
alginic acid and its various salts, carageenan, varoius gums, ing xanthan gum, guar
gum, gum arabic, gum karaya, gum ghatti, konjac and gum tragacanth, glycosaminoglycans
and proteoglycans such as hyaluronic acid and its salts, proteins such as gelatin, collagen,
albumin, and fibrin, other polymers, for example, droxyacids such as polylactide,
polyglycolide, lactide—co—glycolide) and poly(.epsilon.—caprolactone—co—glycolide)—,
carboxyvinyl polymers and their salts (e.g., carbomer), polyvinylpyrrolidone (PVP),
polyacrylic acid and its salts, polyacrylamide, polyacilic acid/acrylamide copolymer,
polyalkylene oxides such as polyethylene oxide, polypropylene oxide, poly(ethylene oxide—
propylene oxide), and a Pluronic polymer, polyoxyethylene thylene glycol),
polyanhydrides, polyvinylalchol, hyleneamine and polypyrridine, polyethylene glycol
(PEG) polymers, such as PEGylated lipids PEG—stearate, l,2—Distearoyl—sn—glycero—3—
Phosphoethanolamine—N—[Methoxy(Polyethylene glycol)—1000], l,2—Distearoyl—sn—glycero—3—
Phosphoethanolamine—N—[Methoxy(Polyethylene glycol)—2000], and l,2—Distearoyl—sn—
o—3—Phosphoethanolamine—N—[Methoxy(Polyethylene glycol)—5000]), copolymers and
salts thereof.
Additionally, the composition may further comprise an emulsifying agent.
Exemplary emulsifying agents e, but are not limited to, a polyethylene glycol (PEG), a
polypropylene glycol, a polyvinyl l, a poly—N—vinyl pyrrolidone and copolymers
thereof, poloxamer nonionic surfactants, neutral water—soluble polysaccharides (e.g., dextran,
Ficoll, celluloses), non—cationic poly(meth)acrylates, non—cationic polyacrylates, such as
poly(meth)acrylic acid, and esters amide and hydroxyalkyl amides f, natural
emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, ux, cholesterol,
xanthan, , gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal
clays (e.g. bentonite [aluminum silicate] and Veegum [magnesium um silicate]), long
chain amino acid derivatives, high molecular weight alcohols (e.g. stearyl alcohol, cetyl
alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl
monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g.
carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer),
carrageenan, cellulosic tives (e.g. carboxymethylcellulose sodium, powdered cellulose,
hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose,
methylcellulose), sorbitan fatty acid esters (e.g. polyoxyethylene sorbitan monolaurate
[Tween 20], polyoxyethylene sorbitan [Tween 60], polyoxyethylene sorbitan eate
[Tween 80], sorbitan monopalmitate [Span 40], sorbitan monostearate [Span 60], sorbitan
tristearate [Span 65], glyceryl monooleate, sorbitan monooleate [Span 80]), polyoxyethylene
esters (e.g. polyoxyethylene monostearate [Myrj 45], polyoxyethylene hydrogenated castor
oil, polyethoxylated castor oil, polyoxymethylene te, and Solutol), sucrose fatty acid
esters, polyethylene glycol fatty acid esters (e.g. Cremophor), polyoxyethylene , (e.g.
polyoxyethylene lauryl ether [Brij 30]), poly(vinyl—pyrrolidone), diethylene glycol
monolaurate, anolamine oleate, sodium , potassium oleate, ethyl oleate, oleic acid,
2012/062222
ethyl laurate, sodium lauryl sulfate, ic F 68, Poloxamer 188, cetrimonium bromide,
cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or ations
thereof. In certain ments, the emulsifying agent is cholesterol.
] Additionally, the ition may further comprise an apolipoprotein. Previous
studies have reported that Apolipoprotein E (ApoE) was able to enhance cell uptake and gene
silencing for a certain type of als. See, e. g., Akinc, A., et al., Targeted delivery ofRNAi
therapeutics with endogenous and exogenous -based mechanisms. Mol Ther. 18(7): p.
1357—64. In n embodiments, the apolipoprotein is ApoA, ApoB, ApoC, ApoE, or ApoH,
or an isoform thereof.
Liquid compositions e emulsions, microemulsions, solutions,
suspensions, syrups, and elixirs. In addition to the APPL, the liquid composition may contain
inert ts commonly used in the art such as, for example, water or other solvents,
solubilizing agents and fiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate,
ethyl e, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3—butylene glycol,
dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, , and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters
of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also
include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening,
flavoring, and perfuming agents.
Injectable compositions, for example, injectable aqueous or oleaginous
suspensions may be formulated according to the known art using suitable dispersing or
wetting agents and suspending agents. The sterile injectable ation may also be a
injectable solution, sion, or emulsion in a nontoxic parenterally acceptable diluent or
solvent, for example, as a on in 1,3—butanediol. Among the acceptable vehicles and
solvents for pharmaceutical or cosmetic compositions that may be employed are water,
Ringer’s solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils
are conventionally employed as a solvent or suspending medium. Any bland fixed oil can be
employed including synthetic mono— or diglycerides. In addition, fatty acids such as oleic
acid are used in the preparation of injectables. In certain embodiments, the particles are
suspended in a carrier fluid comprising 1% (w/v) sodium carboxymethyl cellulose and 0.1%
(v/v) Tween 80. The injectable composition can be sterilized, for example, by tion
through a bacteria—retaining filter, or by incorporating sterilizing agents in the form of sterile
solid compositions which can be dissolved or dispersed in sterile water or other sterile
injectable medium prior to use.
itions for rectal or vaginal stration may be in the form of
suppositories which can be prepared by mixing the particles with suitable non—irritating
excipients or carriers such as cocoa butter, polyethylene , or a suppository wax which
are solid at t temperature but liquid at body temperature and therefore melt in the
rectum or vaginal cavity and release the particles.
Solid compositions include capsules, tablets, pills, powders, and granules. In
such solid compositions, the particles are mixed with at least one excipient and/or a) fillers or
extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders
such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone,
sucrose, and acacia, c) humectants such as ol, d) disintegrating agents such as
agar—agar, calcium carbonate, potato or tapioca , alginic acid, certain silicates, and
sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators
such as quaternary ammonium nds, g) wetting agents such as, for example, cetyl
alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i)
lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols,
sodium lauryl sulfate, and es thereof. In the case of capsules, tablets, and pills, the
dosage form may also comprise buffering . Solid compositions of a similar type may
also be employed as fillers in soft and hard—filled gelatin capsules using such ents as
lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
Tablets, dragees, capsules, pills, and granules can be prepared with coatings and
shells such as enteric gs and other coatings well known in the pharmaceutical
formulating art. They may optionally contain opacifying agents and can also be of a
composition that they release the active ingredient(s) only, or preferentially, in a certain part
of the inal tract, optionally, in a delayed manner. Examples of embedding compositions
which can be used include polymeric substances and waxes.
] Solid compositions of a similar type may also be employed as fillers in soft and
hard—filled gelatin capsules using such excipients as lactose or milk sugar as well as high
molecular weight polyethylene glycols and the like.
Compositions for topical or transdermal administration include nts,
pastes, creams, lotions, gels, powders, ons, sprays, inhalants, or patches. The APPL is
admixed with an excipient and any needed preservatives or s as may be required.
Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the
scope of this invention.
The ointments, pastes, creams, and gels may contain, in addition to the APPL,
excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth,
cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, and zinc
oxide, or mixtures thereof.
Powders and sprays can contain, in addition to the APPL, excipients such as
lactose, talc, silicic acid, aluminum hydroxide, m silicates, and polyamide powder, or
es of these substances. Sprays can additionally n customary propellants such as
fluorohydrocarbons.
ermal patches have the added advantage of providing controlled delivery
of a compound to the body. Such dosage forms can be made by dissolving or dispensing the
microparticles or rticles in a proper medium. Absorption enhancers can also be used
to increase the flux of the compound across the skin. The rate can be controlled by either
providing a rate controlling membrane or by dispersing the particles in a polymer matrix or
gel.
Agents
Agents to be delivered by the systems described herein may be eutic,
diagnostic, or prophylactic . Any chemical compound to be stered to a subject
may be delivered using the complexes, picoparticles, nanoparticles, microparticles, es,
or liposomes, described herein. The agent may be an organic molecule (e.g., a therapeutic
agent, a drug), inorganic molecule, nucleic acid, protein, amino acid, peptide, polypeptide,
polynucleotide, targeting agent, isotopically labeled organic or inorganic molecule, e,
logical agent, etc.
In certain embodiments, the agents are organic molecules with pharmaceutical
activity, 6.57., a drug. In certain ments, the drug is an antibiotic, iral agent,
anesthetic, steroidal agent, anti—inflammatory agent, anti—neoplastic agent, anti—cancer agent,
antigen, vaccine, antibody, decongestant, antihypertensive, ve, birth control agent,
progestational agent, anti—cholinergic, analgesic, anti—depressant, anti—psychotic, B—adrenergic
blocking agent, diuretic, cardiovascular active agent, vasoactive agent, non—steroidal anti—
inflammatory agent, nutritional agent, etc.
In certain embodiments of the present invention, the agent to be delivered may
be a mixture of agents.
Diagnostic agents include gases; metals; commercially available imaging agents
used in positron emissions tomography (PET), computer assisted tomography (CAT), single
photon emission computerized tomography, x—ray, fluoroscopy, and magnetic resonance
imaging (MRI); and st agents. Examples of suitable materials for use as contrast
agents in MRI include gadolinium chelates, as well as iron, magnesium, manganese, copper,
and chromium. Examples of materials useful for CAT and x—ray imaging include —
based materials.
Therapeutic and lactic agents include, but are not limited to, antibiotics,
nutritional supplements, and es. Vaccines may comprise isolated proteins or peptides,
inactivated organisms and viruses, dead organisms and s, genetically altered organisms
or viruses, and cell extracts. Therapeutic and prophylactic agents may be combined with
interleukins, eron, cytokines, and adjuvants such as cholera toxin, alum, Freund’s
adjuvant, etc. Prophylactic agents e antigens of such bacterial organisms as
Streptococccus pneumoniae, Haemophilus zae, Staphylococcus aureus, Streptococcus
pyrogenes, Corynebacterium diphtheriae, Listeria togenes, Bacillus anthracis,
Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Neisseria meningitidis,
Neisseria gonorrhoeae, Streptococcus mutans, Pseudomonas aeruginosa, Salmonella typhi,
Haemopliilus parainfluenzae, Bordetella pertussis, Francisella tularensis, Yersinia pestis,
Vibrio cholerae, Legionella pneumophila, Mycobacterium tuberculosis, Mycobacterium
leprae, Treponema um, Leptospirosis interrogans, Borrelia rferi,
Campliylobacterjejuni, and the like; antigens of such viruses as smallpox, influenza A and B,
respiratory syncytial virus, parainfluenza, s, HIV, varicella—zoster, herpes x l
and 2, galovirus, Epstein—Barr virus, rotavirus, rhinovirus, adenovirus, papillomavirus,
poliovirus, mumps, rabies, rubella, coxsackieviruses, equine encephalitis, Japanese
alitis, yellow fever, Rift Valley fever, hepatitis A, B, C, D, and E virus, and the like;
antigens of fungal, protozoan, and parasitic organisms such as Cryptococcus neoformans,
Histoplasma capsulatum, Candida albicans, a alis, Nocardia asteroides,
Rickettsia sii, Rickettsia typhi, Mycoplasma pneumoniae, Chlamydial psittaci,
Chlamydial trachomatis, Plasmodiumfalciparum, Trypanosoma brucei, Entamoeba
histolytica, Toxoplasma gondii, Trichomonas vaginalis, Schistosoma mansoni, and the like.
These antigens may be in the form of Whole killed organisms, peptides, proteins,
glycoproteins, carbohydrates, or combinations thereof.
Targeting Agents
Since it is often desirable to target a particular cell, collection of cells, or tissue,
an APPL, and the complexes, liposomes, micelles, articles, picoparticles and
nanoparticles, prepared therefrom, may be modified to e targeting agents or targeting
regions. For example, the APPL scaffold may include a targeting region. A variety of agents
or regions that target particular cells are known in the art. See, e. g., Cotten et al., Methods
Enzym. 217:618, 1993. The targeting agents may be included throughout the particle or may
be only on the e. The targeting agent may be a protein, peptide, ydrate,
glycoprotein, lipid, small molecule, nucleic acids, etc. The targeting agent may be used to
target specific cells or s or may be used to promote endocytosis or phagocytosis of the
particle. Examples of ing agents include, but are not limited to, antibodies, fragments
of antibodies, low—density lipoproteins (LDLs), transferrin, asialycoproteins, gp120 envelope
protein of the human immunodeficiency virus (HIV), carbohydrates, receptor s, sialic
acid, rs, etc. If the targeting agent is included throughout the particle, the targeting
agent may be included in the mixture that is used to form the particles. If the targeting agent
is only on the surface, the targeting agent may be associated with (i.e., by nt,
hydrophobic, hydrogen bonding, van der Waals, or other ctions) the formed particles
using standard chemical techniques.
Polynucleotide Complexes
The present invention contemplates APPLs are particularly useful in the
administration of polynucleotides. For example, APPLs comprise secondary or tertiary
amines, and, although these amines are hindered, they are available to non—covalently interact
with a polynucleotide (e. g., DNA, RNA, synthetic s of DNA and/or RNA, DNA/RNA
hydrids, etc.). Polynucleotides or derivatives f are contacted with an APPL under
conditions suitable to form a polynucleotide/APPL non—covalent complex. The interaction of
the APPL with the polynucleotide is thought to at least partially prevent the degradation of
the polynucleotide. By lizing the charge on the backbone of the polynucleotide, the
neutral or slightly—positively—charged complex is also able to more easily pass through the
hydrophobic membranes (e.g., cytoplasmic, lysosomal, endosomal, r) of the cell. In
certain embodiments, the complex is slightly positively charged. In certain embodiments, the
x has a positive C—potential. In certain embodiments the C—potential is between 0 and
+30.
In one aspect, provided is a method of delivering a polynucleotide to a
biological cell, comprising providing a composition comprising an APPL, or salt thereof, and
a cleotide; and exposing the composition to the biological cell under conditions
sufficient to facilitate delivery of the polynucleotide into the interior of the biological cell;
wherein the APPL is an amino acid, a linear or cyclic e, or a linear or cyclic
polypeptide, or structural isomer f, wherein an amino or amide group of the APPL is
conjugated to a group of formula (i), (ii), or (iii). In certain embodiments, the method is an
in viva method. In certain embodiments, the method is an in vitro method.
An APPL may be at least partially provided as a salt (e.g., is protonated) so as
to form a complex with the negatively charged polynucleotide. In n ments, the
polynucleotide/APPL x form particles that are useful in the delivery of
polynucleotides to cells. In certain embodiments, more than one APPL may be associated
with a polynucleotide molecule. For example, the complex may include 1—100 APPLs, 1—
1000 APPLs, 10—1000 APPLs, or 100—10,000 APPLs associated with a polynucleotide
molecule.
Increasing nitrogen:phosphate ratios have been shown to positively influence
delivery of genetic material by increasing nucleic acid g and negatively influence
delivery by increasing toxicity. See, e.g., Incani et al., Soft Matter (2010) 6:2124—2138. In
certain embodiments, the en:phosphate ratio (Le. the ratio between the amino groups
present in the APPL, and the ate groups present in the polynucleotide) is between
about 10:1 to about 50:1, inclusive. In certain embodiments, the nitrogen phosphate ratio is
between about 10:1 to about 45:1, between about 15:1 to about 45:1, or between about 20:1
to about 40:1, inclusive. In certain embodiments, the APPL:polynucleotide mass ratio is
between about 10:1 to about 20: l, inclusive. In certain ments, the
APPL:polynucleotide mass ratio is about 15:1. In certain embodiments, the
APPL:polynucleotide molar ratio is between about 10:1 to about 400:1, inclusive. In certain
embodiments, the olynucleotide molar ratio is between about 10:1 to about 350:1,
between about 15:1 to about 300:1, or between about 20:1 to about 250:1, ive.
In certain ments, the complex may form a particle. In certain
embodiments, the diameter of the particles ranges from 10—500 micrometers. In certain
embodiments, the diameter of the les ranges from 10— 1200 micrometers. In certain
embodiments, the diameter of the particles ranges from 50— 150 micrometers. In certain
embodiments, the diameter of the particles ranges from 10—500 nm, in certain embodiments
the diameter of the particles ranges from 10—1200 nm, and in certain embodimentsfrom 50—
150 nm. The particles may be associated with a targeting agent as described below. In
certain embodiments, the diameter of the particles ranges from 10—500 pm, in certain
embodimentsthe diameter of the particles ranges from 10—1200 pm, and in certain
embodimentsfrom 50—150 pm. The particles may be associated with a targeting agent as
described below. The film architecture is precisely designed and can be controlled to 1 nm
precision with a range from 1 to 150000 nm and with a definite knowledge of its molecular
composition.
The polynucleotide may be complexed, encapsulated by an APPL, or included
in a composition comprising an APPL. The polynucleotide may be any c acid
including, but not limited to, RNA and DNA. In certain embodiments, the cleotide is
DNA. In n embodiments, the polynucleotide is RNA. In certain embodiments, upon
delivery of the RNA into a cell, the RNA is able to ere with the expression of a specific
gene in the biological cell.
In certain embodiments, the polynucleotide is an RNA that carries out RNA
erence (RNAi). The phenomenon of RNAi is discussed in greater detail, for example, in
the following references: ir et al., 2001, Genes Dev., 15: 188; Fire et al., 1998, ,
391:806; Tabara et al., 1999, Cell, 99:123; Hammond et al., Nature, 2000, 404:293; Zamore
et al., 2000, Cell, ; Chakraborty, 2007, Curr. Drug Targets, 8:469; and Morris and
Rossi, 2006, Gene Ther, 13:553. In certain embodiments, the polynucleotide is a dsRNA
(double—stranded RNA). In certain embodiments, the polynucleotide is an siRNA (short
interfering RNA). In certain embodiments, the polynucleotide is an shRNA (short hairpin
RNA). In certain embodiments, the polynucleotide is an miRNA (micro RNA). Micro
RNAs s) are genomically encoded non—coding RNAs of about 21 — 23 nucleotides in
length that help regulate gene expression, particularly during pment. See, e. g., Bartel,
2004, Cell, 116:281; Novina and Sharp, 2004, Nature, 430: 161; and US. Patent Publication
2005/0059005; also reviewed in Wang and Li, 2007, Front. Biosci., 12:3975; and Zhao,
2007, Trends Biochem. Sci., 32: 189. In certain embodiments, the cleotide is an
antisense RNA.
In certain embodiments, the cleotide may be ed as an antisense
agent or RNA interference (RNAi). See, e.g., Fire et al., Nature 391:806—81 1, 1998.
Antisense therapy is meant to include, e. g., administration or in situ provision of single— or
double—stranded oligonucleotides or their derivatives which specifically hybridize, e. g., bind,
under cellular conditions, with ar mRNA and/or genomic DNA, or mutants thereof, so
as to inhibit expression of the encoded protein, e.g., by inhibiting transcription and/or
translation. See, e. g., Crooke “Molecular mechanisms of action of antisense drugs” Biochim.
Biophys. Acta l489(l):31—44, 1999; Crooke “Evaluating the ism of action of
antiproliferative antisense drugs” Antisense Nucleic Acid Drug Dev. 10(2): 123— 126,
discussion 127, 2000; Methods in logy volumes 4, 1999. The binding may be
by conventional base pair mentarity, or, for example, in the case of binding to DNA
duplexes, through specific interactions in the major groove of the double helix (i.e., triple
helix formation). See, e.g., Chan et al., J. Mol. Med. 75(4):267-282, 1997.
In some embodiments, dsRNA, siRNA, shRNA, miRNA, antisense RNA,
and/or RNAi can be ed and/or ted using one or more of a large number of
available algorithms. To give but a few examples, the following ces can be utilized to
design and/or predict polynucleotides: algorithms found at Alnylum Online, Dharmacon
Online, OligoEngine Online, Molecula Online, Ambion Online, BioPredsi Online, RNAi
Web Online, Chang Bioscience Online, Invitrogen Online, LentiWeb Online GenScript
Online, Protocol Online; Reynolds et al., 2004, Nat. Biotechnol, 22:326; Naito et al., 2006,
Nucleic Acids Res., 34:W448; Li et al., 2007, RNA, 13:1765; Yiu et al., 2005, Bioinformatics,
21:144; and Jia et al., 2006, BMC Bioinformatics, 7: 271.
The polynucleotides may be of any size or sequence, and they may be single— or
double—stranded. In certain embodiments, the polynucleotide is greater than 100 base pairs
long. In certain embodiments, the polynucleotide is greater than 1000 base pairs long and
may be greater than 10,000 base pairs long. The polynucleotide is optionally purified and
ntially pure. In certain embodiments, the polynucleotide is greater than 50% pure, in
certain embodiments greater than 75% pure, and in certain embodimentsgreater than 95%
pure. The polynucleotide may be provided by any means known in the art. In certain
embodiments, the polynucleotide has been engineered using recombinant techniques. See,
e.g., Ausubel et al., Current Protocols in Molecular Biology (John Wiley & Sons, Inc., New
York, 1999); Molecular Cloning: A tory Manual, 2nd Ed., ed. by Sambrook, Fritsch,
and is (Cold Spring Harbor tory Press: 1989). The polynucleotide may also be
ed from natural s and purified from contaminating components found normally
in nature. The polynucleotide may also be chemically synthesized in a laboratory. In certain
embodiments, the polynucleotide is synthesized using rd solid phase chemistry.
] The polynucleotide may be modified by chemical or biological means. In
certain embodiments, these modifications lead to increased stability of the polynucleotide.
Modifications include methylation, phosphorylation, end—capping, etc.
Derivatives of polynucleotides may also be used in the present invention.
These derivatives include modifications in the bases, sugars, and/or phosphate es of the
polynucleotide. Modified bases include, but are not limited to, those found in the following
nucleoside analogs: oadenosine, 2—thiothymidine, inosine, pyrrolo—pyrimidine, 3—
methyl adenosine, 5—methylcytidine, mouridine, CS—fluorouridine, ouridine,
C5—propynyl—uridine, C5—propynyl—cytidine, C5—methylcytidine, 7—deazaadenosine,
7—deazaguanosine, 8—oxoadenosine, 8—oxoguanosine, O(6)—methylguanine, and 2—thiocytidine.
Modified sugars include, but are not limited to, 2’—fluororibose, ribose, 2’—deoxyribose, 3’—
2’,3”—dideoxyribose, 2’,3’—dideoxyribose, arabinose (the 2’—epimer of ribose), acyclic
sugars, and hexoses. The nucleosides may be strung together by linkages other than the
phosphodiester linkage found in naturally occurring DNA and RNA. Modified linkages
include, but are not limited to, phosphorothioate and 5’—N—phosphoramidite linkages.
Combinations of the various modifications may be used in a single polynucleotide. These
modified polynucleotides may be provided by any means known in the art; however, as will
be appreciated by those of skill in this art, the modified polynucleotides may be prepared
using synthetic chemistry in vitro.
The polynucleotides to be delivered may be in any form. For e, the
polynucleotide may be a circular plasmid, a linearized d, a cosmid, a viral genome, a
modified viral genome, an artificial some, etc.
] The polynucleotide may be of any sequence. In certain embodiments, the
polynucleotide encodes a n or peptide. The encoded proteins may be enzymes,
structural proteins, ors, soluble receptors, ion channels, pharmaceutically active
proteins, cytokines, interleukins, antibodies, dy fragments, antigens, coagulation
factors, albumin, growth factors, hormones, insulin, etc. The polynucleotide may also
comprise regulatory regions to control the expression of a gene. These regulatory regions
may include, but are not limited to, promoters, enhancer elements, repressor elements, TATA
box, ribosomal binding sites, stop site for transcription, etc. In certain embodiments, the
cleotide is not intended to encode a protein. For example, the cleotide may be
used to fix an error in the genome of the cell being transfected.
In certain embodiments, the polynucleotide to be delivered comprises a
ce encoding an antigenic peptide or protein. Nanoparticles containing these
polynucleotides can be delivered to an individual to induce an immunologic response
sufficient to decrease the chance of a subsequent infection and/or lessen the symptoms
associated with such an infection. The cleotide of these vaccines may be combined
with eukins, interferon, cytokines, and adjuvants such as cholera toxin, alum, Freund’s
nt, etc. A large number of adjuvant compounds are known; a useful dium of
many such compounds is prepared by the National Institutes of Health. See, e. g., Allison
Dev. Biol. Stand. 92:3—11, 1998; Unkeless et al., Annu. Rev. Immunol. 6:251—281, 1998; and
Phillips et al., Vaccine 10:151—158, 1992.
The antigenic protein or peptides encoded by the polynucleotide may be derived
from such ial organisms as Streptococccus pneumoniae, Haemophilus influenzae,
Staphylococcus aureus, Streptococcus pyrogenes, bacterium diphtheriae, Listeria
monocytogenes, Bacillus anthracis, Clostridium tetani, Clostridium botulinum, Clostridium
perfringens, Neisseria meningitidis, Neisseria gonorrhoeae, Streptococcus mutans,
Pseudomonas aeruginosa, Salmonella typhi, Haemopliilus parainfluenzae, Bordetella
pertussis, Francisella tularensis, Yersinia pestis, Vibrio ae, Legionella pneumophila,
Mycobacterium ulosis, cterium leprae, ema pallidum, Leptospirosis
interrogans, Borrelia burgdorferi, Campliylobacterjejuni, and the like; from such viruses as
smallpox, za A and B, respiratory syncytial virus, parainfluenza, measles, HIV,
varicella—zoster, herpes simplex 1 and 2, cytomegalovirus, Epstein—Barr virus, rotavirus,
rhinovirus, irus, papillomavirus, poliovirus, mumps, rabies, rubella, coxsackieviruses,
equine alitis, Japanese encephalitis, yellow fever, Rift Valley fever, hepatitis A, B, C,
D, and E virus, and the like; and from such fungal, protozoan, and parasitic organisms such
as coccus neoformans, Histoplasma capsulatum, Candida albicans, Candida
tropicalis, Nocardia asteroides, tsia sii, Rickettsia typhi, Mycoplasma
pneumoniae, Chlamydial psittaci, Chlamydial trachomatis, Plasmodiumfalciparum,
Trypanosoma brucei, Entamoeba histolytica, Toxoplasma gondii, Trichomonas vaginalis,
Schistosoma mansoni, and the like.
Particles
The present invention also contemplates APPLs useful as a delivery device.
APPLs have several properties that make them particularly suitable for delivery, including: 1)
the ability of an APPL to complex and ct” labile agents; 2) the ability to buffer the pH
in the endosome; 3) the ability to act as a “proton sponge” and cause endosomolysis; and 4)
the ability to neutralize the charge on negatively charged agents.
In certain embodiments, an APPL is used to form particles containing the agent
to be delivered. An APPL may be used to encapsulate agents including, but not limited to,
organic molecules (e.g., cholesterol, drugs), inorganic molecules, nucleic acids, proteins,
peptides, polynucleotides, targeting agents, isotopically d organic or inorganic
molecules, vaccines, immunological agents, etc. Other exemplary agents are described in
greater detail herein. These particles may include other materials such as polymers (e.g.,
synthetic polymers (e.g., PEG, PLGA), l polymers (e.g., phospholipids)). In certain
embodiments, the APPL is mixed with one or more agents (e.g., cholesterol) and/or one or
more other materials (e.g., polymers).
In certain embodiments, the diameter of the particles range from between 1
micrometer to 1,000 micrometers. In certain embodiments, the diameter of the particles
range from between from 1 micrometer to 100 micrometers. In certain embodiments, the
diameter of the particles range from between from 1 micrometer to 10 micrometers. In
n embodiments, the diameter of the particles range from between from 10 micrometer to
100 micrometers. In certain embodiments, the er of the particles range from between
from 100 micrometer to 1,000 micrometers. In certain embodiments, the les range from
l—5 micrometers. In certain embodiments, the er of the particles range from between 1
nm to 1,000 nm. In certain embodiments, the diameter of the particles range from between
from 1 nm to 100 nm. In certain embodiments, the diameter of the les range from
between from 1 nm to 10 nm. In certain embodiments, the diameter of the particles range
from between from 10 nm to 100 nm. In certain embodiments, the diameter of the particles
range from n from 100 nm to 1,000 nm. In certain embodiments, the particles range
from l—5 nm. In certain embodiments, the diameter of the particles range from n 1 pm
to 1,000 pm. In certain embodiments, the diameter of the particles range from between from
1 pm to 100 pm. In certain embodiments, the diameter of the particles range from between
from 1 pm to 10 pm. In certain embodiments, the diameter of the particles range from
between from 10 pm to 100 pm. In certain embodiments, the diameter of the particles range
from between from 100 pm to 1,000 pm. In certain embodiments, the particles range from 1—
pm.
The particles may be prepared using any method known in this art. These
include, but are not limited to, spray drying, single and double emulsion t evaporation,
t tion, phase separation, simple and complex coacervation, and other s
well known to those of ordinary skill in the art. In certain embodiments, methods of
preparing the particles are the double emulsion process and spray drying. The ions
used in preparing the particles may be altered to yield particles of a desired size or property
(e.g., hydrophobicity, hydrophilicity, external morphology, “stickiness”, shape, etc). The
method of preparing the particle and the conditions (e.g., solvent, temperature, concentration,
2012/062222
air flow rate, etc.) used may also depend on the agent being encapsulated and/or the
composition of the matrix.
Methods developed for making particles for delivery of encapsulated agents are
bed in the literature. See, e. g., Doubrow, M., Ed., “Microcapsules and Nanoparticles in
ne and Pharmacy,” CRC Press, Boca Raton, 1992; Mathiowitz and Langer, J.
Controlled Release 5:13—22, 1987; Mathiowitz et al., Reactive Polymers 6:275-283, 1987;
Mathiowitz et al., J. Appl. Polymer Sci. 35:755—774, 1988.
If the particles prepared by any of the above methods have a size range outside
of the desired range, the particles can be sized, for example, using a sieve. The particle may
also be . In certain embodiments, the particles are coated with a targeting agent. In
other embodiments, the particles are coated to achieve desirable surface properties (e.g., a
particular charge).
Micelles and Liposomes
The present invention r contemplates use of APPLs in the preparation of
micelles or liposomes. Any agent may be further included in a e or liposome. es
and liposomes are particularly useful in delivering hydrophobic agents such as hydrophobic
small molecules. When the micelle or liposome is complexed with (e.g., encapsulates or
covers) a polynucleotide it is also referred to as a “lipoplex.” Many techniques for preparing
micelle and liposomes are known in the art, and any such method may be used with an APPL
to make es and liposomes.
In n embodiments, liposomes are formed through neous assembly.
In other embodiments, mes are formed when thin lipid films or lipid cakes are hydrated
and stacks of lipid crystalline bilayers become fluid and swell. The hydrated lipid sheets
detach during agitation and self—close to form large, multilamellar vesicles (LMV). This
ts interaction of water with the hydrocarbon core of the rs at the edges. Once
these particles have formed, ng the size of the particle can be modified through input of
sonic energy (sonication) or mechanical energy (extrusion). See, e. g., Walde, P. “Preparation
of Vesicles (Liposomes)” In Encylopedia ofNanoscience and Nanotechnology; Nalwa, H. S.
Ed. American Scientific Publishers: Los Angeles, 2004; Vol. 9, pp. 43-79; Szoka et al.,
“Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)” Ann.
Rev. Biophys. Bioeng. 9:467—508, 1980; each of which is incorporated herein. The
preparation of lipsomes involves preparing the APPL for ion, hydrating the APPL with
agitation, and sizing the vesicles to achieve a homogenous distribution of liposomes. APPLs
are first dissolved in an organic solvent to assure a homogeneous mixture of the APPL. The
solvent is then removed to form a r—derived film. This polymer—derived film is
thoroughly dried to remove residual organic solvent by placing the vial or flask on a vaccuum
pump overnight. Hydration of the polymer—derived film is accomplished by adding an
aqueous medium and agitating the mixture. Disruption of LMV suspensions using sonic
energy typically produces small unilamellar vesicles (SUV) with diameters in the range of
—50 nm. Lipid extrusion is a technique in which a lipid/polymer suspension is forced
h a polycarbonate filter with a defined pore size to yield particles having a diameter
near the pore size of the filter used. Extrusion through filters with 100 nm pores typically
yields large, unilamellar polymer—derived vesicles (LUV) with a mean diameter of 120—140
nm. In certain embodiments, the amount of APPL in the liposome ranges from 30—80 mol%,
in certain embodiments40—70 mol%, and in certain embodiments 60—70 mol%. In certain
embodiments, the APPL employed further complexes an agent, such as DNA and RNA. In
such ments, the application of the liposome is the delivery of polynucleotides.
The following scientific papers described other methods for preparing
liposomes and es: Narang et al., “Cationic Lipids with Increased DNA Binding
Affinity for Nonviral Gene er in Dividing and Nondividing Cells” Bioconjugate Chem.
16: 156—68, 2005; Hofland et al., “Formation of stable ic lipid/DNA complexes for gene
transfer” Proc. Natl. Acad. Sci. USA 93:7305—7309, July 1996; Byk et al., “Synthesis,
Activity, and Structure—Activity Relationship Studies of Novel Cationic Lipids for DNA
Transfer” J. Med. Chem. 224—235, 1998; Wu et al., “Cationic Lipid Polymerization as a
Novel Approach for Constructing New DNA Delivery Agents” Bioconjugate Chem. 12:251—
57, 2001; Lukyanov et al., “Micelles from lipid derivatives of water—soluble polymers as
delivery systems for poorly e drugs” Advanced Drug Delivery Reviews 56:1273—1289,
2004; Tranchant et al., “Physicochemical optimisation of plasmid delivery by ic lipids”
J. Gene Med. 6:S24—S35, 2004; van Balen et al., ome/Water Lipophilicity: s,
Information Content, and Pharmaceutical ations” Medicinal Research Rev. 24(3):299-
324, 2004.
Treatment Methods
It is estimated that over 10,000 human diseases are caused by c disorders,
which are abnormalities in genes or chromosomes. See, e.g., McClellan, J. and MC. King,
Genetic heterogeneity in human disease. Cell. 141(2): p. 210—7; Leachman, S.A., et al.,
Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J
Derrnatol Sci, 2008. 51(3): p. 151—7. Many of these diseases are fatal, such as , severe
hypercholesterolemia, and familial amyloidotic polyneuropathy. See, e.g., Frank—
Kamenetsky, M., et al., Therapeutic RNAi targeting PCSK9 acutely lowers plasma
cholesterol in rodents and LDL terol in nonhuman primates. Proc Natl Acad Sci U S
A, 2008. ): p. 11915—20; Coelho, T., Familial amyloid polyneuropathy: new
developments in genetics and treatment. Curr Opin Neurol, 1996. 9(5): p. 355—9. Since the
discovery of gene expression silencing via RNA interference (RNAi) by Fire and Mello (Fire,
A., et al., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis
elegans. Nature, 1998. 391(6669): p. 806—1 1), there has been extensive effort toward
developing therapeutic applications for RNAi in humans. See, e.g., Davis, M.E., The first
targeted delivery ofsiRNA in humans via a self-assembling, extrin polymer-based
nanoparticle: from concept to clinic. Mol Pharm, 2009. 6(3): p. 659—68; Whitehead, K.A., R.
Langer, and D.G. Anderson, Knocking down barriers: advances in siRNA ry. Nat. Rev.
Drug Discovery, 2009. 8(2): p. 8; Tan, S.J., et al., ering Nanocarriers for
siRNA Delivery. Small. 7(7): p. 841—56; Castanotto, D. and J .J . Rossi, The promises and
pitfalls ofRNA-interference-based therapeutics. Nature, 2009. 457(7228): p. 426—33; Chen,
Y. and L. Huang, Tumor-targeted delivery of siRNA by non-viral vector: safe and ejfective
cancer therapy. Expert Opin Drug Deliv, 2008. 5(12): p. 1301—1 1; Weinstein, S. and D. Peer,
RNAi nanomedicines: challenges and opportunities within the immune system.
Nanotechnology. 21(23): p. 232001; Fenske, DB. and PR. Cullis, Liposomal dicines.
Expert Opin Drug Deliv, 2008. 5(1): p. 25—44; and Thiel, K.W. and RH. Giangrande,
Therapeutic applications ofDNA and RNA aptamers. Oligonucleotides, 2009. 19(3): p. 209—
22. Currently, there are more than 20 clinical trials ongoing or completed involving siRNA
therapeutics, which have shown promising s for the treatment of various diseases. See,
e.g., Burnett, J .C., J .J . Rossi, and K. Tiemann, Current progress of siRNA/shRNA
therapeutics in clinical trials. Biotechnol J. 6(9): p. 6. However, the efficient and safe
ry of siRNA is still a key challenge in the development of siRNA therapeutics. See, e. g.,
Juliano, R., et al., Biological rs to therapy with nse and siRNA oligonucleotides.
Mol Pharm, 2009. 6(3): p. 686—95.
Thus, in another aspect, provided are methods of using APPLs, e. g., for the
treatment of a disease, disorder or condition from which a subject suffers. It is contemplated
that APPLs will be useful in the treatment of a variety of es, disorders, or conditions,
especially a system for delivering agents useful in the treatment of that particular e,
disorder, or condition. se,” “disorder,” and “condition” are used interchangeably
WO 63468
herein. In certain embodiments, the disease, disorder or condition from which a subject
suffers is caused by an abnormality in a gene or some of the subject.
For example, in one ment, ed is a method of treating disease,
disorder, or condition from which a subject suffers, comprising administering to a subject in
need thereof an ive amount of a composition sing an APPL, or salt thereof.
Exemplary disease, disorder, or conditions contemplated include, but are not limited to,
proliferative disorders, inflammatory disorders, autoimmune disorders, painful conditions,
liver diseases, and amyloid neuropathies.
As used herein, an “active ingredient” is any agent which elicits the desired
biological response. For example, the APPL may be the active ingredient in the composition.
Other agents, e.g., therapeutic agents, as described herein may also be classified as an active
ingredient. In certain embodiments, the composition further ses, in addition to the
APPL, a therapeutic agent useful in treating the e, er, or condition. In certain
embodiments, the APPL encapsulates the other (therapeutic) agent. In certain embodiments,
the APPL and the other peutic) agent form a particle (e.g., a nanoparticle, a
microparticle, a micelle, a liposome, a lipoplex).
In certain embodiments, the condition is a proliferative disorder and, in certain
embodiments, the composition r includes an anti—cancer agent. Exemplary proliferative
diseases include, but are not limited to, tumors, begnin sms, pre—malignant neoplasms
(carcinoma in situ), and anat neoplasms (cancers).
] Exemplary cancers include, but are not limited to, acoustic neuroma,
adenocarcinoma, adrenal gland cancer, anal cancer, angiosarcoma (e.g., lymphangiosarcoma,
lymphangioendotheliosarcoma, hemangiosarcoma), appendix cancer, benign monoclonal
gammopathy, biliary cancer (e.g., cholangiocarcinoma), bladder cancer, breast cancer (e.g.,
adenocarcinoma of the breast, papillary carcinoma of the breast, mammary , medullary
carcinoma of the breast), brain cancer (e.g., meningioma; glioma, e.g., astrocytoma,
endroglioma; medulloblastoma), bronchus cancer, carcinoid tumor, cervical cancer
(e.g., al adenocarcinoma), choriocarcinoma, chordoma, craniopharyngioma, colorectal
cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma), epithelial carcinoma,
ependymoma, endotheliosarcoma (e.g., Kaposi’s sarcoma, multiple idiopathic hemorrhagic
sarcoma), trial cancer (e.g., uterine cancer, uterine sarcoma), esophageal cancer (e.g.,
adenocarcinoma of the esophagus, Barrett’s adenocarinoma), Ewing’s sarcoma, eye cancer
(e.g., intraocular melanoma, retinoblastoma), familiar hypereosinophilia, gall bladder ,
gastric cancer (e.g., h adenocarcinoma), gastrointestinal stromal tumor (GIST), head
and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral
squamous cell carcinoma (OSCC), throat cancer (e.g., eal cancer, pharyngeal cancer,
aryngeal cancer, oropharyngeal cancer)), hematopoietic s (e.g., leukemia such
as acute lymphocytic leukemia (ALL) (e.g., B—cell ALL, T—cell ALL), acute myelocytic
leukemia (AML) (e.g., B—cell AML, T—cell AML), chronic myelocytic leukemia (CML)
(e.g., B—cell CML, T—cell CML), and c lymphocytic leukemia (CLL) (e.g., B—cell
CLL, T—cell CLL); lymphoma such as Hodgkin lymphoma (HL) (e.g., B—cell HL, T—cell HL)
and non—Hodgkin lymphoma (NHL) (e.g., B—cell NHL such as diffuse large cell lymphoma
(DLCL) (e.g., diffuse large B—cell lymphoma (DLBCL)), follicular lymphoma, chronic
lymphocytic leukemia/small lymphocytic ma (CLL/SLL), mantle cell lymphoma
(MCL), marginal zone B—cell lymphomas (e.g., mucosa—associated id tissue (MALT)
lymphomas, nodal marginal zone B—cell lymphoma, splenic marginal zone B—cell
lymphoma), primary mediastinal B—cell lymphoma, Burkitt lymphoma, lymphoplasmacytic
lymphoma (i.e., “Waldenstrom's macroglobulinemia”), hairy cell leukemia (HCL),
immunoblastic large cell lymphoma, precursor B—lymphoblastic lymphoma and primary
l nervous system (CNS) lymphoma; and T—cell NHL such as precursor T—
blastic lymphoma/leukemia, peripheral T—cell lymphoma (PTCL) (e.g., cutaneous T—
cell lymphoma (CTCL) (e.g., mycosis fungiodes, Sezary syndrome), angioimmunoblastic T—
cell lymphoma, odal natural killer T—cell lymphoma, pathy type T—cell
lymphoma, subcutaneous panniculitis—like T—cell lymphoma, anaplastic large cell
lymphoma); a mixture of one or more leukemia/lymphoma as described above; and multiple
myeloma (MM)), heavy chain disease (e.g., alpha chain disease, gamma chain disease, mu
chain disease), hemangioblastoma, atory roblastic tumors, immunocytic
amyloidosis, kidney cancer (e.g., nephroblastoma aka. Wilms’ tumor, renal cell carcinoma),
liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma), lung cancer (e.g.,
bronchogenic carcinoma, small cell lung cancer (SCLC), non—small cell lung cancer
(NSCLC), adenocarcinoma of the lung), leiomyosarcoma (LMS), mastocytosis (e.g.,
systemic mastocytosis), myelodysplastic syndrome (MDS), elioma, myeloproliferative
disorder (MPD) (e.g., polycythemia Vera (PV), essential thrombocytosis (ET), agnogenic
d metaplasia (AMM) a. k.a. myelofibrosis (MF), chronic idiopathic myelofibrosis,
chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL),
hypereosinophilic syndrome (HES)), neuroblastoma, neurofibroma (e.g., neurofibromatosis
(NF) type 1 or type 2, schwannomatosis), neuroendocrine cancer (e.g., gastroenteropancreatic
neuroendoctrine tumor ET), carcinoid tumor), osteosarcoma, ovarian cancer (e.g.,
cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma), papillary
adenocarcinoma, pancreatic cancer (e.g., pancreatic andenocarcinoma, intraductal papillary
mucinous neoplasm , Islet cell tumors), penile cancer (e.g., Paget’s e of the
penis and scrotum), pinealoma, primitive neuroectodermal tumor (PNT), prostate cancer
(e.g., prostate adenocarcinoma), rectal cancer, myosarcoma, salivary gland cancer,
skin cancer (e.g., squamous cell carcinoma (SCC), acanthoma (KA), melanoma, basal
cell carcinoma (BCC)), small bowel cancer (e.g., appendix cancer), soft tissue sarcoma (e.g.,
malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath
tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma), sebaceous gland
carcinoma, sweat gland carcinoma, synovioma, testicular cancer (e.g., seminoma, testicular
embryonal carcinoma), thyroid cancer (e.g., papillary carcinoma of the d, papillary
thyroid carcinoma (PTC), medullary thyroid cancer), urethral cancer, vaginal cancer and
vulvar cancer (e.g., Paget’s disease of the vulva).
] Anti—cancer agents encompass biotherapeutic anti—cancer agents as well as
chemotherapeutic agents.
Exemplary biotherapeutic anti—cancer agents include, but are not limited to,
interferons, cytokines (e.g., tumor necrosis factor, interferon 0t, interferon y), vaccines,
hematopoietic growth factors, monoclonal serotherapy, immunostimulants and/or
immunodulatory agents (e.g., IL—l, 2, 4, 6, or 12), immune cell growth factors (e.g., GM—
CSF) and antibodies (e.g. HERCEPTIN uzumab), T—DMl, AVASTIN (bevacizumab),
ERBITUX (cetuximab), VECTIBIX (panitumumab), RITUXAN (rituximab), BEXXAR
(tositumomab)).
Exemplary chemotherapeutic agents include, but are not limited to, anti—
estrogens (e.g. tamoxifen, raloxifene, and megestrol), LHRH agonists (e.g. goscrclin and
leuprolide), anti—androgens (e.g. de and bicalutamide), ynamic therapies (e.g.
vertoporfin (BPD—MA), phthalocyanine, ensitizer Pc4, and oxy—hypocrellin A
(2BA—2—DMHA)), nitrogen ds (e.g. cyclophosphamide, ifosfamide, trofosfamide,
mbucil, estramustine, and melphalan), nitrosoureas (e.g. tine (BCNU) and
lomustine (CCNU)), alkylsulphonates (e.g. busulfan and treosulfan), triazenes (e.g.
dacarbazine, temozolomide), platinum containing nds (e.g. cisplatin, carboplatin,
oxaliplatin), vinca alkaloids (e.g. vincristine, stine, vindesine, and vinorelbine), taxoids
(e.g. axel or a paclitaxel equivalent such as nanoparticle albumin—bound paclitaxel
(ABRAXANE), docosahexaenoic acid bound—paclitaxel (DHA—paclitaxel,
exin), polyglutamate bound—paclitaxel (PG—paclitaxel, paclitaxel poliglumex, CT—
2103, ), the tumor—activated prodrug (TAP) ANG1005 (Angiopep—2 bound to three
molecules of paclitaxel), paclitaxel—EC—l (paclitaxel bound to the erbB2—recognizing peptide
EC—l), and glucose—conjugated paclitaxel, e.g., 2'—paclitaxel methyl 2—glucopyranosyl
succinate; docetaxel, taxol), ophyllins (e.g. etoposide, ide phosphate, teniposide,
topotecan, 9—aminocamptothecin, camptoirinotecan, irinotecan, crisnatol, mytomycin C),
anti—metabolites, DHFR inhibitors (e.g. methotrexate, dichloromethotrexate, trimetrexate,
xate), IMP ogenase inhibitors (e.g. mycophenolic acid, tiazofurin, ribaVirin, and
EICAR), ribonuclotide reductase inhibitors (e.g. hydroxyurea and deferoxamine), uracil
analogs (e.g. ouracil (S—FU), floxuridine, doxifluridine, ratitrexed, tegafur—uracil,
capecitabine), ne analogs (e.g. cytarabine (ara C), cytosine arabinoside, and
fludarabine), purine analogs (e.g. mercaptopurine and Thioguanine), Vitamin D3 analogs
(e.g. EB 1089, CB 1093, and KH 1060), isoprenylation inhibitors (e.g. lovastatin),
dopaminergic neurotoxins (e.g. 1—methyl—4—phenylpyridinium ion), cell cycle inhibitors (e.g.
staurosporine), actinomycin (e.g. actinomycin D, dactinomycin), bleomycin (e.g. bleomycin
A2, bleomycin B2, peplomycin), anthracycline (e.g. daunorubicin, doxorubicin, pegylated
liposomal bicin, idarubicin, icin, pirarubicin, zorubicin, ntrone), MDR
inhibitors (e.g. verapamil), Ca2+ ATPase inhibitors (e.g. thapsigargin), imatinib, thalidomide,
lenalidomide, ne kinase tors (e.g., aXitinib (AG013736), bosutinib (SKI—606),
cediranib (RECENTINTM, AZD2171), dasatinib (SPRYCEL®, BMS—354825), erlotinib
(TARCEVA®), gefitinib (IRESSA®), imatinib (Gleevec®, CGP57148B, STI—571), lapatinib
(TYKERB®, TYVERB®), lestaurtinib (CEP—701), neratinib 72), nilotinib
(TASIGNA®), semaxanib (semaXinib, SU5416), sunitinib (SUTENT®, SU11248), toceranib
(PALLADIA®), vandetanib (ZACT]MA®, ZD6474), vatalanib (PTK787, ),
zumab (HERCEPTIN®), zumab (AVASTIN®), rituXimab (RITUXAN®),
cetuXimab (ERBITUX®), panitumumab (VECTIBIX®), ranibizumab (Lucentis®), nib
(TASIGNA®), sorafenib (NEXAVAR®), everolimus (AFINITOR®), alemtuzumab
(CAMPATH®), gemtuzumab ozogamicin (MYLOTARG®), temsirolimus (TORISEL®),
ENMD-2076, PCI—32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992
(TOVOKTM), SGX523, PF—04217903, PF-02341066, PF-299804, EMS-777607, ABT-869,
MP470, BIBF 1120 TEF®), AP24534, JNJ-26483327, MGCD265, DCC—2036,
EMS-690154, CEP-11981, tivozanib (AV-951), OSI—930, MM-121, XL—184, XL-647, and/or
XL228), proteasome inhibitors (e.g., bortezomib (VELCADE)), mTOR inhibitors (e.g.,
rapamycin, temsirolimus 79), everolimus (RAD—001), rolimus, AP23573
(Ariad), AZD8055 (AstraZeneca), BEZ235 (Novartis), BGT226 (Norvartis), XL765 (Sanofi
2012/062222
Aventis), PF—4691502 (Pfizer), 0 (Genetech), SF1126 (Semafoe) and 081—027
(081)), oblimersen, gemcitabine, carminomycin, leucovorin, pemetrexed, cyclophosphamide,
dacarbazine, procarbizine, prednisolone, dexamethasone, campathecin, plicamycin,
asparaginase, aminopterin, methopterin, porfiromycin, melphalan, leurosidine, leurosine,
mbucil, trabectedin, procarbazine, discodermolide, carminomycin,, aminopterin, and
hexamethyl ne.
In certain embodiments, the condition is an inflammatory disorder and, in certain
ments, the composition further includes an anti—inflammatory agent. The term
“inflammatory disorder” refers to those diseases, disorders or conditions that are
terized by signs of pain (dolor, from the tion of noxious substances and the
stimulation of nerves), heat (calor, from vasodilatation), redness (rubor, from vasodilatation
and increased blood flow), swelling (tumor, from excessive inflow or restricted outflow of
fluid), and/or loss of function (functio laesa, which can be partial or complete, temporary or
permanent. Inflammation takes on many forms and includes, but is not limited to, acute,
ve, atrophic, catarrhal, chronic, cirrhotic, diffuse, disseminated, exudative, fibrinous,
fibrosing, focal, granulomatous, hyperplastic, hypertrophic, interstitial, atic, necrotic,
obliterative, parenchymatous, plastic, productive, proliferous, pseudomembranous, purulent,
sclerosing, seroplastic, serous, simple, specific, subacute, suppurative, toxic, traumatic,
and/or ulcerative inflammation.
ary inflammatory disorders include, but are not limited to, inflammation
associated with acne, anemia (e.g., aplastic anemia, haemolytic autoimmune anaemia),
asthma, arteritis (e.g., polyarteritis, temporal arteritis, periarteritis nodosa, Takayasu’s
arteritis), arthritis (e.g., crystalline arthritis, osteoarthritis, tic arthritis, gouty arthritis,
reactive tis, rheumatoid arthritis and Reiter’s arthritis), ankylosing spondylitis, amylosis,
amyotrophic lateral sclerosis, autoimmune diseases, allergies or allergic reactions,
sclerosis, bronchitis, is, c prostatitis, ctivitis, Chagas disease, c
obstructive pulmonary disease, cermatomyositis, diverticulitis, es (e.g., type I diabetes
mellitus, type 2 es mellitus), a skin condition (e.g., psoriasis, eczema, burns, dermatitis,
pruritus (itch)), endometriosis, Guillain—Barre syndrome, infection, ischaemic heart disease,
Kawasaki disease, glomerulonephritis, gingivitis, hypersensitivity, headaches (e.g., migraine
headaches, n headaches), ileus (e.g., postoperative ileus and ileus during sepsis),
idiopathic thrombocytopenic purpura, interstitial cystitis (painful bladder me),
gastrointestinal disorder (e.g. , selected from peptic ulcers, regional enteritis, diverticulitis,
gastrointestinal bleeding, eosinophilic gastrointestinal disorders (e.g., eosinophilic
esophagitis, eosinophilic gastritis, philic gastroenteritis, eosinophilic colitis), tis,
diarrhea, gastroesophageal reflux disease (GORD, or its m GERD), atory
bowel e (IBD) (e.g., Crohn’s disease, ulcerative colitis, collagenous colitis,
lymphocytic s, ischaemic colitis, diversion colitis, Behcet’s syndrome, indeterminate
colitis) and inflammatory bowel me , lupus, multiple sclerosis, morphea,
myeasthenia gravis, myocardial ia, nephrotic syndrome, pemphigus vulgaris,
pernicious aneaemia, peptic ulcers, polymyositis, primary biliary cirrhosis,
neuroinflammation associated with brain disorders (e.g., Parkinson’s disease, Huntington’s
disease, and Alzheimer’s disease), prostatitis, chronic inflammation associated with cranial
radiation injury, pelvic inflammatory disease, reperfusion injury, regional enteritis, tic
fever, systemic lupus erythematosus, schleroderma, scierodoma, sarcoidosis,
spondyloarthopathies, Sjogren’s syndrome, thyroiditis, lantation rejection, tendonitis,
trauma or injury (e.g., frostbite, chemical nts, toxins, scarring, burns, physical injury),
vasculitis, vitiligo and Wegener’s omatosis.
] In certain embodiments, the inflammatory disorder is inflammation ated
with a proliferative disorder, e.g., inflammation associated with cancer.
In certain embodiments, the condition is an autoimmune disorder and, in certain
embodiments, the composition further includes an immunomodulatory agent. Exemplary
autoimmune disorders include, but are not limited to, arthritis (including rheumatoid arthritis,
spondyloarthopathies, gouty arthritis, degenerative joint diseases such as osteoarthritis,
systemic lupus erythematosus, Sjogren's me, ankylosing litis, undifferentiated
spondylitis, Behcet's disease, haemolytic autoimmune anaemias, multiple sclerosis,
amyotrophic lateral sclerosis, amylosis, acute painful shoulder, tic, and juvenile
arthritis), asthma, atherosclerosis, osteoporosis, bronchitis, tendonitis, bursitis, skin condition
(e.g., psoriasis, eczema, burns, dermatitis, pruritus (itch)), enuresis, eosinophilic e,
gastrointestinal disorder (e.g. , selected from peptic ulcers, regional enteritis, diverticulitis,
gastrointestinal bleeding, eosinophilic intestinal disorders (e.g., eosinophilic
esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic colitis), gastritis,
diarrhea, gastroesophageal reflux disease (GORD, or its synonym GERD), inflammatory
bowel disease (IBD) (e.g., Crohn's disease, ulcerative colitis, collagenous s, lymphocytic
colitis, ischaemic s, diversion colitis, 's syndrome, indeterminate colitis) and
inflammatory bowel syndrome (IBS)), and disorders ameliorated by a gastroprokinetic agent
(e.g., ileus, postoperative ileus and ileus during sepsis; gastroesophageal reflux disease
(GORD, or its synonym GERD); eosinophilic esophagitis, gastroparesis such as diabetic
gastroparesis; food intolerances and food allergies and other functional bowel disorders, such
as non—ulcerative dyspepsia (NUD) and non—cardiac chest pain (NCCP, including costo—
chondritis)).
In certain ments, the condition is a painful condition and, in certain
embodiments, the composition further includes an analgesic agent. A “painful condition”
includes, but is not limited to, athic pain (e.g., peripheral neuropathic pain), central
pain, deafferentiation pain, chronic pain (e.g., chronic nociceptive pain, and other forms of
chronic pain such as post—operative pain, e.g., pain arising after hip, knee, or other
replacement surgery), pre —operative pain, stimulus of nociceptive receptors (nociceptive
pain), acute pain (e.g. , m and ent acute pain), noninflammatory pain,
inflammatory pain, pain associated with cancer, wound pain, burn pain, postoperative pain,
pain associated with medical ures, pain resulting from pruritus, painful bladder
syndrome, pain associated with premenstrual dysphoric disorder and/or premenstrual
syndrome, pain associated with chronic fatigue syndrome, pain associated with pre—terrn
labor, pain associated with withdrawl symptoms from drug addiction, joint pain, tic pain
(e.g., pain associated with crystalline arthritis, osteoarthritis, psoriatic arthritis, gouty arthritis,
reactive arthritis, rheumatoid arthritis or Reiter's arthritis), lumbosacral pain, musculo—
skeletal pain, headache, migraine, muscle ache, lower back pain, neck pain, toothache,
dental/maxillofacial pain, visceral pain and the like. One or more of the painful conditions
contemplated herein can comprise mixtures of various types of pain provided above and
herein (e.g. nociceptive pain, inflammatory pain, athic pain, etc.). In some
embodiments, a particular pain can te. In other ments, the painful condition
comprises two or more types of pains without one dominating. A skilled clinician can
determine the dosage to e a therapeutically effective amount for a particular subject
based on the painful condition.
In certain ments, the painful ion is inflammatory pain. In certain
embodiments, the l condition (e.g., inflammatory pain) is associated with an
inflammatory disorder and/or an autoimmune disorder.
] In n embodiments, the condition is a liver disease and, in certain
ments, the composition further includes an agent useful in treating liver disease.
Exemplary liver diseases include, but are not limited to, drug—induced liver injury (e.g.,
acetaminophen—induced liver injury), hepatitis (e.g. , chronic hepatitis, viral hepatitis,
alcohol—induced hepatitis, mune hepatitis, steatohepatitis), non—alcoholic fatty liver
disease, alcohol—induced liver disease (e.g., alcoholic fatty liver, lic hepatitis, alcohol—
related cirrhosis), hypercholesterolemia (e.g., severe hypercholesterolemia), transthyretin—
related hereditary amyloidosis, liver cirrhosis, liver cancer, primary biliary cirrhosis,
cholestatis, cystic e of the liver, and primary sclerosing cholangitis. In certain
embodiments the liver disease is associated with inflammation.
In certain embodiments, the condition is a familial amyloid neuropathy and, in
certain embodiments, the composition r es an agent useful in a al amyloid
neuropathy.
A “subject” to which administration is contemplated includes, but is not limited
to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g, , child,
adolescent) or adult t (e.g., young adult, middle—aged adult or senior adult)) and/or
other non—human animals, for example s [e.g., primates (e.g., cynomolgus monkeys,
rhesus monkeys); and commercially nt mammals such as mice, rats, hampsters, cattle,
pigs, horses, sheep, goats, cats, and/or dogs] and birds (e.g., commercially relevant birds such
as chickens, ducks, geese, and/or turkeys). In certain ments, the subject is a non—
human animal. The non—human animal may be a male or female and at any stage of
development. A non—human animal may be a transgenic animal.
As used herein, and unless otherwise specified, the terms “treat,77 4‘treating” and
“treatment” contemplate an action that occurs while a subject is suffering from the specified
disease, disorder or condition, which reduces the severity of the disease, disorder or
condition, or retards or slows the progression of the disease, disorder or ion
(“therapeutic treatment”), and also contemplates an action that occurs before a subject begins
to suffer from the specified disease, disorder or condition (“prophylactic treatment”).
In general, the “effective amount” of an active ingredient refers to an amount
ient to elicit the desired biological response. As will be iated by those of
ry skill in this art, the effective amount of a compound of the ion may vary
depending on such factors as the desired biological endpoint, the pharmacokinetics of the
active ingredient, the disease being treated, the mode of administration, and the age, health,
and condition of the subject. An effective amount asses therapeutic and prophylactic
ent.
As used herein, and unless otherwise specified, a “therapeutically effective
amount” of an active ingredient is an amount sufficient to provide a therapeutic benefit in the
treatment of a disease, disorder or condition, or to delay or minimize one or more symptoms
associated with the disease, disorder or ion. A therapeutically effective amount of an
active ingredient means an amount of the active ingredient, alone or in combination with
other agents or therapies, which provides a therapeutic benefit in the treatment of the disease,
disorder or condition. The term peutically effective ” can encompass an amount
that improves overall therapy, reduces or avoids symptoms or causes of disease or condition,
or enhances the therapeutic efficacy of another therapeutic agent.
As used herein, and unless otherwise specified, a “prophylactically effective
amount” of an active ingredient is an amount sufficient to prevent a disease, er or
condition, or one or more symptoms associated with the disease, disorder or condition, or
prevent its recurrence. A prophylactically effective amount of an active ingredient means an
amount of the active ient, alone or in combination with other agents or ies, which
provides a prophylactic benefit in the prevention of the disease, disorder or condition. The
term ylactically effective amount” can encompass an amount that improves l
prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
The active ingredient may be administered in such amounts, time, and route
deemed necessary in order to achieve the desired result. The exact amount of the active
ingredient will vary from t to subject, depending on the species, age, and general
condition of the subject, the severity of the infection, the particular active ingredient, its mode
of stration, its mode of activity, and the like. The active ingredient, whether the APPL
itself, or the APPL in ation with an agent, is preferably formulated in dosage unit
form for ease of administration and uniformity of dosage. It will be understood, however,
that the total daily usage of the active ingredient will be decided by the attending physician
within the scope of sound medical judgment. The specific therapeutically effective dose level
for any particular subject will depend upon a variety of s including the disorder being
treated and the ty of the disorder; the activity of the active ingredient employed; the
specific composition employed; the age, body weight, general health, sex and diet of the
patient; the time of administration, route of administration, and rate of ion of the
ic active ingredient employed; the on of the treatment; drugs used in combination
or coincidental with the specific active ingredient employed; and like factors well known in
the medical arts.
The active ingredient may be administered by any route. In some embodiments,
the active ingredient is administered via a variety of , including oral, intravenous,
intramuscular, intra—arterial, intramedullary, intrathecal, subcutaneous, intraventricular,
transdermal, ermal, , intravaginal, intraperitoneal, topical (as by powders,
ointments, creams, and/or drops), mucosal, nasal, bucal, enteral, sublingual; by intratracheal
instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray,
and/or l. In general the most riate route of administration will depend upon a
variety of factors including the nature of the active ingredient (e.g., its stability in the
environment of the gastrointestinal tract), the condition of the t (e.g., whether the
subject is able to tolerate oral administration), etc.
The exact amount of an active ingredient required to achieve a therapeutically
or prophylactically ive amount will vary from subject to subject, ing on species,
age, and general condition of a subject, severity of the side effects or disorder, ty of the
particular compound(s), mode of administration, and the like. The amount to be administered
to, for example, a child or an cent can be ined by a medical practitioner or
person skilled in the art and can be lower or the same as that stered to an adult.
Examples
In order that the invention described herein may be more fully understood, the
following examples are set forth. It should be understood that these examples are for
illustrative purposes only and are not to be construed as limiting this invention in any manner.
Amino acid-, peptide-, and polypeptide-lipids (APPL) for drug delivery
To address the challenges associated with delivery efficiency, specificity, and
toxicity of biological agents, we ped a potent and selective siRNA delivery system
with a broad therapeutic window through rational design and optimization of novel amino
acid—based lipid derivatives.
Previously, our group has pursued a combinatorial synthetic approach to
develop new cationic lipids (lipidoids) for siRNA delivery. See, e. g., Akinc, A., et al., A
combinatorial library of lipid-like materials for delivery ofRNAi eutics. Nat
Biotechnol, 2008. 26(5): p. 561—9; Love Kevin, T., et al., Lipid-like materials for low-dose, in
vivo gene silencing. Proc Natl Acad Sci U S A. 107(5): p. 1864—9; Siegwart, D.J., et al.,
Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular
ry. Proc Natl Acad Sci U S A. 108(32): p. 12996—3001. A number of these compounds
have shown significant ing effects in vivo. See, e.g., Leuschner, F., et al., Therapeutic
siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol. 29(l l): p. 1005—10.
Prior studies have identified key chemical and structural features and formulation methods
for the development of new materials. See, e. g., Akinc, A., et al., Development of lipidoid-
siRNA formulations for ic delivery to the liver. Mol Ther, 2009. 17(5): p. 872—9; Akinc,
A., et al., Targeted delivery ofRNAi therapeutics with endogenous and exogenous ligand-
based isms. Mol Ther. 18(7): p. 1357—64; Semple, SC, et al., Rational design of
cationic lipids for siRNA delivery. Nat Biotechnol. 28(2): p. 172—6. For example, active
compounds possess 12 or more s in tail length and multiple tails. See, e. g., Love
Kevin, T., et al., Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci
U S A. 107(5): p. 1864—9. In order to improve efficacy, tissue and cell—type selectivity, and
tolerability, new chemical lds need to be ed and investigated.
Amino acids are natural building blocks of peptides and ns in nature.
Amino acid tives can be metabolized by the human body; therefore, these materials are
likely well tolerated and safe as therapeutics. Additionally, peptides play significant roles in
membrane transport, endogenous cellular signaling and trafficking pathways, and offer
tremendous potential in leveraging such interactions to enhance the delivery efficiency of
systems which orate peptide moieties. e of their significant physiological
functions and safety in humans, amino acid—based materials, such as insulin and trastuzumab,
have been widely d as ments and therapeutic medicines in the clinic for diverse
diseases. Studies have shown that it is feasible to apply amino acid—derivatives for gene
delivery or siRNA delivery. See, e. g., Prata, C.A., et al., Lipopliilic peptides for gene
delivery. Bioconjug Chem, 2008. 19(2): p. ; Adami, R.C., et al., An amino ased
amplioteric mal delivery systemfor systemic administration of siRNA. Mol Ther. 19(6):
p. ll4l—Sl; Margus, H., K. Padari, and M. Pooga, Cell-penetrating peptides as versatile
vehicles for oligonucleotide delivery. Mol Ther. 20(3): p. . Combining the advantages
of both natural properties of amino acids and structural features of lipidoids, we applied a
strategy of structural optimization through an iterative screening process and rationally
designed a series of amino acid—based lipid derivatives. We report the design, synthesis, and
biological evaluation of this new series of amino acid—based lipid derivatives. This efficient
and rational strategy yielded a lead material cKK—El2. We systematically investigated its
delivery efficiency, tissue and cell—type selectivity, tolerability, and mechanism of action.
Current results trate that this delivery system is a novel platform for efficient,
selective, and safe ry of siRNA, which shows great potential for the treatment of
various diseases.
General Methods
Method 1. Preparation of Compounds of Formula (I)-(III). Conjugation to formula (i).
A mixture of amino acids, es or polypeptides and the conjugating reagent
(an epoxide, ne, or aziridine) (a ratio of 1.5:1 to 3:1 conjugating reagent to amine) in
EtOH was irradiated in the microwave oven at 150 0C for 5 h. The reaction mixture was
purified by flash column chromatography. If amino acids, peptides or ptides were in
salt form, triethylamine was added to the solution and stirred for 30 minutes at room
temperature before irradiation.
SchemeA.
o o
o R1 R1
Y 150°C Y ORA4
HZN A4+ A —> +
OR RL EtOH HY/TA/N\)\ / YH
RL HYAVN\r\
R1 RL RL
Y Y
SchemeB.
R1 o YH NH
HZNJ\H/H 150 °c RKHL
N ORA4+ AR L N
EtOH RL\/ fiR']
O R 1 Y=o,s,NRY
Scheme C.
R1 o
H + —> L N
HzN ORA4 ‘/
RL EtOH
NH2 HY\/\J
Scheme D.
RL\J
NH2 r
/\ N
HY RL/\/ 0
o YH NH
H Y 150 °c
+ —> J\/N
H2N ORA4 RL
RL EtOH
0 o HY
Y = o, s, NRY \
NH2 HY\/\J
Scheme E.
L R'-
HY\/\/\ /\/¢YH
NH2 N
o o
H Y R
150 °c
+ K H
é A4
H2N ORA4 0R
RL EtOH
HY j‘
o \ o n
” \/
Y = o s, NRY RL
HY/\/N
RL \l—KRL
Method 2. Preparation of Compounds of Formula II). Conjugation to formula (ii).
A mixture of amino acids, peptides or polypeptides and conjugating reagent
(acrylate or acrylamide) (a ratio of 1.5:1 to 3:1 acrylates or conjugating reagent to amine) in
ethanol (EtOH), isopropanol (iPrOH), or acetonitrile was heated to 90 0C and d for 2
hours to 2 days. The reaction solution was concentrated with silica gel and purified with flash
column chromatography.
Scheme F.
o o
R1 R1
0 ORA4 ORA4
WNW/1k + X‘ &
ORA4 W/ R HN\/\n/x x N X
EtOH \RL RL’ \n/\/ \/\n/ \RL
R1 0
o o o
2012/062222
Scheme G.
o R1 0
\X/“\/\HNNVkORA‘;
R1 O 0 R 1
H + X
90°C
NVKORM /\n/ \ RL —> O 1
EtOH R O
HZN H
0 RL\ N
o R1 x N ORA4
X=o,s,NRX
o R1
Scheme H.
R1 O
H + X & o
H2N 0RA4 N \ RL
EtOH RL’X\n/\/N
o 0 RL
0 O x’
x=o,s,NRX
\x 0
Scheme 1.
NH2 0 X‘RL
x N
x o RL’ W o
H + /\n/ \RLLC>
H2N A4 0
OR EtOH
0 NH
O x=o,s,NRX ,x N
o o X,RL
\x o
Scheme].
0 O
L /U\/\ /\/u\ RL
NH2 R\X N x’
O X O
H H
N \ L—>90°C N
HZN ORA4 + / O N ORA4
EtOH
O L
o n R\XJJ\) o n
NH2 RL’X\”/\/N
O 0
Method 3. Preparation of Compounds of Formula (I)-(III). Conjugation to formula (iii).
To a solution of amino acids, peptides or polypeptides and conjugating reagent
(aldehyde) (a ratio of 1.5:1 to 3:1 des to amine) in THF was added sodium
triacetoxyborohydride (NaBH(OAc)3) at rt. The reaction mixture was stirred for 3 d at rt. The
reaction solution was concentrated with silica gel and purified with flash column
tography.
Scheme K.
O O
O R1 R1
0 Ac)3 $0M“ ORA4
HZN A4+ JL
OR THFt,r HN RL RL N RL
H RL \/ \/ v
Scheme L.
R1 o
RLAN ORA4
R1 O H
H 0 NaHB(OAc)3 O R1
+ —>
H2N ORA4 R1
H RL THF,rt o
O R1
A H
RL N ORA4
RL/i o R1
Scheme M.
R1 o
H 0 NaHB(OAc)3 RK/N
H2N ORA4 HJLRL THF, rt
0 RL
Scheme N.
NH2 rRL
RL\/N O
O O
H Ac)3
+ JL NH
H2N ORA4 H RL THF, rt RL\/N
NH2 j]
Scheme 0.
o NaHB(OAc)3 RL 0
H +
JL L THF,rt H
H2N ORA4 H R N ORA4
O n RLJ O n
R\/NWL NH2
Method 4. Preparation of Compounds of Formula (IV)
Compounds of Formula (IV) may be prepared via condensation of a 1,2—
diamine with an activated oxalic acid, wherein X1 is a leaving group, e.g., bromo, , or
iodo, to provide the cyclized product. Groups of formula (i), (ii), or (iii), may be installed
WO 63468
after cyclization, e.g., for example, via addition to an amino side chain substituent of R1, or to
imino nitrogen groups RQ. Other groups on the scaffold, 6.57., R2 groups, may be led
prior to ation. For example, R2 may be a group of the formula (i), (ii), or (iii) installed
prior to cyclization.
Scheme P.
R1 R2
NH1:12:03
2HX1 12:
1,2-diamine oxalicacid (IV)
derivative
Method 5. Preparation of nds of Formula (V)
Compounds of a (V), and (VI) may be prepared via condensation of a
l,l—diamine with an activated malonic acid, wherein X1 is a leaving group, e.g., bromo,
chloro, or iodo, to provide the cyclized product. Groups of formula (i), (ii), or (iii), may be
installed after cyclization, e.g., for example, via addition to an amino side chain substituent of
R1, or to imino nitrogen groups RQ. Other groups on the scaffold, 6.57., R2 groups, may be
installed prior to cyclization. For e, R2 may be a group of the formula (i), (ii), or (iii)
installed prior to cyclization.
Scheme Q.
R2 Q
‘NH x1
R1—< + R1—<N
[NH X1 l
R2 Q 2HX1
1,1-diamine malonyl
derivative
Method 6. Preparation of Compounds of Formula (V1)
Compounds of Formula (VI) may be ed via condensation of a hydrazine
with an activated succinic acid, wherein X1 is a leaving group, e.g., bromo, chloro, or iodo, to
e the cyclized product. Groups of formula (i), (ii), or (iii), may be installed after
cyclization, e.g., for example, via addition to an amino side chain substituent of R1, or to
imino nitrogen groups RQ. Other groups on the scaffold, 6.57., R2 groups, may be installed
2012/062222
prior to cyclization. For example, R2 may be a group of the formula (i), (ii), or (iii) installed
prior to cyclization.
Scheme R.
Q R: Q
Ri X1 /N
NH R1 R2_ R1
RZ—NH ;
Q R1 2 HX1 Q R1
hydrazine succinic acid (VI)
derivative derivative
Exemplary Precursors
Table 1. Amino Acids and Esters
Name, Symbol Amino acid side chain (R )* Amino acid or ester
N N/ H2N
H ORA4
Arginine R ’
m j]:
NH N NH2
N NH2
VB] 0
:/N’R6 6’N\// HZN
N\ ORA4
H1st1d1ne. . . R
H ’
N“ N“
NH N
N§/ HN\//
ORA4
Lysine K
R7’N‘R6 NH2
’ NH2
Table 1. Amino Acids and Esters
Name, Symbol Amino acid side chain (R )* Amino acid or ester
H2N{3:0
ORA4
Aspartic Acid D
Glutamic Acid E
R50 0 HO 0 WeORA4
IO 0
Serine ORA4
0R6, OH #0
Threonine T ORA4
0R6, OH Wm
o Asparagine N
R7’N‘R6 NH2 {3:0ORA4
ORA4
Glutamine Q
0 N’ 0W0NH2
ne C #0ORA4
Glycine G H2N\/U\ORA4
Table 1. Amino Acids and Esters
Name, Symbol Amino acid side chain (R )* Amino acid or ester
Proline P O/lk‘g O/lk’g ZI
O503:
exemplary RI-R3 cyclized group
Alanine A —CH3 NIZ‘§:O
ORA4
Beta—alanine —H, H /\/u\
HZN 02“
H N2 ILORA“
Valine V —CH(CH3)2
. H2N
Isoleucme I 3)(CH2CH3) ORA4
INZof;
O50)>A
Leucine L —CH2CH(CH3)2
E f3:ORA4 Methionine M
IN263:0
0RA4
Phenylalanine F
Table 1. Amino Acids and Esters
Name, Symbol Amino acid side chain (R )* Amino acid or ester
0R5,
Tyrosine Y
2 ’a
Tryptophan W / /
N HN
* R6 and R7
are hydrogen in the precursor, and, upon conjugation, are independently selected
from the group ting of hydrogen, optionally substituted alkyl, optionally substituted
alkenyl, optionally substituted alkynyl, ally substituted carbocyclyl, optionally
substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a
nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group
when attached to an oxygen atom, and a sulfur ting group when ed to a sulfur
atom, or a group of formula (i), (ii), or (iii).
Table 2. Peptides and Polypeptides
Name, Symbol Amino acid
N H 2
linear lysine—lysine linear K—K H2N OH
Table 2. Peptides and Polypeptides
Name, Symbol Amino acid
H N2
. . . . HN
cychc lysme—lysme cychc K—K
H2N ORA4
K-K-K
polylysine
n = 2
K—K—K—K As above; n = 3
K—K—K—K—K As above; n = 4
ne K—(K)n—K
As above; n = 3—12
(500—2000 g/mol) PK—SOO
polysine K—(K)n—K
As above; n = 6—33
(1000—5000 g/mol) PK-1000
polysine K—(K)n—K
As above; n 2 26—102
(4000—15000 g/mol) PK4000
polysine K—(K)n—K
As above; n = 102—204
(15000—30000 g/mol) PK—15000
ne K—(K)n—K
As above; n = 204-480
(30000—70000 g/mol) PK—30000
Table 2. Peptides and Polypeptides
Name, Symbol Amino acid
HNYNH2
linear arginine—arginine linear R—R
cyclic arginine—arginine cyclic R—R
polyarginine R-(R)n-R
(5000—15000) PR-5000
linear ine—histidine linear H—H
cyclic histidine—histidine cyclic H—H
Table 2. Peptides and Polypeptides
Name, Symbol Amino acid
polyhistidine H-(H)n-H H2N ORA4
25000) PH-5000 o n
n=32—l6l
linear glycine—glycine linear G—G H2N/\n/N\/U\OH
cyclic glycine—glycine cyclic G—G H¢
HzNJY O
linear arginine—lysine linear AK
HzN/[n/ 0
linear cysteine—lysine linear CK O
COZH
HzN/[n/ O
linear aspartic acid—lysine linear DK 0
Table 2. Peptides and Polypeptides
Name, Symbol Amino acid
COZH
llnear glutamlc ac1d—lys1ne. . . . llnear EK. HzN/fif
H N/En/N2 OH
linear phenylalanine—
linear PK 0
lysine
N H2
/N OH
linear glycine—lysine linear GK
N H2
HzNjir O
linear isoleucine—lysine linear 1K
N H2
H2N¢ O
linear leucine—lysine linear LK
Table 2. Peptides and Polypeptides
Name, Symbol Amino acid
ZIf3“
IN20:2—\' 0I
linear nine—lysine linear MK
linear proline—lysine linear PK
CONH2
H2N OH
linear glutamine—lysine linear QK
H2Nj\n/ O
linear serine—lysine linear SK O
Table 2. Peptides and Polypeptides
Name, Symbol Amino acid
linear tryptophan—lysine linear WK N
H2N OH
linear tyrosine—lysine linear YK H2N OH
linear lysine—threonine linear KT 0
H2N OH
linear lysine—valine linear KV 0
H2N OH
Table 3. ating reagents
Table 3. Con'unatin rea_ents
Name ure
E11 WW
E13 W
E14 W
E15 W
E16 W
A11 W
A13 W
010 /
011 \jiOA/W
012 $0
013 \jLO
014 V10
N10 VLN/WVW
N11 VLNWA/
N12 VLN
N13 VL
Table 3. Con'u__atin ts
Name Structure
Synthetic Procedures
Example 1. Synthesis of APPLs
Schemes A—R show the general synthetic routes to APPLs of Formula (I) to
(VI), of the present invention. Application of these methods generated a variety of APPLs,
depicted in Tables 4 and 5.
Compounds were named by combination of the iation of amino acids,
aldehydes (A), acrylates (O), amides (N), or es (E), and the length of carbon chains.
For example, K—E12 represents the reaction of lysine with 1,2—epoxydodecane.
WO 63468
a \\\\\\.\
AXE“
2012/062222
IIIIIIIIIIIIIIIIII
L»5L»Hfifififififififififififififififififififififimv\\\\\\\\\\\\\\\\\xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx\L\\\\\\v\\\f\\yd»5L»L»5L»5L»LavLavLav5L»L»L»L»5L»5L»LavLavLav5L»L»5L»5L»5L»LavLav5L»5L»L»5L»5L»5L»LavLavLuvHfififififififififififififififififififififimv\\\\\\\\\\\\\\\\\\\\\\Vfi.. \x:Nanmwm., .4 .
.m\:
\\\\\\\\\\\\\\\\\\\\\\\\4\\,\\\\\ MMMRNMxmxx .
I81*\f
“Wm., ., .
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx¥xxx\nxxxxxxxxxxxxxxxx\\\\¥\\\\\\\\\\\\\\\,\\\\ ‘
Mn»m.\\\.mx .
ux«xu« ‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘
.MNMM:.
\w.K
Aw~\
gm u««xux
3th .
>0VF.
WO 63468
kéww
mm E‘\k\‘\k\‘\k\‘\k\‘\k\‘\k\‘\k\‘\k\‘\k\‘\k\‘\k\‘\k\‘\k\‘\k\‘\k\‘\k\‘\k\‘:‘kkkkkkkkk‘:a.
gmmfiww
fix“ fix
2012/062222
.mV...
Lx.»
«(r$3.“
SEHMS
my\w fi\\\\\\\\\\\\\\\\\aaaaaaaaaaaaaaaaaaaaaaaa"\“\‘\“\‘\“\‘\“\‘\“\‘\“\‘\“\‘\“\‘\“\‘\“\‘\“\‘\“\‘\“\‘\“\‘\“\‘\“\‘\“\‘\“\‘\“.uuuuuuuuuuuuuuuuuuuuuuwwuuuuuuuuuuuuuuuuuuuuuuu
xxx»xxxxxxxxxxxxxxxxxxxxxxxx smvmfw .K\‘\“\‘\“\‘\“\‘\“\‘\“\‘.
x»xxxx»xxxx»xxxx»xxxx»xxxx»xxxxxxxxx»xxxxxxxxxxxxxxxxxxxxxxxxxxx “$mewa.........mcmmfiwfi ‘\“\‘\“\‘\“\‘\“\‘\“\‘\“\;\“\‘\“\‘\“\‘\“\‘\“\‘\“\‘\‘.
xxxxx»xxxx»xxxx»xxxx»xxxxxxxxxxxxxxxxxxxxxxxxxx mxxmwmmum“ “v \‘\“\‘\“\‘\“\‘\“\‘\“
WO 63468
nnnnnnnn.‘ \
,k»--------~....
.wc».
.v..3..v..3..v..3..v..3..v..3..v..3..v..3..v..3..v..3..v..3..v.-----------~u... ‘u«u?
........xi\xxExxx{xixiiiixifiiii “wwm‘wa‘ a
Em“ M
xix...
fi$§u
........xixxxExxx{xixiiiiiiiii wwm“§§m§
xv. {2...
mg ......................................................................................vvvvvvvvvvvvvvvvvvvvvvExxxxxxxxxxxxxxxxxxxx»x»Exttxttxttxt‘........................................
M ..............................t................................
mxxmwww
“MS xxx i“ ...............................................
‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘
.......................................................................................................................... \A\\\\v‘~~~~
4% «unnnnnnnnnnnuu\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\"»‘»"»‘»"»‘»"»‘»‘mwwwwwwwwwwwwwwwwwwwwuuuuuuuuuuuuuuuuuuuuuv\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
aw ¢xa
ANN”,
N.» Mm
“,‘““““““““‘““““““““““‘““““““““““‘““““““““““‘““““““““““"+“““““““““‘““““““““““‘““““““““
x»o x»o
+"""‘“"“"""‘“"“"""““““““““““““\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\«\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\‘\\\\\\\\\\\\\\\\\\\\\\\\\\1
2012/062222
‘‘‘‘‘‘‘‘k‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘
“$3“
kKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkK:3::::§:===awwwwfim vnnnnnnnnnnnnnnnn.\\\\\\\\\\\\\\\\\\\\\\\\x\x\\\\x\\\\x\\\\x\\\\x\\\\x\\\\x\\\\x\\\\x\\\\x\\\\x\\\\x\\\\x\\\\x\\\\x\\\\x\\\\x\\\\x\\\\x\\\uuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuu\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
.33».
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ kimffim \\\\x\\\\\\\\\\\\\\\\\\\\\\\\\\
\\\\\\\\\\\\\\\\\\\\\\\\\‘c\\\\\\\\\\\\\\\\\\\filmy“ x\x\\\\x\\\\x\\\\x\\\\x\\\¢\\\\\\\\\\\\\\\\\\\\ w¢x
fim NH
\\\\\\\\\~\\\\\\\\\"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“‘““““““““““““
2012/062222
v»fififlpfim.x
ecu.
\\\\\\\\\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
.fiwfiafifim z“ 3
WO 63468
‘\ a 3‘ng \\\\\\§\
$221K. kw“
3‘ e22.
ii???
WO 63468
KkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKkKk:5§:=::==== ..1................................................................................................................................................................
\\\\\\\\\\\\\\\mmmmmmmmmmmmmmmmmmmm.xxixxxixxxixxxixxxixxxixxxixxxixxxixxxixxxixxxixxxixxxixxxixxxixxxixxxixxxixxxixxxixMmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmm.xxxix{iiiiiiiiiii 8:3
mm.“
waxwwfifi
(“-i
2012/062222
”warn”;
\ ¢
\ M}
\ ‘Q
........................4.......................... M
...............................
“u“‘u "u"‘u.x‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u"‘u‘“u““u“u““u“u
WO 63468
§- 00'»
£3 ‘
at; S
‘ Si N
\\.\.\.\.\'
* ..- m
‘ . . A»
gm“ 1w»!
E‘ifimfimi E
WO 63468
6%.»
NM, mum
w w
www.mymfi
\\\\\\\\\\\\\\\\\\\\\\\\\\\v\\\u\\\\\\\\\\\\\\\\\\\\\\\\\\ Lam.»«Ram\\\\\\\\memwmwwm
m3 \\\\\\\\\\\\\\\\\\\ «Nam. .M
.................................................................................................................................................v4v4vv4v4vv4v4vv4v4vv4v4vv4vvvvvvvvvvvvvvvvvvvvvvvv...................................................v4vv4v4vv4v4vv4v4vv4v4vv4v4vv4v4vv4v4vv4v4vv4v4vv4v4vv4v4vv4v4vv4v4vv4vvvvvv;uuuuuuuuuuuuuuuuu 44444444444444444444444444444444444444444444444444WWW44444444444444444444444444444444444444444444444444444444444444444444444«44;;.v.v.v.v.v.v.v.v.v.v.v.v.v.v.v.v.v(
fiién
\\\\\\\\\ ""“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘““““““““““““
$1???
2/5321: 2
\\\\\\\\\\\\\|||||||||||||||||||||||||||||||||||||..............................................................................................||||||||||||||||||||||||||||||||||||||||||||||||||||||||n.......................................................................................................................................L.....L. sxsxssxsxssxsxs
‘\\\\\\\\V
{\K.12
imccqx
”rim
WO 63468
»"K.
S:x:
{.. <
“““N‘
\xwfigr
.w,.m\
\\\\
\- . '\
wwmfim
wgfiwam x»
Nu m """"‘."."““.“.“““.“.““““‘.“““"‘.""""‘."."““.“.“““.“.“““"‘.""‘.................."““.“.“““.“.““““‘.““““‘.““““‘.“ «««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««««.uuuuuuuuuuuuuuuuuu««««««««««««««««««««««««««««««««««««««««««««««««««««
. ..............................\............................... “““.“.““““‘.“““"‘.*"""".“.“““.“.“““.“ Rmfi
. ,me
“figmmwmfiw tf'wi r3
m ‘««««««««««««««««««««««««««««««\«««««««««««««««««««««««««««««««
......................... ““.“.“““.“.“““‘ w ««««««««««««««««««««««««««
................... ‘.“.“““.“.““ Km ««««««««««««««««««««
WO 63468
\\\\\\\\\ “nun“-
T“ .x
‘3‘ \u
Eggst‘!"""!‘!"""!‘!"""!‘!"""!‘!"""""~»--~»»»»~»--~»»»»~»--~»»»»~»~tttttttttttt"!‘!"""!‘!"""!‘!"""!‘!"""!‘!"""‘»»»~»--~»»»»~»--~»»»»~»--~»»»»~»--~»»»»~»--~»»»»~»--~»»»»~»--~»»»»~»--~»»»»~»--~»»»»~»--~»»»»~»--tttttttttttt ttmfittt
..‘«kw!»
fl.\.
mam» \‘xxxxxxxx‘xxx‘xxl::.::.::.::.::.:.a.\.\.\.\.\RRRRRRRRRRRD...........................................................nwwwwn«QQQQQQQwQQQDi.hi.hi.hi.hi.hih.................................
..............................
\mwfimmmwmwxmam ..............................+.........................
x ...................
.xxx
‘‘‘‘‘‘‘‘‘
2012/062222
wwwwwwwwwwwwv.....................................................................................................h......p..p............................................................................................................. \~~~~~~\ ¢.~.~.~.\~.~.‘
\‘ kahuna}?i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i“‘{ii‘i‘i‘i‘i‘}
.............................. ‘3. ‘6
\ \‘o
................................ can“
mm {V\
(Mmm "i"‘i"‘i"‘i"‘i"‘i‘«‘i"‘i“‘{ii‘i‘i‘i‘i‘}
......................p...mkwwmw M. ‘i{{{{{““““{“‘
............h......* mm. {““““““““‘J
2012/062222
«~\\ \‘sss \
-:w .\\\~.\\
la...a...a...a...a...a...a...a...a...a...a...a...a...a...a...a...a...a...a...a...a...a...a...a...a...a...a............................ 23,.yams'I. 34
E::3::3::3::3::3::3::3::3::3::3::3:"""‘33:33:33::::3::3::3:""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""‘33:33:33? ‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘
Wmfi as
. ......... ..
T__\_\__\_\__\_»\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\.........‘......... \\\\\\\\\Ammmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmm. g
.w é
‘¢\\\\\\\\
Q........¢
h§§§mm
$.me
‘\\\\\\\\\\'
gamma
....h.... ................................................................................................................................
anuuuuuuuuuuuuuuuuuuuuuuK
vveueeee:
‘\\\\\\\\\‘
.\.\.\.\.\’ \\\\\\\\\ “"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘““““““““““““‘«x‘uuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuw............................................................‘;‘;;‘;‘;;‘;‘;;‘;‘;;‘;‘;;‘;‘;‘uuuuuuuuuuuuuuuuuuuuuuuuuuuuuw.................................u...............................
...........................................................
WO 63468
\x\«{3 \_
\....\“
\...........X
r. \x
wwwwwww
mfififi
xx{xxxmxxxxxxxxxxxxxxxxxxm
"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘i"‘+"‘i‘“i““ii‘i‘i‘i‘i mwx
n"‘n"‘n"‘n"‘n"‘n"‘n"‘n"‘n"‘n"‘n"‘n"‘n"‘n"‘n"‘n"‘n"‘n"‘n“““nnnn‘nnnn
.fiwwfififiwmmm
WO 63468
-.
n.- '
06}\:
.~.~.~.~.~.\_
_.\sssssss}._
¢ \
‘ \_
\MM ...........................................................................................................................................................1,if,»if,»if,»if.»if.»if.»if.»if.»nannnnnnnnn,,,,,,,,,,,,,,,,
‘4“:
.h....h. ""“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘““““““““““““
:33. ‘...................A
2012/062222
.........................................................................................................................................................................................................................................................................................................................................-.r.r”””””” S“\“\“\ .V".
.6 F‘\\\\\\\\\\‘I\\A\\\\\\‘
553‘.
....h.... “"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘“"‘““““““““““““‘
Table 5.
Compd Chemical formula Calcd. Observed Tail #
A—E12 C27H54NO3+ 440.4098 440.4336 2
C—E12 NO3S+ 472.3819 472.4303 2
D—E12 C28H54NO5+ 97 484.4327 2
E—E12 C29H56NO5+ 53 498.4117 2
I—E12 C30H60NO3+ 482.4568 482.4461 2
K—E12 C42H85N204+ 681.6504 681.6009 3
L—E12 C30H60NO3+ 482.4568 482.4771 2
M—E12 C29H58NO3S+ 500.4132 500.4471 2
N—E12 N205+ 667 .5984 667.5894 3
P—E12 C17H32NO2+ 282.2428 282.2585 1
Q—E12 C29H57N204+ 497.4313 497.4268 2
R—E12 9N405+ 893.8392 893.8400 4
cKG—E12 C32H64N304+ 554.4891 554.4852 2
cKT—E12 C34H68N305+ 598.5153 598.5179 2
2 C39H70N305+ 660.5310 660.5350 2
cLK—E12 C36H72N304+ 610.5517 610.5556 2
cDK—E12* N306+ 640.5259 640.5316 2
2 N304S+ 628.5082 628.5072 2
cKV—E12 C35H70N304+ 596.5361 596.5330 2
cAK—E12 C33H66N304+ 568.5048 568.4992 2
cEK—E12 C35H68N306+ 626.5103 626.5053 2
cIK—E12 C36H72N304+ 610.5517 610.5501 2
cSK—E12 C33H66N305+ 584.4997 584.5029 2
cKK—E10 C52H105N406+ 881.8029 881.8042 4
cKK—E12 C60H121N406+ 993.9281 993.9224 4
cKK—E14 C68H137N406+ 1106.0533 1106.0709 4
6 C76H153N406+ 1218.1785 1218.2002 4
Table 5.
Compd Chemical formula Calcd. Observed Tail #
A—A12 C27H56NO2+ 426.4306 426.4244 2
C—A12 C27H56NO2S+ 458.4026 458.3857 2
D—A12 C28H56NO4+ 470.4204 470.4188 2
E—A12 C29H58NO4+ 484.4360 484.4319 2
I—A12 C30H62NO2+ 468.4775 468.4714 2
K—A12 C54H111N202+ 819.8640 819.8657 4
L—A12 NO2+ 468.4775 468.4752 2
M—A12 C29H60NO2S+ 486.4339 486.4318 2
N—A12 C28H57N203+ 64 469.4328 2
P—A12 C17H34NO2+ 284.2584 284.2512 1
Q—A12 C29H59N203+ 483.4520 483.4543 2
R—A12 C42H87N402+ 679.6824 679.6783 3
KK—A12 C84H171N403+ 1284.3346 1284.3458 6
2 C114H231N604+ 1748.8051 1748.8340 8
2 C60H121N402+ 929.9484 929.9445 4
A—O12 C18H36NO4+ 330.2639 330.2582 1
C—012 C33H64NO6S+ 602.4449 602.4426 2
D—012 C19H36NO6+ 374.2537 374.2492 1
E—012 C20H38NO6+ 388.2694 388.2672 1
F—O12 C24H40NO4+ 406.2952 406.2896 1
H—012 C36H66N306+ 46 636.4969 2
K—O12 C66H127N2010+ 1107.9485 1107.9417 4
M—O12 C20H40NO4S+ 390.2673 390.2628 1
N—012 C19H37N205+ 373.2697 373.2668 1
P—012 C20H38NO4+ 356.2795 356.2779 1
Q—012 C20H39N205+ 387 .2853 387.2831 1
R—O12 N404+ 415.3279 415.3235 1
S—012 NO5+ 346.2588 346.2521 1
T—012 C19H38NO5+ 44 360.2733 1
Chemical formula Observed
V—012 C20H40NO4+ 358.2952 358.2905
W—Ol2 N204+ 445.3061 445.3010
* formation of ethyl ester. Compounds derived from poly—L—lysine
are not included.
ary compounds of Table 5:
OH OH
C10"‘21/g C10H21’g C10Hz1/g
M% W101I:M1:3”
A-E12 C-E12 D-E12 OH
OH OH
C10H21I$C1OH21/$ OH
OH C10"‘21/g
C10H21 C10Hz1
E-E12 C1on1
F-E12 (3-E12
C10Hz1
N C10"‘21’g
C1on1
OH / C10"‘21
N§/ V010H21
H-E12
HO I-E12
9 9
WO 63468
C10"121/g C10H21
C10H21/</N CH C1on1
L-E12 M-E12
P-E12
R-E12
C10H21’g O
OH OH
/g O
N K-E12
C10H21 HO
OH C10H21KKOH
Y-E12 C10H21
O OHO
m MNH
HN HN
O HOD/C1OH21 O HO C10H21
N Nj/
C10H21 C10H21
cKG-E12 cKT-E12
OH OH
O O
HN NNHHN
O HOD/C10H21 O HOj/C10H21
N N
C10H21 C10H21
cYK-E12 cLK-E12
OH OH
O O
HONNH 8
/ MNH
O HN HN
O HOj/C1oH21 O HOj/C10H21
N N
C10H21 C10H21
cDK-E12 cMK-E12
OH OH
O O
NH YLNH
HN HN
O HOj/C1oH21 O HOD/C10H21
N N
C10H21 C10H21
cKV-E12 2
OH OH
SH 0 H2N o
KHkNH NH
HN HN
O HOD/CmHm O HOD/C1OH21
N N
C10"‘21 C10H21
cCK-E12 CQK-E12
OH OH
O O
O HOD/C10H21HOj/C10H21
N N
C10Hz1 C10Hz1
cPK-E12 2
OH OH
O HOWNH
Nj/j/C10H21j/C10H21Nj/
CWK-E12 YC10H21S/C10H21CEK-E12
OH OH
O Flo/\HOkNI—I
Wmoj/C1OH21Nj/ HNfiLOj/C10H21Nj/
C1on1
clK-E12 YC10H21 CSK-E12
OH OH
C11 H
C11"‘23 23W O C11H23
W 0 7
N OH
( O“ l/N
c11 H23
C11"‘23 SH C11st
A-A12 C-A12 D-A12 OH
2012/062222
C11H23W C11H23W
CMHZBfi O
C11Hz3 C11H23 OH
E'A12 C11"‘23
F-A12 G-A12
C11H23
N N
C11Hz3
/ C11 H23 C11"‘23
H-A12 I-A12 L-A12
C H C11 H
11 23W 0 23w 0
N N C1 1 H23
r r \\ O
OH OH
C11"‘23 C11Hz3 N
8\ NH2
M-A12 N-A12 P-A12
O NH2
Q-A12 R-A12
C11H23W O C11H23W O C11H23W O
N N N
1/ OH I/ OH 1/ OH
C11 H23 C11 H23 C11 H23
OH OH
S-A12 T-A12 V-A12
WO 63468
( OH rN OH
NH C11H23
W-A12 OH
Y_A12
C11H23
W O (312st
N ('312st (I) O
OH O O
C11H23
K-A12 N
HN OH
C11H23VNW SH
C11H23 A-012 C12H25/ C-012
C12Hz5
(I) O ([312H25 $12H25
O O O O ('312H25
O O
O O
OH HN “N O
OH OH
O HN\)J\
OH E-012
D-012 HO 0 F-O12 G-O12
'12 25
C12H25 C12HZS
O O I l
O O O O
O O
OH HN HN
OH OH
/O N§/
012st H-O12 l-O12 L-O12
$12H25 $12H25
O O O 0
C12st
(‘3 o
O O
HN HN
OH OH
0 GAO“
S NH2
M-O12 N-012 P-012
('312H25
O O
3312st
O O
C H
N N/Qk / 12 25
H H
0 NH2
0-012 R-O12
€312st 25 $312st
0 O O O O O
O O O
HN HN HN
OH OH OH
OH OH
3-012 T-O12 V-012
([312st $312st
0 o o o
OH HN
w-o12 0H
Y-O12
’ ,and
2012/062222
O O
C312H25/
O N
C12H25/ OH
K-O12
O N
C12H25/
O o
\C12H25
Example 2. Alternative synthesis of compound 23 (cKK-E12)
BocHN-CHC-O 0
(EH CszN
. 1. TFA, rt NH Pol/Q H2
9H2 —’ HN —>
CH2 2. pyridine, rt ACOH/CHZCIZ
(:ZHZ 0 NHCbz
NHCbz
A B
C10H21 O
o VAN
HO NH
HZN HO
NH 2AcOH TEA. EtOH HN C1oH21
HN C H /—<
MW 10 21
O N OH
O 1
HO C10H21
c 23 (cKK-E12)
Synthesis of compound B. Compound A (487 mg, 1.02 mmol) was charged in a
ml flask and trifluoroacetic acid (TFA, 1.3 mL) was added dropwise at 0 0C. The reaction
mixture was warmed to room temperature and stirred for 30 min. The solvents were
evaporated under reduced re and the TFA salts in DMF (3.5 mL) were added dropwise
to ne (100 mL) at 0 0C. The reaction mixture was slowly warmed to room temperature
and stirred for overnight. The solvents were evaporated under reduced pressure and the white
solid was washed with EtOAc to give pure B in 69% yield. MS: m/z 525 (M+H+); 1H NMR
(500 MHZ, DMSO, ppm): 5 1.29-1.40 (m, 8H, ), 1.61-1.68 (m, 4H, CH2), 2.97 (dd, J
= 6.0, 12.5 Hz, 4H, NCHZ), 3.79 (br, 2H, COCH), 7.22 (t, J: 5.5 Hz, 2H, aromatic), 7.33-
7.37 (m, 8H, aromatic), 8.10 (s, 2H, NH).
Synthesis of compound C. A cloudy solution of compound B (95 mg, 0.18
mmol) in 50% acetic acid/CHZClZ (6 mL) was added Pd on charcoal (10 wt %, 36.5 mg). The
black suspension was degassed for 5 mins and hydrogen gas introduced. The reaction mixture
stirred at rt overnight and was then filtered through a layer of Celite, which was washed
several times with MeOH. The combined filtrates were concentrated to obtain a yellow
viscous oil, which was solidified by adding EtOAc. The solid was washed by ethyl acetate to
yield compound C in 90% yield. MS: m/z 257 (M+H+); 1H NMR (500 MHz, D20, ppm): 5
1.39-1.52 (m, 4H, CH2), 1.67-1.71 (m, 4H, CH2), .88 (m, 4H, CH2), 2.99 (t, J: 7.5 Hz,
4H, NCHZ), 4.14 (t, J: 5.0 Hz, 2H, COCH).
Synthesis 0fcomp0und 23 (cKK-EIZ). A mixture of compound C (169.2 mg,
0.45 mmol) and 1,2—epoxydodecane (523 mg, 2.7 mmol) in EtOH was added triethylamine
(182 mg, 1.8 mmol), which was stirred 30 mins at rt. The reaction mixture was then ated
in the ave oven at 150 0C for 5 h. The mixture was purified by flash column
tography to obtain compound 23 (in 52% yield) as a light yellow oil. MS: m/z 993
(M+H+); 1H NMR (500 MHz, DMSO, ppm): 8 0.87 (t, J = 7.0 Hz, 12H, CH3), 1.21-1.39 (m,
80H, CH2), 1.64-1.67 (m, 4H, CH2), 2.25-2.44 (m, 12H, NCHZ), 3.44 (br, 4H, CHOH), 3.79
(br, 2H, COCH), 4.21 (d, J: 3.0 Hz, 2H, CHOH), 4.27 (d, J: 3.0 Hz, 2H, CHOH), 8.11 (br,
2H, CONH).
e 3. Synthesis of Compound D
It is envisioned compound D can be sized by reaction of 23 with
Lawesson’ s reagent in dry toluene.
23 D
Example 4. Synthesis of Compound E
It is oned compound E can be synthesized by reaction of 23 with
hydroxylamine hydrochloride or other substituted amines in methanol.
23 E
Biolo ical s
siRNA Formulations
Formulation A
APPL, distearoyl phosphatidylcholine (DSPC), cholesterol and mPEG2000—
DMG were solubilized in 90% ethanol at a molar ratio of 50:10:38.5:l.5. The siRNA (against
firefly luciferase or fVII) was solubilized in 10 mM citrate, pH 3 buffer at a concentration of
0.4 mg/mL. The ethanolic lipid solution and the aqueous siRNA solution were pumped by
means of a syringe pump through a microfluidic mixing chamber to spontaneously form
siRNA—containing lipid nanoparticles. Lipids were combined with siRNA at a total lipid to
siRNA ratio of 7:1 (wt:wt). These ations were ed against PBS to remove ethanol
and exchange buffer.
Formulation B
APPLs were formulated with cholesterol (Sigma—Aldrich), DSPC (1,2—
distearoyl—sn—glycero—3—phosphocholine, Avanti), mPEG2000—DMG (synthesized by
Alnylam), and siRNA via a microfluidic based mixing device See, e. 57., Chen, D., et al.,
Rapid Discovery ofPotent siRNA-Containing Lipid Nanoparticles Enabled by lled
Microflnidic Formnlation. J Am Chem Soc. Formulations were then dialyzed against PBS in
3,500 MWCO dialysis cassettes (Pierce) overnight. les were characterized with a
modified Ribogreen assay (Invitrogen) for siRNA entrapment and dynamic light scattering
(ZetaPALS, Brookhaven Instruments) for mean particle er. cKK—E12 formulations
were made from cholesterol, DSPC, and 00—DMG using a similar method at a molar
ratio of 50:10:38.5:l.5. This formulation afforded a le diameter of 60—70 nm with
approximately 65% siRNA entrapment.
In Vitro rase Gene Silencing
HeLa cells, stably expressing firefly luciferase and Renilla luciferase, were
seeded 0 cells/well) into each well of an opaque white 96—well plate(Coming—Costar)
and allowed to attach overnight in growth . Growth medium was composed of 90%
phenol red—free DMEM, 10% FBS, 100 units/ml penicillin, 100 mg/ml streptomycin
rogen). Cells were transfected with LNPs formulated with anti—luciferase siRNA by
addition of formulated particles to growth medium. Transfections were performed in
quadruplicate. Cells were allowed to grow for 1 d at 37°C, 5% CO2 and were then analyzed
for luciferase expression. Control experiments were performed with Lipofectamine 2000, as
described by the vendor (Invitrogen). Firefly and Renilla luciferase expression was analyzed
using Dual—Glo assay kits ga). Luminescence was measured using a Victor3
luminometer (Perkin Elmer).
In Vivo Factor VII Gene Silencing in Mice
C57BL/6 mice (Charles River Labs) were used for siRNA ing
experiments. Prior to injection, formulations were diluted in PBS at siRNA concentrations
(SEQ ID NO 1 (siFVII sense): 5’—GGAucAucucAAGucuuAcTi‘T—3’; SEQ ID NO 2
(antisense): 5’(EuA;»\(‘n»\cuuGAGAuGAuccTi‘Tl}’) such that each mouse was stered
a dose of 0.01 mI/g body—weight. Formulations were administered intravenously via tail vein
injection. After 48 or 72 h, body—weight oss was measured and mice were anaesthetized
by isofluorane inhalation for blood sample collection by retroorbital eye bleed. Serum was
isolated with serum separation tubes (Falcon tubes, Becton Dickinson) and Factor VII protein
levels were analyzed by chromogenic assay (Biophen FVII, Aniara Corporation). A standard
curve was constructed using s from PBS—injected mice and relative Factor VII
expression was determined by comparing treated groups to ted PBS control.
Biodistribution Cy5.5-labled siRNA-cKK-E12 formulation in mice.
The mice mentioned above were systemically injected with formulated Cy5.5—
labeled siRNA at a dose of 1 mg/kg of total siRNA. The mice were sacrificed 1 hour or 24
hours post injection; the pancreas, spleen, liver, kidneys, ovaries, uterus, heart, lungs, and
thymus as well as a n of the adipose tissue and muscle tissue were then removed and
imaged. The organs were ed with an Ivis imaging system from Caliper using an
excitation wavelength of 675nm and an on wavelength of 720nm. The data were
processed using the Living Image software from Caliper. Signal strength of the individual
organs was normalized against the total signal strength of all organs.
In Vitro siRNA Transfection Assay and Microscopy.
Effects of apolipoproteins were evaluated through an in: vitro siRNA
transfeetitm assay in l’lelsa cells as previously ed. l’lelia cells, stably expressing firetl y
lueiferase and a lueiferase were seeded in an opaque white 96—well plate (Corning—
Costar) overnight. Cells were transfeeted by eKK—El2 formulated with 50 ng of firefly—
speeifle siluc in quadruplicate. Apolipeproteins (lilitzgeraltl industries) were incubated with
cKK~El2 formulations for 5 mins befere adding to cells. After 24 h incubation at 37 0C, 5%
C02, eells were analyzed for lueiferase sion using Dual—file assay kits (Prernega). For
visualizatien of cell uptake, eKK-E. 32 was formulated with an Alexa-E'luer {i47mlabeled
siRNA and incubated with Belt: eells fer 3 l1. Cells were then fixed in 4% paraformaldehyde,
permeabilized with 0.1% saponin and stained with Hoescht. All images were acquired using
an Opera spinning disc confocal system (Perkin Elmer), and the data was analyzed using
Acapella Software (Perkin .
Discussion
Single amino acids were d with aldehydes, acrylates, and epoxides to
produce APPLs. The newly—synthesized single amino acid—based lipid derivatives were
evaluated for their capacity to silence hepatic genes in mice. A validated genetic ,
Factor VII (a blood clotting factor), was selected as a silencing . See, e. g., Akinc, A.,
et al., A combinatorial library of lipid-like als for ry ofRNAi therapeutics. Nat
Biotechnol, 2008. 26(5): p. 561—9. New lipid derivatives were formulated with cholesterol,
DSPC, PEG—lipid, and siRNA via a microfluidic based mixing technology. See, e. 57., Chen,
D., et al., Rapid Discovery ofPotent siRNA-Containing Lipid rticles Enabled by
Controlled Microflaidic Formalation. J Am Chem Soc. Formulations that were instable in
solution or had no siRNA entrapment were not screened. Stable formulations were injected in
mice through systemic stration at a dose of 1 mg/kg (Figure 1). From this initial
screening, we identified that K—El2 was more potent than others. The hit rate (over 50%
silencing) was one out of 60 compounds (i.e. 1.7%, including those compounds not screened
due to le instability or no entrapment of siRNA).
] The enhanced potency of K—El2 led to our design of a second set of lysine—
based peptide and polypeptide—lipid derivatives. —based dipeptides were reacted with
epoxides to give diketopiperizine APPLs. Microwave irradiation was utilized to produce
these scaffolds, which dramatically reduced the reaction time from 3 days to 5 hours. In
addition, to further confirm the chemical structure and improve chemical availability for
large—scale synthesis, an alternative tic route was developed for the synthesis of cKK-
E12 le 2). Diamine 5 was synthesized ing to the method reported previously
(Bergeron, R.J., et al., Macromolecular Self-Assembly ofDiketopiperazine Tetrapeptides. J.
Am. Chem. Soc., 1994. 116(19): p. 8479—84; Kaur, N., et al., A Delineation of
Diketopiperazine Self-Assembly Processes: Understanding the Molecular Events ed in
N—(Fumaroyl)diketopiperazine ofL-Lys (FDKP) Interactions. Mol. Pharmaceutics, 2008.
(2): p. 5), which reacted with 1,2—epoxydodecane to afford cKK-E12. Compound (C)
underwent reductive amination or Michael addition reactions with dodecanal or dodecyl
acrylate to yield cKK-A12 and cKK-012. Reactions between lysine—lysine and poly—L—lysine
(molecular weight from 500—70000 g/mol) and aldehydes and acrylates were r to those
of single amino acids.
The silencing effects were next evaluated. Ten out of 43 compounds showed
around 50% silencing at a dose of 1 mg/kg. The hit rate of the second set of compounds was
23%, which was over 10—fold more efficient compared to the first set of materials. The results
suggested that our ive screening process is an efficient strategy for identifying lead
compounds. The s from the second set also showed that epoxide derivatives were more
potent than aldehyde and acrylate derivatives (such as cKK—E12 vs cKK—A12 & cKK—Ol2).
Hit materials were r tested at a lower dose of 0.1 mg/kg. The tail length significantly
affects silencing and 12—14 carbon tail lengths appeared favorable 10, —E12, —E14, & —
E16). cKK—E12 was the most potent material and was selected for further exploration.
Biodistribution Study
A biodistribution study was performed with naked Cy5.5 labeled siRNA and
formulated cKK—E12. By subtracting the contribution of free siRNA in the formulation of
cKK—E12, over 80% of particles were located in the liver at 1 hr and most residual siRNA
was cleared by 24 hr h kidney (Figure 2).
Efi‘ects ofApolipoproteins on Cell Uptake and Gene Silencing
] Previous studies have ed that Apolipoprotein E (ApoE) was able to
enhance cell uptake and gene ing for a certain type of materials. Akinc, A., et al.,
Targeted delivery ofRNAi eutics with endogenous and exogenous ligand-based
mechanisms. Mol Ther. 18(7): p. 1357—64. In order to test the effects of diverse apoliproteins
on cell uptake and gene silencing, and explore the mechanism of action, ments were
performed with cKK—E12 and ll isoforms of ApoA, ApoB, ApoC, ApoE, and ApoH. Results
in Hela cells showed that most apolipoproteins did not affect cell ity with the exception
of ApoB. ApoA, ApoC, and ApoH did not show icant effects on silencing compared to
free cKK—E12 (Figure 3). However, four different ApoE isoforms significantly improved
luciferase silencing.
The activity of cKK—ElZ, cKK—AlZ, and cKK—012 was compared with and
without addition of apoE3 (apoE3 is the dominant isoform in humans. Figure 4A). Without
addition of ApoE3, cKK—A12 was more potent than cKK—E12 and cKK—OlZ. However, with
on of ApoE3, the order of ing effects was cKK—E12 > cKK—A12 > cKK—OlZ,
which correlated well with in vivo activity. The results suggested that a cell assay with
addition of ApoE might be a practical and effective model for preliminary ing for liver
hepatocytes silencing. In addition, the cell uptake of cKK—E12 formulated with an Alexa—
Fluor 647 labeled siRNA was visualized using automated confocal microscopy (Figure 4B).
Other Embodiments
] In the claims articles such as “a,” “an,” and “the” may mean one or more than
one unless indicated to the contrary or otherwise evident from the context. Claims or
descriptions that include “or” between one or more s of a group are ered
satisfied if one, more than one, or all of the group members are present in, employed in, or
otherwise relevant to a given product or process unless indicated to the contrary or otherwise
t from the context. The invention includes embodiments in which exactly one member
of the group is t in, employed in, or ise relevant to a given product or process.
The invention includes embodiments in which more than one, or all of the group members are
present in, employed in, or otherwise relevant to a given product or process.
] Furthermore, the invention encompasses all variations, combinations, and
permutations in which one or more limitations, elements, clauses, and descriptive terms from
one or more of the listed claims is uced into another claim. For example, any claim that
is dependent on another claim can be modified to include one or more limitations found in
any other claim that is dependent on the same base claim. Where elements are presented as
lists, e. g., in Markush group format, each subgroup of the elements is also disclosed, and any
element(s) can be removed from the group. It should it be understood that, in general, where
the invention, or aspects of the invention, is/are referred to as comprising particular elements
and/or features, certain ments of the invention or aspects of the invention consist, or
consist essentially of, such elements and/or features. For purposes of simplicity, those
embodiments have not been specifically set forth in haec verba . It is also noted that
the terms “comprising” and “containing” are intended to be open and permits the inclusion of
additional elements or steps. Where ranges are given, endpoints are included. Furthermore,
unless otherwise indicated or otherwise t from the context and understanding of one of
ordinary skill in the art, values that are expressed as ranges can assume any specific value or
sub—range within the stated ranges in different embodiments of the invention, to the tenth of
the unit of the lower limit of the range, unless the context clearly dictates otherwise.
This application refers to various issued patents, published patent applications,
l articles, books, manuals, and other publications, all of which are incorporated herein
by nce. If there is a conflict between any of the incorporated references and the instant
specification, the specification shall control. In addition, any particular embodiment of the
present invention that falls within the prior art may be itly excluded from any one or
more of the claims. Because such embodiments are deemed to be known to one of ordinary
skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein.
Any particular embodiment of the invention can be excluded from any claim, for any ,
whether or not d to the existence of prior art.
Those skilled in the art will recognize or be able to ascertain using no more than
routine experimentation many equivalents to the specific embodiments described herein. The
scope of the present embodiments described herein is not intended to be limited to the above
Description, but rather is as set forth in the ed claims. Those of ry skill in the
art will appreciate that various changes and modifications to this ption may be made
without departing from the spirit or scope of the present ion, as defined in the following
claims.
Claims (38)
1. A compound of Formula (I): or salt thereof; wherein: n is 0 or 1; each instance of m is independently 1; each instance of Z is O; each instance of R1 is independently selected from the group ting of: -H, -CH(CH3)2, -CH(CH3)(CH2CH3), -CH2CH(CH3)2, , , , , , , , , , , , , , , and or is a group of formula (iv): (iv) wherein L is an optionally substituted alkylene; R6 and R7 are each independently a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, or a group of the formula (i), provided that at least one instance of R6 and R7 is a group of formula (i); R2 is a group of formula (i); R3 is a group of the a (i); R4 is -ORA4, or -N(RA4)2; wherein each occurrence of RA4 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a nitrogen ting group when attached to a nitrogen atom, or two RA4 groups are joined to form an optionally substituted heterocyclic or optionally substituted aryl ring; R5 is en, or optionally substituted alkyl; and Formula (i) is: wherein formula (i) is selected from formula (i-a) and formula (i-b): (i-a) (i-b) wherein: each instance of R′ is independently hydrogen or optionally substituted alkyl; Y is O, S, NRY, n RY is hydrogen, ally substituted alkyl, ally substituted alkenyl, optionally substituted alkynyl, optionally tuted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group; RP is hydrogen; and RL is C7-12alkyl; wherein “optionally substituted” refers to a carbon atom of a group which may be unsubstituted or independently tuted with halogen, –CN, –NO2, –N3, –SO2H, –SO3H, –OH, –ORaa, –N(Rbb)2, –SH, –SRaa, –SSRcc, –C(=O)Raa, –CO2H, –CHO, –CO2Raa, –OC(=O)Raa, – OCO2Raa, –C(=O)N(Rbb)2, –OC(=O)N(Rbb)2, –NRbbC(=O)Raa, O2Raa, – NRbbC(=O)N(Rbb)2, –C(=O)NRbbSO2Raa, –NRbbSO2Raa, –SO2N(Rbb)2, –SO2Raa, –SO2ORaa, – OSO2Raa, –S(=O)Raa, –OS(=O)Raa, –Si(Raa)3, C1–10 alkyl, C2–10 alkenyl, C2–10 alkynyl, C3–10 carbocyclyl, 3–14 membered heterocyclyl having ring carbon atoms and 1-4 ring heteroatoms selected from oxygen, sulfur, and nitrogen, C6–14 aryl, or 5–14 membered heteroaryl having ring carbon atoms and 1-4 ring atoms selected from , sulfur, and nitrogen, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups; or two geminal hydrogens of the carbon atom are replaced with the group =O, =S, or =NRbb; or refers to a nitrogen atom of a group which may be unsubstituted or independently substituted with –OH, –ORaa, Raa, –C(=O)N(Rcc)2, – CO2Raa, –SO2Raa, C1–10 alkyl, C2–10 alkenyl, C2–10 alkynyl, C3–10 yclyl, 3–14 membered heterocyclyl having ring carbon atoms and 1-4 ring heteroatoms selected from oxygen, sulfur, and en, C6–14 aryl, and 5–14 membered aryl having ring carbon atoms and 1-4 ring heteroatoms selected from oxygen, sulfur, and nitrogen, or two Rcc groups attached to an N atom are joined to form a 3–14 membered heterocyclyl having ring carbon atoms and 1-4 ring heteroatoms selected from oxygen, sulfur, and en or 5–14 membered heteroaryl ring having ring carbon atoms and 1-4 ring heteroatoms selected from , sulfur, and nitrogen, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently tuted with 0, 1, 2, 3, 4, or 5 Rdd groups; each of Raa is ndently C1–10 alkyl, C2–10 alkenyl, C2–10 alkynyl, C3–10 carbocyclyl, 3–14 membered heterocyclyl having ring carbon atoms and 1-4 ring heteroatoms selected from oxygen, sulfur, and nitrogen, C6–14 aryl, and 5–14 membered heteroaryl, or two Raa groups are joined to form a 3–14 membered heterocyclyl or 5–14 membered heteroaryl ring having ring carbon atoms and 1-4 ring heteroatoms selected from oxygen, sulfur, and en, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently tuted with 0, 1, 2, 3, 4, or 5 Rdd groups; each of Rbb is independently hydrogen, –OH, –ORaa, –N(Rcc)2, –CN, –C(=O)Raa, – C(=O)N(Rcc)2, –CO2Raa, –SO2Raa,–SO2N(Rcc)2, –SO2Rcc, –SO2ORcc, –SORaa, C1–10 alkyl, C2–10 alkenyl, C2–10 alkynyl, C3–10 yclyl, 3–14 membered heterocyclyl having ring carbon atoms and 1-4 ring heteroatoms ed from oxygen, sulfur, and nitrogen, C6–14 aryl, or 5–14 membered heteroaryl having ring carbon atoms and 1-4 ring heteroatoms selected from oxygen, sulfur, and nitrogen, or two Rbb groups are joined to form a 3–14 membered heterocyclyl or 5–14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups; each of Rcc is independently hydrogen, C1–10 alkyl, C2–10 alkenyl, C2–10 alkynyl, C3–10 carbocyclyl, 3–14 membered heterocyclyl having ring carbon atoms and 1-4 ring atoms selected from oxygen, sulfur, and nitrogen, C6–14 aryl, or 5–14 ed heteroaryl having ring carbon atoms and 1-4 ring atoms selected from oxygen, sulfur, and nitrogen, or two Rcc groups are joined to form a 3–14 membered heterocyclyl or 5–14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups; each of Rdd is independently halogen, –CN, –NO2, –N3, –SO2H, –SO3H, –OH, –ORee, – 2,–SH, –SRee, , –C(=O)Ree, –CO2H, –CO2Ree, –OC(=O)Ree, –OCO2Ree, – C(=O)N(Rff)2, –OC(=O)N(Rff)2, (=O)Ree, –NRffCO2Ree, –NRffC(=O)N(Rff)2,– NRffSO2Ree, –SO2N(Rff)2, –SO2Ree, –SO2ORee, –OSO2Ree, –S(=O)Ree, –Si(Ree)3, C1–10 alkyl, C2– 10 alkenyl, C2–10 alkynyl, C3–10 carbocyclyl, 3–10 membered heterocyclyl having ring carbon atoms and 1-4 ring heteroatoms selected from oxygen, sulfur, and nitrogen, C6–10 aryl, 5–10 membered heteroaryl having ring carbon atoms and 1-4 ring heteroatoms ed from oxygen, sulfur, and nitrogen, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgg groups, or two geminal Rdd substituents can be joined to form =O; each of Ree is independently C1–10 alkyl, C2–10 l, C2–10 alkynyl, C3–10 carbocyclyl, C6–10 aryl, 3–10 membered cyclyl having ring carbon atoms and 1-4 ring heteroatoms ed from oxygen, sulfur, and nitrogen, and 5–10 membered heteroaryl having ring carbon atoms and 1-4 ring heteroatoms selected from oxygen, sulfur, and nitrogen, wherein each alkyl, alkenyl, alkynyl, yclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgg groups; each of Rff is independently hydrogen, C1–10 alkyl, C2–10 alkenyl, C2–10 alkynyl, C3–10 carbocyclyl, 3–10 membered cyclyl having ring carbon atoms and 1-4 ring heteroatoms selected from oxygen, sulfur, and nitrogen, C6–10 aryl and 5–10 membered aryl having ring carbon atoms and 1-4 ring heteroatoms ed from oxygen, sulfur, and nitrogen, or two Rff groups are joined to form a 3–14 ed heterocyclyl or 5–14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgg groups; each of Rgg is independently halogen, –CN, –NO2, –N3, –SO2H, –SO3H, –OH, –OC1–10 alkyl, 10 alkyl)2, –SH, –SC1–10 alkyl, –SS(C1–10 alkyl), –C(=O)(C1–10 alkyl), –CO2H, – CO2(C1–10 alkyl), –OC(=O)(C1–10 , –OCO2(C1–10 alkyl), –C(=O)NH2, –C(=O)N(C1–10 alkyl)2, –OC(=O)NH(C1–10 alkyl), O)( C1–10 alkyl), –N(C1–10 alkyl)C(=O)( C1–10 alkyl), –NHCO2(C1–10 alkyl), –NHC(=O)N(C1–10 alkyl)2, –NHC(=O)NH(C1–10 alkyl), –NHC(=O)NH2, –NHSO2(C1–10 alkyl), –SO2N(C1–10 alkyl)2, –SO2NH(C1–10 alkyl), –SO2NH2,–SO2C1–10 alkyl, – SO2OC1–10 alkyl, –OSO2C1–6 alkyl, –SOC1–6 alkyl, –Si(C1–10 alkyl)3, C1–10 alkyl, C2–10 alkenyl, C2–10 alkynyl, C3–10 carbocyclyl, C6–10 aryl, 3–10 membered heterocyclyl having ring carbon atoms and 1-4 ring heteroatoms ed from oxygen, sulfur, and nitrogen, 5–10 membered heteroaryl having ring carbon atoms and 1-4 ring heteroatoms ed from oxygen, sulfur, and en; or two geminal Rgg substituents can be joined to form =O; a nitrogen protecting group is selected from the group consisting of –OH, –ORaa, – N(Rcc)2, –C(=O)Raa, –C(=O)N(Rcc)2, –CO2Raa, –SO2Raa, –C(=NRcc)Raa, –C(=NRcc)ORaa, – C(=NRcc)N(Rcc)2, –SO2N(Rcc)2, –SO2Rcc, –SO2ORcc, , –C(=S)N(Rcc)2, –C(=O)SRcc, – Rcc, C1–10 alkyl, aralkyl, heteroaralkyl, C2–10 l, C2–10 alkynyl, C3–10 carbocyclyl, 3– 14 membered heterocyclyl, C6–14 aryl, and 5–14 membered heteroaryl groups, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups, wherein Raa, Rbb, Rcc and Rdd are as d herein; an oxygen protecting group and a sulfur protecting group are independently selected from the group consisting of –Raa, )2, –C(=O)SRaa, –C(=O)Raa, –CO2Raa, –C(=O)N(Rbb)2, – C(=NRbb)Raa, –C(=NRbb)ORaa, –C(=NRbb)N(Rbb)2, –S(=O)Raa, –SO2Raa, and –Si(Raa)3, wherein Raa, Rbb, and Rcc are as defined herein; provided that when n is 0, R1 is not H.
2. The compound of claim 1, n the group of formula (iv) is of the formula: wherein q is an integer between 1 and 50, inclusive.
3. The compound of claim 1, wherein each instance of R1 is a group of formula (iv).
4. The compound of claim 1, wherein each instance of R5 is hydrogen.
5. The compound of claim 1, wherein the group of formula (i-a) is a group of formula (i-a1) or a group of formula (i-a2): (i-a1) (i-a2).
6. The compound of claim 1, wherein the group of formula (i-b) is a group of formula (i-b1) or a group of a (i-b2): (i-b1) (i-b2)
7. The compound of claim 1, wherein the compound is of Formula (I-f4): (I-f4) or salt thereof.
8. The compound of claim 1, wherein the compound is of Formula (I-f5): (I-f5) or salt thereof.
9. The nd of claim 1, wherein the compound is selected from the group consisting of: , , , , , , and salts thereof.
10. The compound of claim 1, wherein the compound is ed from the group consisting of: , , , , , , , , , , , and salts thereof.
11. A composition comprising a compound of any one of the preceding claims, or salt thereof, and an excipient.
12. The composition of claim 11, wherein the composition is a pharmaceutical composition, a cosmetic composition, a nutraceutical ition, or a composition with non-medical ation.
13. The composition of claim 11, wherein the composition is a pharmaceutical composition.
14. The composition of claim 13, wherein the ition further comprises cholesterol.
15. The composition of claim 13, wherein the composition r comprises a PEGylated lipid.
16. The composition of claim 13, wherein the composition further comprises a phospholipid.
17. The composition of claim 13, wherein the composition further comprises an apolipoprotein.
18. The composition of claim 11, wherein the composition further comprises an agent.
19. The composition of claim 18, wherein the agent is an organic molecule, inorganic molecule, nucleic acid, protein, peptide, polynucleotide, targeting agent, an isotopically d chemical nd, vaccine, an immunological agent, or an agent useful in bioprocessing.
20. The composition of claim 18, wherein the agent is a polynucleotide.
21. The composition of claim 20, wherein the polynucleotide is DNA.
22. The composition of claim 20, wherein the polynucleotide is RNA.
23. The composition of claim 22, n the RNA is RNAi, dsRNA, siRNA, shRNA, miRNA, or antisense RNA.
24. The composition of claim 18, wherein the agent and the compound are not covalently attached.
25. The composition of claim 11, wherein the composition is in the form of a particle.
26. The composition of claim 25, wherein the particle is a nanoparticle or microparticle.
27. The composition of claim 25, n the particle is a e, liposome, or lipoplex.
28. The composition of claim 25, wherein the particle encapsulates an agent.
29. A method of screening a compound y, the method comprising: providing a plurality of compounds according to any one of claims 1-10, or salts f; performing at least one assay with the compound library to determine the presence or absence of a desired property; wherein the desired property is solubility in water, solubility at different pH, ability to bind polynucleotides, ability to bind heparin, ability to bind small les, ability to bind protein, ability to form microparticles, ability to increase tranfection efficiency, ability to support cell , ability to support cell attachment, ability to support tissue growth, and/or intracellular delivery of the compound and/or an agent complexed or ed thereto to aid in bioprocessing.
30. A composition for use in treating a e, disorder, or condition from which a subject suffers, comprising a compound according to any one of claims 1-10, or a salt thereof, and an agent.
31. The composition of claim 30, n the disease, disorder, or condition is selected from the group consisting of proliferative disorders, inflammatory disorders, autoimmune disorders, l conditions, liver diseases, and familial amyloid neuropathies.
32. The composition of claim 30, wherein the e, disorder, or condition is a liver disease.
33. The composition of claim 28, wherein the agent is an organic le, inorganic molecule, nucleic acid, protein, peptide, polynucleotide, targeting agent, an isotopically labeled chemical compound, vaccine, or an immunological agent.
34. The composition of claim 33, wherein the agent is a polynucleotide.
35. The composition of claim 34, wherein the polynucleotide is DNA.
36. The composition of claim 34, wherein the polynucleotide is RNA.
37. The composition of claim 36, wherein the RNA carries out RNA interference.
38. The ition of claim 36, wherein the RNA is RNAi, dsRNA, siRNA, shRNA, miRNA, or antisense RNA.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ747501A NZ747501A (en) | 2011-10-27 | 2012-10-26 | Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552423P | 2011-10-27 | 2011-10-27 | |
US61/552,423 | 2011-10-27 | ||
NZ719941A NZ719941B2 (en) | 2011-10-27 | 2012-10-26 | Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ733610A NZ733610A (en) | 2019-11-29 |
NZ733610B2 true NZ733610B2 (en) | 2020-03-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021257964B2 (en) | Amino acid derivatives functionalized on the n-terminus capable of forming drug encapsulating microspheres and uses thereof | |
NZ733610B2 (en) | Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres | |
NZ719941B2 (en) | Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres | |
NZ624223B2 (en) | Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres |